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Obesity was formally recognized as a disease by the World Health Organization 
(WHO) in 1997, and its prevalence is increasing at epidemic proportions worldwide. 
The enormous changes in human life regarding labor, exercise and diet habits have 
largely provoked the development of this multi-factorial disease. It has been 
confirmed that obesity causes many diseases, including cardiovascular disorders, type 
2 diabetes mellitus, obstructive sleep apnea and degenerative joint disease. Even 
though many kinds of medical treatment are recommended, most therapies have not 
been successful in keeping sustained weight loss and controlling obesity-related 
comorbidity, especially in morbid obesity. Until now, only bariatric surgery has 
proven to be an effective procedure, and in the last 40 years, the number of bariatric 
procedures has been increasing exponentially in the world. This book provides an 
overview and updated knowledge of bariatric surgery and patient care. In it, we 
discussed various procedures, preoperative preparation, perioperative care and 
postoperative nutrition support, and the brand new, “transformed” bariatric surgery 
in type 2 diabetes–metabolic surgery and scarless bariatric surgery has also been 
included. We hope that this book will contribute to the future development of weight 
loss management.  
 
Chih-Kun Huang 
Bariatric & Metabolic International (B.M.I) Surgery Center, E-Da hospital, Taiwan 
International Minimally Invasive Surgery Training Center of E-Da hospital, Taiwan 
Republic of China 
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Surgical Procedures to Achieve Weight Loss 




Obesity is one of the leading medical problems facing our society today. At least two thirds 
of the U.S. adult population is considered overweight and approximately one-third of 
American adults are obese, creating an epidemic of obesity. Clearly, there has been an 
increase in the number of individuals struggling to lose weight. Additionally, obesity has 
become increasingly prevalent in the pediatric population and 30% of U.S. children have a 
BMI greater than the 85th percentile for their age.1 The relationship of childhood and 
adolescent obesity to adult obesity is a strong one with 20% of children who are obese at 4 
years of age and 80% of adolescents who are obese will be obese as adults.2 The annual cost 
of managing obesity in the United States alone amounts to approximately $100 billion, of 
which $52 billion are direct healthcare costs. Hypertension, sleep apnea, diabetes, stroke, 
myocardial infarction and malignancy is a short but representative list of problems 
associated with obesity. Approximately 300,000 U.S. deaths per year are related to obesity. 
While medical options such as weight loss programs, diets and drug therapies are ever-present 
and increasing, only 3-7% of patients with a diagnosis of obesity are able to achieve effective 
and consistent weight loss. 3 This statistic demonstrates the continued failure of the medical 
management of obesity. On the other hand, patients undergoing bariatric surgery demonstrate 
23% weight loss at 2 years after operative intervention and 16% by 10 years.4 These patients 
had dramatic improvement in quality of life scores and validated measures of psychiatric 
dysfunction compared with only minor and inconsistent improvement in patients undergoing 
medical treatment for their obesity. After 10 years of follow up the improvement in the 
surgical group diminished somewhat due to weight regain. Regardless, outcomes of groups of 
patients undergoing surgical treatment were superior to those treated medically.5,6 Surgical 
options for weight loss have been consistently more successful at helping individuals to lose 
weight and maintain that achievement permanently.7-9   
Weight loss surgery has been evolving since its inception and the final chapter is yet to be 
written.  Since the 1950’s astute minds and dedicated surgeons have tried to find the one 
operation that would yield the definitive answer to the problem of obesity. As time has 
progressed, no silver bullet has been identified.  It is clear that there is no procedure that is 
superior to another for every patient. 
Each operation that will be discussed here has its own story to tell in terms of patient 
selection, operative technique, outcomes and complications. Each has an important role to 
play in the world of weight loss surgery and it behooves those involved in the trenches of 
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2 
bariatric surgery and the subsequent care of these patients to be familiar with the individual 
nuances of the operations. In this chapter, we will discuss the various common, and not so 
common, surgical options currently being employed to assist the morbidly obese patient. 
1.1 Patient selection 
The patient selection criteria consist of a group of objective and variable components. The 
objective component was set by the National Institutes of Health (NIH) in 1991. In order to 
be eligible for bariatric surgery the patient must have a body mass index (BMI) of 40kg/m2 
or a BMI of 35 kg/m2 with associated co-morbidities.  These co-morbidities can include 
medical conditions such as:  
1. Hypertension 
2. Diabetes 
3. Obstructive sleep apnea 
4. Hyperlipidemia 
5. GERD 
6. Degenerative joint disease4  
Other subjective criteria include:  
1. Sustained attempts at weight loss over a period of at least five years 
2. Recognition of the effect of morbid obesity on the patient’s health 
3. Demonstration of a reasonable understanding of the surgical tools available for weight 
loss with the associated risks and benefits 
4. Ability to understand and conform to the postoperative diet and lifestyle changes 
necessary for success 
5. Realistic expectations of the desired surgical procedure.10,11 
1.2 Weight loss 
Weight loss patterns in bariatric surgery are one of the major differences between the 
various surgical tools available.  While most patients are concerned about the absolute 
weight loss in terms of pounds or kilograms, in order for there to be an objective method of 
comparing the differences in weight loss between the different procedures other means of 
measurement have evolved with time.  Weight loss is generally measured according to the 
patient’s BMI or a change in the percentage of excess weight lost (%EWL).12,13 
1.3 Complications 
Intimate knowledge of the exact operation is necessary for any clinician to be able to assess 
and manage post bariatric surgical patients.  Some postoperative complications such as 
infection, pneumonia, urinary tract infections, deep venous thrombosis and pulmonary 
embolism may be standard concerns after intra-abdominal surgery but other issues such as 
erosions or slippage of a gastric band, internal hernias, bleeding and anastomotic leakage 
require a physician to be knowledgeable about the intricacies and variations of weight loss 
operations, as many complications may be overlooked or missed by the unsuspecting 
observer. Complications specific to each operation will be discussed with the review of each 
operation. 
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2. Laparoscopic vs. Open Approach 
All bariatric operations have been performed using the open approach. With increases in 
knowledge, technology, skill and ingenuity, all of these procedures are now possible via a 
laparoscopic approach. Over time, laparoscopic surgery has gained wide acceptance and is 
now more common in primary procedures in bariatric surgery than the open approach.14-16 
Regardless of the method used to perform any particular weight loss procedure the surgical 
endpoints are the same. All primary bariatric procedures can generally be performed 
laparoscopically with clinical results comparable to those of an open counterpart. The major 
reported benefits of the laparoscopic approach include: superior exposure, reduced soft 
tissue trauma, better postoperative pulmonary function, less postoperative pain, decreased 
rates of wound infection, decreased rates of abdominal wall hernias, earlier return to 
physical activities, decreased length of stay, earlier return to work and better cosmetic 
results. The laparoscopic approach can also serve as a useful diagnostic tool in bariatric 
patients when imaging studies may be impossible to perform, or when signs and symptoms 
of an ongoing surgical problem may be vague due to the patient’s body habitus. 
Disadvantages of the laparoscopic approach primarily include higher operative costs, longer 
operative times, need for specialized training and steep learning curves.  
3. Types of Surgery 
In general, the bariatric surgical procedures are classified by their mechanism of action.  
They are subdivided in three types: 
1. Restrictive operations are based on decreasing the size of the stomach, limiting portion 
size, and increasing early satiety. 17,18 
 Vertical Banded Gastroplasty (VBG) 
 Sleeve Gastrectomy (SG) 
 Adjustable Gastric Banding (AGB) 
2.  Malabsorptive operations rely on the surgical rearrangement of the gastrointestinal 
system to decrease the absorption by limiting the exposure of the small bowel to the 
ingested meal. 17,18 
 Jejuno-ileal bypass (JIB) 
3. Mixed operations are a combination of the restrictive and malabsorptive procedures.17,18 
 Roux-en-Y Gastric Bypass (RYGB) 
 Biliopancreatic Bypass with Duodenal Switch (BPD-DS) 
 Laparoscopic Sleeve Gastrectomy with Duodenojejunal Bypass (LSG-DB) 
 Ileal Interposition with Sleeve Gastrectomy (IL-SG) 
4. Vertical Banded Gastroplasty 
The Vertical Banded Gastroplasty (VGB) is like many other bariatric operations which 
experienced changes from its initial inception until the accepted version that was performed. 
The procedure, which was first performed in 1971 by Mason, underwent an evolution.  The 
initial operation included a transverse gastroplasty which served to partition the stomach.  
The final variation involved the creation of a vertical gastroplasty along the lesser curvature.  
Operatively, a window is made through the anterior and posterior gastric wall using a 
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circular stapler positioned close to the lesser curvature.  A linear non-cutting stapler is then 
applied through the gastric window, created by the circular stapler, in a vertical fashion 
directed towards the angle of His. A ring of polypropylene mesh is then placed through the 
gastric window around the lesser curvature (see Figure 1).  This procedure has since been 
adapted to the laparoscopic approach in which the stomach is generally transected 
vertically.17,18,19,20  This anatomic change results in early satiety with reduced meal portions. 
 
Fig. 1. Vertical Banded Gastroplasty 
4.1 Weight loss 
This procedure generally was able to effect a 50-60% EWL within two years. The VBG 
appears to be more dependent on the patient's ability to maintain lifelong alterations of his 
or her eating habits. These changes include avoiding high-calorie liquids and such calorie-
rich foods as cake, cookies, and other junk foods that undergo substantial liquefaction in the 
mouth and thus arrive in the VBG pouch as a liquid slurry that is not restricted by the 
outlet. This dependence on patient behavior led to a higher failure rate due to weight regain 
which in turn has led many to abandon the VBG in preference to other simpler restrictive 
procedures.20-22 
4.2 Complications 
The majority of problems with the VBG generally surrounded stomal issues.  The stoma could 
be too loose which would lead to little restriction and ultimately poor weight loss.  Conversely, 
the stoma could develop a stricture which could then lead to difficulty with oral intake.  
Staple-line dehiscence was also a well known problem. Small dehiscences do not 
substantially impede the restrictive effects of the operation. A dehiscence larger than 1 cm 
would generally lead to both weight regain and gastroesophageal reflux disease. This would 
render the operation ineffective as the restriction would be lost, yield inadequate long-term 
weight loss and require revision of the initial operation. Sporadic staple–line dehiscence was 
also seen in postpartum patients—the reason for this association is unknown.23,24 It is 
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possible to restaple a dehisced staple line; however, reapplying staples to a thickened, 
scarred stomach wall may be associated with not only another dehiscence, but tearing of the 
tissue. The success rate in resuming and maintaining weight loss with reapplication of 
staples is also generally less satisfactory when compared to the degree of weight loss after 
the initial operation. 
Pouch enlargement was another well recognized complication of this procedure leading to 
gastric stasis and reflux. It primarily occurs due to repetitive vomiting, inclusion of an 
excessive amount of fundus during the initial procedure or continued overeating. One 
should be aware of the fact that one of the innate functions of the fundus is to dilate to 
accommodate ingestion of the food bolus. Thus, inclusion of a significant amount of fundus 
may promote pouch dilation. To help to avoid this, the initial vertical staple line should be 
placed precisely at the angle of His. The VBG was quite popular in the 1970’s but is much 
less commonly performed today. 25,26  
5. Sleeve Gastrectomy 
The Sleeve Gastrectomy (SG) was initially used as the first part of a two-stage procedure for 
the super-obese patients who were considered poor surgical candidates and who would not 
tolerate a prolonged or more involved procedure. The operation was designed to allow the 
patients an opportunity to achieve some weight loss before being converted to the more 
complex gastric bypass or biliopancreatic diversion with duodenal switch (BPD-DS).27 Keen 
observation noted that the weight loss with the gastric sleeve alone was significant and, in 
fact, many patients refused further operative intervention to promote continued weight loss. 
Currently, this procedure is used as a definitive weight loss procedure. Despite the 
perceived simplicity and efficacy of gastric sleeve, enthusiasm for this procedure is often 
tempered by the lack of data on long-term outcomes beyond 5 years. It was discovered that 
SG also produces a decrease in ghrelin levels for up to a year, which may reduce the desire 
for food.28,29 
 
Fig. 2. Sleeve Gastrectomy 
The operation involves a vertical gastrectomy performed parallel to the lesser curvature. 
The more receptive greater curvature is resected and the patient is left with a long tube-like 
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possible to restaple a dehisced staple line; however, reapplying staples to a thickened, 
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Fig. 2. Sleeve Gastrectomy 
The operation involves a vertical gastrectomy performed parallel to the lesser curvature. 
The more receptive greater curvature is resected and the patient is left with a long tube-like 
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stomach (see Figure 2). The operation consists of releasing the vascular supply of the greater 
curvature as well as the posterior gastric attachments. A bougie is advanced into the distal 
stomach or duodenum and the greater curvature of the stomach is resected. The transection 
of the stomach is begun approximately 4-5cm proximal to the pylorus. With the bougie in 
place to size the stomach along the lesser curvature, a vertical gastrectomy is created using a 
linear cutting stapler.27 Different sized bougies have been used to date, somewhat limiting 
the comparison of available results. Standardization is still awaited for this procedure that is 
certainly a valuable addition to the surgical armamentarium. 
5.1 Weight loss 
While no long term weight loss statistics are available, medium-term results are indeed 
encouraging with an expected 62% EWL at 12 months and 68% EWL at 24 months.27,30  
Review of current literature also demonstrates that at 6 years, the %EWL is approximately 
57.3-72.3%.24,31 
5.2 Complications 
Along with the standard postoperative concerns, the most common complications with the 
SG have surrounded staple line disruption, leakage from the long staple line and bleeding.  
The majority of leaks occur in the area of gastroesophageal junction.32,33 It most likely occurs 
because this area has diminished blood supply compared to the rest of the stomach. Also the 
stomach wall in this area is thinner and hence less resistant to ischemia and thermal injuries 
by energy devices. 32,33 Another common site for a leak is along the antral staple line. 
Disruption of the staple line in this location is believed to occur due to the relative 
obstruction caused by the nearby pylorus. 
Stenosis and dilatation of this narrow tubular stomach has also been reported. 
The gastroesophageal junction and the angularis incisura are the two most common areas 
where stenosis occurs, and this can be diagnosed by an upper gastrointestinal series. The 
most common reasons for the development of narrowing or stenosis are over-sewing the 
staple line, using a bougie that is too small, creating non-parallel staple lines or using non-
absorbable suture material. 
Even though we mentioned that variable bougie sizes are being used by different surgeons, 
a 32 to 40 French bougie is most often utilized when SG is performed as a definitive 
operation. Larger bougie sizes, up to 60 French, can be used when SG is being performed as 
a part of a staged procedure such as BPD-DS.32 Management of stenosis primarily consists of 
endoscopic dilation vs. stent placement. If the area of stenosis is too long, surgical 
intervention may be necessary with conversion to a gastric stricturoplasty, RYGB or 
resection with gastrogastrostomy.  Management of gastric sleeve stretching is currently 
controversial. There are multiple reports of successful repeat sleeve gastrectomy as well as 
conversion of SG to RYGB or BPD-DS. 
6. Adjustable Gastric Banding 
In 1983, while looking for a safe surgical method to fight obesity, Dr. Lubomyr Kuzmak 
introduced a Dacron-reinforced silicon band. This original system had no ability to adjust 
the gastric restriction and was considered a permanent implant. The Adjustable Gastric 
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Banding System was introduced in 1985 by Dr. Dag Hallberg of Sweden. Laparoscopic 
adjustable gastric banding (LAGB) was advocated in 1992 by Favretti and Cadiere and made 
a revolutionary change in the history of bariatric surgery. Over time and with technological 
improvements, the first laparoscopic adjustable gastric band device was approved by the 
FDA for use in the United States in 2001. 
 
Fig. 3. Adjustable Gastric Banding 
Adjustable Gastric Banding (AGB) procedures have now virtually replaced the VBG 
throughout the world.  A number of bands are available on the market, but only two devices 
are currently FDA approved and available in the United States.  
Gastric banding procedures rely on the restriction of enteral intake to achieve weight loss 
and its maintenance. There is no alteration of the native anatomy and as such the 
neurohormonal mechanisms involved in weight control are largely left intact.34,35   
Over a period of time many modifications to the gastric band were created by different 
manufacturers.  
The AGB is commonly placed laparoscopically, generally with a short operative time and 
limited morbidity.  Hospital stay is often one day and, recently, is more commonly being 
performed as an outpatient procedure. Operatively, the goal is to place the band in a 
position at the gastric cardia near the gastroesophageal junction that will yield a small 
gastric pouch with a 20-30 mL capacity. The small pouch provides the restriction needed to 
assist in weight loss. The optimal technique has changed with time and is now agreed upon 
to be the pars flaccida technique. The band encircles the upper stomach, and its ultimate 
position is determined by using a calibration tube as a guide intraoperatively. It is then 
sutured in place with the use of anterior gastro-gastric sutures for stability, while posteriorly 
the band is held in place by natural attachments between the posterior stomach and the 
right diaphragmatic crus.34,35  
The band system consists of three components (see Figure 3):   
1. The band which is placed at the gastric cardia near the gastroesophageal junction and 
effectively divides the stomach into two segments; an upper smaller pouch and the 
larger intact stomach.   
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2. The port which is the access point for adjustments. The port is placed on the abdominal 
wall, directly attached to the rectus abdominis fascia. An adjustment consists of using a 
Huber needle to access the subcutaneous port at which point normal saline can be 
injected or aspirated from the band. The injection or aspiration of fluid changes the 
tightness of the band around the stomach and can therefore assist with the management 
of food consumption, appropriate early satiety and subsequent weight loss. 
3. The silastic tubing which connects the band to the port.   
The major advantages of the gastric band include the minimally invasive nature of the 
operation, its reversibility, the adjustability of the band and the maintenance of 
gastrointestinal anatomy. 
6.1 Weight loss 
The weight loss patterns for the two available AGBs are comparable.  The expectations for 
weight loss are for the patient to obtain a 30-35% EWL in the first year, 50% EWL at the 
second year and 60% EWL in the third year.  Ultimately the goal is to achieve a gradual, 
effective and durable means to lose weight. These results have been quite variable in the 
literature and ultimately are still being debated.34-37 
6.2 Complications 
Perioperative complications occur in 1-2% of cases and this safety profile associated with the 
AGBs make them an attractive choice for many patients and surgeons when compared to 
the other surgical options available for weight loss. One band-related complication includes 
stoma obstruction. This occurs most commonly due to inclusion of excess perigastric fat, use 
of a band of insufficient diameter for the thickness of the tissue, significant tissue edema, 
band infection, delayed gastric emptying or gastric perforation. The majority of these 
require surgical management, including band removal or repositioning. 
Late band related complications include erosions, slippage or gastric prolapse, port or 
tubing malfunction, port migration, leakage at the port site, tubing or band, pouch or 
esophageal dilatation and esophagitis.35 Slippage is diagnosed when a portion of the 
stomach below the band has traversed the band and now lies above it. This movement 
initially creates a large upper gastric pouch which diminishes the restrictive function of the 
adjustable band.  As more of the inferior stomach passes cephalad, it ultimately leads to 
obstruction of the stoma which will present with persistent nausea and vomiting and 
inability to tolerate even saliva.  This is a scenario which must be diagnosed early as it can 
lead to gastric necrosis if not identified and treated in a timely fashion. Erosion is an 
infrequent but serious complication of gastric banding. It often presents with evidence of a 
port site infection, but there have been reports of gastric outlet obstruction from an 
intraluminal band. A high index of suspicion is crucial to avoid a delay in diagnosis. The 
diagnosis of an erosion mandates the removal of the gastric band. This can be done 
operatively or endoscopically in select cases. 
7. Jejunoileal Bypass (JIB) 
The jejunoileal bypass (JIB) was first introduced in the 1950s at the University of Minnesota.  
It was the first most commonly used procedure for the treatment of severe obesity. The 
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operation consisted of creating a jejunoileostomy and shortening the effective length of the 
small intestine. Observing patients suffering from short gut syndrome spawned the idea of 
using jejunoileal bypass in order to lose weight. A short length of proximal jejunum (8 to 14 
inches from the ligament of Treitz) was connected to the distal ileum (4 to 12 inches 
proximal to the ileocecal valve) as an end-to-end or end-to-side anastomosis (see Figure 4). 
Patients with the end-to-end anastomosis, which could achieve a higher degree of weight 
loss, also required decompression of the bypassed small intestine into the colon via an 
ileocecostomy. The diminished length of the functional small bowel exposed to food boluses 
as well as the diminished surface area for absorption was the key to the JIB.  It was indeed 
successful in its objective of weight loss but it later became apparent that the dramatic 
weight loss was not the only outcome.  
 
Fig. 4. Jejunoileal Bypass 
Approximately 25,000 patients underwent JIB in the United States when it was realized that 
complications of this procedure were, ultimately, common and would present with 
significant morbidity and mortality. Complications such as severe diarrhea, electrolyte 
imbalance, kidney stones, kidney failure, gastro-intestinal tract bacterial overgrowth and 
liver failure were unexpected problems which ultimately led to the abandonment of this 
procedure and the reversal of JIB in many patients. Variations of this small bowel bypass 
were used in the 1960’s, but over time these were abandoned as well given inadequate 
weight loss or unacceptable complication rates. As a result, the JIB is only discussed today 
for its historical significance. Armed with the knowledge that surgical manipulation of the 
gastrointestinal (GI) tract could lead to significant and reproducible weight loss, many 
surgeons embarked on this journey in pursuit of the perfect operation which could 
produced the desired weight loss with an acceptable complication profile.17,18,38 
8. Gastric Bypass 
The Gastric Bypass (GB) has emerged as the most common operation performed for weight 
loss in the United States. In fact, it is often referred to as the “gold standard” of bariatric 
 
Advanced Bariatric and Metabolic Surgery 
 
8 
2. The port which is the access point for adjustments. The port is placed on the abdominal 
wall, directly attached to the rectus abdominis fascia. An adjustment consists of using a 
Huber needle to access the subcutaneous port at which point normal saline can be 
injected or aspirated from the band. The injection or aspiration of fluid changes the 
tightness of the band around the stomach and can therefore assist with the management 
of food consumption, appropriate early satiety and subsequent weight loss. 
3. The silastic tubing which connects the band to the port.   
The major advantages of the gastric band include the minimally invasive nature of the 
operation, its reversibility, the adjustability of the band and the maintenance of 
gastrointestinal anatomy. 
6.1 Weight loss 
The weight loss patterns for the two available AGBs are comparable.  The expectations for 
weight loss are for the patient to obtain a 30-35% EWL in the first year, 50% EWL at the 
second year and 60% EWL in the third year.  Ultimately the goal is to achieve a gradual, 
effective and durable means to lose weight. These results have been quite variable in the 
literature and ultimately are still being debated.34-37 
6.2 Complications 
Perioperative complications occur in 1-2% of cases and this safety profile associated with the 
AGBs make them an attractive choice for many patients and surgeons when compared to 
the other surgical options available for weight loss. One band-related complication includes 
stoma obstruction. This occurs most commonly due to inclusion of excess perigastric fat, use 
of a band of insufficient diameter for the thickness of the tissue, significant tissue edema, 
band infection, delayed gastric emptying or gastric perforation. The majority of these 
require surgical management, including band removal or repositioning. 
Late band related complications include erosions, slippage or gastric prolapse, port or 
tubing malfunction, port migration, leakage at the port site, tubing or band, pouch or 
esophageal dilatation and esophagitis.35 Slippage is diagnosed when a portion of the 
stomach below the band has traversed the band and now lies above it. This movement 
initially creates a large upper gastric pouch which diminishes the restrictive function of the 
adjustable band.  As more of the inferior stomach passes cephalad, it ultimately leads to 
obstruction of the stoma which will present with persistent nausea and vomiting and 
inability to tolerate even saliva.  This is a scenario which must be diagnosed early as it can 
lead to gastric necrosis if not identified and treated in a timely fashion. Erosion is an 
infrequent but serious complication of gastric banding. It often presents with evidence of a 
port site infection, but there have been reports of gastric outlet obstruction from an 
intraluminal band. A high index of suspicion is crucial to avoid a delay in diagnosis. The 
diagnosis of an erosion mandates the removal of the gastric band. This can be done 
operatively or endoscopically in select cases. 
7. Jejunoileal Bypass (JIB) 
The jejunoileal bypass (JIB) was first introduced in the 1950s at the University of Minnesota.  
It was the first most commonly used procedure for the treatment of severe obesity. The 
 
Surgical Procedures to Achieve Weight Loss 
 
9 
operation consisted of creating a jejunoileostomy and shortening the effective length of the 
small intestine. Observing patients suffering from short gut syndrome spawned the idea of 
using jejunoileal bypass in order to lose weight. A short length of proximal jejunum (8 to 14 
inches from the ligament of Treitz) was connected to the distal ileum (4 to 12 inches 
proximal to the ileocecal valve) as an end-to-end or end-to-side anastomosis (see Figure 4). 
Patients with the end-to-end anastomosis, which could achieve a higher degree of weight 
loss, also required decompression of the bypassed small intestine into the colon via an 
ileocecostomy. The diminished length of the functional small bowel exposed to food boluses 
as well as the diminished surface area for absorption was the key to the JIB.  It was indeed 
successful in its objective of weight loss but it later became apparent that the dramatic 
weight loss was not the only outcome.  
 
Fig. 4. Jejunoileal Bypass 
Approximately 25,000 patients underwent JIB in the United States when it was realized that 
complications of this procedure were, ultimately, common and would present with 
significant morbidity and mortality. Complications such as severe diarrhea, electrolyte 
imbalance, kidney stones, kidney failure, gastro-intestinal tract bacterial overgrowth and 
liver failure were unexpected problems which ultimately led to the abandonment of this 
procedure and the reversal of JIB in many patients. Variations of this small bowel bypass 
were used in the 1960’s, but over time these were abandoned as well given inadequate 
weight loss or unacceptable complication rates. As a result, the JIB is only discussed today 
for its historical significance. Armed with the knowledge that surgical manipulation of the 
gastrointestinal (GI) tract could lead to significant and reproducible weight loss, many 
surgeons embarked on this journey in pursuit of the perfect operation which could 
produced the desired weight loss with an acceptable complication profile.17,18,38 
8. Gastric Bypass 
The Gastric Bypass (GB) has emerged as the most common operation performed for weight 
loss in the United States. In fact, it is often referred to as the “gold standard” of bariatric 
 
Advanced Bariatric and Metabolic Surgery 
 
10
surgery. Its long history of good weight loss with low complication rates have led to this 
status. The original GB was performed by Mason and Ito in 1967, after they recognized that 
patients undergoing partial gastrectomy for indications other than weight loss, like peptic 
ulcer disease, had difficulty gaining weight in the postoperative period.39 The original 
version of gastric bypass consisted of a 150-mL gastric pouch and a loop gastrojejunostomy. 
It has subsequently undergone a number of modifications until it was recognized that a 
smaller gastric pouch of 20 – 30 mL in conjunction with a Roux-en-Y reconstruction is the 
most effective combination to achieve maximum weight loss with the lowest rates of 
amount of complications. The laparoscopic Roux-en-Y gastric bypass (LRYGB) was 
introduced in 1994 by Wittgrove and Clark. 
 
Fig. 5. Gastric Bypass 
The operation uses two methods to achieve weight loss. First, the restrictive component of 
the procedure is created by dividing the stomach to create a smaller gastric pouch. The 
larger remnant is left in situ.  Second, the malabsorptive component is created when the 
remnant stomach, duodenum, and a short segment of the proximal jejunum is bypassed. 
Initially the jejunum is divided 30-50 cm distal to the ligament of Treitz. The length of the 
Roux limb, which consists of the distal transected jejunum, is selected based on the patient’s 
BMI. A 75-100 cm long Roux limb is chosen for a BMI < 50 kg/m2 and a 150 cm long Roux 
limb is used for a BMI ≥ 50 kg/m2. A jejunojejunostomy between the Roux limb and 
biliopancreatic limb is created in a side-to-side fashion. The Roux limb is brought up to the 
transected stomach and a gastrojejunostomy is created (see Figure 5). 
Several techniques for the creation of the gastrojejunostomy exist. It can be hand sewn or 
stapled with either a linear stapler or circular stapler. The gastrojejunostomy can be created 
in a retrogastric or antegastric fashion, while the Roux limb can be passed in an antecolic or 
retrocolic fashion. The decision for which approach is used ultimately depends on a few 
factors, but is largely surgeon preference.17,40,41 There are advantages and disadvantages to 
each approach and the surgeon should be familiar with these so as to be able to address 
post-operative complications.  
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8.1 Weight loss 
The overall expectation of the operation is a 60-70% EWL over the course of 12-18 months. 
During this period of time, close follow-up is essential in order to identify any potential 
problems which the patient may experience and prevent micronutrient and protein 
deficiencies.40 
8.2 Complications 
Complications associated with LRYGB are often divided into early and late complications. 
The most notable early complications after the gastric bypass operation are: bleeding, 
pulmonary embolism, and anastomotic dehiscence.  Pulmonary embolism and anastomotic 
dehiscence are the two most common reasons for mortality associated with the gastric 
bypass. The mortality rate varies between reports but generally ranges between 0.5 to 1%.  
Bleeding can occur from a number of sites including:  
1. Incision/port sites  
2. Anastomotic sites (gastrojejunostomy is more common) 
3. Gastric pouch or remnant staple line 
4. Divided mesentery   
The bleeding can be either intra-luminal or extra-luminal. Intraluminal bleeding may 
present with signs and symptoms of upper or lower GI bleeding such as hematemesis, 
bright red blood per rectum or melena. Extra-luminal bleeding may only be suspected by 
clinical findings such as hypotension and tachycardia with a falling hematocrit and 
decreased urine output. Abdominal distention and abdominal pain are often not reliable 
physical findings in the morbidly obese patient. 
Leakage, likewise, can occur at a number of sites:  
1. Gastrojejunostomy  
2. Gastric pouch staple line 
3. Gastric remnant staple line 
4. Jejunojejunostomy 
Persistent tachycardia is the hallmark sign for a leak and requires immediate investigation, 
with a low threshold to return to the operating room.  Late complications of the gastric 
bypass include anastomotic stricture (2-16%). The etiology is unclear, however tissue 
ischemia or increased tension on the gastrojejunostomy are the most likely reasons. The rate 
of stenosis is higher when a circular stapler is used for creation of the gastrojejunostomy or 
when the Roux limb is in an ante-colic position. Marginal ulceration (1-5%), another late 
complication of RYGB, can develop due to different reasons including re-exposure of the 
gastrojejunostomy to gastric acid via a gastro-gastric fistula, ischemic changes to the 
anastomosis most often due to nicotine use, the presence of foreign material (sutures and 
staples), chronic NSAID use and H. pylori infection.  
Iron deficiency (6-52%), vitamin B12 deficiency (3-37%), calcium, thiamine and folate 
deficiency are the most common micronutrient deficiencies observed in post-bariatric surgery 
patients. If dietary changes are not maintained, protein malnutrition can result which presents 
as hair loss. This is reversible if adjustments are made to increase protein intake. 
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as hair loss. This is reversible if adjustments are made to increase protein intake. 
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Along with vitamin deficiencies gastric bypass, due to the lack of a pylorus, can result in 
dumping syndrome. Dumping syndrome occurs in early and late forms. Early dumping 
syndrome (10 to 30 minutes after ingestion of a meal) is the more common form and occurs 
in about 25% of patients after gastric surgery. It is characterized by the rapid gastric 
emptying of hyperosmolar contents into the small bowel. Patients can suffer from 
abdominal cramps, nausea, explosive diarrhea, tachycardia, lightheadedness and syncope.  
This is often a self-limited phenomenon and can be treated by dietary modification or 
manipulation. Late dumping syndrome is usually associated with meals that have high 
carbohydrate contents. The symptom onset begins from 1 to 4 hours after ingestion of such 
meals and invariably includes reactive hypoglycemia in addition to some of the vasomotor 
symptoms seen with early dumping syndrome.  
Endoscopic access to the gastric remnant and proximal small bowel becomes challenging 
and poses potential difficulties in the future, specifically when evaluating for remnant 
gastric lesions or attempting endoscopic retrograde cholangiopancreatography.4 
Small bowel obstructions are a standard postoperative risk after any abdominal surgery.  
They can occur in 1-10% of patients and can be specifically related to trocar sites in 
laparoscopic surgery. Internal hernias are a special cause of bowel obstructions and have 
occurred most frequently in the setting of marked weight loss and the creation of inter-
mesenteric defects or by failure to close mesenteric defects at the primary operation. 
Three potential areas of internal herniation are: 
 The mesenteric defect at the jejunojejunostomy  
 The space between the transverse mesocolon and Roux-limb mesentery (Peterson's 
space)  
 The defect in the transverse mesocolon if the Roux-limb is passed in a retrocolic fashion 
Internal hernias can be intermittent and, therefore, difficult to detect radiographically. 
Several studies have shown that the "mesenteric swirl" sign on computed tomography (CT) 
scan is the best indicator of an internal hernia following gastric bypass.42 Although often 
debated, closure of all potential sites for internal hernias is highly recommended at the 
original operation. Long-term follow-up is essential with these patients as complications, 
such as internal hernias and nutritional deficiencies, can occur at any time.  Intimate 
knowledge of the new anatomy is essential in order to optimally diagnose and treat these 
potential complications.43 
9. Biliopancreatic Diversion with Duodenal Switch 
The Biliopancreatic Diversion (BPD) was described and championed by Dr. Nicola 
Scopinaro of Italy in 1979. To date it still remains the most effective surgical intervention 
for morbid obesity. It is particularly suited for patients who fall in the super-obese 
category with a BMI greater than 50kg/m2. The main limitation has been that which is 
common to intense malabsorptive procedures: potential significant long-term nutritional 
deficiencies.  
The BPD involves a horizontal gastrectomy that leaves a gastric pouch of about 250 mL that 
is anastomosed to a 200- to 250-cm Roux limb. The long biliopancreatic limb is anastomosed 
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to this Roux limb at 50 cm from the ileocecal valve to create the common channel (see Figure 
6). This results in malabsorptive anatomy with modest restriction and without many of the 
side effects of the JIB. In 1993 Marceau described modifications to the BPD which have come 
to be known as the biliopancreatic diversion with duodenal switch (BPD-DS).10,44-46   In this 
modification the horizontal gastrectomy was substituted by SG, which allowed for 
preservation of the pylorus and a decreased incidence of dumping syndrome.  
 
Fig. 6. Biliopancreatic Diversion with Duodenal Switch 
Even with the combined restrictive and malabsorptive properties of the gastric bypass, 
many super-obese patients fail to obtain the desired weight loss. The BPD-DS takes the 
surgical intensity to another level. It combines a moderate food restriction in the form of a 
vertical sleeve gastrectomy with the malabsorption of a long intestinal bypass. The sleeve 
gastrectomy capacity is approximately 100-150 mL. After completion of the sleeve 
gastrectomy, the pylorus is preserved and the duodenum is transected.  The small bowel is 
then measured and marked 100 cm proximal from the ileocecal valve.  This ultimately 
serves as the site for the anastomosis of a 100 cm common channel.  An additional 150 cm of 
small bowel is measured from the future common channel towards the stomach.  The small 
bowel is then transected at this site.  The proximal site of transection is brought up and a 
duodenoilieal anastomosis is created. The distal small bowel transection site is brought to 
the 100 cm site and an ileoileal anastomosis performed.  Ultimately the alimentary channel 
is 150 cm and the common channel is 100cm.  The remaining small bowel is bypassed.10,17  
Modifications to these measurements are common in clinical practice. The first laparoscopic 
duodenal switch was performed by Gagner in 2000. 
9.1 Weight loss  
At 24 months postoperatively the patients can achieve up to 80% EWL with the BPD-DS, 
and an average of 76% at 10 years.  Weight loss certainly exceeds that of the other bariatric 
procedures but it comes with a greater risk of nutritional complications.     
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Dedicated, long term follow up with nutritional counseling is essential. Patients are 
educated on the importance of a protein rich, low-carbohydrate diet and the necessity of 
life-time daily vitamin supplementation which includes iron, calcium, vitamin B12, folate, 
and a multivitamin. Separate fat soluble vitamin supplementation is also necessary.44-46 
As with the gastric bypass, other significant complications include bleeding and leaks.  
Leaks can occur at a number of locations including the gastrectomy site, the anastomosis of 
the ileum to the duodenum or at the distal Roux-en-Y.  These complications require the 
attention of the knowledgeable and astute physician for diagnosis and management. 
Internal hernias can also occur if mesenteric defects are not closed or if they reopen after 
significant weight loss.47 
10. Laparoscopic Sleeve Gastrectomy with Duodenojejunal Bypass 
Laparoscopic Sleeve Gastrectomy with Duodenojejunal Bypass (LSG-DJB) was introduced 
as a valuable bariatric procedure. The advantage of not having an excluded stomach after 
SG eliminates the need for technically complicated double-balloon enteroscopy used for 
surveillance of the excluded stomach after a RYGB. This advantage and the potential 
significant durable weight loss has made LSG-DJB a very popular surgical intervention in 
Asia, where the incidence of gastric cancer has been high and obesity is now on the rise.48  
The sleeve gastrectomy is performed, then the first portion of the duodenum is mobilized 
and subsequently divided with a linear cutting stapler. The biliopancreatic limb is measured 
to a distance of 150-200 cm and, at this location the small intestine is divided with a linear 
cutting stapler. A jejunojejunostomy is created, after which the mesenteric defect is closed. A 
gastrojejunostomy is created in an end-to-side fashion with the distal limb to restore 
intestinal continuity (see Figure 7). This procedure combines both restrictive and 
malabsorptive components to achieve weight loss. 
 
Fig. 7. Laparoscopic Sleeve  Gastrectomy with Duodenojejunal Bypass 
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10.1 Weight loss & complications 
Short term EWL after LSG-DJB is comparable to EWL after LRYGB.49 However, long-term 
data is lacking as this procedure is relatively new. Complications specific for LSG-DJB 
include bleeding, leak, stenosis at any of the anastomotic sites, marginal ulceration, 
duodenal stump blowout and dumping syndrome.48 
11. Ileal Interposition with Sleeve Gastrectomy 
Ileal Interposition with Sleeve Gastrectomy (II-SG) is another operation that has been 
performed outside of the United States. It was one of many bariatric operations to treat 
morbid obesity, but also is used in non-obese patients with BMI 21-29 kg/m2 to treat poorly 
controlled diabetes. In this case, II-SG is also called the neuroendocrine brake.50 The sleeve 
gastrectomy is performed and then the jejunum is divided with a linear stapler 50 cm distal 
to the ligament of Treitz. The distal ileum is divided 30 cm proximal to the ileocecal valve. 
Subsequently, the ileum is divided a further 170-200 cm proximally. This segment of ileum 
is interposed with the proximal jejunum and anastomosed in an isoperistaltic fashion. Then 
three enteroanastomoses are performed to complete the operation: ileoileostomy, 
jejunoileostomy, ileojejunostomy (see Figure 8).    
 
Fig. 8. Ileal Interposition with Sleeve Gastrectomy 
11.1 Weight loss & complications 
After 5-year follow up, the EWL associated with II-SG is 60%. It is still unclear what 
percentage of the total weight loss that each part of the operation is responsible for and this 
requires further investigation. The rate of diabetes remission is reported at 84%.51 The 
potential complications of II-SG combine complications of small bowel bypass and SG. The 
incidence of complications after II-SG is approximately 0.8-2.0% and they include gastric 
and anastomotic leak, intestinal obstruction, internal hernia, gastric sleeve stricture, GI bleed 
and nutritional deficiencies.52 
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Weight loss surgery has been in evolution since the very beginning with the introduction of 
the JIB. The GB was introduced in the 1960’s. Various gastroplasties were in common 
practice in the 1970s. We returned to the GB in the 1980’s given the failure of the 
gastroplasties.  The Scopinaro procedure (BPD) was introduced in the 1979. Modifications of 
the BPD were introduced in the 1980’s.  The 1990’s brought us the AGBs. The SG became a 
distinct entity unto itself in the early 21st century and is the newest contender on the field.  
Finally, we have briefly described two other operations that are not widely used in the U.S. 
but may become much more common in the future. Not one operation has met all the needs 
of every patient and as such the search continues for the ultimate operation which will be 
performed using minimally invasive techniques and produce outstanding and sustainable 
weight loss with a limited complication profile. 
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1. Introduction 
This chapter is a review of the effects of excessive, formerly known as morbid, obesity on 
circulating levels and gene expression of adipokines and related factors in the visceral omental 
adipose tissue of women undergoing bariatric surgery. The current paradigm is that most of 
the deleterious metabolic effects of excessive obesity are due to Type 2 diabetes and/or 
hypertension secondary to the mild inflammatory process resulting from visceral adiposity. 
The visceral adipose tissue, which is primarily omental fat, acts as an endocrine tumor 
secreting adipokines that result in hypertension and diabetes. These deleterious effects are 
reversible after bariatric surgery due to a massive reduction in adipose tissue mass. 
The circulating levels and gene expression in fat of many adipokines are affected by 
excessive obesity. However, a major problem is determining which adipokine alterations are 
causally related and which are secondary effects of the inflammatory state seen in obesity. 
Many reports have focused on only one adipokine and suggested that it has a causal 
relationship but at least 40 adipokines have been linked to excessive obesity by one or more 
investigators. The relative role of each of these adipokines in human obesity is discussed in 
this review. It should be noted that the term adipokine refers to any factor, including 
cytokines, whose circulating levels are affected by release from either the fat or nonfat cells 
of human adipose tissue.  
2. The deleterious effects of human obesity are secondary to enhanced 
accumulation of visceral adipose tissue 
The visceral omental fat of women is important because 
i. it plays a key role in the pathogenesis of the deleterious metabolic consequences of 
obesity and  
ii.  women comprise 80 to 90% of bariatric surgery patients and  
iii.  most intra-abdominal fat is omental fat. The omentum also has a central role in an 
inflammatory response that involves macrophages in defending against peritonitis 
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(Platell et al., 2000). In obesity per se, this macrophage infiltration into the omentum 
may result in an enhanced inflammatory response that promotes insulin resistance and 
ultimately diabetes/hypertension and it has been reported that omentectomy in 
connection with open bariatric surgery resulted in an enhanced insulin sensitivity as 
compared to patients undergoing open bariatric surgery without omentectomy (Thorne 
et al., 2002).  
Extreme obesity results in increased risk for hypertension and/or diabetes (Cottam et al., 
2004, Pories, 2008, Sugerman et al., 2003). The type 2 diabetes is reversible since, after weight 
loss of approximately 40 kg or more due to bariatric surgery, the diabetes disappears in over 
80% of humans (Pories, 2008; Sugerman et al., 2003). Not all extremely obese individuals 
develop diabetes or hypertension and for these individuals there is no increased risk of 
morbidity (Livingston & Ko, 2005). However, there is increasing evidence that the 
accumulation of visceral omental fat is associated with the development of 
diabetes/hypertension (Despres & Lemieux, 2006). It is recognized that waist circumference 
is an effective and inexpensive measure of visceral fat accumulation (Scherzer et al., 2008; 
Shen et al., 2006) and is a better predictor of coronary heart disease than is BMI (Canoy et al., 
2007; Despres et al., 2008; Pischon et al, 2008). Waist circumference correlates with visceral 
fat accumulation as measured by MRI (Scherzer et al., 2008), DEXA (Shen et al., 2006) or fat 
mass as measured by bioelectrical impedance (Madan et al., 2006).  
3. Most release of adipokines is by the nonfat cells in human adipose tissue 
except for leptin 
Originally it was postulated that most of the adipokine release by adipose tissue was due to 
the fat cells but it is now clear that leptin is the only adipokine released exclusively by the 
fat cells. In fact, over a 48h incubation, the release of leptin was 1800% of that by the nonfat 
cells derived from the same amount of human adipose tissue, while that of adiponectin, 
amyloid proteins 1&2, haptoglobin and NGF was only 64, 144, 75 and 72% respectively of 
that by nonfat cells (Fain, 2006). Release of MIF and PAI-1 by fat cells was 37 and 23% of that 
by nonfat cells while that of cathepsin S, HGF, IL-1, IL-1Ra, IL-6, IL-8, IL-10 MCP-1, TGF-
1, VCAM-1 and VEGF was 12% or less of that by nonfat cells (Fain, 2006). Clearly, the 
majority of the inflammatory adipokines are released by the nonfat cells of human adipose 
tissue, which is hardly surprising since per g of fat in obese women two-thirds of the cells 
are nonfat cells (Fain, et al., 2006) and it is established that obesity is accompanied by 
macrophage infiltration into human adipose tissue (Weisberg et al., 2003; Xu et al., 2003).  
4. Relationship between circulating levels of adipokines and obesity 
There is evidence that the circulating levels of many adipokines are elevated in obesity 
(Fain, 2010). Since the deleterious effects of obesity on diabetes is reversed in over 80% of the 
patients after bariatric surgery which reduced the BMI from above 45 to 35 or less (Pories, 
2008), it is clear that the appropriate criteria for correlating decreases or increases in 
circulating adipokines is what happens over the range of BMI values from 30 to 70. Another 
way of assessing effects of obesity is to examine which adipokines show decreases in their 
circulating levels after bariatric surgery. An additional problem with regard to circulating 
adipokines is that the circulating levels of some are either at or below the limits of sensitivity 
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for their assay and this is a special problem with regard to TNF and IL-1. These 
adipokines may be very important in the inflammatory response seen in obesity but they 
primarily act as local autocrine or paracrine mediators of inflammation rather than as 
circulating hormones.  
The effects of obesity and coronary artery disease on circulating levels of 16 adipokines are 
summarized in Table 1. The coronary artery disease patients were 16 individuals 
undergoing coronary artery bypass surgery. They had an average BMI of 30.1 and were 
compared with 12 controls undergoing open heart surgery for other reasons. The controls 
had a BMI of 27.3 and were younger than the coronary artery disease patients. The data 
were adjusted for age which eliminated effect of CAD on circulating levels of IL-8 and 
osteoprotegerin leaving only CD14 and adipsin as adipokines affected by coronary artery 
disease (Sacks et al., 2011). In contrast, obesity over the BMI range of 38 to 66 [mean was 50], 
in women undergoing bariatric surgery increased the circulating levels of adipsin, FABP4, 
and secretory phospholipase A2 [PLA2] (Table 1).  
 
Circulating levels are 
elevated in obesity
Circulating levels are 
elevated in CAD
Circulating levels are not elevated by 
excessive obesity or CAD 
 
Adipsin Adipsin CD-163 IL-8 NGF 
FABP4 CD14 sFLT1 Lipocalin-2 RANTES 
IL-1Ra  GPX-3 MCP-1 IL-10 
sPLA2  ZAG Osteoprotegerin  
Table 1. Comparison of effects of obesity versus CAD on circulating levels of 17 adipokines. 
The effects of severe coronary artery disease (CAD) are taken from the report by (Sacks et al., 
2011) while the data for obese women is for the same circulating adipokines with significant 
positive correlation coefficients [Pearson r of  0.51] between waist circumference and 
circulating levels in 12-23 bariatric surgery patients not taking drugs for hypertension with 
BMI values ranging from 38 to 66 and waist circumference from 107 to 168 cm (Fain, 2011). 
Only with IL-1Ra was a significant positive correlation seen between waist circumference 
and circulating levels as well as mRNA expression in omental fat of severely obese female 
bariatric patients (Fain, 2011). There was no significant correlation between waist 
circumference and mRNA level for FABP4, adipsin, & PLA2 in omental fat (Fain, 2011). 
Circulating levels of adipsin, FABP4 & PLA2 correlated with waist circumference but not 
with mRNA levels in omental fat. These data suggest that if mRNA levels in omental fat are 
equivalent to protein expression, then the circulating levels are not regulated solely by 
omental fat mRNA expression. It may well be that the source of these adipokines is other fat 
depots. Alternatively the data could be interpreted as compatible with the hypothesis that 
protein expression is not equivalent to gene expression.  
I have examined the effects of obesity in women on gene expression of almost all the 
putative adipokines discussed in the next section, except for CRP, which is not released by 
human fat (Fain, 2006). I found significant positive correlations between waist circumference 
and mRNA levels in human omental fat for 4 of the 40 proteins: amyloid A [r = 0.57], PAI-1 
[r = 0.53], IL-1Ra [r = 0.45] and leptin [r = 0.48] (Fain, 2011). Of these proteins only amyloid 
A and leptin are preferentially expressed in the fat cells of human omental fat (Fain, 2010).  
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bariatric patients (Fain, 2011). There was no significant correlation between waist 
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with mRNA levels in omental fat. These data suggest that if mRNA levels in omental fat are 
equivalent to protein expression, then the circulating levels are not regulated solely by 
omental fat mRNA expression. It may well be that the source of these adipokines is other fat 
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5. Individual adipokines 
The following sections discuss 40 putative adipokines listed in alphabetical order that have 
been linked to obesity and inflammation. It should be noted that correlations between waist 
circumference or BMI and circulating levels of any protein indicate only that the protein is a 
marker molecule rather than the maker of obesity. In view of the many known circulating 
marker molecules for obesity, caution should be exercised and direct proof demanded 
before any causal relationship is established. Furthermore, most reports are linked to a 
particular molecule and the professional careers of the authors are directly linked to their 
ability to persuade others that the particular marker of interest to them is causally linked to 
obesity.  
5.1 Adiponectin 
Adiponectin is a protein that circulates at relatively high levels in humans and is related to 
the C1q complement factor. Adiponectin, unlike leptin, is not produced solely by fat cells in 
humans (Fain et al., 2008c). Within 10 years of its discovery adiponectin was accepted as an 
anti-diabetic, anti-atherosclerotic and anti-inflammatory agent secreted by adipocytes whose 
low levels in obesity were related to the insulin-resistance in obesity (Trujillo & Scherer, 
2005). While the circulating levels of most adipokines are elevated in obesity, this is not the 
case for adiponectin whose circulating levels negatively correlate with BMI values between 
18 and 30, but in males there was no further drop in circulating adiponectin at BMI values 
above 32 (Arita et al., 1999). Negative effects of obesity on circulating adiponectin have been 
reported comparing individuals with mean BMI values of 27 versus 35 by Engeli et al., 
(2003) and by Hoffstedt et al., (2004) comparing humans with BMI values of 24 versus 37. 
One complexity with regard to circulating levels of adiponectin (Hung et al., 2008) and 
leptin (Thomas et al., 2000) is that they are both higher in women than in men but the 
significance of this is not yet understood.  
Elevated concentrations of circulating adiponectin have been associated with a lower 
incidence of type 2 diabetes (Li et al., 2009; Zhu et al., 2010). However, circulating 
adiponectin is actually positively correlated with all cause mortality as well as 
cardiovascular mortality in type 2 diabetics (Forsblom et al., 2011). In another study Luc et 
al., (2010) found no correlation between total circulating adiponectin and cardiovascular 
disease in men enrolled in the PRIME study. Elevated levels of adiponectin have also been 
associated with stroke mortality (Nagasawa et al, 2011). Clearly low adiponectin levels in 
plasma of obese individuals may not necessarily be linked to increased mortality or 
development of type 2 diabetes and are not consistently seen. I conclude that adiponectin is 
not produced solely by fat cells and the function of adiponectin remains to be elucidated as 
well as whether it is causally linked to the development of type 2 diabetes in obesity. It may 
just be a unique marker of obesity whose levels are sometimes, but not always, lower in 
obesity. 
5.2 Adipsin/complement D 
Adipsin is another name for complement factor D that is a novel serine protease whose only 
known substrate is another complement serine protease known as factor B (Volanakis and 
Narayan, 1996). Complement factor D was re-discovered and named adipsin since it was 
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found in murine adipocytes and circulating levels were lower in several animal models of 
obesity (Rosen et al., 1989). However, Napolitano et al., (1994) found that in humans just the 
opposite was seen in that circulating levels of adipsin positively correlated with the extent of 
obesity. I found a similar correlation between circulating adipsin and BMI but there was no 
effect of obesity on the gene expression of adipsin in omental adipose tissue of obese women 
(Fain, 2011). The complement system is an essential element in our innate defense system and 
it is possible that the increase in adipsin/complement D seen in human obesity is a reflection 
of an enhanced inflammatory response to obesity. What accounts for the elevations in 
circulating adipsin/complement D in obesity is unclear, but it is an obesity marker.  
5.3 Amyloid A 
The serum amyloid A proteins are major acute-phase reactants released by the liver whose 
circulating levels increase dramatically in inflammation and obesity (Poitou et al., 2005; 
2006; Yang et al., 2006a). Circulating levels of amyloid A (Yang et al., 2006a) as well as gene 
expression in adipose tissue (Yang et al., 2006a; Fain, 2011) correlated with BMI. In fact of 
over 100 genes whose expression was correlated in omental adipose tissue with BMI, the 
highest positive correlation was seen for amyloid A (Fain 2011). A major expression site of 
Amyloid A is adipose tissue, which is postulated to contribute to circulating levels (Poitou et 
al., 2005; Sjoholm et al., 2005) and Yang et al (2006a) have suggested that amyloid A is both a 
proinflammatory and lipolytic adipokine in humans. Whether this is the case remains to be 
demonstrated but these are intriguing possibilities.  
5.4 Angiotensin converting enzyme (ACE)  
ACE is a zinc metallopeptidase that cleaves the C-terminal dipeptide from angiotensin I to 
form Angiotensin II. The presence of the major components of the renin-angiotensin system 
in human adipose tissue has led to the suggestion that its regulation and function are 
involved in the hypertension linked to visceral adiposity (Giacchetti et al., 2002). The 
circulating levels of ACE are unchanged in obesity as is its gene expression in adipose tissue 
of humans but there is a positive correlation with blood pressure (Gorzelniak et al, 2002). It 
has been difficult to get evidence for a key role of ACE but recently it was reported that ACE 
inhibition using captopril treatment of mice on a high fat diet reduced the extent of obesity 
and the expression of markers of inflammation in murine adipose tissue (Premaratna et al. 
2011). Lee at al (2008a) reported that in obese rats, angiotensin receptor blockade reduced 
insulin resistance by modification of adipose tissue metabolism. Abuissa et al (2005) 
demonstrated that anti-hypertensive agents such as ACE inhibitors or angiotensin receptor 
blockers can reduce the onset of diabetes in humans by approximately 25%. However, there 
is no evidence that circulating levels of ACE are altered in obesity. 
5.5 Angiotensinogen 
This protein is made in large quantities by the liver and secreted into the circulation where it 
can be cleaved by renin and/or cathepsin D to form angiotensin I. Karlsson et al (1998) 
demonstrated that angiotensinogen is also made in adipose tissue and is enriched in 
adipocytes, which was confirmed by Fain et al., (2008a). The reason for this is still not well 
understood but it could be a link between obesity and hypertension. Gorzelniak et al (2002) 
reported that angiotensinogen gene expression in human subcutaneous adipocytes was 
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development of type 2 diabetes and are not consistently seen. I conclude that adiponectin is 
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found in murine adipocytes and circulating levels were lower in several animal models of 
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opposite was seen in that circulating levels of adipsin positively correlated with the extent of 
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it is possible that the increase in adipsin/complement D seen in human obesity is a reflection 
of an enhanced inflammatory response to obesity. What accounts for the elevations in 
circulating adipsin/complement D in obesity is unclear, but it is an obesity marker.  
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and the expression of markers of inflammation in murine adipose tissue (Premaratna et al. 
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demonstrated that anti-hypertensive agents such as ACE inhibitors or angiotensin receptor 
blockers can reduce the onset of diabetes in humans by approximately 25%. However, there 
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negatively correlated with the BMI of the adipocyte donors and this may be an adaptive 
response to reduce angiotensin II formation in obesity. Angiotensinogen gene expression 
has consistently been reported to be lower in subcutaneous than in omental adipose tissue 
of humans (Giacchetti et al., 2002, van Harmelen et al., 2000; Fain, 2010) but the significance 
of this is also unknown. However, this might be linked to the deleterious effects of visceral 
obesity on the development of hypertension and diabetes in obese humans but the role of 
angiotensinogen made in fat is unclear.  
5.6 Apelin 
Apelin is a novel bioactive peptide that is the endogenous ligand of the orphan G protein-
coupled receptor AJP (Masri et al., 2005; Castan-Laurell et al., 2011). The circulating levels of 
apelin and leptin are elevated in obesity but unlike leptin, the gene expression of apelin is 
found to the same extent in both nonfat and fat cells of human adipose tissue (Boucher et al., 
2005; Heinonen et al., 2005). The apelin receptor is expressed on the surface of T 
lymphocytes and endothelial cells (Masri et al., 2005) and the enhanced levels seen in 
obesity may reflect release by nonfat cells of fat. A null mutation of the apelin receptor in 
mice had little effect except for an enhanced vasopressor response to apelin (Ishida et al., 
2004). Hung et al (2011) found that inhibitors of the renin-angiotensin system enhanced the 
secretion of apelin by adipocytes. Fain (2011) found that extremely obese women taking 
anti-hypertensive agents had decreased expression of apelin in their omental adipose tissue 
that was accompanied by an enhanced expression of the renin receptor and CD150/SLAMF-
1. These data suggest a counter regulatory role of apelin signaling to that of the angiotensin 
with regard to blood pressure regulation in humans. 
5.7 Cathepsin S  
Cathepsins are endopeptidase cysteine proteases that are secreted by inflammatory cells. 
Lafarge et al., (2010) suggested that cathepsin S is one of the most dysregulated genes in 
adipose tissue of obese subjects since its expression and circulating levels positively 
correlated with BMI. While in humans there are other cathepsins, it is cathepsin S that is 
more influenced by obesity (Naour et al., Lafarge et al., 2010). It has been suggested that 
cathepsin S is the link between obesity and inflammation in obesity (Taleb and Clement, 
2007) but all the studies to date are correlative. For example Jobs et al., (2010) found a high 
correlation between circulating cathepsin S and c-reactive protein [CRP] but what this 
means is unclear since both are inflammatory response proteins made by the liver. It is 
perhaps better to describe the elevations in cathepsin S seen in obesity as a response to the 
inflammation with no proof yet for any type of causal relationship.  
5.8 CD14 
CD14 is a glycolipid-anchored membrane protein that functions as a receptor for the complex 
of lipopolysaccharide binding protein plus lipopolysaccharide and is also released into the 
circulation. In knockout mice lacking CD14 there is less diet-induced obesity and macrophage 
accumulation in adipose tissue (Cani et al., 2007; Roncon-Albuquerque et al., 2008). CD 14 is a 
co-receptor with toll-like receptor 4 [TLR4] for activation of macrophages by 
lipopolysaccharide and by free fatty acids, which Fessler et al (2009) have postulated to be the 
link between obesity and inflammation. However, there is no evidence that obesity affects the 
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circulating levels of CD 14 (Fain, 2011; Manco et al., 2007) despite the fact that release of CD14 
by explants of human omental adipose tissue was enhanced in fat from obese individuals (Fain 
et al., 2010). I conclude that circulating CD 14 is not an obesity marker. 
5.9 C reactive protein [CRP] 
CRP is a prototypical acute phase protein released by the liver and its circulating levels can 
increase by 10,000-fold within hours of infection or injury. Recently CRP has been proposed as 
a predictive biomarker for cardiovascular disease risk although it has poor predictive value in 
humans (Levinson et al., 2004). Yudkin et al., (1999) originally reported that obesity is 
associated with elevated release of IL-6 by human adipose tissue and enhanced circulating 
levels of IL-6 and CRP. These results have been confirmed by Festa et al., (2001), Hanusch-
Enserer et al., (2003) and Maachi et al., (2004). There is virtually no synthesis of CRP by 
adipose tissue and the small amount of release seen in vitro could be due to release of CRP 
taken up from the circulation (Fain, 2006). CRP levels in humans correlate with those of serum 
amyloid (Larsson and Hansson, 2003) suggesting that both are inflammatory markers released 
by the liver in response to the low-grade inflammation induced by obesity. At least for CRP in 
mice there is direct evidence that it is not involved in the development of atherosclerosis, 
clearly indicating that it is a marker not a maker of atherosclerosis (Nilsson, 2005).  
5.10 Endothelin-1 
Endothelin is a potent vasoconstrictor peptide that is released by endothelial cells. Yudkin 
(2007) pointed out that obese humans show endothelial dysfunction that may be due to 
vascular insulin resistance. Takahashi et al., (1990) had earlier reported that circulating 
levels of endothelin-1 are 3-fold higher in diabetics than in non-diabetic humans. Van 
Harmelen et al., (2008) reported that the release of endothelin-1 by subcutaneous adipose 
tissue in vivo was greater in obese individuals and that endothelin blocked the anti-lipolytic 
action of insulin in omental but not subcutaneous adipocytes. Gogg et al., (2009) 
subsequently reported that in microvascular endothelial cells isolated from subcutaneous 
adipose tissue of type 2 diabetics, insulin action was impaired at the level of IRS-1 and the PI 
3-kinase pathways. They suggested that enhanced endothelin-1 was responsible for this 
impairment. These results suggest that studies should be designed to test the hypothesis 
that impaired insulin action in obesity is secondary to enhanced endothelin-1 release by 
endothelial cells.  
5.11 Fatty acid binding protein 4 [FABP-4] 
FABP4 is a member of a family of lipid chaperone proteins that bind with high affinity 
hydrophobic ligands such as long chain fatty acids (Furuhashi et al., 2008). FABP4 is also 
known as aP2 and appears to be involved in the movement of fatty acid out of the fat cell 
during lipolysis (Coe et al., 1999). In the absence of FABP4 there is enhanced accumulation 
of fatty acids in fat cells (Coe et al., 1999) and reduced expression of inflammatory cytokines 
in macrophages (Furahashi et al, 2008). Hotamisligil et al., (1996) reported that in FABP4-
knockout mice, obesity still developed on a high-fat diet but insulin resistance or diabetes 
was not seen. These data support the hypothesis that the link between obesity and 
inflammation in adipose tissue is enhanced lipolysis and free fatty acid release seen in the 
enlarged fat cells that accumulate in obese animals. In the absence of FABP4 the release of 
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fatty acids by fat cells is impaired which results in reduced lipolysis. In obesity the 
circulating levels of FABP4 show a positive correlation with BMI (Xu et al., 2007; Terra et al., 
2011; Fain, 2011). This suggests that the levels of FABP4 are elevated in obesity ensuring that 
fatty acid release is enhanced and the TLR4 receptors are activated in the monocytes and 
neutrophils surrounding the fat cells. This results in inflammatory adipokine release and 
recruitment of macrophages (Fessler et al., 2009). An alternative hypothesis is that the TLR4 
receptors are less important in transmitting free fatty acid effects and that the role of FABP4 
in macrophages is to move toxic free fatty acids into the macrophages. Furuhashi et al., 
(2007) have pointed out that inhibition of this protein with small molecules might be an 
effective way to prevent the development of diabetes in obesity. However, Lan et al., (2011) 
reported that such a drug ameliorated dyslipidemia but not the insulin resistance due to 
diet-induced obesity in mice.  
5.12 Glutathione peroxidase 3 [GPX-3] 
GPX-3 along with glutathione reductase are enzymes involved in the removal of hydrogen 
peroxide formed in mitochondria and are thus able to reduce the level of reactive oxygen 
species in cells (Haddad and Harb, 2005). Circulating levels of GPX-3 are down in patients 
with coronary atherosclerosis but by only 14% (Dogru-Abbasoglu et al., 1999) and slightly 
lower in obese humans as well (Lee et al, 2008b). However, negative effects of GPX-3 
knockout studies in mice on the development of obesity (Yang et al, 2009) and of obesity in 
women on circulating levels of GPX-3 (Fain, 2011) suggest that the role of this enzyme in 
obesity is unclear. In conclusion, the general consensus is that obesity does not result in 
enhanced circulating levels of GPX-3.  
5.13 Haptoglobin 
Haptoglobin is an acute phase protein primarily synthesized in the liver of humans that 
binds hemoglobin (Quaye, 2008). Obesity is associated with elevated circulating levels of 
haptoglobin (Scriba et al., 1979; Chiellini et al., 2004). In murine in vitro differentiated 
adipocytes a proteomic approach identified haptoglobin as the most abundant protein 
secreted by these cells (Kratchmarova et al., 2002). However, in human adipose tissue 
haptoglobin release in vitro by both the nonfat and the fat cells was 1 to 5% of that for IL-8, 
IL-6 or adiponectin (Fain et al., 2004b). They concluded that adipose tissue release of 
haptoglobin probably contributed very little to circulating levels as did Taes et al., (2005). In 
contrast, Chiellini et al., (2004) concluded that haptoglobin was a novel marker of adiposity 
and that adipose tissue contributes to circulating levels in humans was important. 
Unfortunately haptoglobin does not appear to be a novel or unique marker for adiposity but 
a member of the acute phase response family released by liver whose circulating levels are 
elevated in mild inflammatory states such as those seen in obesity.  
5.14 Interleukin-1 [IL-1] and IL-1 receptor antagonist [IL-1 Ra] 
IL-1 and TNF are generally thought of as prototypical pro-inflammatory cytokines. 
Blockade of both pathways, but neither one alone, inhibited the inflammatory response 
based on IL-8 and IL-6 release by 40 to 50% when explants of human visceral omental 
adipose tissue are incubated for 48 h (Fain et al., 2005a). In interleukin-1 receptor knockout 
mice the insulin resistance and adipose tissue inflammation induced by a high fat diet is 
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abolished suggesting a key role for IL-1 in the inflammatory response due to obesity 
(McGillicuddy et al., 2011). IL-1 is primarily paracrine factor acting locally since circulating 
levels are below the sensitivity of available assays (Jung et al., 2010). However, IL-1 gene 
expression in both adipose tissue and liver decreases 6 months after bariatric surgery 
indicating a reduction in the chronic inflammatory state (Moschen et al., 2011). 
In contrast, the circulating levels of IL-1 Ra are elevated in obesity (Fain, 2011; Juge-Aubry et 
al., 2003: Jung et al., 2010; Meier et al., 2002). Furthermore the gene expression of this 
protein, unlike that of IL-1, in omental adipose tissue of humans correlates with waist 
circumference or BMI of obese women (Fain, 2011). IL-1Ra is a physiological antagonist of 
IL-1 since it competes with the IL-1 receptors for the available IL-1 and is sold as an 
injectable drug [anakinra] for the reduction of immune-mediated inflammatory conditions 
(Goldbach-Mansky, 2009). The elevated circulating levels of IL-1Ra that are seen in obesity 
as well as enhanced formation in adipose tissue in obesity are perhaps the best evidence that 
IL-1 formation is enhanced in obesity. Fain (2011) found that the mRNA expression in 
omental fat of IL-1Ra was the only one showing a positive correlation between waist 
circumference and mRNA levels in massively obese women taking anti-hypertensive drugs. 
In contrast, a positive correlation was seen for p67 phox, PAI-1 and 11 HSD1 mRNA 
expressions only in women not taking anti-hypertensive drugs. What this means is unclear 
but suggests that unexpected interactions exist between obesity and hypertension with 
regard to mRNA expression in omental fat. 
5.15 Interleukin-6 [IL-6] 
IL-6 is a well-established stimulator of acute-phase protein secretion by liver that can 
produce dramatic increases in circulating CRP, amyloid protein and haptoglobin (Heinrich 
et al., 1990). Yudkin et al., (2000) postulated that enhanced formation of IL-6 is important in 
the development of coronary heart disease based on the assumption that IL-6 is the most 
important mediator of an inflammatory response. It is established that obesity results in 
elevations in circulating IL-6 (Khaodhiar et al., 2004; Vozarova et al., 2001). While in adipose 
tissue the IL-6 content positively relates to an enhanced insulin resistance (Bastard et al., 
2002) there is evidence that IL-6 is beneficial for insulin action on muscle (Carey and 
Febbraio, 2004; Kim et al., 2009). Furthermore IL-6 knockout mice develop obesity indicating 
complexities in IL-6 action in rodents (Wallenius, et al., 2002). Whatever its function, the 
circulating levels of IL-6 are clearly elevated in obesity. 
5.16 Interleukin-8 [IL-8] 
IL-8 is the prototypical human chemokine that is involved in the recruitment of circulating 
neutrophils to its site of release (Reape and Groot, 1999). Circulating levels of IL-8 are 
elevated in obesity (Bruun et al., 2003; Straczkowski et al., 2002). Release by adipose tissue 
explants, but not by adipocytes, of women with an average BMI of 42, was elevated as 
compared to those with a BMI of 32 (Fain et al., 2004a). IL-8 release was primarily by the 
nonfat cells of adipose tissue and release by omental was greater than that by subcutaneous 
adipose tissue explants incubated in vitro for 48 h (Bruun et al., 2004). It is possible that IL-8 
is more important than any other adipokine in the inflammatory response to obesity 
especially with regard to recruitment of neutrophils and conversion to macrophages in 
adipose tissue. 
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fatty acids by fat cells is impaired which results in reduced lipolysis. In obesity the 
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(2007) have pointed out that inhibition of this protein with small molecules might be an 
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5.17 Interleukin-10 [IL-10] 
IL-10 is a cytokine commonly thought to have anti-inflammatory properties whose secretion 
by macrophages is coordinated with that of pro-inflammatory cytokines in that 
lipopolysaccharide will increase the release of IL-10 as well as inflammatory cytokines 
(Mocellin et al., 2003). In vitro studies with human adipose tissue indicated that IL-10 
release is predominantly by the nonfat cells such as macrophages and is enhanced in 
adipose tissue from obese women (Fain, 2010). While adipose tissue macrophages are 
predominately of the classic-anti-inflammatory M2 phenotype, based on surface markers 
expression, they secrete higher amounts of pro-inflammatory adipokines such as TNF-, IL-
6, Il-1 and MCP-1 than the M1 macrophages (Zeyda et al., 2007). Esposito et al., (2003) 
reported that circulating levels of IL-10 were elevated in obesity in women and reduced, 
along with those of IL-6 and CRP, in obese women without the metabolic syndrome after a 
significant [11 kg] loss of weight. However, Fain (2011) reported no effect of BMI on 
circulating levels of IL-10 and Manigrasso et al., (2005) reported that after body weight 
reduction of 8 kg in android obese women there was no significant change in circulating 
levels of adiponectin or IL-10 while low adiponectin correlated with low IL-10 levels. 
Apparently, there is no large or reproducible effect of obesity on circulating levels of IL-10 
and whether it is always an anti-inflammatory adipokine is unclear (Mocellin et al., 2003). 
5.18 Leptin 
Leptin was discovered in 1994 through positional cloning of the mouse ob gene (Zhang et al., 
1994) and its absence leads to massive obesity in mice and men as well as delayed sexual 
maturation and immune defects (Dagogo-Jack, 2001; Gautron and Elmquist, 2011). However, 
few cases of human obesity are due to an absence of leptin since the vast majority of obese 
humans have elevated levels of leptin that correlate with BMI (Considine et al., 1996). There 
are sex differences as well since the circulating levels of leptin are higher in women than in 
men at all BMI values (Smirnoff et al., 2001). Furthermore, similar correlations of circulating 
values with BMI were soon reported for acute phase proteins such as amyloid and CRP as well 
as with soluble TNF receptors and PAI (van Dielen et al., 2001). Their report and many others 
have amply demonstrated that elevated body fat content is associated with a pro-
inflammatory state and enhanced circulating levels of leptin. Furthermore, Kshatriya, et al., 
(2011) recently suggested that leptin might have a pathophysiological role in the development 
of hypertension and vascular heart disease in obesity. 
Whether leptin is a pro-inflammatory hormone in obese humans is unclear but unlike all the 
known inflammatory factors it is released only by fat cells. The in vitro release of leptin is 
almost exclusively by fat cells as compared to the nonfat cells derived from human visceral 
omental adipose tissue while release of LPL is about 80%, amyloid about 60 % and 
adiponectin about 40% of total release by fat cells plus nonfat cells (Fain, 2010). To date, 
leptin appears to be the only protein made exclusively by fat cells and its formation 
apparently reflects fat cell size as reviewed by Fain and Bahouth (2000). In incubated fat 
cells or adipose tissue explants the greatest stimulation of leptin release is due to 
glucocorticoids which may be secondary to their anti-inflammatory effect (Fain et al., 2008d) 
and in vivo administration of glucocorticoids elevated circulating levels of leptin (Dagogo-
jack, 2001). However, the link between fat cell size and enhanced leptin release remains to be 
demonstrated but one theoretical possibility is stretch receptors within fat cells.  
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This protein was originally found as a protein secreted by human neutrophils. All 
lipocalins have an eight-stranded continuously hydrogen-bonded antiparallel -barrel 
that can bind and transport a wide variety of small hydrophobic molecules such as fatty 
acids (Zhang et al., 2008). Based on studies in rodents, Yan et al., (2007) and Wang et al., 
(2007) concluded that lipocalin-2 was an inflammatory marker released by adipocytes 
whose release was enhanced by obesity. However, Jun et al., (2011) found no effect of 
global ablation of lipocalin-2 on obesity-mediated insulin resistance in vivo. In obese 
humans no statistically significant effect of BMI was found on circulating levels of 
lipocalin-2 (Stejskal et al., 2008) and this was confirmed by Fain (2011). Furthermore 
lipocalin-2 was found in and released almost exclusively by the nonfat cells rather than 
the fat cells isolated from human omental adipose tissue (Fain, 2010). Total lipocalin-2 
release by explants of incubated human omental adipose tissue in vitro positively 
correlated with BMI of the humans from whom fat was obtained as was the case for 
release of pro-inflammatory adipokines such as IL-8, IL-10, CD14, and RANTES (Fain, 
2010). However, the circulating levels of IL-8, IL-10, CD14, and RANTES did not correlate 
with BMI (Fain, 2011). Lipocalin-2 thus appears to be an inflammatory marker whose 
circulating levels are not invariably elevated in obesity. 
5.20 Lipoprotein lipase [LPL] 
This multi-functional enzyme is the rate-limiting enzyme for the hydrolysis of circulating 
lipids containing triglycerides (Wang and Eckel, 2009). LPL was shown by Rodbell (1964) to 
be preferentially released by fat cells rather than the non-fat cells of rat adipose tissue. 
Similar results are seen in human omental adipose tissue and the total release of LPL by 
adipose tissue correlated with BMI (Fain, 2010). The circulating levels of LPL have been 
reported to be unrelated to BMI (Kobayashi et al, 2007; Magkos et al., 2009). However, the 
elevated subcutaneous adipose tissue expression of LPL was reduced to control values in 
individuals 12 months after bariatric surgery (Pardina et al., 2009). Fain (2010) also found a 
positive correlation between BMI and the release of LPL by explants of human omental fat 
incubated in vitro. The available data indicate that LPL protein expression in adipose tissue, 
but not the circulating levels, correlate positively with obesity.  
5.21 Macrophage migration inhibitory factor [MIF] 
MIF is a pro-inflammatory cytokine that is involved in many inflammatory disorders (Donn 
and Ray, 2004; Kleemann and Bucala, 2010). Both MIF and MCP-1 seem to be especially 
important in macrophage recruitment into adipose tissue. Verschuren et al., (2009) found 
that in MIF knockout mice the development of obesity with age was not affected but the 
development of the inflammatory cascade and insulin resistance were markedly reduced. 
MIF release in vitro by incubated explants of human adipose tissue or adipocytes (Skurk et 
al., 2005) had a positive correlation coefficient of approximately 0.5 with BMI of the fat 
donors. Dandona et al., (2004) reported a similar correlation between circulating levels of 
MIF and BMI. Church et al., (2005) reported that a weight loss of approximately 14 kg over 
8.5 months resulted in a 40% decrease in circulating levels of MIF. MIF appears to be an 
obesity-linked inflammatory factor whose circulating levels are elevated in obesity. 
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5.22 Monocyte chemoattractant protein 1 [MCP-1] 
MCP-1 is also known as chemokine CCL2 and is a mononuclear cell chemoattractant protein 
that is a pro-inflammatory adipokine (Frangogiannis, 2004). Circulating levels of MCP-1 
have been reported to be elevated in obese humans (Malavazos et al., 2005) and to have a 
positive correlation with BMI (Christiansen et al., 2005). However, neither Miller et al., 
(2002) or Fain (2011) found any effect of obesity on circulating levels of MCP-1. Madani et 
al., (2009) reported that MCP-1 and IL-6, but not RANTES, were released in vivo by human 
abdominal subcutaneous adipose tissue to a far greater extent in individuals with a BMI of 
43 as compared to controls with a BMI of 25. Dahlman et al (2005) found that obesity 
increased the mRNA level of MCP-1 in human subcutaneous adipose tissue by 2.6-fold. The 
in vitro release of MCP-1 by adipose tissue explants was also increased by 6 to 10-fold 
without any change in the in vivo release. These data indicate that while obesity enhances 
MCP-1 release by adipose tissue there appears to be little contribution of adipose tissue to its 
circulating levels.  
5.23 Nesfatin-1 
This novel anorexigenic peptide is processed from nucleobindin-2 and released by adipose 
tissue (Ramanjaneya et al., 2010). While they reported a positive correlation of 0.63 between 
circulating levels of nesfatin-1 and BMI, the opposite was reported by Tsuchiya et al., (2010). 
However, Tan et al., (2011) found a positive correlation of 0.83 between the circulating 
nesfatin-1 and BMI, in 38 subjects [20 were women] with BMI values ranging from 16 to 38. 
It is unlikely that nesfatin-1 is derived from nucleobindin-2 gene expression solely in fat 
cells as is the case with leptin. I [unpublished studies] have found that the ratio of 
nucleobindin-2 gene expression in fat as compared to nonfat cells derived from human 
omental adipose tissue was 0.44 while that for leptin was 28. Furthermore, nucleobindin-2 is 
a ubiquitous Ca2+ binding protein that may participate in Ca2+ storage in the Golgi as well 
as in other biological processes involving DNA-binding and protein-protein interactions (de 
Alba and Tjandra, 2004). There is also evidence that it associates with cyclooxygenase-2 in 
human neutrophils (Leclerc et al., 2008). It is strange that nesfatin-1 is derived from a 
precursor protein with so many functions. However, it is possible that nesfatin-1 is formed 
in fat cells from nucleobindin-2. This hypothesis remains to be tested and at the moment the 
relationship of nesfatin-1 to fat cell metabolism is unclear and it also remains to be proven 
that nesfatin-1 is formed and released by fat cells much less that it functions physiologically 
as an anorexigenic peptide.  
5.24 Omentin/intelectin 
Omentin has been described as a novel adipokine secreted by omental adipose tissue 
(Schaffler et al., 2005; Yang et al., 2006b; Tan et al., 2008) but it is actually a lectin that binds 
to the galactofuranose moiety in the carbohydrate chains of bacterial cell walls (Tsuji et al., 
2001). Omentin/intelectin is involved in mucosal defense mechanisms in the small intestinal 
brush border (Wrackmeyer et al., 2006). Fain et al., (2008b) found that omentin/intelectin 
gene expression was almost exclusively in the nonfat cells of omental fat and its expression 
in epicardial fat was 100-fold higher than that in subcutaneous fat. This is what is expected if 
omentin is made in endothelial cells of blood vessels derived from mesothelial cells of the 
sphlanchopleuric mesoderm of the gut. Thus it is hardly surprising that circulating levels of 
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omentin/intelectin are negatively correlated with the extent of carotid intima-media 
thickness (Shibata et al., 2011) since they are probably derived from the endothelial cells of 
the blood vessels. Female subjects have higher circulating levels of omentin than male 
subjects and those levels correlate with the circulating levels of adiponectin, both being 
negatively associated with insulin resistance (Yan et al., 2011). These findings confirm the 
original report by de Souza Batista et al., (2007) that circulating levels of omentin/intelectin 
are negatively correlated with BMI and insulin resistance. I conclude that omentin/intelectin 
is not really an adipokine but a circulating factor derived from the endothelial cells of all the 
blood vessels in the abdominal cavity. It appears to be a marker of endothelial cells rather 
than of fat cells. 
5.25 Orsomucoid/1 acid glycoprotein  
Orsomucoid is also known as 1 acid glycoprotein and is one of the most abundant plasma 
proteins (Lee et al., 2010). It is an acute phase protein secreted by the liver in response to 
stress and inflammation. In mice, it is also induced in the adipose tissue in obesity and its 
formation is not further enhanced by inflammatory stimuli or reduced in the diabetic state 
(Lin et al., 2001; Lee et al., 2010). It is clearly not an inflammatory adipokine since in human 
omental adipose tissue incubated in primary culture, its gene expression is markedly 
enhanced by dexamethasone which inhibited expression of inflammatory adipokines (Fain 
et al., 2010b). In humans, circulating levels of orsomucoid are not lower in diabetic subjects 
and show a weak positive correlation with BMI as expected of an inflammatory response 
protein (Akbay et al., 2004; Maachi et al., 2004). Orsomucoid appears to be a unique 
inflammatory response protein whose circulating levels poorly respond to the degree of 
obesity or diabetes in humans.  
5.26 Osteoprotegerin [OPG] 
OPG is a secreted glycoprotein of the TNF receptor family that is released by many cells 
including those in atherosclerotic plaque lesions in response to inflammatory stimuli 
(Venuraju et al., 2010). There is evidence in humans for a positive relationship between 
circulating levels of OPG and the severity of atherosclerosis (Venuraju et al., 2010). 
However, circulating levels of OPG increase with age (Gannage-Yared et al., 2008; Sacks et 
al., 2011) and after correcting for age there was no effect of severe coronary artery disease on 
circulating levels of OPG (Sacks et al., 2011). Obesity effects on circulating OPG have been 
contradictory to say the least. Gannage-Yared et al., (2008) and Fain (2011) reported no 
change while Holecki et al., (2007) and Ashley et al., (2011) reported decreases in obesity. 
Venuraju et al., (2010) concluded that there is no consensus on the relationship between BMI 
or other cardiovascular risk factors and the circulating levels of OPG much less the function 
of this protein in humans.  
5.27 Plasminogen activator inhibitor protein-1 [PAI-1] 
PAI-1 is also known as serpin E1 and is a member of the serpin family of serine protease 
inhibitors. PAI-1 is the predominant inhibitor of the fibrinolytic system (Alessi et al., 2007). 
The release of PAI-1 by visceral adipose tissue is primarily by nonfat cells such as 
macrophages and greater than that by subcutaneous human fat (Bastelica et al., 2002; Fain et 
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5.22 Monocyte chemoattractant protein 1 [MCP-1] 
MCP-1 is also known as chemokine CCL2 and is a mononuclear cell chemoattractant protein 
that is a pro-inflammatory adipokine (Frangogiannis, 2004). Circulating levels of MCP-1 
have been reported to be elevated in obese humans (Malavazos et al., 2005) and to have a 
positive correlation with BMI (Christiansen et al., 2005). However, neither Miller et al., 
(2002) or Fain (2011) found any effect of obesity on circulating levels of MCP-1. Madani et 
al., (2009) reported that MCP-1 and IL-6, but not RANTES, were released in vivo by human 
abdominal subcutaneous adipose tissue to a far greater extent in individuals with a BMI of 
43 as compared to controls with a BMI of 25. Dahlman et al (2005) found that obesity 
increased the mRNA level of MCP-1 in human subcutaneous adipose tissue by 2.6-fold. The 
in vitro release of MCP-1 by adipose tissue explants was also increased by 6 to 10-fold 
without any change in the in vivo release. These data indicate that while obesity enhances 
MCP-1 release by adipose tissue there appears to be little contribution of adipose tissue to its 
circulating levels.  
5.23 Nesfatin-1 
This novel anorexigenic peptide is processed from nucleobindin-2 and released by adipose 
tissue (Ramanjaneya et al., 2010). While they reported a positive correlation of 0.63 between 
circulating levels of nesfatin-1 and BMI, the opposite was reported by Tsuchiya et al., (2010). 
However, Tan et al., (2011) found a positive correlation of 0.83 between the circulating 
nesfatin-1 and BMI, in 38 subjects [20 were women] with BMI values ranging from 16 to 38. 
It is unlikely that nesfatin-1 is derived from nucleobindin-2 gene expression solely in fat 
cells as is the case with leptin. I [unpublished studies] have found that the ratio of 
nucleobindin-2 gene expression in fat as compared to nonfat cells derived from human 
omental adipose tissue was 0.44 while that for leptin was 28. Furthermore, nucleobindin-2 is 
a ubiquitous Ca2+ binding protein that may participate in Ca2+ storage in the Golgi as well 
as in other biological processes involving DNA-binding and protein-protein interactions (de 
Alba and Tjandra, 2004). There is also evidence that it associates with cyclooxygenase-2 in 
human neutrophils (Leclerc et al., 2008). It is strange that nesfatin-1 is derived from a 
precursor protein with so many functions. However, it is possible that nesfatin-1 is formed 
in fat cells from nucleobindin-2. This hypothesis remains to be tested and at the moment the 
relationship of nesfatin-1 to fat cell metabolism is unclear and it also remains to be proven 
that nesfatin-1 is formed and released by fat cells much less that it functions physiologically 
as an anorexigenic peptide.  
5.24 Omentin/intelectin 
Omentin has been described as a novel adipokine secreted by omental adipose tissue 
(Schaffler et al., 2005; Yang et al., 2006b; Tan et al., 2008) but it is actually a lectin that binds 
to the galactofuranose moiety in the carbohydrate chains of bacterial cell walls (Tsuji et al., 
2001). Omentin/intelectin is involved in mucosal defense mechanisms in the small intestinal 
brush border (Wrackmeyer et al., 2006). Fain et al., (2008b) found that omentin/intelectin 
gene expression was almost exclusively in the nonfat cells of omental fat and its expression 
in epicardial fat was 100-fold higher than that in subcutaneous fat. This is what is expected if 
omentin is made in endothelial cells of blood vessels derived from mesothelial cells of the 
sphlanchopleuric mesoderm of the gut. Thus it is hardly surprising that circulating levels of 
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omentin/intelectin are negatively correlated with the extent of carotid intima-media 
thickness (Shibata et al., 2011) since they are probably derived from the endothelial cells of 
the blood vessels. Female subjects have higher circulating levels of omentin than male 
subjects and those levels correlate with the circulating levels of adiponectin, both being 
negatively associated with insulin resistance (Yan et al., 2011). These findings confirm the 
original report by de Souza Batista et al., (2007) that circulating levels of omentin/intelectin 
are negatively correlated with BMI and insulin resistance. I conclude that omentin/intelectin 
is not really an adipokine but a circulating factor derived from the endothelial cells of all the 
blood vessels in the abdominal cavity. It appears to be a marker of endothelial cells rather 
than of fat cells. 
5.25 Orsomucoid/1 acid glycoprotein  
Orsomucoid is also known as 1 acid glycoprotein and is one of the most abundant plasma 
proteins (Lee et al., 2010). It is an acute phase protein secreted by the liver in response to 
stress and inflammation. In mice, it is also induced in the adipose tissue in obesity and its 
formation is not further enhanced by inflammatory stimuli or reduced in the diabetic state 
(Lin et al., 2001; Lee et al., 2010). It is clearly not an inflammatory adipokine since in human 
omental adipose tissue incubated in primary culture, its gene expression is markedly 
enhanced by dexamethasone which inhibited expression of inflammatory adipokines (Fain 
et al., 2010b). In humans, circulating levels of orsomucoid are not lower in diabetic subjects 
and show a weak positive correlation with BMI as expected of an inflammatory response 
protein (Akbay et al., 2004; Maachi et al., 2004). Orsomucoid appears to be a unique 
inflammatory response protein whose circulating levels poorly respond to the degree of 
obesity or diabetes in humans.  
5.26 Osteoprotegerin [OPG] 
OPG is a secreted glycoprotein of the TNF receptor family that is released by many cells 
including those in atherosclerotic plaque lesions in response to inflammatory stimuli 
(Venuraju et al., 2010). There is evidence in humans for a positive relationship between 
circulating levels of OPG and the severity of atherosclerosis (Venuraju et al., 2010). 
However, circulating levels of OPG increase with age (Gannage-Yared et al., 2008; Sacks et 
al., 2011) and after correcting for age there was no effect of severe coronary artery disease on 
circulating levels of OPG (Sacks et al., 2011). Obesity effects on circulating OPG have been 
contradictory to say the least. Gannage-Yared et al., (2008) and Fain (2011) reported no 
change while Holecki et al., (2007) and Ashley et al., (2011) reported decreases in obesity. 
Venuraju et al., (2010) concluded that there is no consensus on the relationship between BMI 
or other cardiovascular risk factors and the circulating levels of OPG much less the function 
of this protein in humans.  
5.27 Plasminogen activator inhibitor protein-1 [PAI-1] 
PAI-1 is also known as serpin E1 and is a member of the serpin family of serine protease 
inhibitors. PAI-1 is the predominant inhibitor of the fibrinolytic system (Alessi et al., 2007). 
The release of PAI-1 by visceral adipose tissue is primarily by nonfat cells such as 
macrophages and greater than that by subcutaneous human fat (Bastelica et al., 2002; Fain et 
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al., 2004a). Total release by human fat in vitro correlates with BMI (Fain, 2010) and the gene 
expression of PAI-1 in visceral omental fat of obese women correlated to a greater extent 
with BMI than that of inflammatory adipokines such as TNF, MCP-1, IL-1, IL-6, IL-8 or 
MIF (Fain, 2011). Alessi et al., (2007) have reviewed the evidence that circulating PAI-1 
levels are enhanced in obesity and are primarily produced by macrophages in adipose 
tissue. While Lindeman et al., (2004) confirmed the high correlation between visceral fat and 
circulating PAI-1, their in vivo measurements of release from visceral fat were negative. 
They concluded that the relationship between PAI-levels and visceral fat is as co-correlates 
rather than a causal relationship.  
5.28 Secretory type II phospholipase A2 [PLA2] 
PLA2 is an acute phase protein that is able to degrade phospholipids present in lipoproteins 
and cell membranes thus releasing inflammatory molecules (Rosenson and Gelb, 2009). It is 
reported to be, like CRP, an independent risk factor for coronary heart disease (Kugiyama et 
al., 1999). Circulating levels of PLA2 are higher in women than in men and reported to be 
positively correlated with waist circumference in obese women (Rana et al., 2011; Weyer et 
al., 2002; Fain, 2011). It has been claimed that PLA2 is secreted by epicardial adipose tissue 
and over expressed in humans with coronary artery disease (Dutour et al., 2010) but Sacks et 
al., (2011) failed to see elevations in circulating PLA2 in humans with severe coronary artery 
disease or any difference in its gene expression in epicardial, sternal or substernal fat of 
controls as compared to those with coronary artery disease. I conclude that PLA2 is 
primarily an obesity marker. 
5.29 Regulated on activation, normal T cell expressed and secreted [RANTES] 
In obese mice, both the levels of mRNA in fat and protein secretion of RANTES are 
enhanced by obesity that is accompanied by increased accumulation in adipose tissue of T 
cells as well as macrophages (Wu et al., 2007). Maury et al., (2007) reported that RANTES 
was released in greater amounts by fat cells isolated from the omental adipose tissue of 
obese humans but Fain et al., (2010a) found no effects of obesity on the total release of 
RANTES by explants of human adipose tissue in primary culture. Furthermore, Madani et 
al., (2009) found no effect of obesity on in vivo release of RANTES by human 
subcutaneous adipose tissue under conditions where increases in IL-6 and MCP-1 could 
be readily detected. Madani et al., (2009) also observed that circulating levels of RANTES 
were far higher than could be accounted for release by adipose tissue. They concluded 
that it is more likely that RANTES acts on adipose tissue. 
5.30 Renin receptor protein 
This is an intracellular protein that is expressed in the nonfat cells of human adipose tissue. 
It may increase angiotensin I generation from angiotensinogen by enhancing the uptake of 
circulating renin thus enhancing the activity of the renin-angiotensin system in visceral 
adipose tissue (Engeli et al., 1999; Achard et al., 2007). In severely obese (BMI of 49) non-
diabetic women taking anti-hypertensive agents the gene expression in omental adipose 
tissue of the renin receptor was increased by 60% while that of ACE and angiotensinogen 
was unaffected (Fain, 2011). Fowler et al., (2009) have shown in rodents that adipose tissue 
may control its own local renin concentration independent of plasma renin. These data 
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suggest that the renin receptor protein is important in local regulation of angiotensin II 
formation in adipose tissue. This is a promising area for future studies and suggests that the 
regulation of the renin-angiotensin system in adipose tissue is both more important and 
more complex than originally envisioned.  
5.31 Resistin 
Steppan et al., (2001) based on studies in rodents, postulated that resistin was secreted by fat 
cells and was the missing link between obesity and diabetes. However, studies in human 
adipose tissue have shown that resistin is neither released by fat cells (Fain et al., 2003) nor 
are detectable amounts of resistin mRNA expressed in human fat cells (Nagaev and Smith, 
2001; Savage et al., 2001; Janke et al., 2002; Fain, 2010). It is now accepted that resistin is 
produced largely by macrophages (Lehrke et al., 2004) and not linked to markers for insulin 
resistance or adiposity (Hasegawa et al., 2005). The consensus is that circulating resistin is 
not derived from adipose tissue but is involved in inflammation under some conditions. 
Clearly in humans, resistin is not an important factor released by fat cells that links insulin 
resistance and obesity. 
5.32 Retinol binding protein 4 [RBP-4] 
This protein is a member of the lipocalin family of molecules that bind small hydrophobic 
molecules such as retinol and is expressed at high levels in liver as well as adipose tissue 
(Kotnik et al., 2011). Like leptin, but unlike most putative adipokines, it is expressed 
exclusively in the fat cells of human adipose tissue (Fain, 2010). The laboratory of Barbara 
Kahn suggested that RBP-4 is causally related to insulin resistance in obesity and type 2 
diabetes (Yang et al., 2005; Graham et al., 2006). However, Kotnik et al., (2011) suggested 
that the evidence for an association between obesity and circulating as well as adipose tissue 
levels of RBP4 is not a consistent finding in clinical studies. Some of these differences could 
be due to confounding factors such as procedures for collection of blood and the antibodies 
used for the assays as well as sex differences, age, retinol status, iron status and kidney 
function which have all been shown to affect circulating levels of RBP4. Most probably, as 
suggested by Yao-Borengasser et al., (2007), RBP-4 gene expression in human fat correlates 
with inflammation rather than insulin resistance and the great hope that this would be a link 
between obesity and insulin resistance is still just a great hope.  
5.33 Thrombospondin-1 [TSP1] 
TSP1 is an inhibitor of angiogenesis that is able to activate the latent TGF1 complex and 
interact with CD36 on endothelial cells leading to apoptosis (Bornstein, 2009). Varma et al., 
(2008) postulated that TSP-1 is an adipokine associated with obesity, inflammation and 
insulin resistance. While they workers reported that its gene expression in fat cells was 4-
fold that of nonfat cells, Fain (2010) found only a non-significant 1.8-fold increase in fat cells 
over that in nonfat cells of omental adipose tissue. Bornstein (2009) pointed out that TSP-1 is 
synthesized and secreted by a wide variety of cells in culture including endothelial cells, 
fibroblasts and smooth muscle cells. Clearly TSP-1 is not an adipokine in the sense of being a 
protein preferentially expressed in fat cells but is rather found in all cells examined to date. 
The major function of TSP-1 is to regulate angiogenesis and knockout mice have an 
increased density of capillaries in cardiac and skeletal muscle. Endothelial-derived TSP-1 
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al., 2004a). Total release by human fat in vitro correlates with BMI (Fain, 2010) and the gene 
expression of PAI-1 in visceral omental fat of obese women correlated to a greater extent 
with BMI than that of inflammatory adipokines such as TNF, MCP-1, IL-1, IL-6, IL-8 or 
MIF (Fain, 2011). Alessi et al., (2007) have reviewed the evidence that circulating PAI-1 
levels are enhanced in obesity and are primarily produced by macrophages in adipose 
tissue. While Lindeman et al., (2004) confirmed the high correlation between visceral fat and 
circulating PAI-1, their in vivo measurements of release from visceral fat were negative. 
They concluded that the relationship between PAI-levels and visceral fat is as co-correlates 
rather than a causal relationship.  
5.28 Secretory type II phospholipase A2 [PLA2] 
PLA2 is an acute phase protein that is able to degrade phospholipids present in lipoproteins 
and cell membranes thus releasing inflammatory molecules (Rosenson and Gelb, 2009). It is 
reported to be, like CRP, an independent risk factor for coronary heart disease (Kugiyama et 
al., 1999). Circulating levels of PLA2 are higher in women than in men and reported to be 
positively correlated with waist circumference in obese women (Rana et al., 2011; Weyer et 
al., 2002; Fain, 2011). It has been claimed that PLA2 is secreted by epicardial adipose tissue 
and over expressed in humans with coronary artery disease (Dutour et al., 2010) but Sacks et 
al., (2011) failed to see elevations in circulating PLA2 in humans with severe coronary artery 
disease or any difference in its gene expression in epicardial, sternal or substernal fat of 
controls as compared to those with coronary artery disease. I conclude that PLA2 is 
primarily an obesity marker. 
5.29 Regulated on activation, normal T cell expressed and secreted [RANTES] 
In obese mice, both the levels of mRNA in fat and protein secretion of RANTES are 
enhanced by obesity that is accompanied by increased accumulation in adipose tissue of T 
cells as well as macrophages (Wu et al., 2007). Maury et al., (2007) reported that RANTES 
was released in greater amounts by fat cells isolated from the omental adipose tissue of 
obese humans but Fain et al., (2010a) found no effects of obesity on the total release of 
RANTES by explants of human adipose tissue in primary culture. Furthermore, Madani et 
al., (2009) found no effect of obesity on in vivo release of RANTES by human 
subcutaneous adipose tissue under conditions where increases in IL-6 and MCP-1 could 
be readily detected. Madani et al., (2009) also observed that circulating levels of RANTES 
were far higher than could be accounted for release by adipose tissue. They concluded 
that it is more likely that RANTES acts on adipose tissue. 
5.30 Renin receptor protein 
This is an intracellular protein that is expressed in the nonfat cells of human adipose tissue. 
It may increase angiotensin I generation from angiotensinogen by enhancing the uptake of 
circulating renin thus enhancing the activity of the renin-angiotensin system in visceral 
adipose tissue (Engeli et al., 1999; Achard et al., 2007). In severely obese (BMI of 49) non-
diabetic women taking anti-hypertensive agents the gene expression in omental adipose 
tissue of the renin receptor was increased by 60% while that of ACE and angiotensinogen 
was unaffected (Fain, 2011). Fowler et al., (2009) have shown in rodents that adipose tissue 
may control its own local renin concentration independent of plasma renin. These data 
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suggest that the renin receptor protein is important in local regulation of angiotensin II 
formation in adipose tissue. This is a promising area for future studies and suggests that the 
regulation of the renin-angiotensin system in adipose tissue is both more important and 
more complex than originally envisioned.  
5.31 Resistin 
Steppan et al., (2001) based on studies in rodents, postulated that resistin was secreted by fat 
cells and was the missing link between obesity and diabetes. However, studies in human 
adipose tissue have shown that resistin is neither released by fat cells (Fain et al., 2003) nor 
are detectable amounts of resistin mRNA expressed in human fat cells (Nagaev and Smith, 
2001; Savage et al., 2001; Janke et al., 2002; Fain, 2010). It is now accepted that resistin is 
produced largely by macrophages (Lehrke et al., 2004) and not linked to markers for insulin 
resistance or adiposity (Hasegawa et al., 2005). The consensus is that circulating resistin is 
not derived from adipose tissue but is involved in inflammation under some conditions. 
Clearly in humans, resistin is not an important factor released by fat cells that links insulin 
resistance and obesity. 
5.32 Retinol binding protein 4 [RBP-4] 
This protein is a member of the lipocalin family of molecules that bind small hydrophobic 
molecules such as retinol and is expressed at high levels in liver as well as adipose tissue 
(Kotnik et al., 2011). Like leptin, but unlike most putative adipokines, it is expressed 
exclusively in the fat cells of human adipose tissue (Fain, 2010). The laboratory of Barbara 
Kahn suggested that RBP-4 is causally related to insulin resistance in obesity and type 2 
diabetes (Yang et al., 2005; Graham et al., 2006). However, Kotnik et al., (2011) suggested 
that the evidence for an association between obesity and circulating as well as adipose tissue 
levels of RBP4 is not a consistent finding in clinical studies. Some of these differences could 
be due to confounding factors such as procedures for collection of blood and the antibodies 
used for the assays as well as sex differences, age, retinol status, iron status and kidney 
function which have all been shown to affect circulating levels of RBP4. Most probably, as 
suggested by Yao-Borengasser et al., (2007), RBP-4 gene expression in human fat correlates 
with inflammation rather than insulin resistance and the great hope that this would be a link 
between obesity and insulin resistance is still just a great hope.  
5.33 Thrombospondin-1 [TSP1] 
TSP1 is an inhibitor of angiogenesis that is able to activate the latent TGF1 complex and 
interact with CD36 on endothelial cells leading to apoptosis (Bornstein, 2009). Varma et al., 
(2008) postulated that TSP-1 is an adipokine associated with obesity, inflammation and 
insulin resistance. While they workers reported that its gene expression in fat cells was 4-
fold that of nonfat cells, Fain (2010) found only a non-significant 1.8-fold increase in fat cells 
over that in nonfat cells of omental adipose tissue. Bornstein (2009) pointed out that TSP-1 is 
synthesized and secreted by a wide variety of cells in culture including endothelial cells, 
fibroblasts and smooth muscle cells. Clearly TSP-1 is not an adipokine in the sense of being a 
protein preferentially expressed in fat cells but is rather found in all cells examined to date. 
The major function of TSP-1 is to regulate angiogenesis and knockout mice have an 
increased density of capillaries in cardiac and skeletal muscle. Endothelial-derived TSP-1 
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has also been claimed to promote macrophage recruitment (Kirsch et al., 2010). Varma et al., 
(2008) reported a small but positive correlation between gene expression of TSP-1 in adipose 
tissue and BMI with no effect of prior metformin administration. However, Tan et al., (2009) 
found that 6-months treatment with metformin of women with PCOS elevated the low 
circulating levels of TSP-1. The available evidence does not support the claim that TSP-1 is 
an adipokine released by fat cells that has any causal relationship to obesity and insulin 
resistance.  
5.34 TGF-1 
TGF-1 is now accepted to be multifunctional regulator of the immune and inflammatory 
processes and works through regulating the activity of Smad proteins (Shi and Massague, 
2003). Smad-3 deficient mice are protected from diet-induced obesity and diabetes and the 
adipocytes had marked increases in mitochondrial biogenesis and respiration accompanied 
by increased PGC-1 mRNA (Yadav et al., (2011). There is other evidence for perturbation 
of mitochondrial function, specifically reactive oxygen species formation, due to TGF-1 
since it enhanced mitochondrial reactive oxygen species formation in rodent hepatocytes 
(Albright et al., 2003) while preventing cell death due to caspase activation in synovial cells 
(Kawakami et al., 2004). 
In obese hypertensive humans, circulating levels of TGF-1 correlated with BMI (Scaglione 
et al., 2003) but not in a study where only 10% of the humans were hypertensive (Bastelica et 
al., 2002). In another study comparing circulating TGF-1 in women with an average BMI of 
32 against lean controls with a BMI of 21, the values were actually higher in the lean controls 
(Corica et al., 1997). However, both protein and gene expression (Alessi et al., 2000) of TGF-
1 in human adipose tissue positively correlates with BMI as does release of TGF1 by 
human adipose tissue in primary culture (Fain et al., 2005b). The formation and release of 
TGF1 by human adipose tissue is almost exclusively by the nonfat cells and is not inhibited 
by dexamethasone, as is the case for release of inflammatory adipokines such as the 
interleukins and IL-1Ra (Fain et al., 2005b; Fain et al., 2010b).  While circulating levels of 
TGF1 do not appear to be elevated in obesity, one caveat is that what is measured is 
actually the latent form of TGF1. This accounts for most of the circulating TGF1 and 
obesity could affect conversion to the active form with a much shorter half-life (Flaumenhaft 
et al., 1993). I conclude that TGF1 is formed by the nonfat cells in human adipose tissue 
and acts as a local paracrine/autocrine factor that is required for the development of obesity 
and insulin resistance. However, this does not necessarily mean that it plays a causal role 
since it is a multifunctional regulator of cellular metabolism. The recent findings of Yadav et 
al., (2011) suggest that the inhibition of TGF1 release and/or action might have favorable 
effects on the development of insulin resistance in obesity by uncoupling respiration in 
white fat thus preventing fatty acid accumulation.  
5.35 Tumor necrosis factor  [TNF] 
Hotamisligil et al., (1993) found elevated levels of TNF and its gene expression in several 
rodent models of obesity and diabetes and neutralization of TNF significantly reduced 
insulin resistance. In humans, Hotamisligil et al., (1995) found that obesity greatly enhanced 
TNF release by adipose tissue explants and its gene expression in adipose tissue correlated 
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with both BMI and circulating levels of insulin, which is a marker for insulin resistance. Fain 
et al., (2004c) confirmed that the release of TNF by both explants of human adipose tissue 
and adipocytes positively correlates with the BMI of the fat donors but the release of TNF 
is primarily by the non-fat cells. In obesity there is increased accumulation of macrophages 
in adipose tissue and these cells release massive amounts of cytokines such as TNF (Xu et 
al., 2003; Weisberg et al., 2003). However, Kern et al., (1995) and Fain et al., (2004c) found 
that TNF is also released by nonfat cells other than macrophages in human adipose tissue. 
There is a reproducible correlation between BMI and TNF release by human adipose tissue 
explants (Fain et al., 2004c; Arner et al., 2010) or adipocytes (Fain et al., 2004c). However, this 
has not been seen in all studies with respect to TNF gene expression in adipose tissue and 
BMI (Kern et al., 1995; Koistinen et al., 2000).  
It has been difficult to obtain evidence in humans by blocking TNF action in vivo with 
etanercept that this improves insulin sensitivity (Lo et al., 2007). However, Fain et al., 
(2005a) found that blocking endogenous TNF action on incubated human fat explants 
using etanercept had little effect on the release of IL-6 or IL-8. However, in combination with 
an antibody that blocked the action of endogenous IL-1 there was a 55 to 60% decrease in 
the release of IL-6 and IL-8. There is little evidence that TNF circulates as an adipokine. 
Rather it acts as an autocrine/paracrine factor since circulating levels are generally below 
the sensitivity of available assays. There is no evidence for its release in vivo into the 
circulation under conditions where release of IL-6 could be detected (Mohamed-Ali et al., 
1997). I conclude that TNF is an important component of the inflammatory response acting 
as an autocrine/paracrine adipokine along with IL-1 to activate the inflammatory cascade 
in adipose tissue in all cells resulting in enhanced release of pro-inflammatory adipokines 
such as IL-6 and IL-8. It will be important to understand how human adipocytes even after 
isolation from the adipose tissue environment and washed several times still show rates of 
TNF release that reflect the BMI of the person from whom the adipocytes were obtained. 
The simplest explanation is that this reflects the average fat cell size as shown by Arner et 
al., (2010) and that ‘stretch receptors’ are involved that stimulate TNF and leptin release.  
5.36 Tumor necrosis factor receptor 2 [TNFR2] 
The actual receptor for TNF is TNFR1 but there is also a second soluble form of the 
receptor known as TNFR2 that can be cleaved from the TNFR1 or expressed directly and its 
expression in adipose tissue is markedly enhanced in obesity (Hotamisligil et al., 1997). 
Similar increases in circulating TNFR2 but not TNFR1 have been seen in obese humans 
(Fernandez-Real et al., 1998). These data suggest that increased formation of the TNFR2 is 
part of a feedback system designed to reduce the effects of TNF since the soluble TNFR2 
protein binds to and thus reduces the level of active TNF. 
5.37 Vascular endothelial growth factor A [VEGF] and VEGFR1 & 2 
There is evidence that VEGF is involved in angiogenesis in adipose tissue which is a highly 
vascularized tissue (Cao, 2010) and that adipose tissue mass can be regulated through the 
vasculature (Rupnick et al., 2002). In overweight/obese humans, there is an inverse 
correlation between obesity and pO2, temperature, capillaries per 1000 m2 and VEGF gene 
expression suggesting that the reduced pO2 did not result in VEGF release and 
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has also been claimed to promote macrophage recruitment (Kirsch et al., 2010). Varma et al., 
(2008) reported a small but positive correlation between gene expression of TSP-1 in adipose 
tissue and BMI with no effect of prior metformin administration. However, Tan et al., (2009) 
found that 6-months treatment with metformin of women with PCOS elevated the low 
circulating levels of TSP-1. The available evidence does not support the claim that TSP-1 is 
an adipokine released by fat cells that has any causal relationship to obesity and insulin 
resistance.  
5.34 TGF-1 
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2003). Smad-3 deficient mice are protected from diet-induced obesity and diabetes and the 
adipocytes had marked increases in mitochondrial biogenesis and respiration accompanied 
by increased PGC-1 mRNA (Yadav et al., (2011). There is other evidence for perturbation 
of mitochondrial function, specifically reactive oxygen species formation, due to TGF-1 
since it enhanced mitochondrial reactive oxygen species formation in rodent hepatocytes 
(Albright et al., 2003) while preventing cell death due to caspase activation in synovial cells 
(Kawakami et al., 2004). 
In obese hypertensive humans, circulating levels of TGF-1 correlated with BMI (Scaglione 
et al., 2003) but not in a study where only 10% of the humans were hypertensive (Bastelica et 
al., 2002). In another study comparing circulating TGF-1 in women with an average BMI of 
32 against lean controls with a BMI of 21, the values were actually higher in the lean controls 
(Corica et al., 1997). However, both protein and gene expression (Alessi et al., 2000) of TGF-
1 in human adipose tissue positively correlates with BMI as does release of TGF1 by 
human adipose tissue in primary culture (Fain et al., 2005b). The formation and release of 
TGF1 by human adipose tissue is almost exclusively by the nonfat cells and is not inhibited 
by dexamethasone, as is the case for release of inflammatory adipokines such as the 
interleukins and IL-1Ra (Fain et al., 2005b; Fain et al., 2010b).  While circulating levels of 
TGF1 do not appear to be elevated in obesity, one caveat is that what is measured is 
actually the latent form of TGF1. This accounts for most of the circulating TGF1 and 
obesity could affect conversion to the active form with a much shorter half-life (Flaumenhaft 
et al., 1993). I conclude that TGF1 is formed by the nonfat cells in human adipose tissue 
and acts as a local paracrine/autocrine factor that is required for the development of obesity 
and insulin resistance. However, this does not necessarily mean that it plays a causal role 
since it is a multifunctional regulator of cellular metabolism. The recent findings of Yadav et 
al., (2011) suggest that the inhibition of TGF1 release and/or action might have favorable 
effects on the development of insulin resistance in obesity by uncoupling respiration in 
white fat thus preventing fatty acid accumulation.  
5.35 Tumor necrosis factor  [TNF] 
Hotamisligil et al., (1993) found elevated levels of TNF and its gene expression in several 
rodent models of obesity and diabetes and neutralization of TNF significantly reduced 
insulin resistance. In humans, Hotamisligil et al., (1995) found that obesity greatly enhanced 
TNF release by adipose tissue explants and its gene expression in adipose tissue correlated 
Effect of Obesity on Circulating Adipokines and 
Their Expression in Omental Adipose Tissue of Female Bariatric Surgery Patients 
 
35 
with both BMI and circulating levels of insulin, which is a marker for insulin resistance. Fain 
et al., (2004c) confirmed that the release of TNF by both explants of human adipose tissue 
and adipocytes positively correlates with the BMI of the fat donors but the release of TNF 
is primarily by the non-fat cells. In obesity there is increased accumulation of macrophages 
in adipose tissue and these cells release massive amounts of cytokines such as TNF (Xu et 
al., 2003; Weisberg et al., 2003). However, Kern et al., (1995) and Fain et al., (2004c) found 
that TNF is also released by nonfat cells other than macrophages in human adipose tissue. 
There is a reproducible correlation between BMI and TNF release by human adipose tissue 
explants (Fain et al., 2004c; Arner et al., 2010) or adipocytes (Fain et al., 2004c). However, this 
has not been seen in all studies with respect to TNF gene expression in adipose tissue and 
BMI (Kern et al., 1995; Koistinen et al., 2000).  
It has been difficult to obtain evidence in humans by blocking TNF action in vivo with 
etanercept that this improves insulin sensitivity (Lo et al., 2007). However, Fain et al., 
(2005a) found that blocking endogenous TNF action on incubated human fat explants 
using etanercept had little effect on the release of IL-6 or IL-8. However, in combination with 
an antibody that blocked the action of endogenous IL-1 there was a 55 to 60% decrease in 
the release of IL-6 and IL-8. There is little evidence that TNF circulates as an adipokine. 
Rather it acts as an autocrine/paracrine factor since circulating levels are generally below 
the sensitivity of available assays. There is no evidence for its release in vivo into the 
circulation under conditions where release of IL-6 could be detected (Mohamed-Ali et al., 
1997). I conclude that TNF is an important component of the inflammatory response acting 
as an autocrine/paracrine adipokine along with IL-1 to activate the inflammatory cascade 
in adipose tissue in all cells resulting in enhanced release of pro-inflammatory adipokines 
such as IL-6 and IL-8. It will be important to understand how human adipocytes even after 
isolation from the adipose tissue environment and washed several times still show rates of 
TNF release that reflect the BMI of the person from whom the adipocytes were obtained. 
The simplest explanation is that this reflects the average fat cell size as shown by Arner et 
al., (2010) and that ‘stretch receptors’ are involved that stimulate TNF and leptin release.  
5.36 Tumor necrosis factor receptor 2 [TNFR2] 
The actual receptor for TNF is TNFR1 but there is also a second soluble form of the 
receptor known as TNFR2 that can be cleaved from the TNFR1 or expressed directly and its 
expression in adipose tissue is markedly enhanced in obesity (Hotamisligil et al., 1997). 
Similar increases in circulating TNFR2 but not TNFR1 have been seen in obese humans 
(Fernandez-Real et al., 1998). These data suggest that increased formation of the TNFR2 is 
part of a feedback system designed to reduce the effects of TNF since the soluble TNFR2 
protein binds to and thus reduces the level of active TNF. 
5.37 Vascular endothelial growth factor A [VEGF] and VEGFR1 & 2 
There is evidence that VEGF is involved in angiogenesis in adipose tissue which is a highly 
vascularized tissue (Cao, 2010) and that adipose tissue mass can be regulated through the 
vasculature (Rupnick et al., 2002). In overweight/obese humans, there is an inverse 
correlation between obesity and pO2, temperature, capillaries per 1000 m2 and VEGF gene 
expression suggesting that the reduced pO2 did not result in VEGF release and 
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neovascularization (Pasarica et al., 2009). Kabon et al., (2004) had previously reported that 
obesity decreased adipose tissue oxygenation in humans. Thus the question is why in 
obesity the reduced pO2 in the expanding fat mass does not result in release of VEGF and 
growth of more blood vessels to enhance pO2. But obesity in humans does enhance the 
circulating levels of VEGF and the best correlation [Pearson r of 0.49] was seen with visceral 
fat mass (Miyazawa-Hoshimoto et al., 2003). Cao (2010) has suggested that adipose tissue 
angiogenesis is a good therapeutic target for the treatment of obesity. However, we know so 
little about what regulates the growth of adipocytes and the endothelial cells of the blood 
vessels that we are literally groping in the dark. One way to regulate the activity of VEGF is 
through the formation and release of the soluble form of the VEGFR-1 receptor, known as 
sFlt-1, which competes with the VEGFR1 and VEGFR2 receptors for binding of VEGF. 
Obesity in rodents and man is associated with reduced mRNA content as well as release of 
sFlt1 while in isolated human adipocytes hypoxia enhances the expression of VEGF but not 
of sFlt1 (Herse et al., 2011).  
5.38 Vaspin 
This protein was originally described as a serine protease inhibitor derived from visceral 
adipose tissue (Hida et al., 2005) but Kloting et al., (2006) reported that it was present to the 
same extent in visceral as in subcutaneous adipose tissue of humans. It is not found in fat 
cells of human visceral omental adipose tissue but is found in the nonfat cells (Fain, 2010). 
Circulating levels of vaspin are not elevated in massively obese women (Auguet et al., 2011). 
Similarly a 10-month lifestyle intervention program led to a favorable change in metabolic 
parameters and circulating adiponectin but not vaspin (Kim et al., 2011). I conclude that 
vaspin is probably not an adipokine but rather a member of the serpin protease family with 
unknown functions whose circulating levels are not appreciably altered in obesity. 
5.39 Visfatin/PBEF/Nampt 
This putative adipokine was originally described as a protein selectively expressed in 
visceral fat with insulin-mimetic properties whose circulating levels are elevated in obesity 
(Fukuhara et al., 2005). However, this protein turned out to be identical to PBEF [pre-B-
colony-enhancing factor] and Nampt [nicotinamide phosphoribosyltransferase]. 
Furthermore, the claim that visfatin was an insulin-like peptide has been withdrawn 
(Sommer et al., 2008) and its gene expression in human visceral fat is no higher than in 
subcutaneous fat (Berndt et al., 2005; Fain, 2010). Circulating concentrations of visfatin as 
measured by an ELISA specific for full-length visfatin are not elevated in obesity 
(Retnakaran et al., 2008; Korner et al., 2007). Visfatin gene expression is primarily in the 
nonfat cells of human adipose tissue (Fain et al., 2010a) and it is unclear at this time whether 
it is more than an intracellular enzyme involved in NAD biosynthesis in all fat depots not 
just visceral adipose tissue.   
5.40 Zinc 2 glycoprotein [ZAG] 
This protein has been postulated to be an adipokine modulator of body fat mass (Bing et al., 
2010). However, ZAG is a novel adhesive protein (Takagaki et al., 1994) secreted by epithelial 
cells, sweat glands and many tumors that is found in high concentrations in seminal plasma 
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(Bing et al., 2010). ZAG is identical to a lipid mobilizing factor isolated from the urine of 
humans with cancer cachexia that causes selective loss of fat in rodents but there is no 
evidence that ZAG either enhances lipid mobilization or lipid utilization in humans (Bing et 
al., 2010). ZAG has been postulated to be a candidate gene for obesity, but like adiponectin and 
unlike most adipokines, its gene expression in adipose tissue is lower in obese than in lean 
humans (Bing et al., 2010). There is also an inverse relationship between circulating levels of 
ZAG in humans and insulin resistance but no effect of BMI on circulating levels of ZAG 
(Ceperuelo-Mallafre et al., 2009). However, Selva et al., (2009) reported just the opposite 
results, with obesity lowering both circulating levels and gene expression of ZAG in adipose 
tissue but no correlation was observed between ZAG levels and insulin resistance. ZAG, like 
adiponectin, is preferentially expressed in the fat cells of human omental adipose tissue where 
it is expressed at higher levels than in subcutaneous adipose tissue (Fain, 2010). While the 
available data are conflicting with regard to circulating levels of ZAG, there is consensus that 
gene expression of ZAG in adipose tissue correlates with that of adiponectin (Mracek et al., 
2010) and that weight loss reduces insulin resistance in humans while enhancing gene 
expression of ZAG in adipose tissue. However, what we have are correlations and there is no 
consistent relationship between circulating levels of ZAG and obesity. 
6. Summary of adipokines most likely linked in a causal way to morbid 
obesity 
Of the 40 adipokines mentioned in the previous sections, the circulating levels of only 
adiponectin and ZAG appear to be reduced under some conditions by obesity. The 
circulating levels of 14 of the remaining 38 putative adipokines are elevated in obesity, and 
of these only leptin appears to be released exclusively by the fat cells of human adipose 
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 FABP4 Apelin CRP 
 VEGF IL-6 & IL-8 Haptoglobin 
  MIF  
  PAI-1  
  IL-1Ra  
  sPLA2  
Table 2. Circulating adipokines whose release is reproducibly elevated in obesity over BMI 
values from 25 to 70 
While amyloid A, FABP4 and VEGF levels are elevated in obesity there is no proof that their 
circulating levels are derived primarily from adipose tissue release. Furthermore, there is 
ample evidence that both the fat cells and the nonfat cells of adipose tissue release all three 
and with amyloid A, the liver makes and releases large amount of this acute phase protein. I 
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neovascularization (Pasarica et al., 2009). Kabon et al., (2004) had previously reported that 
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angiogenesis is a good therapeutic target for the treatment of obesity. However, we know so 
little about what regulates the growth of adipocytes and the endothelial cells of the blood 
vessels that we are literally groping in the dark. One way to regulate the activity of VEGF is 
through the formation and release of the soluble form of the VEGFR-1 receptor, known as 
sFlt-1, which competes with the VEGFR1 and VEGFR2 receptors for binding of VEGF. 
Obesity in rodents and man is associated with reduced mRNA content as well as release of 
sFlt1 while in isolated human adipocytes hypoxia enhances the expression of VEGF but not 
of sFlt1 (Herse et al., 2011).  
5.38 Vaspin 
This protein was originally described as a serine protease inhibitor derived from visceral 
adipose tissue (Hida et al., 2005) but Kloting et al., (2006) reported that it was present to the 
same extent in visceral as in subcutaneous adipose tissue of humans. It is not found in fat 
cells of human visceral omental adipose tissue but is found in the nonfat cells (Fain, 2010). 
Circulating levels of vaspin are not elevated in massively obese women (Auguet et al., 2011). 
Similarly a 10-month lifestyle intervention program led to a favorable change in metabolic 
parameters and circulating adiponectin but not vaspin (Kim et al., 2011). I conclude that 
vaspin is probably not an adipokine but rather a member of the serpin protease family with 
unknown functions whose circulating levels are not appreciably altered in obesity. 
5.39 Visfatin/PBEF/Nampt 
This putative adipokine was originally described as a protein selectively expressed in 
visceral fat with insulin-mimetic properties whose circulating levels are elevated in obesity 
(Fukuhara et al., 2005). However, this protein turned out to be identical to PBEF [pre-B-
colony-enhancing factor] and Nampt [nicotinamide phosphoribosyltransferase]. 
Furthermore, the claim that visfatin was an insulin-like peptide has been withdrawn 
(Sommer et al., 2008) and its gene expression in human visceral fat is no higher than in 
subcutaneous fat (Berndt et al., 2005; Fain, 2010). Circulating concentrations of visfatin as 
measured by an ELISA specific for full-length visfatin are not elevated in obesity 
(Retnakaran et al., 2008; Korner et al., 2007). Visfatin gene expression is primarily in the 
nonfat cells of human adipose tissue (Fain et al., 2010a) and it is unclear at this time whether 
it is more than an intracellular enzyme involved in NAD biosynthesis in all fat depots not 
just visceral adipose tissue.   
5.40 Zinc 2 glycoprotein [ZAG] 
This protein has been postulated to be an adipokine modulator of body fat mass (Bing et al., 
2010). However, ZAG is a novel adhesive protein (Takagaki et al., 1994) secreted by epithelial 
cells, sweat glands and many tumors that is found in high concentrations in seminal plasma 
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(Bing et al., 2010). ZAG is identical to a lipid mobilizing factor isolated from the urine of 
humans with cancer cachexia that causes selective loss of fat in rodents but there is no 
evidence that ZAG either enhances lipid mobilization or lipid utilization in humans (Bing et 
al., 2010). ZAG has been postulated to be a candidate gene for obesity, but like adiponectin and 
unlike most adipokines, its gene expression in adipose tissue is lower in obese than in lean 
humans (Bing et al., 2010). There is also an inverse relationship between circulating levels of 
ZAG in humans and insulin resistance but no effect of BMI on circulating levels of ZAG 
(Ceperuelo-Mallafre et al., 2009). However, Selva et al., (2009) reported just the opposite 
results, with obesity lowering both circulating levels and gene expression of ZAG in adipose 
tissue but no correlation was observed between ZAG levels and insulin resistance. ZAG, like 
adiponectin, is preferentially expressed in the fat cells of human omental adipose tissue where 
it is expressed at higher levels than in subcutaneous adipose tissue (Fain, 2010). While the 
available data are conflicting with regard to circulating levels of ZAG, there is consensus that 
gene expression of ZAG in adipose tissue correlates with that of adiponectin (Mracek et al., 
2010) and that weight loss reduces insulin resistance in humans while enhancing gene 
expression of ZAG in adipose tissue. However, what we have are correlations and there is no 
consistent relationship between circulating levels of ZAG and obesity. 
6. Summary of adipokines most likely linked in a causal way to morbid 
obesity 
Of the 40 adipokines mentioned in the previous sections, the circulating levels of only 
adiponectin and ZAG appear to be reduced under some conditions by obesity. The 
circulating levels of 14 of the remaining 38 putative adipokines are elevated in obesity, and 
of these only leptin appears to be released exclusively by the fat cells of human adipose 
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ample evidence that both the fat cells and the nonfat cells of adipose tissue release all three 
and with amyloid A, the liver makes and releases large amount of this acute phase protein. I 
 
Advanced Bariatric and Metabolic Surgery 
 
38
refer to amyloid A as an adipokine because it is formed and released by adipose tissue in 
appreciable amounts in contrast to CRP where the release by adipose tissue is too small to 
contribute to circulating levels. Except for leptin, there is no evidence that the circulating 
levels of the other putative adipokines are derived exclusively from adipose tissue or even 
that release by adipose tissue regulates their circulating levels. Probably the circulating 
levels of adipsin, apelin and IL-6 are influenced primarily by release by lymphoid tissues 
but in any case it is unlikely that release by adipose tissue is derived from fat cells. Finally, 
we have acute phase proteins such as CRP and haptoglobin whose circulating levels are 
elevated in obesity along with that of cathepsin S and are released primarily by liver in 
response to circulating inflammatory factors such as IL-6.  
Interestingly in female bariatric surgery patients, the mRNA levels in omental adipose tissue 
positively correlated with visceral obesity as measured by waist circumference for only four 
of the 12 adipokines whose circulating levels are consistently elevated in obesity as shown 
in Table 3. Furthermore, except for IL-1Ra, the increased mRNA expression in omental 
adipose tissue in obese women was abolished in those taking anti-hypertensive drugs (Fain, 
2011). It is unclear why only IL-1Ra mRNA expression correlate with waist circumference 
but not that for MIF, IL-8 and IL-6. This suggests that hypertension in obese women has 
profound effects upon mRNA levels and abolishes the effect of obesity. The increase in 
leptin is expected and so far it is the only adipokine released solely by fat cells whose 
circulating levels are elevated in obesity. The elevated mRNA levels in visceral omental 
adipose tissue and circulating levels of both PAI-1 and Amyloid A suggest that these 
proteins may have a special role in visceral obesity.  
 
Positive correlations for these adipokines with severe obesity in women and 
mRNA levels in Omental fat Circulating levels 
Amyloid A Amyloid A Adipsin IL-8 
IL-1Ra IL-1Ra Apelin MIF 
Leptin Leptin FABP4 sPLA2 
PAI-1 PAI-1 IL-6 VEGF 
Table 3. Comparison of effects of severe obesity in women based on gene expression in 
visceral omental adipose tissue as compared to effects on circulating levels. The data on 
mRNA levels are from Fain (2011) and on circulating levels the data reviewed in sections 5.1 
to 5.40 of this chapter. 
The division between primary signals, pro- and anti-inflammatory molecules, secondary 
response molecules and unlikely adipokines is outlined in Table 4. The levels of secondary 
response molecules are elevated in obesity but are probably not regulated by release from 
adipose tissue. In contrast unlikely adipokines are those proteins whose circulating levels 
are not appreciably altered in obesity and are derived from sources other than adipose 
tissue in humans. The primary response signal in obesity is probably related to the 
expansion of the fat cells, which results in enhanced release of both fatty acids and leptin. 
Either or both of these signals could act as autocrine/paracrine factors to enhance the release 
of inflammatory mediators by both the fat and nonfat cells of visceral omental adipose 
tissue. This is accompanied by decreased release of adiponectin and enhanced release of IL-
1Ra, IL-10 and TNF-R2 that act as anti-inflammatory mediators to reduce inflammation. The 
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inflammatory response is associated with enhanced formation of the so-called secondary 
response molecules whose role in promoting insulin resistance is unclear while apelin is 













Unlikely adipokines in humans 
Fatty 
acids IL-1 Adiponectin Adipsin Cathepsin S Nesfatin RBP-4 
Leptin IL-6 IL-1Ra Amyloid A CD14 Omentin TSP-1 
 IL-8 IL-10 Apelin CRP Orsomucoid Vaspin 
 MCP-1 TNF-R2 FABP4 Endothelin-1 OPG Visfatin 
 MIF  PAI-1 Haptoglobin RANTES ZAG 
 TNF  sPLA2 Lipocalin-2 Resistin  
Table 4. Separation of putative adipokines by their role in the inflammatory response seen in 
obesity  
It should be noted that correlations of obesity with regards to mRNA levels in omental 
adipose tissue and elevations in the circulating levels of any protein do not prove a cause 
and effect relationship and most likely these are marker not maker molecules of obesity. 
Furthermore, it is likely that additional proteins other than those listed as unlikely 
adipokines will be found whose circulating levels are altered in obesity under some 
circumstances. Of the 12 listed in Table 3 as adipokines whose circulating levels are elevated 
in obesity, only leptin still remains as a primary response signal by fat cells in obesity.  
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refer to amyloid A as an adipokine because it is formed and released by adipose tissue in 
appreciable amounts in contrast to CRP where the release by adipose tissue is too small to 
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levels of the other putative adipokines are derived exclusively from adipose tissue or even 
that release by adipose tissue regulates their circulating levels. Probably the circulating 
levels of adipsin, apelin and IL-6 are influenced primarily by release by lymphoid tissues 
but in any case it is unlikely that release by adipose tissue is derived from fat cells. Finally, 
we have acute phase proteins such as CRP and haptoglobin whose circulating levels are 
elevated in obesity along with that of cathepsin S and are released primarily by liver in 
response to circulating inflammatory factors such as IL-6.  
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of the 12 adipokines whose circulating levels are consistently elevated in obesity as shown 
in Table 3. Furthermore, except for IL-1Ra, the increased mRNA expression in omental 
adipose tissue in obese women was abolished in those taking anti-hypertensive drugs (Fain, 
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adipose tissue and circulating levels of both PAI-1 and Amyloid A suggest that these 
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It is estimated that 5.7% of American adults, or approximately 14.5 million people, are 
morbidly obese, defined as a body mass index (BMI) of >40 kg/m2 and thus are eligible for 
bariatric surgery. (Flegal et al. 2010) If in one year, only 10% of these morbidly obese patients 
(approximately 1.45 Million) would undergo bariatric surgery, with an average expenditure of 
approximately $20,000, this would result in a total cost of US$ 29 billion. This amount is 
equivalent to about 1% of the total healthcare expenditure in the USA.(National Health 
Expenditure Data 2011) This estimate most likely underestimates the potential cost because the 
obesity epidemic is still growing in the USA, which has an obesity rate of over 30%.(Aasheim 
and Søvik 2011; Finucane et al. 2011; Flegal et al. 2010; Shao and Chin 2011) Because of the 
potentially significant impact on overall healthcare expenditures, policy makers and payers 
are very careful to allow free access to bariatric surgery for all severely or morbidly obese 
patients. In addition to appraising the impact on the future health status of morbidly obese 
patients, payers and decision makers want to be able to estimate the impact of bariatric 
surgery on their budgets and resources as well as to understand the potential return on such 
an investment. To determine the most recent knowledge on the economic consequences 
relating to bariatric surgery for payers in different healthcare settings, a literature review of 
economic or outcome publications was conducted and is summarized in this book chapter. 
Short-term cost is often a major barrier to payers and other interested parties. 
Understanding the full cost consequences of bariatric surgery includes consideration and 
comparison of both conventional treatment and surgery for morbid obesity against the 
associated overall health outcome. This information is needed to make rational decisions. 
Nonsurgical approaches to weight loss, however, are often requested or even reimbursed 
before agreeing to surgery – despite the fact that the impact of these therapies has been 
shown to be modest and short term for most patients. (Bockelbrink et al. 2008; Picot et al. 
2009; Li et al. 2005; Snow et al. 2005) To allow a rational decision, it is important to assess 
how bariatric surgery impacts health outcomes in comparison to the best existing 
alternatives and how much total expenditure is generated by bariatric surgery in 
comparison to the alternative approaches to weight loss. 
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1.1 Short introduction to health economics 
This section gives a brief introduction to health economics relevant to this chapter. Those 
familiar with health economics can skip this introduction.  
Cost-effectiveness analysis is an attempt to answer the question: “How much more (than 
today) are we willing pay for an improvement in health outcomes?” Improvements in health 
outcomes include a gain of life years, a reduction of disability or an improvement in the 
quality of life. In the cost-utility analysis, clinical and humanistic parameters are combined 
as quality adjusted life years (QALY) and the cost to improve the outcome by one QALY is 
calculated. (Berger and International Society for Pharmacoeconomics and Outcomes 
Research 2003)  
A QALY is a measure of additional life-time gained by a medical intervention (which could 
be a drug, surgery, diagnostic, etc.) adjusted by the utility or quality of life of the patients. 
The utility is evaluated through standardized and validated questionnaires (which can be 
general quality of life questionnaires or tailored to specific diseases) and quantified by health 
utilities or quality of life indices. These range from 1, a perfect state of health, to 0, equivalent 
to death. QALYs are determined by multiplying the number of additional life years by the 
health utilities (for example, 4 years with a utility of 0.75 = 3 QALYs). Cost-utility analysis 
allows comparing a broad range of healthcare interventions for their cost-utility and 
consequently help setting healthcare investment priorities. The incremental cost-
effectiveness or cost-utility ratios (ICER or ICUR) how much more has to be spent for a new 
technology over the comparator (usually the current standard of care) to achieve one 
additional QALY. (Berger and International Society for Pharmacoeconomics and Outcomes 
Research 2003)  
Authorities in some countries, such as UK, Canada, Australia and Sweden, are using the 
incremental cost per QALY for making decisions on the degree of reimbursement for 
interventions. Theoretically, interventions achieving improved outcomes at lower total 
healthcare cost are dominant and should be used and reimbursed; interventions with a 
worse outcome at higher cost should never be reimbursed. For technologies which result in 
increased cost but produce better outcomes, there should be an agreed upon threshold of 
acceptable cost per QALY or cost-utility ratios. This threshold varies and is subject of many 
discussions, but usually lies around 1 to 3 times the gross domestic product per capita. 
(Landa 2008; Shiroiwa et al. 2010) Technologies with higher cost per QALY should not be 
reimbursed as a general rule. However, other factors are also taken into consideration when 
deciding whether to reimburse or not (e.g. local economy, culture, ethics, innovation factor, 
budget impact, others). In other countries, such as the USA, France or Germany, the cost per 
QALY is not generally considered a key decision criterion. In these countries, cost-
effectiveness or budget impact over a limited time period might be considered more 
important by payer decision makers.  
Another way to estimate the value of bariatric surgery is to calculate the return on 
investment (ROI). ROI is a measure used to evaluate the efficiency of the investment in the 
surgery and is calculated for a defined time span by dividing the net financial gain (dollars 
gained from surgery minus the cost of surgery) by the cost of surgery. 
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2. Economic outcomes of bariatric surgery 
The general agreement is that patients with a BMI>40 kg/m2, or with a BMI>35 kg/m2 and a 
serious obesity-related comorbidity, who have failed to respond to conservative treatment 
(diet, exercise, pharmacology) are eligible for bariatric surgery. Despite this, less than 2% of 
these patients actually are offered or choose bariatric surgery. (Kim, White, and Buffington 
2010) A core question to payers before extending access to bariatric surgery will be what 
impact the increased use of bariatric surgery will have on their overall budgets. (Powers, 
Rehrig, and Jones 2007) 
2.1 Cost associated with obesity and bariatric surgery 
The key cost components of obesity are: 
 The need for ongoing dietary and behavioral interventions. 
 Treatment of the health consequences of obesity such as type 2 diabetes and 
cardiovascular disease. 
 Decreased work productivity. 
 Increased overall cost of living (e.g., additional services needed because of decreased 
mobility, adaptation of articles of daily use or furniture, etc.).  
The substantial health and quality of life benefits of decreased weight have been described 
in other chapters in this book. The question is whether the decreased costs of obesity listed 
above offset the cost of bariatric surgery, which is perceived as a costly procedure. The key 
cost components of surgery are (1) the surgical procedure and the associated hospital stay, 
(2) potentially serious short term and long term complications (e.g. surgical risk, food 
intolerance and micronutrient deficiencies, surgery related mortality), (3) supportive care 
services and treatments, and if necessary, potential reversal surgery. 
2.1.1 Cost of obesity  
Many studies have shown that obesity is associated with increased mortality, decreased 
quality of life, increased disability, and increased healthcare costs. (Finkelstein et al. 2009; 
Pendergast et al. 2010; Cawley 2010) The amount of this increase is different across different 
countries as shown by the following studies. Finkelstein et al estimated obesity-related 
diseases to account for $147 billion in the USA in 2006. The same study showed that the rate 
of obesity in the US increased by 37% from 1998 to 2006 with an increase of 89% in money 
spent on obesity-related diseases. This resulted in an increase from 6.5% to 9.1% of the total 
US healthcare budget spent on obesity and obesity related diseases. Finkelstein et al. 
calculated the adult annual per capita medical spending attributable to obesity (compared to 
a normal weight population) was $1,429 (42% higher than non-obese cost per capita). 
(Finkelstein et al. 2009) Significantly higher estimates of increased healthcare spending due 
to obesity were obtained by Pendergast et al. who calculated the annualized healthcare 
utilization costs for the US and Germany and found that in the US obese patients spent 73% 
more than non-obese people ($4,780 more) and 59% more in Germany ($1,035 more). 
(Pendergast et al. 2010) Cawley et al. estimated that obesity raises annual medical costs by 
$2,826 (2005 dollars) per obese patient and that the total annual cost of treating obesity in the 
US adult non-institutionalized population was $168 billion, or 16.5% of national spending 
on medical care. (Cawley 2010) Future trends exacerbate the problem.  
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1.1 Short introduction to health economics 
This section gives a brief introduction to health economics relevant to this chapter. Those 
familiar with health economics can skip this introduction.  
Cost-effectiveness analysis is an attempt to answer the question: “How much more (than 
today) are we willing pay for an improvement in health outcomes?” Improvements in health 
outcomes include a gain of life years, a reduction of disability or an improvement in the 
quality of life. In the cost-utility analysis, clinical and humanistic parameters are combined 
as quality adjusted life years (QALY) and the cost to improve the outcome by one QALY is 
calculated. (Berger and International Society for Pharmacoeconomics and Outcomes 
Research 2003)  
A QALY is a measure of additional life-time gained by a medical intervention (which could 
be a drug, surgery, diagnostic, etc.) adjusted by the utility or quality of life of the patients. 
The utility is evaluated through standardized and validated questionnaires (which can be 
general quality of life questionnaires or tailored to specific diseases) and quantified by health 
utilities or quality of life indices. These range from 1, a perfect state of health, to 0, equivalent 
to death. QALYs are determined by multiplying the number of additional life years by the 
health utilities (for example, 4 years with a utility of 0.75 = 3 QALYs). Cost-utility analysis 
allows comparing a broad range of healthcare interventions for their cost-utility and 
consequently help setting healthcare investment priorities. The incremental cost-
effectiveness or cost-utility ratios (ICER or ICUR) how much more has to be spent for a new 
technology over the comparator (usually the current standard of care) to achieve one 
additional QALY. (Berger and International Society for Pharmacoeconomics and Outcomes 
Research 2003)  
Authorities in some countries, such as UK, Canada, Australia and Sweden, are using the 
incremental cost per QALY for making decisions on the degree of reimbursement for 
interventions. Theoretically, interventions achieving improved outcomes at lower total 
healthcare cost are dominant and should be used and reimbursed; interventions with a 
worse outcome at higher cost should never be reimbursed. For technologies which result in 
increased cost but produce better outcomes, there should be an agreed upon threshold of 
acceptable cost per QALY or cost-utility ratios. This threshold varies and is subject of many 
discussions, but usually lies around 1 to 3 times the gross domestic product per capita. 
(Landa 2008; Shiroiwa et al. 2010) Technologies with higher cost per QALY should not be 
reimbursed as a general rule. However, other factors are also taken into consideration when 
deciding whether to reimburse or not (e.g. local economy, culture, ethics, innovation factor, 
budget impact, others). In other countries, such as the USA, France or Germany, the cost per 
QALY is not generally considered a key decision criterion. In these countries, cost-
effectiveness or budget impact over a limited time period might be considered more 
important by payer decision makers.  
Another way to estimate the value of bariatric surgery is to calculate the return on 
investment (ROI). ROI is a measure used to evaluate the efficiency of the investment in the 
surgery and is calculated for a defined time span by dividing the net financial gain (dollars 
gained from surgery minus the cost of surgery) by the cost of surgery. 
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2. Economic outcomes of bariatric surgery 
The general agreement is that patients with a BMI>40 kg/m2, or with a BMI>35 kg/m2 and a 
serious obesity-related comorbidity, who have failed to respond to conservative treatment 
(diet, exercise, pharmacology) are eligible for bariatric surgery. Despite this, less than 2% of 
these patients actually are offered or choose bariatric surgery. (Kim, White, and Buffington 
2010) A core question to payers before extending access to bariatric surgery will be what 
impact the increased use of bariatric surgery will have on their overall budgets. (Powers, 
Rehrig, and Jones 2007) 
2.1 Cost associated with obesity and bariatric surgery 
The key cost components of obesity are: 
 The need for ongoing dietary and behavioral interventions. 
 Treatment of the health consequences of obesity such as type 2 diabetes and 
cardiovascular disease. 
 Decreased work productivity. 
 Increased overall cost of living (e.g., additional services needed because of decreased 
mobility, adaptation of articles of daily use or furniture, etc.).  
The substantial health and quality of life benefits of decreased weight have been described 
in other chapters in this book. The question is whether the decreased costs of obesity listed 
above offset the cost of bariatric surgery, which is perceived as a costly procedure. The key 
cost components of surgery are (1) the surgical procedure and the associated hospital stay, 
(2) potentially serious short term and long term complications (e.g. surgical risk, food 
intolerance and micronutrient deficiencies, surgery related mortality), (3) supportive care 
services and treatments, and if necessary, potential reversal surgery. 
2.1.1 Cost of obesity  
Many studies have shown that obesity is associated with increased mortality, decreased 
quality of life, increased disability, and increased healthcare costs. (Finkelstein et al. 2009; 
Pendergast et al. 2010; Cawley 2010) The amount of this increase is different across different 
countries as shown by the following studies. Finkelstein et al estimated obesity-related 
diseases to account for $147 billion in the USA in 2006. The same study showed that the rate 
of obesity in the US increased by 37% from 1998 to 2006 with an increase of 89% in money 
spent on obesity-related diseases. This resulted in an increase from 6.5% to 9.1% of the total 
US healthcare budget spent on obesity and obesity related diseases. Finkelstein et al. 
calculated the adult annual per capita medical spending attributable to obesity (compared to 
a normal weight population) was $1,429 (42% higher than non-obese cost per capita). 
(Finkelstein et al. 2009) Significantly higher estimates of increased healthcare spending due 
to obesity were obtained by Pendergast et al. who calculated the annualized healthcare 
utilization costs for the US and Germany and found that in the US obese patients spent 73% 
more than non-obese people ($4,780 more) and 59% more in Germany ($1,035 more). 
(Pendergast et al. 2010) Cawley et al. estimated that obesity raises annual medical costs by 
$2,826 (2005 dollars) per obese patient and that the total annual cost of treating obesity in the 
US adult non-institutionalized population was $168 billion, or 16.5% of national spending 
on medical care. (Cawley 2010) Future trends exacerbate the problem.  
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2.1.2 Cost of bariatric surgery 
2.1.2.1 Cost of surgery procedure 
The cost of bariatric surgery has been estimated in several countries and from diverse 
perspectives. A summary of the cost estimates is listed in Table 1. For example for 
laparoscopic gastric banding (LAGB) the reported cost of surgery ranges from US$7,125 in 
the UK to US$25,000 in the US. The total short and long term cost of obesity or bariatric 
surgery is influenced by several factors, such as the cost of the intervention, the cost of 
adaptations (e.g. band adjustment) adverse events, reversals, nutritional supplements, 
secondary health-related cost such as treating the consequences of the fast and extensive 
weight loss, and cost of the general supportive care (e.g., dietary, educational, psychosocial). 
There is high variability amongst the existing studies as to which cost had been considered. 
A study in the UK estimated the immediate direct medical cost in the first year of LAGB to 
be £4,750 ($7,125). In this study, conventional obesity therapy was calculated to be £336 
(US$500) in the first year. (Clegg et al. 2002) A year later, the same authors compared the 
direct medical cost of two types of surgery by calculating the direct medical cost over 20 
years (£10,795 for LAGB and £9,627 for vertical gastric banding (VBG)1) with conventional 
care (£6,964). (Clegg et al. 2002)  
Some cost factors that have strongly affected the surgery-related cost for gastric banding in 
the early years, e.g. regular readjustment of the gastric band in the hospital, have been 
decreasing with greater experience and further development of the technology. Increasingly, 
the adjustments can now be performed during the regular visits in the outpatient setting, 
without the need for high cost hospital interventions. (Jan et al. 2007) 
2.1.2.2 Cost offset of usual care for those not receiving surgery 
It is crucial to consider, in addition to the immediate intervention-related cost, the cost 
from the longer-term consequences of obesity, such as type 2 diabetes mellitus, 
hypertension, cardiovascular diseases and increased cancer risk, in addition to reduced 
work productivity. For example, Ackroyd et al. published a model for bariatric surgery 
projected over five years for patients with type 2 diabetes in UK, France or Germany. 
(Ackroyd et al. 2006) The five-year cost of adjustable gastric banding in Germany was 
€13,610, in UK €12,838 (£9,072) and in France €14,796. While in UK the five-year direct 
medical cost of conventional care was lower than the surgical interventions (£7,080 
equivalent to €10,030), in both Germany and France the cost for usual care exceeded that 
of the surgical interventions (€17,197 and €19,267 respectively). This modelling study 
focused on patients with diabetes and incorporated all direct medical cost from third 
party payers’ perspective. Thus, the conventional treatment cost not only included the 
cost for diet and exercise therapy but also the treatment of comorbidities and office visits 
during the five-year time frame in this patient segment (see Table 1). This model was 
based on the conservative assumption that the length of stay after LAGB would be five 
days. In newer research, this time is much shorter (Jan et al. 2007). This means that this 
study probably overestimates the cost of LAGB. 
                                                 
1 £10,000 would be equivalent to €15’800 or US$15,000 
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Publication Data Year Cost Country 
Salem, 2008 2004 $16,200 USA 
Paxton, 2005 Before 2005 $17,660 - $29,443 USA 
Livingston, 2005 2001/2002 $19,794 - $23,355 USA 
Ikramuddin, 2009 2007 $19,760 USA 
Hoerger, 2010 2005 $15,536 - $20,326 USA 
Chang, 2011 2010 $23,778 - $64,784 USA 
Clegg, 2003 Before 2001 £9,627 - £10,795 UK 
Ackroyd, 2006 1998-2003 £7,088 - £9,121 UK 
Ackroyd, 2006 1998-2003 €12,166 - €17,197 GER 
Ackroyd, 2006 1998-2003 €13,399 - €19,276 FRA 
Table 1. Summary of publications reporting cost of bariatric surgery. 
Salem et al calculated the three-year cost of LAGB at US$16,200 and for Roux-en-Y gastric 
bypass (RYGB) at US$27,560, based on 2004 hospital charges associated with the surgery, 
including procedural fees, treatment of postoperative complications, follow-up care, and 
treatment of obesity-related diseases, such as coronary heart disease, stroke, type 2 diabetes, 
hypercholesterolemia, and hypertension. 
More recent publications estimate an additional cost of US$15,000 – US$20,000 over the 32-
38 years after surgery. (Ikramuddin et al. 2009; Hoerger et al. 2010) Chang et al 
differentiated between patients with obesity related diseases (ORD) and those without 
ORDs and analyzed the cost for three BMI classes, BMI above 35 and below 40, BMI 
between 40 and 50, and BMI above 50kg/m2. (Chang, Stoll, and Colditz 2011) Bariatric 
surgery in patients without ORDs incurred higher incremental cost over conventional 
therapy than in patient who had ORDs. In addition, the authors found that the incremental 
cost diminished with increasing BMI. This may be explained by the positive impact of 
bariatric surgery on ORDs, which lead to a prevention of costs related to the ORDs. On the 
other hand, higher BMI is a risk factor for developing ORDs and therefore, the total 
incremental cost of bariatric surgery as compared to non-surgery decreases with higher 
BMI. 
2.2 Cost and outcomes of bariatric surgery depending on the hospital’s experience  
The more experienced the care team is the lower the cost of bariatric surgery. Nguyen et al 
compared bariatric surgery (Roux-en-Y gastric bypass) performed at low volume hospitals 
(less than 50 procedures per year) with high volume hospitals (more than 100 procedures 
per year). They found that high volume hospitals had shorter length of stay (3.8 days vs. 5.1 
days for low volume hospitals), lower overall complications (10.2% vs. 14.5%) and lower 
cost ($10,292 vs. $13,908), (Nguyen 2004) which was driven to a large extent by the shorter 
hospital stay. The reduction of time in the hospital depends on the success rate of surgery 
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2.1.2 Cost of bariatric surgery 
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secondary health-related cost such as treating the consequences of the fast and extensive 
weight loss, and cost of the general supportive care (e.g., dietary, educational, psychosocial). 
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A study in the UK estimated the immediate direct medical cost in the first year of LAGB to 
be £4,750 ($7,125). In this study, conventional obesity therapy was calculated to be £336 
(US$500) in the first year. (Clegg et al. 2002) A year later, the same authors compared the 
direct medical cost of two types of surgery by calculating the direct medical cost over 20 
years (£10,795 for LAGB and £9,627 for vertical gastric banding (VBG)1) with conventional 
care (£6,964). (Clegg et al. 2002)  
Some cost factors that have strongly affected the surgery-related cost for gastric banding in 
the early years, e.g. regular readjustment of the gastric band in the hospital, have been 
decreasing with greater experience and further development of the technology. Increasingly, 
the adjustments can now be performed during the regular visits in the outpatient setting, 
without the need for high cost hospital interventions. (Jan et al. 2007) 
2.1.2.2 Cost offset of usual care for those not receiving surgery 
It is crucial to consider, in addition to the immediate intervention-related cost, the cost 
from the longer-term consequences of obesity, such as type 2 diabetes mellitus, 
hypertension, cardiovascular diseases and increased cancer risk, in addition to reduced 
work productivity. For example, Ackroyd et al. published a model for bariatric surgery 
projected over five years for patients with type 2 diabetes in UK, France or Germany. 
(Ackroyd et al. 2006) The five-year cost of adjustable gastric banding in Germany was 
€13,610, in UK €12,838 (£9,072) and in France €14,796. While in UK the five-year direct 
medical cost of conventional care was lower than the surgical interventions (£7,080 
equivalent to €10,030), in both Germany and France the cost for usual care exceeded that 
of the surgical interventions (€17,197 and €19,267 respectively). This modelling study 
focused on patients with diabetes and incorporated all direct medical cost from third 
party payers’ perspective. Thus, the conventional treatment cost not only included the 
cost for diet and exercise therapy but also the treatment of comorbidities and office visits 
during the five-year time frame in this patient segment (see Table 1). This model was 
based on the conservative assumption that the length of stay after LAGB would be five 
days. In newer research, this time is much shorter (Jan et al. 2007). This means that this 
study probably overestimates the cost of LAGB. 
                                                 
1 £10,000 would be equivalent to €15’800 or US$15,000 
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Salem et al calculated the three-year cost of LAGB at US$16,200 and for Roux-en-Y gastric 
bypass (RYGB) at US$27,560, based on 2004 hospital charges associated with the surgery, 
including procedural fees, treatment of postoperative complications, follow-up care, and 
treatment of obesity-related diseases, such as coronary heart disease, stroke, type 2 diabetes, 
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More recent publications estimate an additional cost of US$15,000 – US$20,000 over the 32-
38 years after surgery. (Ikramuddin et al. 2009; Hoerger et al. 2010) Chang et al 
differentiated between patients with obesity related diseases (ORD) and those without 
ORDs and analyzed the cost for three BMI classes, BMI above 35 and below 40, BMI 
between 40 and 50, and BMI above 50kg/m2. (Chang, Stoll, and Colditz 2011) Bariatric 
surgery in patients without ORDs incurred higher incremental cost over conventional 
therapy than in patient who had ORDs. In addition, the authors found that the incremental 
cost diminished with increasing BMI. This may be explained by the positive impact of 
bariatric surgery on ORDs, which lead to a prevention of costs related to the ORDs. On the 
other hand, higher BMI is a risk factor for developing ORDs and therefore, the total 
incremental cost of bariatric surgery as compared to non-surgery decreases with higher 
BMI. 
2.2 Cost and outcomes of bariatric surgery depending on the hospital’s experience  
The more experienced the care team is the lower the cost of bariatric surgery. Nguyen et al 
compared bariatric surgery (Roux-en-Y gastric bypass) performed at low volume hospitals 
(less than 50 procedures per year) with high volume hospitals (more than 100 procedures 
per year). They found that high volume hospitals had shorter length of stay (3.8 days vs. 5.1 
days for low volume hospitals), lower overall complications (10.2% vs. 14.5%) and lower 
cost ($10,292 vs. $13,908), (Nguyen 2004) which was driven to a large extent by the shorter 
hospital stay. The reduction of time in the hospital depends on the success rate of surgery 
 
Advanced Bariatric and Metabolic Surgery 
 
66
and the avoidance of complications. (Encinosa 2009) Since hospital cost is a major driver in 
the overall cost of surgery, a reduction in the length of stay leads to an improved cost-
effectiveness ratio.  
Increased improvement in the efficiency of surgery will improve the cost-utility ratio. For 
example, Jan et al. found in their retrospective analysis of data of a US hospital (in the high 
volume or Center of Excellence category) an average length of stay for LAGB of 1.1 days, 
while the time assumed in earlier models, or in studies integrating both open and 
laparoscopic adjustable gastric bypass, was more than 3 times as much. (Jan et al. 2007) As 
in the example of Ackroyd’s analysis of surgery for diabetic patients, better patient profiling 
may also improve the cost-effectiveness ratio with improved targeting of the intervention 
and consequently, improved outcomes. (Ayckrod 2006) 
2.3 Cost-effectiveness of bariatric surgery 
When assessing the cost impact of bariatric surgery, it is important to compare the surgery 
related cost versus the cost consequences of obesity over time. The resulting cost difference 
can be assessed in relation to the desired outcomes, such as the length of life and the health 
related quality of life of the patients. 
Ikramuddin et al. prospectively collected outcomes data in a practical real-life setting from 
567 obese patients with type 2 diabetes that underwent Roux-en-Y gastric by-pass surgery 
between 2001 and 2007 at the University of Minnesota Medical Center, Minneapolis. The 
data was entered into a health economic model (CORE Model). (Ikramuddin et al. 2009) In 
the model, the patient data was compared to a standard population of obese diabetic 
patients based on data obtained from the United Kingdom Prospective Diabetes Study 
(UKPDS), and the Framingham Heart Study. (Palmer et al. 2004a,b) At baseline, the patients 
were on average 50.1 years old, had a mean duration of diabetes or pre-diabetes of 8.7 years 
and 77.9% were female. The model projected cost and outcome over a time period of 35 
years and predicted that, after discounting cost and outcomes, patients that had bariatric 
surgery would on average live 11.54 years (undiscounted 15.94 years), while those only 
treated with conservative medical intervention would survive on average 10.87 years 
(undiscounted 14.66 years). In addition, the patients undergoing bariatric surgery would 
experience a better quality of life as measured by standardized quality of life questionnaires. 
Therefore, the model estimated a significant increase in QALYs by 0.9 to 6.78 compared to 
5.88 QALYs achieved by conservative medical treatment. The model projected cost savings 
from bariatric surgery in the areas of patient management of type 2 diabetes (screening 
procedures, medication), cardiovascular disease, renal complications, while additional costs 
were incurred by the surgery. The overall incremental cost-effectiveness was estimated to be 
US$ 21,973 per QALY, which would generally be accepted as cost-effective. The incremental 
cost per life year gained was US$ 29,676. It is important to note that the degree of cost-
effectiveness was strongly dependent on the long-term perspective and on the estimated 
improvement in quality of life. The highest costs in both cohorts were those associated with 
cardiovascular disease (CVD), which were higher for the medical-management cohort 
($37,824) than for the bariatric surgery cohort ($34,811) and represented an 8% decrease in 
CVD-related costs. Limitations of this study were that the model was extrapolated far 
beyond the time frame of the prospective data collection and that instead of collecting 
comparative control data these were extrapolated from previous UK studies. In sensitivity 
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analyses, shortening the time horizon to 5 and 10 years and excluding the negative impact of 
increased body mass index on the patient’s quality of life had the greatest adverse impact on 
the ICERs (i.e. higher cost per QALY). (Ikramuddin et al. 2009) 
Chang and his collaborators used a model for a representative US population (National 
Health and Nutrition Examination Survey III/NHANES III) and retrieved clinical and 
quality of life outcomes data from a meta-analysis. They gave a preference to newer data 
because the outcomes of bariatric surgery have greatly improved over the last 20 years. 
(Chang, Stoll, and Colditz 2011) Bariatric surgery was cost-effective for obese people with 
BMI greater than 35 kg/m2, with a cost per incremental QALY of less than US$4,000. It was 
also cost-saving for patients with a BMI greater than 50 kg/m2 with one or more obesity-
related comorbidity before surgery. Even for patients with a BMI above 30kg/m2, the cost 
per incremental QALY was only US$4,222 for patients without comorbidities or US$2,926 if 
they had comorbidities. If the willingness-to-pay-threshold is assumed to be US$40-60,000 
per QALY the results of this analysis support a broader use of bariatric surgery. 
In all studies, bariatric surgery remained cost-effective in the eligible patient group. 
Differences could be seen among subgroups. 
2.3.1 BMI level 
Craig et al. showed decreasing cost per QALY with increasing BMI. (Craig and Tseng 2002) 
That means that the more obese patients are the more value they can get from the surgery. 
This is probably connected to the risk of comorbidities increasing with higher BMI. 
Similarly, Chang et al used a model to analyze the cost-utility ratio in different BMI groups. 
(Chang, Stoll, and Colditz 2011) While the surgery intervention was cost-effective for all 
levels of BMI above 35kg/m2, the cost-utility ratio decreased with increasing BMI (over 
35kg/m2, over 40kg/m2, over 50kg/m2). 
2.3.2 Gender 
Salem et al. published an analysis of lifetime cost and incremental cost-utility for men and 
women from two laparoscopic bariatric surgery techniques as compared to conventional 
therapy. The incremental cost-utility for men aged 35 and a BMI of 40 or over was US$11,604 
per incremental QALY for laparoscopic adjustable gastric banding (LAGB) while for women 
it was US$8,878. For Roux-en-Y gastric bypass (RYGB) the cost per incremental QALY was 
US$18,543 for men and US$14,680/QALY for women. (Salem et al. 2008)  
2.3.3 Cost-effectiveness for obese patients with BMI over 35 and type 2 diabetes 
As already mentioned in the previous discussion, a large proportion of the potential savings 
induced by bariatric surgery is due to the reduction in comorbidities. The reduction of 
medical needs and degree of remission in type 2 diabetes from bariatric surgery is best 
supported by data. It is, therefore, no surprise that the favourable cost-effectiveness of 
bariatric surgery becomes most apparent for morbidly obese patients with type 2 diabetes. 
In a study conducted in Italy, Austria and Spain, a cost-effectiveness and budget impact 
model was used to estimate the resource utilization and cost of adjustable gastric banding 
and gastric bypass vs. conventional treatment in patients with a BMI ≥ 35 kg/m2 and type 2 
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treated with conservative medical intervention would survive on average 10.87 years 
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Therefore, the model estimated a significant increase in QALYs by 0.9 to 6.78 compared to 
5.88 QALYs achieved by conservative medical treatment. The model projected cost savings 
from bariatric surgery in the areas of patient management of type 2 diabetes (screening 
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were incurred by the surgery. The overall incremental cost-effectiveness was estimated to be 
US$ 21,973 per QALY, which would generally be accepted as cost-effective. The incremental 
cost per life year gained was US$ 29,676. It is important to note that the degree of cost-
effectiveness was strongly dependent on the long-term perspective and on the estimated 
improvement in quality of life. The highest costs in both cohorts were those associated with 
cardiovascular disease (CVD), which were higher for the medical-management cohort 
($37,824) than for the bariatric surgery cohort ($34,811) and represented an 8% decrease in 
CVD-related costs. Limitations of this study were that the model was extrapolated far 
beyond the time frame of the prospective data collection and that instead of collecting 
comparative control data these were extrapolated from previous UK studies. In sensitivity 
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analyses, shortening the time horizon to 5 and 10 years and excluding the negative impact of 
increased body mass index on the patient’s quality of life had the greatest adverse impact on 
the ICERs (i.e. higher cost per QALY). (Ikramuddin et al. 2009) 
Chang and his collaborators used a model for a representative US population (National 
Health and Nutrition Examination Survey III/NHANES III) and retrieved clinical and 
quality of life outcomes data from a meta-analysis. They gave a preference to newer data 
because the outcomes of bariatric surgery have greatly improved over the last 20 years. 
(Chang, Stoll, and Colditz 2011) Bariatric surgery was cost-effective for obese people with 
BMI greater than 35 kg/m2, with a cost per incremental QALY of less than US$4,000. It was 
also cost-saving for patients with a BMI greater than 50 kg/m2 with one or more obesity-
related comorbidity before surgery. Even for patients with a BMI above 30kg/m2, the cost 
per incremental QALY was only US$4,222 for patients without comorbidities or US$2,926 if 
they had comorbidities. If the willingness-to-pay-threshold is assumed to be US$40-60,000 
per QALY the results of this analysis support a broader use of bariatric surgery. 
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induced by bariatric surgery is due to the reduction in comorbidities. The reduction of 
medical needs and degree of remission in type 2 diabetes from bariatric surgery is best 
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and gastric bypass vs. conventional treatment in patients with a BMI ≥ 35 kg/m2 and type 2 
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diabetes. (Anselmino et al. 2009) In all scenarios analyzed for Italy and Austria, over a time 
span of 5 years, both procedures turned out to be cost-saving versus conventional treatment. 
In Spain there was incremental overall cost associated with both surgical interventions when 
compared to conventional treatment, but remained cost-effective even in the worst case 
scenario. Ackroyd et al. showed savings in addition to improved outcomes (QALYs) from 
bariatric surgery in German and French patients with type 2 diabetes. (Ackroyd et al. 2006)  
An American group used the Center of Disease Control (CDC)-RTI Diabetes Cost-
Effectiveness Markov Simulation Model to estimate the overall cost of gastric bypass or 
gastric banding surgery relative to conventional therapy throughout disease progression 
(from diagnosis of type 2 diabetes to either death or age 95 years). (Hoerger et al. 2010) The 
model also simulated diabetes-related complications on three microvascular disease paths 
(nephropathy, neuropathy, and retinopathy) and two macrovascular disease paths 
(coronary heart disease and stroke) and of remission and relapse of type 2 diabetes. Both 
surgical alternatives remained cost-effective in all scenarios but did not achieve cost-saving 
in this US based model. Gastric bypass surgery resulted in US$7,000/QALY for patients 
with BMI > 35 and newly diagnosed type 2 diabetes and US$12,000/QALY for those with 
diabetes existing for a longer time. Similarly, gastric banding surgery resulted in 
US$11,000/QALY and US$13,000/QALY for the respective groups. With this cost-
effectiveness range, both surgical alternatives remained below the typical cost-effectiveness 
of current anti-diabetic medications. (Hoerger et al. 2010) As an example, intensive glycemic 
and lipid control in comparison to conventional risk factor control have been shown to have 
incremental cost effectiveness ratio of US$41,384/QALY for patients with BMI > 35 and 
newly diagnosed diabetes and US$51,889/QALY for those with diabetes existing for a 
longer time. (CDC Diabetes Cost Effectiveness Group 2002)  
A study was conducted in seven Blue Cross/Blue Shield health care plans. It was a 
retrospective time-series study of patients who had undergone bariatric surgery and had 
evidence of preoperative diabetes based on medication use. The authors concluded that 
bariatric surgery was associated with a reduction of 98% in the total use of medication and 
in a reduction of overall health care costs in patients with type 2 diabetes. They, therefore, 
recommended that health insurers should cover bariatric surgery because of its health and 
cost benefits. (Makary et al. 2010)  
Another retrospective US database analysis by Klein and collaborators compared the 
economic impact between two matched cohorts of obese patients (BMI > 35) with type 2 
diabetes with or without bariatric surgery. In this database all types of bariatric surgery 
before 2004 were recorded under the same code. (Klein et al. 2011) Between 2004 and 2007, 
65% of the procedures were performed as laparoscopic interventions, and by 2007 they 
reached 94% of all bariatric surgeries. Approximately half of these were gastric banding 
procedures. The authors found that in the latter years, on average it took 29 months (range 
21-38) to fully recoup the cost of open surgery (US$ 28,845) and 26 months (range 20-32) for 
the cost of laparoscopic procedures (US$ 19,124). While in the no surgery control group, the 
rate of diabetes diagnosis or prescription claims fell to approximately 80%, it dropped to 
around 25% in the surgery group. In addition, medication supply cost slightly increased in 
the control group and it dropped by 80% in the surgery group, and remained stable 
throughout 36 months after surgery. (Klein et al. 2011) 
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Because of the strong clinical evidence the International Diabetes Federation (IDF) in 2011 
officially published a consensus statement supporting the positive impact of bariatric 
surgery on clinical and economic diabetes related outcomes. Consequently, IDF called for 
National guidelines for bariatric surgery in patients with type 2 diabetes and a BMI of 35 kg 
m2 or more to be developed and promoted. (J B Dixon et al. 2011)  
In a recent discussion of existing evidence, Villamizar suggested that due to both the 
positive clinical and economic impact to extend the eligibility criteria for bariatric surgery in 
the diabetic population even further to include patients a BMI of 30 kg m2 or above. 
(Villamizar and Pryor 2011) Health plans and other budget holders would have to expect 
increased short term cost, with a negative impact on their short term financial resources, and 
savings would only be expected two to three years after surgery. This may be one reason 
why payer organizations hesitate to give better access to bariatric surgery for all patients 
eligible per guideline definitions. 
2.4 Comparison of types of surgery 
After conservative weight reduction attempts failed and a decision to perform bariatric 
surgery has been made, there are different methodological approaches to bariatric surgery, 
which have been presented and discussed in other chapters of this book. Each intervention 
has advantages or disadvantages for specific patient groups. The three currently most used 
methods are gastric bypass surgery2, adjustable gastric banding3, and sleeve gastrectomy4. 
The individual patient profile (e.g. eating habits, BMI, general health, readiness to assume 
risk, eagerness for fast results) should be considered when making the decision for the most 
suitable surgical type. From the patient’s perspective, the surgery center’s capabilities and 
historical success rates in the specific type of surgery are important factors to consider.  
There is sufficient evidence to support offering a choice of procedures and making the 
decision together with the patient. The choice depends on his or her risk profile, eating 
habits, BMI, psychosocial situation, and personal preferences (Table 2 and Fig. 1). When 
performed in a surgical center experienced in obesity care, bariatric surgery usually achieves 
the goals of obesity therapy with acceptable low risk of surgery-related complications. In 
addition, Encinosa et al. were able to show in a retrospective insurance claims data analysis 
in the USA that the use of laparoscopy reduced total healthcare costs by 12%, while gastric 
banding decreased costs by 20%. Laparoscopy had no impact on readmissions; the increase 
in banding without bypass reduced readmissions. (Encinosa 2009).  
In the USA, laparoscopic gastric bypass and laparoscopic gastric banding are currently the 
two most commonly performed operations for the treatment of morbid obesity, (Hinojosa et 
al. 2009) although sleeve gastrectomy is increasingly used as an effective method of bariatric 
                                                 
2 Gastric bypass surgery involves the creation of a small gastric pouch and a shortcut of the remaining 
stomach and parts of the GI tract (bypass) 
3 A band placed around the upper part of the stomach to create a small pouch limits the amount of food 
intake at a time and can be adjusted regularly to maintain the effectiveness. 
4 The stomach is reduced to about 25% of its original size, by surgical removal of a large portion of the 
stomach, following the major curve. The open edges are then attached together to form a sleeve or tube. 
The procedure permanently reduces the size of the stomach. 
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surgery. Many cost-utility studies which evaluated various types of surgery methods in 
different patient groups have been published and are summarized in Table 2.  
Nguyen et al. conducted a randomized controlled trial comparing gastric bypass and gastric 
banding with respect to short and long term clinical outcomes, cost, and quality of life 
impact with 111 patients undergoing gastric bypass surgery and 86 patients receiving 
gastric banding surgery. (Nguyen et al. 2009) The study showed that a higher complexity of 
gastric bypass surgery is reflected in a longer time needed for surgery and recovery (see 
Table 3). Increasing complexity was also associated with higher complication rates and 
higher total cost. On the other hand, gastric bypass surgery was more effective for weight 
loss in terms of the extent of weight loss and the response rate. The authors suggested 
considering the trade-offs of increased complexity, cost, and complications versus improved 
weight outcomes, when making the decision on which type of surgery is the best for the 
individual patient. They also argued that even the inferior weight loss after the gastric 
banding procedure is far better than any non-surgical intervention and led to the same 
improvement of quality of life for the patients as gastric bypass surgery. 
 
Fig. 1. Conceptual treatment path of obese patients 
A smaller study was conducted by Ojo et al. in a hospital in New Haven, CT / USA and 
compared the cost of 83 laparoscopic adjustable gastric banding (LAGB) procedures with 
the cost of 59 laparoscopic vertical banded gastroplasty (LVBG) procedures. (Ojo and Valin 
2009) This group found in their setting a cost advantage for LVBG (US$1,927 lower cost of 
surgery but a somewhat higher follow-up cost). The authors found however, that the excess 
weight loss in LVBG patients was realized more rapidly than in LAGB patients. 
Another research group in the USA (Campbell et al. 2010) used the results of a five year 
European randomized clinical trial published in 2007 (Angrisani, Lorenzo, and Borrelli 2007) 
and base data from a systematic review of 36 English-language studies of weight loss 
outcomes following LAGB or laparoscopic RYGB (O’Brien et al. 2006). The authors 
conclusion was that both LAGB and LRYGB provided significant weight loss and were cost-
effective compared to conventional treatment at accepted thresholds for medical 
interventions. (Campbell et al. 2010) In the base case of the overall eligible population the 
incremental cost per life year saved was US$9,300 for LAGB and US$10,200 for LRYGB 
versus conventional therapy. The cost-utility was US$5,400 for LAGB and US$5,600 for 
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LRYGB versus conventional therapy. Comparing the two methods, LRYGB had an ICER of 
US$12,900 / Life Year saved versus LAGB and an ICUR of US$6,200 per QALY. The cost 
utility ratio improved with increasing morbidity and was generally better for females. 
However, in all cases the ICUR remained below US$15,000/QALY and the surgical 
procedures both were cost saving and improved clinical outcomes for females with a BMI > 
50 kg/m2. (Campbell et al. 2010) Since the input data originated from data collected before 
2006, it can be assumed that the rate of surgery related mortality and complications were 
overestimated in this model compared to today. Therefore the cost-effectiveness would be 
expected to be even more favourable for both types of surgery. 
Table 2 summarizes studies that reported on cost-utility analyses of bariatric surgery. 
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ORD=Obesity Related Disease 
 
Advanced Bariatric and Metabolic Surgery 
 
70
surgery. Many cost-utility studies which evaluated various types of surgery methods in 
different patient groups have been published and are summarized in Table 2.  
Nguyen et al. conducted a randomized controlled trial comparing gastric bypass and gastric 
banding with respect to short and long term clinical outcomes, cost, and quality of life 
impact with 111 patients undergoing gastric bypass surgery and 86 patients receiving 
gastric banding surgery. (Nguyen et al. 2009) The study showed that a higher complexity of 
gastric bypass surgery is reflected in a longer time needed for surgery and recovery (see 
Table 3). Increasing complexity was also associated with higher complication rates and 
higher total cost. On the other hand, gastric bypass surgery was more effective for weight 
loss in terms of the extent of weight loss and the response rate. The authors suggested 
considering the trade-offs of increased complexity, cost, and complications versus improved 
weight outcomes, when making the decision on which type of surgery is the best for the 
individual patient. They also argued that even the inferior weight loss after the gastric 
banding procedure is far better than any non-surgical intervention and led to the same 
improvement of quality of life for the patients as gastric bypass surgery. 
 
Fig. 1. Conceptual treatment path of obese patients 
A smaller study was conducted by Ojo et al. in a hospital in New Haven, CT / USA and 
compared the cost of 83 laparoscopic adjustable gastric banding (LAGB) procedures with 
the cost of 59 laparoscopic vertical banded gastroplasty (LVBG) procedures. (Ojo and Valin 
2009) This group found in their setting a cost advantage for LVBG (US$1,927 lower cost of 
surgery but a somewhat higher follow-up cost). The authors found however, that the excess 
weight loss in LVBG patients was realized more rapidly than in LAGB patients. 
Another research group in the USA (Campbell et al. 2010) used the results of a five year 
European randomized clinical trial published in 2007 (Angrisani, Lorenzo, and Borrelli 2007) 
and base data from a systematic review of 36 English-language studies of weight loss 
outcomes following LAGB or laparoscopic RYGB (O’Brien et al. 2006). The authors 
conclusion was that both LAGB and LRYGB provided significant weight loss and were cost-
effective compared to conventional treatment at accepted thresholds for medical 
interventions. (Campbell et al. 2010) In the base case of the overall eligible population the 
incremental cost per life year saved was US$9,300 for LAGB and US$10,200 for LRYGB 
versus conventional therapy. The cost-utility was US$5,400 for LAGB and US$5,600 for 
 
The Economic Impact of Bariatric Surgery 
 
71 
LRYGB versus conventional therapy. Comparing the two methods, LRYGB had an ICER of 
US$12,900 / Life Year saved versus LAGB and an ICUR of US$6,200 per QALY. The cost 
utility ratio improved with increasing morbidity and was generally better for females. 
However, in all cases the ICUR remained below US$15,000/QALY and the surgical 
procedures both were cost saving and improved clinical outcomes for females with a BMI > 
50 kg/m2. (Campbell et al. 2010) Since the input data originated from data collected before 
2006, it can be assumed that the rate of surgery related mortality and complications were 
overestimated in this model compared to today. Therefore the cost-effectiveness would be 
expected to be even more favourable for both types of surgery. 
Table 2 summarizes studies that reported on cost-utility analyses of bariatric surgery. 
 











M. BMI > 40, A 35 
Cost for treatment for many obesity-related 
diseases (such as gastro-esophageal reflux 
disease, sleep apnea, and degenerative joint 
disease) were not included 
$ 10,700 M, BMI > 50, A 35 
$ 14,700 W, BMI > 40, A 35 
$ 5,700 W, BMI > 50, A 35 
$ 35,600 M. BMI > 40, A 50 
$ 13,300 M, BMI > 50, A 50 
$ 16,100 W, BMI > 40, A 50 
$ 5,400 W, BMI > 50, A 50 
Clegg et al. 
2003 < 2002 
£ 6,289 GB/UK Cost estimates after one year only based on 
expert opinion. Only diabetes as cost of 
comorbidity; no productivity considerations. 
£ 8,527 AGB/UK 
£ 10,237 VBG/UK   
Ackroyd et 
al. 2006 < 2005 
£ 3,251 AGB/UK 
Patients with  
T2DM 
Payor perspective. No productivity data. 5-
year time frame. Limited sensitivity analysis 
i.e. testing of extreme points 
£ 2,599 GB/UK 
€ (1,305) AGB/GER 
€ (2,208) GB/GER 
€ (1,379) AGB/FRA 
€ (4,000) GB/FRA 
Salem et al. 
2008* 2004 
 $ 11,604 LAGB/USA
M. A 35; BMI 40  Incremental cost effectiveness ratio (ICER) 
of LAGB or LRYGB as compared with 
medical interventions 
 $ 18,543 RYGB/USA
 $ 8,878  LAGB/USA
W. A 35; BMI 40  
 $ 14,680 RYGB/USA
Ikramuddin 
et al. 2009 
2001 - 
2007 
 $ 21,973 
GB/USA 
35 year time horizon CORE Diabetes Model for T2DM or pre-
diabetes. Comparison GB surgery versus 
Medical Treatment.   $ 122,001 10 year time horizon 
Campbell et 
al. 2010 < 2006 
 $5,400  LAGB/USA Input data from previous European or 
literature review  $ 5,600  LRYGB 





 $ 2,413  
all types 
BMI >35<40, ORD 
Model for a population (age ≥ 17), obtained 
from National Health and Nutrition 
Examination Survey (NHANES) III and data 
from meta-Analysis including RCT and non-
RCT data 
$ 3,872 BMI >35<40, no ORD 
$ 1,853 BMI >40<50, ORD 
$ 3,770 BMI >40<50, no ORD 
dominant BMI >50, ORD 








Newly diag. T2DM 
Centers for Disease Control and Prevention–
RTI Diabetes Cost-Effectiveness Model 
extended to bariatric surgery 
$ 1,000 Established T2DM 
$ 12,000 
AGB/USA 
Newly diag. T2DM 
$ 13,000 Established T2DM 
Table 2. List of studies reporting cost-utility ratios (Cost/QALY). M=Men; W=Women; 
ORD=Obesity Related Disease 
 
Advanced Bariatric and Metabolic Surgery 
 
72






Operative time (minutes) 136.9±31.9 68.21 ±24.7 <0.01 
Estimated blood loss 4x Reference (1) <0.01 
Length of hospital stay 3.1 ± 1.5 1.5 ± 1.1 <0.01 
ICU use 2.7% 1.2% N.S. 
30 day mortality 0 0 N.S. 
Recovery 
Return to daily living activities (d) 14.5 ± 12.7 10.4 ± 10.1 <0.02 
Return to work (d) 21.0 ± 13.65 14.0 ± 10.1 <0.01 
Complications 
Major early complications 6.3% 2.3% N.S. 
Minor early complications 15.3% 4.7% 0.02 
Major late complications 26.1% 11.6% 0.01 
Minor late complications 13.5% 0% <0.01 
30 day reoperation 5.4% 1.2% N.S. 
Late reoperation 7.2% 11.6% N.S. 
90 day mortality 0 0 N.S. 
Weight Loss 
Excess weight loss 2 yrs 68.9% 41.8%  
Excess weight loss 4 yrs 68.4% 45.4%  
Treatment success and failure rate 
Treatment failure rate (excl. patients lost to 
follow-up) 0% 16.7%  
Treatment failure rate (incl. patients lost to 
follow-up) 15.3% 23.3%  
%age of patients with adequate or good weight 
loss 35.9% 67.9%  
%age of patients with excellent or exceptional 
weight loss 54.1% 15.3%  
Total Cost 
Total cost (US$) 12,310 ± 3,099 10,767 ± 1,631 <0.01 
Quality of Life (SF 36) 
QoL after 1 month Improved in 5 of 8 domains 
Improved in 1 
of 8 domains  
QoL after 1 year 
Improved to 
normal in all 
domains 
Improved to 




Table 3. Summary of study results of randomized controlled trial comparing laparoscopic 
gastric bypass surgery and laparoscopic gastric banding for clinical, economic, and quality 
of life outcomes 
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The evidence shows that both LAGB and RYGB are cost-effective. However, there is no clear 
evidence supporting superior cost-effectiveness of either surgical intervention compared to 
the other but there is a tendency that with increasing proficiency and experience LAGB may 
decrease cost by (1) requiring shorter time for surgery, hospitalization and recovery (2) 
lowering peri-surgical morbidity and mortality and (3) reducing severe surgery-related 
morbidity in the short and long term. 
2.5 Budget impact, break-even or time to payback 
A study by Cremieux et al., using a private insurer claims database, quantified the effect of 
bariatric surgery on direct medical costs in 3,651 US patients for up to five years after bariatric 
surgery. (Cremieux et al. 2008) Compared to a matched group of morbidly obese patients with 
similar comorbidity profile, but did not receive bariatric surgery, the authors found that the 
surgery group accrued incremental costs of approximately US$24,500 for all types of bariatric 
surgery combined (US$26,000 for open surgery, and US$17,000 for laparoscopic surgery) 
during the period from one month before surgery to two months following surgery. From 
month three onwards, cost savings associated with the bariatric surgery patients started 
accumulating. One and a half years after surgery the monthly savings associated with bariatric 
surgery reached more than US$500 for the whole sample. Monthly savings associated with 
laparoscopic bariatric surgery reached more than US$900 as early as 13 months following 
surgery (P<0.01). Open surgery between 2003 and 2005 achieved the break-even after 49 
months (95% CI, –35 to 63 months), and the cost of laparoscopic surgery were fully recovered 
after 25 months (95% CI, –16 to 34 months). The savings came from reductions in prescription 
drug costs, physician visit costs and hospital costs (including emergency department visits and 
inpatient and outpatient visits). The reduced cost was associated with multiple major 
diagnosis categories, including type 2 diabetes, coronary artery disease, hypertension, and 
sleep apnea. This analysis had several conclusions:  
 The cost of laparoscopic bariatric surgery could be recovered after a little over two 
years. The savings accrued came mainly from reduced use of medication and healthcare 
services originating from comorbidities.  
 Laparoscopic interventions were more cost-effective than the open surgery alternatives.  
 Outcomes from surgery improved over time as the surgical team gained more 
experience, especially during the first few years. When analyzing the accumulated cost 
in the surgery group before 2003, an average of 77 months was needed to recover the 
investment (95% CI, –48 to 106 months).  
 Third-party payers should invest in bariatric surgery because it generally will pay for 
itself through decreased comorbidities within two to four years in addition to potential 
quality-of-life and length-of-life benefits, as well as reduction in disability and work loss. 
To confirm the observation of effective reduction of comorbidities, Cremieux et al. 
conducted another study where they analyzed data from 5,502 patients in the same database 
for comorbidity related claims before and after surgery. (Cremieux et al. 2008) Compared to 
the period before surgery, significant decreases (p<0.05) were observed as early as 120 days 
after surgery and remained lower until three years after surgery. All cardiovascular 
disorders decreased from 43.6% pre-surgery to 14.2% post-surgery. The diagnosis of 
diabetes mellitus fell from 19.9% to 7.7%. Chronic obstructive pulmonary disease and other 
respiratory conditions also improved by over 40 percentage points (from 57.7% before to 
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Table 3. Summary of study results of randomized controlled trial comparing laparoscopic 
gastric bypass surgery and laparoscopic gastric banding for clinical, economic, and quality 
of life outcomes 
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in the surgery group before 2003, an average of 77 months was needed to recover the 
investment (95% CI, –48 to 106 months).  
 Third-party payers should invest in bariatric surgery because it generally will pay for 
itself through decreased comorbidities within two to four years in addition to potential 
quality-of-life and length-of-life benefits, as well as reduction in disability and work loss. 
To confirm the observation of effective reduction of comorbidities, Cremieux et al. 
conducted another study where they analyzed data from 5,502 patients in the same database 
for comorbidity related claims before and after surgery. (Cremieux et al. 2008) Compared to 
the period before surgery, significant decreases (p<0.05) were observed as early as 120 days 
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disorders decreased from 43.6% pre-surgery to 14.2% post-surgery. The diagnosis of 
diabetes mellitus fell from 19.9% to 7.7%. Chronic obstructive pulmonary disease and other 
respiratory conditions also improved by over 40 percentage points (from 57.7% before to 
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16.2% after surgery). In addition, prevalence of diseases of the musculoskeletal system and 
connective tissue was reduced from 32.6% to 27.7%, and mental disorders were 
approximately halved with 30.7% before and 14.8% after surgery.  
Simultaneously, the medication use dropped significantly for a number of conditions 
including infections, pain, respiratory disease, cardiovascular disease, gastroenterological 
diseases, and diabetes. In addition, there was an improvement in the lipid profile of the 
patients. Anemia, however, increased from 3.8% to 9.9% and use of nutritional supplements 
increased significantly. Both are known consequences of the surgery. 
A similar analysis of claims data (US MarketScan Commercial Claims and Encounters 
Database from January 1, 2003 to March 31, 2008) of more than 7,000 patients having 
undergone laparoscopic adjustable gastric banding surgery was published in 2011. 
(Finkelstein et al. (a) 2011) They determined that the average cost of surgery was 
approximately US$20,000 and that this investment was recouped within two years for the 
diabetic population and within four years for the non-diabetic patient group due to 
decreased utilization of healthcare services and medication.  
A subsequent study used data from the US Medical Expenditure Panel Survey (MEPS) and 
data from the US National Health and Wellness Survey (NHWS) to calculate the time 
needed to recoup the cost of bariatric surgery when including direct medical cost (hospital, 
drugs, clinical services, etc.) and indirect cost (absenteeism and presenteeism) of obese 
patients who were eligible for bariatric surgery. (Finkelstein et al. (b) 2011) They concluded 
that it takes nine quarters to recoup the cost of surgery. The improvement in absenteeism or 
presenteeism balanced the time of lost work when the patients underwent the surgery. 
Beyond the break-even time horizon there are additional indirect benefits that accrue to 
employers as a result of the procedure. 
Perry et al. analyzed 11,903 surgery patients matched to 11,901 controls selected from 
190,448 Medicare patients matched for age, sex and comorbidity in the USA. (Perry et al. 
2008) Throughout two years, the incidence of several obesity related diseases were reduced 
when compared to the control group (all results were statistically highly significant): 
- Diabetes fell by 21% 
- Sleep apnoea by 10% 
- Hypertension by 21% 
- Hyperlipidemia by 30% 
- Coronary artery disease by 32%.  
In contrast to the above studies, an analysis of long-term health care utilization and 
expenditures among veterans in the USA that underwent bariatric surgery in 12 Veteran 
Affairs (VA) medical centers from 2000 to 2006 did not reveal a reduction in overall health 
expenditures by the end of three years. The data indicated a significant decrease in 
outpatient health expenditures, but this reduction was offset by a significant increase in 
inpatient health expenditures. (Maciejewski et al. 2010) Several factors may have contributed 
to this result, including the fact that the analysis targeted a special subset of patients usually 
older than average patients undergoing bariatric surgery, had a higher degree of long 
established comorbidities and were male. In addition, none of the patients received 
laparoscopic banding procedures and only a minority of the surgeries used laparoscopic or 
less invasive methods. 
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More studies and models have attempted to calculate the time to break-even, or the time 
needed until an intervention starts to generate more savings than it cost. 
Table 4 lists the results from several studies and, depending on the point of view, these authors 
expected the break-even in one to ten years. It depends on the type of cost and the 
comparators considered when the break-even point is reached — or even if it is reached. 
Employers paying for the healthcare of their employees would be interested in improved 
productivity and reduced absenteeism. From their point of view productivity and absenteeism 
should be included in the beak-even or time to pay-back calculations. On the other hand, 
insurers or national health systems might only be interested in the direct medical cost. 
 
Publikacation Country Break-even or time to pay-back 
Finkelstein; Brown 2005 USA 5-10 years for employer to recover cost 
Snow et al. 2004 USA Break-even after 2-3 years 
Narbro et al. 2002 Sweden Total cost similar 
Christou et al. 2004 Canada 2-3 years 
Sampalis et al. 2004 Canada 2-3 years 
Gallagher et al. 2003 USA Cost is off set in year 1 through reduction of 
outpatient visits in Veterans Affairs population 
Maciejewski et al. 2010 USA No break-even in Veterans Affairs population 
Mullen; Marr 2010 USA 3.5 years after gastric baypass 
Cremieux et al. 2008 USA 53 months for bariatric surgery overall 
25 months for laparoscopic bariatric surgery 
Finkelstein et al. 2011(a) USA 2 years for diabetic patients 
4 years for non-diabetic patients 
Finkelstein et al. 2011(b) USA 2.25 years for all patients, including direct and 
indirect cost & savings 
Table 4. Summary of studies, which report a ‘break-even’ time for bariatric surgery cost 
Several studies find that LAGB and RYGB are cost saving and improve clinical outcomes 
when compared to conventional therapy. Both procedures also have a relatively short time 
before reaching break-even (two to 10 years). (Cremieux et al. 2008) 
2.6 Geographic areas 
Most of the evidence on economic impact of bariatric surgery has been generated in the 
United States and in Europe. Several European countries as well as Canadian authorities 
and some US payer organizations have assessed the technology systematically by looking at 
the clinical and the economic evidence. The conclusions were not always consistent and 
depended on the evidence reviewed, the perspective of the evaluation, and the time frame 
assessed. Therefore, many assessments remain indecisive in their final conclusion and 
requested further evidence to be generated. 
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The recent health technology assessment in the UK, performed in 2009, included a literature 
review of the key published clinical studies and cost-effectiveness analysis. In addition, the 
cost-effectiveness of bariatric surgery was further analyzed in two models. (Picot et al. 2009) 
The incremental cost-effectiveness ratios (ICERs) ranged between £2,000 and £4,000 per 
QALY gained. The results were generally robust to changes in assumptions in the sensitivity 
analysis, and in all cases the ICERs remained within the range conventionally regarded as 
cost-effective from an NHS decision-making perspective. Surgical management (with AGB) 
of moderate to severe obesity (BMI ≥ 30 and < 40) in patients with type 2 diabetes was more 
costly than nonsurgical management, but resulted in improved clinical outcomes. The ICER 
was reduced with a longer time horizon, from £18,930 at two years to £1,367 at 20 years. The 
authors also analyzed the cost effectiveness of the intervention for the patients with a BMI 
between 30 and 35. Based on data from two clinical trials, the QALY gain at two years was 
small (0.08). The ICER was again reduced with a longer time horizon, from £60,754 at two 
years to £12,763 at 20 years. (Picot et al. 2009) The general conclusion was that bariatric 
surgery was a clinically effective and cost-effective intervention for moderately to severely 
obese people compared with non-surgical interventions. 
The UK National Institute for Health and Clinical Excellence (NICE) guidelines state that 
bariatric surgery should be offered to patients with a BMI of 35 - 40 who have other conditions 
caused by being overweight, such as diabetes and obstructive sleep apnea or hypertension and 
all appropriate non-surgical measures have been tried but have failed to achieve or maintain 
adequate, clinically beneficial weight loss for at least 6 months or for those with a BMI of 40-50 
with no other weight related conditions. For those with a BMI of 50 and over bariatric surgery 
can be offered as a first-line treatment (NICE Guideline CG43, 2010). 
A health technology assessment conducted by a German expert group came to the 
conclusion that bariatric surgery seemed to be clinically effective and cost-effective, based 
on an extensive literature analysis. (Bockelbrink et al. 2008) At this time, no specific German 
cost-effectiveness analysis has been conducted.  
Finland’s health technology assessment agency (FINOHTA) included a cost-utility analysis 
for the most commonly used surgical techniques from the healthcare provider perspective 
over a ten year time frame. They concluded that bariatric surgery in Finland was more 
effective and less costly than the conventional therapy for morbid obesity and was the 
dominant technology. (Mäklin et al. 2009)  
2.6.2 Canada 
A recent health technology assessment from the Canadian authorities concluded that over a 
time period of 20 years, bariatric surgery for morbidly obese patients appeared to be cost-
effective with an ICER of US$5,000 to US$30,000 / QALY. (Padwal et al. 2011; Klarenbach et 
al. 2010) For patients with type 2 diabetes, the intervention was recognized as cost saving 
and with improved outcomes. A retrospective data analysis performed in Quebec found 
cost savings after 3.5 years from bariatric surgery due to reduced health care utilization for a 
variety of obesity related disorders. (Sampalis et al. 2004) A new analysis is currently 
ongoing, where three patient groups are compared for clinical, quality of life, and cost 
outcomes for one year retrospectively and two years prospectively after referral or surgery. 
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The study will include 150 surgical cases, 200 medically treated controls, and 150 wait-listed 
controls. (APPLES study; (Padwal et al. 2010)). Final results for the APPLES analysis are 
anticipated by late 2012 or early 2013. 
2.6.3 Australia 
Keating and colleagues compared the cost to achieve diabetic remission in 60 morbidly obese 
patients through LAGB or conventional treatment in a two year randomized clinical trial in 
Australia. (Keating et al. 2009a) The study showed that in the time frame of the two-year study 
period, AU$16,000 additional expenditure for the surgical intervention was needed per 
additional remission of diabetes. The highest cost difference was detected in the first six 
months of the study period including the cost of the surgery and the short-term complications. 
Savings were subsequently demonstrated for the surgery group in the consumption of anti-
diabetic medicine, with increasing consumption by the patients without bariatric surgery.  
Subsequently, the same group of researchers extended the study results into an incremental 
cost-effectiveness Markov model and extrapolated the intervention costs based on the 
observed resource utilization during the trial. (Keating et al. 2009b) In this lifetime model, 
the mean discounted cost per patient was AU$98,900 for surgical therapy and AU$101,400 
for conventional therapy. Over a lifetime, the health-care cost to treat type 2 diabetes became 
the overwhelming cost driver and cost differential between the two intervention groups. 
The researchers found a 57% chance of surgery to be cost saving, a 98% chance to be very 
cost-effective (below AU$7,000/QALY) and even in the worst-case scenario, surgery 
remained cost-effective with AU$39,700/QALY. The authors concluded that based on this 
trial in the Australian setting the cost of bariatric surgery (LAGB) for patients with BMI > 35 
and type 2 diabetes should be recovered within 10 years after surgery. 
2.6.4 Latin America  
There is limited literature available for the use and cost-effectiveness of bariatric surgery in 
Latin America. One publication by Salgado et al. calculated the actual cost of bariatric 
surgery in the hospital setting and contrasted it with the very low standard reimbursed rate 
by the public health insurance (R$3,260 in 2004; R$4,615 after August 2007). (Salgado Júnior 
et al. 2010) The calculation was only based on 9 patients treated in 2004 (average cost of 
R$6,845/surgery) and 7 patients treated in 2007 (average cost of R$7,525/surgery) and no 
outcomes or cost-effectiveness were reported. 
2.7 Effect on productivity (paid work) 
Obesity tends to lead to reduced income. (Flum et al. 2005; Martin et al. 2010) It was 
estimated in New Mexico that the total labor income impact of obesity was nearly US$200 
million, representing US$1,660 of output income and US$245 of labor income per household. 
Obesity may cost New Mexico more than 7,300 jobs and cuts state and local tax revenues by 
more than US$48 million. (Frezza and Wachtel 2009)  
Few studies have examined the impact of bariatric surgery on productivity. According to a 
US analysis, obese workers eligible for bariatric surgery have 5.1 (P <0.01) additional days of 
absenteeism and US$2,230 (in 2004 dollars) (P<0.01) higher annual medical costs than 
persons of a BMI of less than 25. (Finkelstein and Brown 2005) Given that bariatric surgery 
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et al. 2010) The calculation was only based on 9 patients treated in 2004 (average cost of 
R$6,845/surgery) and 7 patients treated in 2007 (average cost of R$7,525/surgery) and no 
outcomes or cost-effectiveness were reported. 
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Obesity tends to lead to reduced income. (Flum et al. 2005; Martin et al. 2010) It was 
estimated in New Mexico that the total labor income impact of obesity was nearly US$200 
million, representing US$1,660 of output income and US$245 of labor income per household. 
Obesity may cost New Mexico more than 7,300 jobs and cuts state and local tax revenues by 
more than US$48 million. (Frezza and Wachtel 2009)  
Few studies have examined the impact of bariatric surgery on productivity. According to a 
US analysis, obese workers eligible for bariatric surgery have 5.1 (P <0.01) additional days of 
absenteeism and US$2,230 (in 2004 dollars) (P<0.01) higher annual medical costs than 
persons of a BMI of less than 25. (Finkelstein and Brown 2005) Given that bariatric surgery 
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has been shown to increase life expectancy and to reduce the impact of overweight and 
comorbidities an increase in productivity would be expected. (Frezza and Wachtel 2009) 
A retrospective analysis in the Duke Health and Safety Surveillance System compared data 
of morbidly obese workers (BMI ≥ 40) with workers with a BMI 18.5 to 24.9 and revealed 
that the obese workers generated twice the amount of claims with 6.8 times higher medical 
claims cost and 11 times higher indemnity claims cost. In addition they lost 12.9 times more 
workdays than the non-obese workers. (Ostbye et al. 2007) 
A UK study followed 59 patients for 14 months after bariatric surgery. (Hawkins et al. 2007) 
Before the surgery 58% of the patients worked, with an average work week of 30.1 hours, 
and 32% claimed some sort of incapacity benefits. After surgery 76% of the patients worked, 
with an average work week of 35.8 hours, and only 10% claimed benefits. The work or 
productivity profile of the patients after bariatric surgery looked very similar to that of the 
average population. Taking both the increase in percentage of people that worked and the 
increase in average number of hours worked per week, there was a 57% total increase in 
number of hours worked per week.  
In a Dutch study the employment level was 53% before bariatric surgery and after surgery 
rose to 80%. (van Gemert et al. 1998) Since 1998, when the Dutch study was published, the 
outcome of bariatric surgery has improved significantly and it can be assumed that the 
impact on productivity would be even higher today. 
2.8 The cost impact of full reimbursement of bariatric surgery 
As was outlined in the beginning of this paper, payers are concerned with the potential high 
short-term cost as a consequence of broader access to bariatric surgery according to the clinical 
guidelines. There is, however, evidence that the utilization might not grow at a very high rate. 
In 2010, Kim et al. published their analysis of frequency of bariatric surgery in an employer 
insurance setting, which had decided to give free access to bariatric surgery to those who were 
eligible. The data showed that one year before the new policy 18 persons had a bariatric 
surgery with a utilization rate of 1.71%. In the year after the policy change, 16 people elected 
surgery with a utilization rate of 1.42%.(Kim, White, and Buffington 2010) The frequency of 
bariatric surgery in the United States may even have levelled at around 110-120,000 
procedures per year despite an increasing prevalence of obesity and a prominent decrease in 
complication rates. (Livingston 2010) This indicates that there is a considerable barrier for 
patients to elect this intervention and it may not be the preferred solution for all morbidly 
obese patients. Fears connected to the perceived risk of the procedure and the perceived 
negative impact on quality of life after the intervention may be a reason for the barrier. 
It may appear that the utilization of bariatric surgery will only increase slowly and the 
additional short term burden on payer budgets will remain a relatively controlled level. In 
addition, the evidence is strong that the number of bariatric surgeries might increase short 
term cost, but can be expected to generate mid- to long-term benefits at acceptable costs or 
even savings.  
3. Conclusions on the value of bariatric surgery 
Based on currently available clinical evidence, bariatric surgery is an effective method to 
decrease the long-term risk of obesity for morbidly obese patients. Bariatric surgery can 
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effectively reduce disease sequelae of obesity such as diabetes, hypertension, sleep apnea, 
cancer and cardiovascular disease and reduces mortality from these diseases. 
The different types of bariatric surgery have all been effective in reducing weight and 
diseases related to obesity. They do, however, have different levels of intervention risk as 
conceptualized in Fig. 2. 
 
Fig. 2. Conceptual summary of clinical outcomes of treatment alternatives for morbidly obese 
patients. LAGB: Laparoscopic Adjustable Gastric Banding; LGBP: Laparoscopic Gastric Bypass 
The investment in bariatric surgery is generally considered relatively high (US$7,000 to 
US$25,000) and there is reluctance to reimburse this kind of surgery. When a longer 
timeframe is considered, which would include reduction in cost of comorbidities, bariatric 
surgery for eligible obese patients is cost effective or even cost saving for many patients. For 
obese patients with existing obesity related comorbidities, like type 2 diabetes, bariatric 
surgery becomes even more cost effective and some studies have shown it to be cost saving. 
Evidence has also shown that the more experience the surgeons and the care team have, the 
more clinical outcomes are improved and bariatric surgery becomes more cost-effective. 
Despite the evidence supporting the cost-effectiveness or even cost savings for bariatric 
surgery, it seems that there are only a limited number of patients willing to elect this type of 
intervention. This may be due to the risk perceived by the patients and the fear of the 
behavioural consequences of the surgery and their impact on the subsequent lifestyle.  
In conclusion: Bariatric surgery is cost-effective or cost saving for eligible patients, usually 
with a relatively short payback time. It can be even more cost-effective or often cost saving, 
for patients with obesity related comorbidities, especially when they are treated by 
experienced surgical and care teams. Given the positive impact on length of life and quality 
of life and considering the increasingly efficient and reliable methodologies and care process 
used today, bariatric surgery has become an attractive investment for eligible obese patients. 
4. Appendix - methods (review of health economic publications on bariatric 
surgery) 
The English-language literature was searched with Medline, PubMedCentral and the 
National Library of Medicine Catalog in 2008, 2009 and 2011. A search for relevant articles 
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was conducted by entering the terms “bariatric surgery”, “obesity surgery” or “morbid 
obesity” and “outcomes”. For relevant article that were found, a “related article” search was 
performed. Additionally a search was based on MESH terms as listed below. 
 MESH Terms: 
 Gastric Bypass + Treatment Outcome 
 Gastric Bypass/economics 
 Gastroplasty + Treatment Outcome 
 Gastroplasty /economics 
 Treatment Outcome + Obesity,  
 Morbid Obesity/ complications,  
 Morbid Obesity + Treatment Outcome 
 Obesity, Morbid  
 Obesity, Morbid/complications 
 Obesity, Morbid/complications 
 Obesity, Morbid + Cost, Cost Analysis 
 Obesity, Morbid/diet therapy 
 Obesity, Morbid/drug therapy 
 Obesity/economics/*surgery 
 Obesity, Morbid + Health Care Cost 
 Obesity, Morbid/*surgery 
 Obesity, Morbid + Treatment Outcome 
 
Fig. 3. Search strategy for review 
The search strategy is outlined in Fig. 3 and screening and the assessment were performed 
by 2 evaluators. 
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All titles for potential interest to the subject of ‘value of bariatric surgery’ were screened for 
relevance. This excluded approximately 30%. Throughout the work process additional 
articles were added either from reference lists of core articles or as result of targeted 
subsequent search. 
The remaining list was analyzed based on the abstracts, where available, and were then 
categorized. The categories were created before this second screen to help to differentiate 
the articles. The categories are: Economic or cost focus, HTA, Guideline, Outcomes 
Assessment, Geography (supportive if from Europe), Patient numbers, Length of study, 
Risk & complications, Comparison of surgery vs. Drug or diet / behavioral therapy, Study 
Type (Prospective/Retrospective, RCT etc.) Comparisons of surgery techniques were only 
considered if they reported relevant overall outcomes criteria but not if the comparison 
seemed to be limited to 1 or few specific factors. 
The remaining publications were ranked from 1 (not relevant) to 5 (highly relevant; key 
publication) for relevance based on the categories. 
Those were graded as 5 and used for the report.  
Throughout the process original articles were consulted case of doubt and availability.  
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1. Introduction 
Bariatric surgery is an important option for patients with extreme obesity and co-
morbidities. Bariatric surgery, however, has risks and complications involved. Obesity is 
associated with many health related complications such as cardiovascular disease, type 2 
diabetes mellitus, dyslipidaemia, hypertension, and obstructive sleep apnoea (Avenell, 
Broom et al. 2004; Tsigos, Hainer et al. 2008; Mechanick, Kushner et al. 2009; Scottish 
Intercollegiate Guidelines and Scotland 2010). It is important to prepare patients to be at 
their best medical status prior to surgery to prevent adverse outcomes (Mechanick, Kushner 
et al. 2009). Detailed medical, nutritional and psychological assessments are crucial to 
improve patients’ outcomes post surgery. This usually involves a multidisciplinary team 
working hand in hand with individual patients guiding them through the whole process as 
well as continuing lifelong follow up care. A multidisciplinary team usually includes a 
physician with interest in metabolism, nutrition and bariatric medicine, dietitian with 
special interest in obesity, a bariatric surgeon, a bariatric specialist nurse and psychologist, 
and finally a bariatric coordinator (Mechanick, Kushner et al. 2009). Additional expertise 
includes a psychiatrist, endocrinologist, sleep medicine specialist, cardiologist, 
gastroenterologist, physician nutrition specialist and certified nutrition support clinician 
(Mechanick, Kushner et al. 2009). However, the most important factor in the entire process is 
the individual patient and therefore it is important to individualise each patient’s care. Good 
medical assessment with appropriate information provided for patients will help ease 
progress through bariatric surgery. 
2. Patients’ motivation and expectations 
Patients undergo bariatric surgical procedures for different reasons. It is important to 
understand each patient’s expectations prior to surgery. Studies have shown improvements 
in psychological or physical health, better quality of life and self esteem as well as better 
emotional satisfaction in relation with food post operatively (Wolfe and Terry 2006). 
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1. Introduction 
Bariatric surgery is an important option for patients with extreme obesity and co-
morbidities. Bariatric surgery, however, has risks and complications involved. Obesity is 
associated with many health related complications such as cardiovascular disease, type 2 
diabetes mellitus, dyslipidaemia, hypertension, and obstructive sleep apnoea (Avenell, 
Broom et al. 2004; Tsigos, Hainer et al. 2008; Mechanick, Kushner et al. 2009; Scottish 
Intercollegiate Guidelines and Scotland 2010). It is important to prepare patients to be at 
their best medical status prior to surgery to prevent adverse outcomes (Mechanick, Kushner 
et al. 2009). Detailed medical, nutritional and psychological assessments are crucial to 
improve patients’ outcomes post surgery. This usually involves a multidisciplinary team 
working hand in hand with individual patients guiding them through the whole process as 
well as continuing lifelong follow up care. A multidisciplinary team usually includes a 
physician with interest in metabolism, nutrition and bariatric medicine, dietitian with 
special interest in obesity, a bariatric surgeon, a bariatric specialist nurse and psychologist, 
and finally a bariatric coordinator (Mechanick, Kushner et al. 2009). Additional expertise 
includes a psychiatrist, endocrinologist, sleep medicine specialist, cardiologist, 
gastroenterologist, physician nutrition specialist and certified nutrition support clinician 
(Mechanick, Kushner et al. 2009). However, the most important factor in the entire process is 
the individual patient and therefore it is important to individualise each patient’s care. Good 
medical assessment with appropriate information provided for patients will help ease 
progress through bariatric surgery. 
2. Patients’ motivation and expectations 
Patients undergo bariatric surgical procedures for different reasons. It is important to 
understand each patient’s expectations prior to surgery. Studies have shown improvements 
in psychological or physical health, better quality of life and self esteem as well as better 
emotional satisfaction in relation with food post operatively (Wolfe and Terry 2006). 
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However, there is no gain in romantic and professional relationships post surgery (Wolfe 
and Terry 2006) and patients should be warned and be prepared for this. 
Bariatric surgery offers reduction in body weight of between 20-32% within 2 years and 
between 10-25% after 10 year (Sjostrom, Narbro et al. 2007), or a reduction of 55.9% in excess 
weight within 2 years(Buchwald, Estok et al. 2009). Studies have shown of the discrepancies 
in opinion between medical professionals of a successful surgical outcome and patients’ 
expectations (Foster, Wadden et al. 2001; Wee, Jones et al. 2006; Mechanick, Kushner et al. 
2009; Heinberg, Keating et al. 2010). One study showed that the average patient ‘dream’ 
weight loss is 55kg, attributing to 94% of excess weight loss or losing 43% of their pre-
surgical weight. About 90% of the patients in the study were willing to risk death in order 
achieve their ‘dream’ weight and almost all patients were willing to risk dying to have a 
perfect health and their ‘dream’ weight (Wee, Jones et al. 2006). Younger, Caucasian females 
with higher body mass index are more likely to have unrealistic expectations (Heinberg, 
Keating et al. 2010). The team will need to work with patients and provide clear 
understanding and information regarding realistic outcomes (Tsigos, Hainer et al. 2008) 
prior to surgery. The team will need to work with patients to negotiate achievable end 
points and set small feasible goals during the short term period. Providing good education 
and developing good relationships with patients are vital as this enhances compliance in the 
future. 
Apart from patients’ expectation, patients’ attitude towards weight loss is also important. It 
has been shown that 2 years post bariatric surgery, dietary changes and physical activity 
become lax and patients start to gain weight (Sjostrom, Lindroos et al. 2004). The team will 
need to assess their likelihood and willingness to make life long changes in their eating 
habits and engagement in physical activities (National Heart, Blood et al. 1998; UK 2007; 
Tsigos, Hainer et al. 2008; Scottish Intercollegiate Guidelines and Scotland 2010) to prevent 
further weight gain pre or post surgery. Motivation could change over time due to various 
influences (UK 2007). Understanding the medical consequences of obesity will help 
motivate patients. Other areas to assess motivation are the likelihood to attend follow up 
appointments, potential barriers to initiate weight loss such as lack of self esteem or 
confidence in themselves and potential support from family and friends (National Heart, 
Blood et al. 1998). 
3. Medical assessment 
3.1 Clinic set up 
Clinic set up is important to provide a safe and friendly environment for patients. Entrances 
and rooms should be spacious enough for bariatric wheel chair access. Chairs in the waiting 
area and in clinic rooms should provide armless bariatric chair (Mechanick, Kushner et al. 
2009). Wheelchairs availability in hospital should accommodate both the weight and size of 
patients (Barr and Cunneen 2001). Other essential patient care equipments such as suitable 
examination table in the clinic room, appropriate weighing scales and stadiometer should be 
available (Mechanick, Kushner et al. 2009). Facilities such as toilets should not be 
overlooked and fixtures to help individuals with mobility problems may need to be adapted 
for bariatric patients (Barr and Cunneen 2001). 
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3.2 Medical history 
A thorough medical history and good physical examination will help identify potential 
health problems. The most important history will be the patient’s eating behaviour covering 
their history of weight gain and previous attempts for weight loss (Tsigos, Hainer et al. 2008; 
Mechanick, Kushner et al. 2009). History of weight gain, detailed food history and amount 
of physical activity is also important. Onset of weight gain could be a consequence of 
various factors including marriage, pregnancy, and smoking cessation, stress or drug 
induced. Eating patterns and dietary habits are useful to help exclude eating disorders 
(Tsigos, Hainer et al. 2008) and this will be covered in the nutritional and psychological 
section. 
History should be holistic, including respiratory, cardiovascular, neurological, 
gastrointestinal, endocrine, musculoskeletal and genital urinary systems including sexual 
history. Medication and drug histories are also important as many drugs causes weight 
gain. It is also important to include usage of illegal drugs and over the counter medication. 
All past medical history must include mood disorders or other mental health illness 
(Mechanick, Kushner et al. 2009) as well as family history. 
Apart from medical history, it is also essential to obtain the patient’s functional status 
including activities of daily living. It is also important to ask about social history including 
support available either by family members or friends if patient is deemed suitable for 
surgery (Mechanick, Kushner et al. 2009). Occupation, alcohol and smoking histories should 
not be missed (Mechanick, Kushner et al. 2009). The patient should be advised to stop 
smoking but this should be monitored closely as quitting smoking is associated with 
weight gain. This holistic approach will paint a better picture of how obesity is affecting 
the patient. Patients with excessive alcohol intake need to be advised to return to 
recommended levels. 
3.3 Physical examination 
Physical examination should be thorough including all anthropometric measurement of 
height and weight to obtain body mass index (Mechanick, Kushner et al. 2009), and waist 
circumference. Cardiovascular, respiratory, neurology and abdominal systems should be 
assessed. Neck circumference is an important assessment for obstructive sleep apnoea 
(Scottish Intercollegiate Guidelines 2003; Epstein, Kristo et al. 2009). Acanthosis nigricans is a 
sign for insulin resistance (Tsigos, Hainer et al. 2008; Mechanick, Kushner et al. 2009). Other 
signs include striae distensae (stretch mark), lymphoedema, stasis pigmentation of the lower 
limbs, intertrigo, hidradenitis suppurativa and acrochordon (Mechanick, Kushner et al. 
2009). In patients with history of uncontrolled hypertension and insulin resistance, 
Cushing’s syndrome should be excluded. Signs of Cushing’s syndrome are moon facies, 
posterior cervical fat pads, easy bruisability and purple striae on the abdomen. These signs 
are, however, rarely seen in clinical bariatric practice. 
3.4 Investigations 
All patients should have routine blood tests to screen for any potential health problems and 
treat accordingly prior to surgery (Mechanick, Kushner et al. 2009). 
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 Full blood count   Anaemia 
 Renal function    Kidney disease, hypo or hyperkalaemia 
 Liver function test   Hepatitis, non alcoholic induced fatty liver (see 
     lower section) 
 Coagulation profile   Coagulopathy, bleeding disorder 
 Fasting glucose    Diabetes mellitus (see lower section) 
 HbA1c    Diabetes mellitus (see lower section) 
 Fasting lipid profile   Dyslipidaemia 
 Urine pregnancy test   Pregnancy 
If secondary causes of obesity are suspected, patient should be evaluated for primary 
endocrine disorder such as hypothyroidism and Cushing’s syndrome (Tsigos, Hainer et al. 
2008; Mechanick, Kushner et al. 2009). Screening tests for these are as below (Mechanick, 
Kushner et al. 2009): 
 Hypothyroidism  Thyroid function test 
 Cushing’s syndrome  Bedtime salivary cortisol level or 
    1mg low dose dexamethasone suppression test or 
    24 hour urine cortisol excretion 
Interpretation of tests for Cushing’s syndrome can be difficult and more detailed tests may 
be required. There is no indication for routine testing in this patient population. Only 
patients with indicative signs, history (including relevant metabolic and cardiovascular 
abnormalities) and where there is an inability to lose weight despite maximal effort, should 
be investigated. 
Any patients undergoing malabsorptive procedure should have their micronutrients status 
checked prior to surgery and any deficiencies should be corrected (Mechanick, Kushner et 
al. 2009). If there is an indication of celiac disease based on these investigations, specific 
coeliac disease investigations should be carried out. 
 Iron status     Iron deficiency anaemia 
(total iron binding capacity, ferritin, iron, transferring receptor) 
 Vitamin B12 level   Pernicious anaemia, Vitamin B12 deficiency 
 25-OH Vitamin D   Vitamin D deficiency 
 Parathyroid hormone (PTH)  Vitamin D deficiency 
 Folate levels    Folic acid deficiency, hyperhomocysteinaemia 
 Bone profile    Hypocalcaemia, hypophosphataemia 
 Magnesium     Hypomagnesaemia 
Testing for PTH can be costly and should only be undertaken if there are indications based 
on other test results. 
4. Review of systems 
4.1 Respiratory status 
Chest x-ray has been recommended to be done for all patients to exclude any pulmonary 
disorders (Mechanick, Kushner et al. 2009). Chest X-ray, and indeed any imaging 
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investigations are difficult to conduct and interpret in this patient population and may not 
provide any additional information. Any patients with previous history of respiratory 
disorder should have arterial blood gas and undergo pulmonary function tests (Mechanick, 
Kushner et al. 2009). Arterial gases are also useful for assessment of the obesity 
hypoventilation syndrome. Advising patient to quit smoking will help reduce peri-operative 
respiratory complications (Mechanick, Kushner et al. 2009). 
4.1.1 Lung function in obesity 
Breathlessness is a very common symptom among obese patients. It is shown that obesity 
could affect respiratory physiology including reduction in respiratory compliance and 
respiratory muscle strength (McClean, Kee et al. 2008; Sood 2009). In fact, many obese 
patients have problems with their respiratory function. If cardiac causes have been excluded 
and the patient is complaining of breathlessness, lung function and exercise tests are useful 
investigations to assess and rule out other significant respiratory problems such as chronic 
obstructive airway disease or asthma. 
At baseline, pulmonary function tests are different between an obese patient and one with 
normal body mass index. The most significant difference in an obese patient is the reduction 
in functional residual capacity (FRC) and expiratory reserve volume (ERV) (Gibson 2000; 
Jones and Nzekwu 2006; Sood 2009). The higher the body mass index, the greater the effect 
of reduction (Jones and Nzekwu 2006) hence increasing the work of breathing at rest leading 
to dyspnoea. This can be explained by the effects of abdominal distension from visceral fat 
on the diaphragm (Gibson 2000; Rabec, de Lucas Ramos et al. 2011) as well as the reduction 
in chest wall distensibility (Jones and Nzekwu 2006; Rabec, de Lucas Ramos et al. 2011). 
There may also be an association in the reduction of forced expiratory volume in 1 second 
(FEV1) (McClean, Kee et al. 2008; Sood 2009; Rabec, de Lucas Ramos et al. 2011). 
4.1.2 Obstructive sleep apnoea (OSA) 
Obstructive sleep apnoea (OSA) is a condition characterised by episodic complete or partial 
obstruction of the upper airway during sleep (Rabec, de Lucas Ramos et al. 2011). Obesity is 
one of the major risk factor for developing OSA. There is an increased in subcutaneous and 
periluminal fat causing narrowing of the pharynx leading to obstruction (Epstein, Kristo et 
al. 2009). This could cause difficulties during peri-operative airway management 
(Mechanick, Kushner et al. 2009) and presence of OSA has been shown in LABS study to 
increase 30 day operative mortality (Flum, Belle et al. 2009) hence the importance of the 
diagnosis leading to more stringent perioperative care of these individuals. About 40% of 
obese patients suffer with OSA (Sood 2009) and the prevalence can be as high as 98% in the 
morbidly obese patients (Valencia-Flores, Orea et al. 2000). 
Excessive daytime somnolence, snoring at night, feeling unrefreshed on waking, restless 
sleep, impaired concentration, irritability and apnoeic episodes during sleep are some of the 
common symptoms of OSA. It has been recommended that all obese patients should be 
assessed to exclude OSA either by respiratory physician or use the validated questionnaires 
such as the Epworth’s Sleepiness Score (ESS) (Johns 1991) or the Berlin Questionnaire 
(Netzer, Stoohs et al. 1999) The ESS should be completed by both the patient and the partner 
if possible. ESS has a maximum score of 24 and a score of > 18 is suggestive of severe 
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subjective daytime somnolence, score of between 15 and 18 is moderate while score of 
between 11 and 14 is mild (Scottish Intercollegiate Guidelines 2003). Berlin questionnaire 
looked at 3 different categories; which are snoring, wake time sleepiness or drowsy driving 
and hypertension or obesity. High risk for OSA is defined as persistent symptoms in at least 
2 of the categories with a sensitivity of 86% and specificity of 77% (Netzer, Stoohs et al. 
1999). In our experience, the Berlin and Epworth questionnaires are not good indicators of 
OSA and we recommend formal evaluation for OSA in all bariatric patients. 
All patients should undergo sleep studies depending on facilities available. 
Polysomnography is the investigation of choice to assess OSA and it consists of 
electroencephalogram (EEG), electroculogram (EOG), chin electromyogram, oxygen 
saturation, respiratory airflow, thoracic movements and electrocardiography (ECG) 
(Scottish Intercollegiate Guidelines 2003; Epstein, Kristo et al. 2009). Body position and 
snoring is monitored as well (Scottish Intercollegiate Guidelines 2003; Epstein, Kristo et al. 
2009). Overnight monitoring is ideal and results will then be interpreted. If a full 
polysomnography is not available, then the sleep study usually consists of respiratory 
assessment, thoraco-abdominal movement, and monitor for snoring episodes (Scottish 
Intercollegiate Guidelines 2003). In-laboratory polysomnography may not be routinely 
available to all patients due to high cost and technical complexity (Collop, Anderson et al. 
2007). In that case, unattended portable monitors could be alternative choice. American 
Academy of Sleep Medicine guideline stated the use of portable monitors should be ‘in 
conjunction with a comprehensive sleep evaluation’ for ‘patients with high pretest 
probability of or moderate to severe OSA’ who do not have significant co-morbidies such as 
severe pulmonary disease, neuromuscular disease or congestive heart failure (Collop, 
Anderson et al. 2007). 
The aim of polysomnography is to measure apnoea or hypopnoea episodes. These episodes 
are reported as apnoea/hypopnoea index (AHI) or respiratory disturbance index (RDI) and 
can be divided into (Scottish Intercollegiate Guidelines 2003; Epstein, Kristo et al. 2009): 
 Mild  OSA  AHI/RDI  5 – 14 per hour 
 Moderate  OSA  AHI/RDI  15-30 per hour 
 Severe OSA  AHI/RDI  > 30 per hour 
Treatment for OSA is weight reduction hence bariatric surgery could help the condition. 
Non surgical treatment of OSA includes continuous positive airway pressures. Positive 
airway pressure can be continuous (CPAP), autotitrating (APAP) or bilevel (BPAP) (Scottish 
Intercollegiate Guidelines 2003; Epstein, Kristo et al. 2009). Sedatives and alcohol should be 
avoided in the evenings and at night as they reduce airway dilator function hence 
worsening of OSA (Scottish Intercollegiate Guidelines 2003). Post-operatively, these patients 
need to be monitored closely and to continue to use their positive airway pressure 
appliances (Mechanick, Kushner et al. 2009). There is debate regarding duration of CPAP 
use prior to operation (some centres recommending 3 months), peri-operatively (theoretical 
potential to disturb anastomoses in non gastric band operations), and post-operatively. 
4.1.3 Obesity hypoventilation syndrome (OHS) 
Obesity hypoventilation syndrome is a diagnosis of exclusion. The definition of OHS is a 
condition of consists of daytime hypercapnia and hypoxemia, sleep disordered breathing 
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and obese patient (Mokhlesi 2010). The majority of OHS patients will also have OSA. 
Other respiratory conditions including intrinsic respiratory disorders, central 
hypoventilation syndromes and neuromuscular disorders should be excluded (Mokhlesi, 
Kryger et al. 2008).  
Clinical features of OHS are similar to OSA consisting of hypersomnia and headache when 
awake, snoring and disturbed sleep (Casey, Cantillo et al. 2007). Pathogenesis is likely to be 
multifactorial. Reduction in respiratory compliance and lung volume, effects of leptin on 
central ventilatory drive, inspiratory muscle fatigue and depressed central ventilator control 
from sleep disturbances and raised PaCO2 on central ventilation are likely to play a role in 
this condition (Casey, Cantillo et al. 2007). Non-invasive positive pressure ventilation is 
effective and well tolerated in treating this condition (Mokhlesi and Tulaimat 2007; Priou, 
Hamel et al. 2010).  
4.1.4 Smoking 
Smoking causes adverse effects on health. The most common respiratory diseases associated 
with smoking are increased risk of chronic obstructive pulmonary disease and bronchogenic 
carcinoma. Smoking also increases risk of cardiovascular disease leading to myocardial 
infarction and peripheral vascular disease. Obese patients are already at higher risk of 
developing various health problems so these patients should be encouraged and assisted to 
stop smoking to help improve life expectancy (Scottish Intercollegiate Guidelines and 
Scotland 2010). It is recommended that patients should quit smoking at least 8 weeks prior 
to surgery to help reduce risk of respiratory complications (Mechanick, Kushner et al. 2009). 
Unfortunately, smoking cessation is associated with weight gain (Williamson, Madans et al. 
1991; Flegal, Troiano et al. 1995; Wise, Enright et al. 1998; Scottish Intercollegiate Guidelines 
and Scotland 2010) and patients might be reluctant to quit (McClean, Kee et al. 2008). 
Weight gain from smoking cessation is more pronounced in females compared to males 
(Williamson, Madans et al. 1991; Wise, Enright et al. 1998). Mean weight gain is between 
2.8kg (Williamson, Madans et al. 1991) to 5kg (Flegal, Troiano et al. 1995; Wise, Enright et al. 
1998) with females gaining approximately 1kg more than males (Williamson, Madans et al. 
1991). A proportion of patients will gain more than 13kg in weight (Williamson, Madans et 
al. 1991). Weight gain from quitting smoking has been associated with increased in 
prevalence in overweight population (Flegal, Troiano et al. 1995) and this could lead to 
obesity in the future. Although there is risk of weight gain, the benefits from smoking 
cessation is greater in improvement in lung function in particular FEV1 and FVC (Wise, 
Enright et al. 1998). The Framingham Heart Study found that obese smokers have almost 
doubled the reduction in life expectancy as compared to obese non smokers (Peeters, 
Barendregt et al. 2003). 
Patient should be given advice to seek help for smoking cessation. The reasons for weight 
gain might be due to various mechanisms. An increased in food consumption (2010) of up to 
250 to 300 kilocalories a day after stopping smoking, reduction in physical activity 
(Chiolero, Faeh et al. 2008), changes in fat metabolism e.g. lipoprotein activity (Williamson, 
Madans et al. 1991; Chiolero, Faeh et al. 2008) and changes in insulin homeostasis 
(Williamson, Madans et al. 1991) could all contribute to weight gain. Patients should be 
advised have low calorie diet, reduce in portion sizes during meal times and avoid second 
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subjective daytime somnolence, score of between 15 and 18 is moderate while score of 
between 11 and 14 is mild (Scottish Intercollegiate Guidelines 2003). Berlin questionnaire 
looked at 3 different categories; which are snoring, wake time sleepiness or drowsy driving 
and hypertension or obesity. High risk for OSA is defined as persistent symptoms in at least 
2 of the categories with a sensitivity of 86% and specificity of 77% (Netzer, Stoohs et al. 
1999). In our experience, the Berlin and Epworth questionnaires are not good indicators of 
OSA and we recommend formal evaluation for OSA in all bariatric patients. 
All patients should undergo sleep studies depending on facilities available. 
Polysomnography is the investigation of choice to assess OSA and it consists of 
electroencephalogram (EEG), electroculogram (EOG), chin electromyogram, oxygen 
saturation, respiratory airflow, thoracic movements and electrocardiography (ECG) 
(Scottish Intercollegiate Guidelines 2003; Epstein, Kristo et al. 2009). Body position and 
snoring is monitored as well (Scottish Intercollegiate Guidelines 2003; Epstein, Kristo et al. 
2009). Overnight monitoring is ideal and results will then be interpreted. If a full 
polysomnography is not available, then the sleep study usually consists of respiratory 
assessment, thoraco-abdominal movement, and monitor for snoring episodes (Scottish 
Intercollegiate Guidelines 2003). In-laboratory polysomnography may not be routinely 
available to all patients due to high cost and technical complexity (Collop, Anderson et al. 
2007). In that case, unattended portable monitors could be alternative choice. American 
Academy of Sleep Medicine guideline stated the use of portable monitors should be ‘in 
conjunction with a comprehensive sleep evaluation’ for ‘patients with high pretest 
probability of or moderate to severe OSA’ who do not have significant co-morbidies such as 
severe pulmonary disease, neuromuscular disease or congestive heart failure (Collop, 
Anderson et al. 2007). 
The aim of polysomnography is to measure apnoea or hypopnoea episodes. These episodes 
are reported as apnoea/hypopnoea index (AHI) or respiratory disturbance index (RDI) and 
can be divided into (Scottish Intercollegiate Guidelines 2003; Epstein, Kristo et al. 2009): 
 Mild  OSA  AHI/RDI  5 – 14 per hour 
 Moderate  OSA  AHI/RDI  15-30 per hour 
 Severe OSA  AHI/RDI  > 30 per hour 
Treatment for OSA is weight reduction hence bariatric surgery could help the condition. 
Non surgical treatment of OSA includes continuous positive airway pressures. Positive 
airway pressure can be continuous (CPAP), autotitrating (APAP) or bilevel (BPAP) (Scottish 
Intercollegiate Guidelines 2003; Epstein, Kristo et al. 2009). Sedatives and alcohol should be 
avoided in the evenings and at night as they reduce airway dilator function hence 
worsening of OSA (Scottish Intercollegiate Guidelines 2003). Post-operatively, these patients 
need to be monitored closely and to continue to use their positive airway pressure 
appliances (Mechanick, Kushner et al. 2009). There is debate regarding duration of CPAP 
use prior to operation (some centres recommending 3 months), peri-operatively (theoretical 
potential to disturb anastomoses in non gastric band operations), and post-operatively. 
4.1.3 Obesity hypoventilation syndrome (OHS) 
Obesity hypoventilation syndrome is a diagnosis of exclusion. The definition of OHS is a 
condition of consists of daytime hypercapnia and hypoxemia, sleep disordered breathing 
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and obese patient (Mokhlesi 2010). The majority of OHS patients will also have OSA. 
Other respiratory conditions including intrinsic respiratory disorders, central 
hypoventilation syndromes and neuromuscular disorders should be excluded (Mokhlesi, 
Kryger et al. 2008).  
Clinical features of OHS are similar to OSA consisting of hypersomnia and headache when 
awake, snoring and disturbed sleep (Casey, Cantillo et al. 2007). Pathogenesis is likely to be 
multifactorial. Reduction in respiratory compliance and lung volume, effects of leptin on 
central ventilatory drive, inspiratory muscle fatigue and depressed central ventilator control 
from sleep disturbances and raised PaCO2 on central ventilation are likely to play a role in 
this condition (Casey, Cantillo et al. 2007). Non-invasive positive pressure ventilation is 
effective and well tolerated in treating this condition (Mokhlesi and Tulaimat 2007; Priou, 
Hamel et al. 2010).  
4.1.4 Smoking 
Smoking causes adverse effects on health. The most common respiratory diseases associated 
with smoking are increased risk of chronic obstructive pulmonary disease and bronchogenic 
carcinoma. Smoking also increases risk of cardiovascular disease leading to myocardial 
infarction and peripheral vascular disease. Obese patients are already at higher risk of 
developing various health problems so these patients should be encouraged and assisted to 
stop smoking to help improve life expectancy (Scottish Intercollegiate Guidelines and 
Scotland 2010). It is recommended that patients should quit smoking at least 8 weeks prior 
to surgery to help reduce risk of respiratory complications (Mechanick, Kushner et al. 2009). 
Unfortunately, smoking cessation is associated with weight gain (Williamson, Madans et al. 
1991; Flegal, Troiano et al. 1995; Wise, Enright et al. 1998; Scottish Intercollegiate Guidelines 
and Scotland 2010) and patients might be reluctant to quit (McClean, Kee et al. 2008). 
Weight gain from smoking cessation is more pronounced in females compared to males 
(Williamson, Madans et al. 1991; Wise, Enright et al. 1998). Mean weight gain is between 
2.8kg (Williamson, Madans et al. 1991) to 5kg (Flegal, Troiano et al. 1995; Wise, Enright et al. 
1998) with females gaining approximately 1kg more than males (Williamson, Madans et al. 
1991). A proportion of patients will gain more than 13kg in weight (Williamson, Madans et 
al. 1991). Weight gain from quitting smoking has been associated with increased in 
prevalence in overweight population (Flegal, Troiano et al. 1995) and this could lead to 
obesity in the future. Although there is risk of weight gain, the benefits from smoking 
cessation is greater in improvement in lung function in particular FEV1 and FVC (Wise, 
Enright et al. 1998). The Framingham Heart Study found that obese smokers have almost 
doubled the reduction in life expectancy as compared to obese non smokers (Peeters, 
Barendregt et al. 2003). 
Patient should be given advice to seek help for smoking cessation. The reasons for weight 
gain might be due to various mechanisms. An increased in food consumption (2010) of up to 
250 to 300 kilocalories a day after stopping smoking, reduction in physical activity 
(Chiolero, Faeh et al. 2008), changes in fat metabolism e.g. lipoprotein activity (Williamson, 
Madans et al. 1991; Chiolero, Faeh et al. 2008) and changes in insulin homeostasis 
(Williamson, Madans et al. 1991) could all contribute to weight gain. Patients should be 
advised have low calorie diet, reduce in portion sizes during meal times and avoid second 
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helpings (2008). Chewing gum or nicotine gum helps to prevent snacking. Dietary advice on 
healthy balanced diet and increase in physical activities, getting new hobbies to relieve 
boredom are some simple advice for patients to stop smoking (2008). Individualised 
treatment plan with dietary and cognitive behavioural intervention will help potential 
quitters prevent weight gain (Scottish Intercollegiate Guidelines and Scotland 2010). 
Buproprion helps with weight loss (Davtyan and Ma 2008) and this could be use along side 
with nicotine replacement therapy. Smokers tend to have a longer hospital stay and 
smoking cessation should be recommended well in advance of bariatric surgery. 
4.2 Cardiovascular status 
Obesity increases risk for cardiovascular disorder (Hubert, Feinleib et al. 1983; Jonsson, 
Hedblad et al. 2002; Wilson, D'Agostino et al. 2002; Wolk, Berger et al. 2003) and premature 
death (Jonsson, Hedblad et al. 2002; Peeters, Barendregt et al. 2003) but is not a risk factor for 
post-operative cardiac complication (Mechanick, Kushner et al. 2009). Blood pressure 
monitoring to assess for hypertension and electrocardiography are basic investigations to 
assess cardiovascular function. Cardiac sounding chest pain or angina episodes should be 
investigated further, but investigations are limited given body habitus and lack of resolution 
of diagnostic tests. Difficulties lie with patient complaining of dyspnoea as this could 
present as cardiac disease or obesity related dyspnoea. Exercise tolerance will be useful to 
assess cardiac risk. Presence of other metabolic risk factors especially diabetes mellitus 
increases the patient’s risk for coronary artery disease (Fox, Coady et al. 2007). 
4.2.1 Electrocardiogram (ECG) 
Obesity may cause changes in ECG readings. Some common changes include left axis 
deviation likely due to displacement of the heart from raised diaphragm due to abdominal 
visceral fat and small voltages (Eisenstein, Edelstein et al. 1982; Frank, Colliver et al. 1986; 
Alpert, Terry et al. 2000; Poirier, Giles et al. 2006) from the increased distance between the 
heart and the chest wall (Poirier, Giles et al. 2006). Cardiac work load is also increased 
(Lavie, Milani et al. 2009) and this could lead to left ventricular hypertrophy (Lauer, 
Anderson et al. 1991; Poirier, Giles et al. 2006; Avelar, Cloward et al. 2007; Lavie, Milani et 
al. 2009; Movahed, Martinez et al. 2009). Pulmonary diseases such as obstructive sleep 
apnoea could cause cor pulmonale changes. Other possible ECG changes are increased in 
heart rate (Frank, Colliver et al. 1986; Poirier, Giles et al. 2006), prolonged PR interval 
(Frank, Colliver et al. 1986; Poirier, Giles et al. 2006; Seyfeli, Duru et al. 2006), prolonged 
QRS interval (Frank, Colliver et al. 1986; Poirier, Giles et al. 2006), prolonged QTc interval 
(Frank, Colliver et al. 1986; Alpert, Terry et al. 2000; Pontiroli, Pizzocri et al. 2004; Poirier, 
Giles et al. 2006; Arslan, Yiginer et al. 2010), ST-T wave abnormalities (Frank, Colliver et al. 
1986; Poirier, Giles et al. 2006) and flattening of the T wave especially in the inferolateral 
leads (Eisenstein, Edelstein et al. 1982; Alpert, Terry et al. 2000; Lopez-Jimenez and Cortes-
Bergoderi 2011). 
4.2.2 Echocardiography 
Technical difficulty in echocardiography is common in obese patients due to the size as well 
as the distance between chest wall and heart. Obesity increases the risk of left ventricular 
hypertrophy (LVH) (Lauer, Anderson et al. 1991; de la Maza, Estevez et al. 1994; Poirier, 
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Giles et al. 2006; Avelar, Cloward et al. 2007; Lavie, Milani et al. 2009; Movahed, Martinez et 
al. 2009) and this could be assessed using echocardiography. Presence of LVH increase risk 
of mortality as it is associated with coronary heart disease and stroke(Benjamin and Levy 
1999). Other potential abnormality include left atrial enlargement (Lavie, Milani et al. 2009; 
Arslan, Yiginer et al. 2010), difficulty in the assessment of pericardial fluid due to thickened 
epicardial tissue (Poirier, Giles et al. 2006). Dobutamine stress echocardiography is probably 
more useful than conventional echocardiogram to assess cardiac function (Mechanick, 
Kushner et al. 2009). 
4.2.3 Hypertension 
Hypertension is a well-recognised risk factor for coronary artery disease (Kannel 1996; Diaz 
2002; I 2010). Prevalence of hypertension is higher among overweight and obese 
population(Stamler, Stamler et al. 1978; Brown, Higgins et al. 2000) and is not associated 
with ethnicity or socioeconomic status (Diaz 2002). Indeed, increased in visceral abdominal 
fat in obesity increases the risk of hypertension (Narkiewicz 2006). Uncontrolled 
hypertension with blood pressure levels above 180/110mmHg should be corrected as this 
could lead to perioperative ischaemic events (Mechanick, Kushner et al. 2009). 
Many mechanisms have been postulated for the causation of hypertension and this includes 
changes in substances released from adipose tissue (Benjamin and Levy 1999; I 2010), 
increased in sympathetic activity (Narkiewicz 2006; Poirier, Giles et al. 2006, Wilcox 2010) 
and presence of obstructive sleep apnoea (Diaz 2002; Avelar, Cloward et al. 2007). Increase 
in body weight leads to increase in sympathetic activity (Narkiewicz 2006; Poirier, Giles et 
al. 2006; Wilcox 2010); and this could be explained by the activation of renin-angiotensin-
aldosterone system (Narkiewicz 2006; Wilcox 2010). Hypoxaemia and hypercapnic episodes 
as well as changes in the intrathoracic pressure in obstructive sleep apnoea has been found 
to increase blood pressure (Diaz 2002; Avelar, Cloward et al. 2007). 
Adipose tissue releases several adipokines (Maenhaut and Van de Voorde 2011). One 
adipokine is the hormone leptin (Wilcox 2010; Maenhaut and Can de Voorde 2011). Leptin 
levels are elevated in hypertension and its effect could be via the activation of the 
sympathetic nervous system or dysfunction of the endothelium causing vasoconstriction 
leading to increase in peripheral vascular resistance (Maenhaut and Van de Voorde 2011). 
Apart from increased risk in coronary heart disease, hypertension also increases the risk of 
developing renal failure (Narkiewicz 2006; Wilcox 2010). It is important to treat this 
condition vigilantly to prevent perioperative ischaemic event (Mechanick, Kushner et al. 
2009). Many guidelines are available as references for the treatment of hypertension such as 
the JNC VII report (Chobanian, Bakris et al. 2003) and British Hypertension Society 
guidelines (Williams, Poulter et al. 2004). 
4.2.4 Coronary heart disease 
Obesity increases the risk of myocardial infarction and coronary heart disease and is an 
independent risk factor for cardiovascular disease (Hubert, Feinleib et al. 1983; Wilson, 
D'Agostino et al. 2002). Given that there is increasing prevalence in hypertensive patients 
and obesity related obstructive sleep apnoea as well as increased risk of dyslipidaemia 
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helpings (2008). Chewing gum or nicotine gum helps to prevent snacking. Dietary advice on 
healthy balanced diet and increase in physical activities, getting new hobbies to relieve 
boredom are some simple advice for patients to stop smoking (2008). Individualised 
treatment plan with dietary and cognitive behavioural intervention will help potential 
quitters prevent weight gain (Scottish Intercollegiate Guidelines and Scotland 2010). 
Buproprion helps with weight loss (Davtyan and Ma 2008) and this could be use along side 
with nicotine replacement therapy. Smokers tend to have a longer hospital stay and 
smoking cessation should be recommended well in advance of bariatric surgery. 
4.2 Cardiovascular status 
Obesity increases risk for cardiovascular disorder (Hubert, Feinleib et al. 1983; Jonsson, 
Hedblad et al. 2002; Wilson, D'Agostino et al. 2002; Wolk, Berger et al. 2003) and premature 
death (Jonsson, Hedblad et al. 2002; Peeters, Barendregt et al. 2003) but is not a risk factor for 
post-operative cardiac complication (Mechanick, Kushner et al. 2009). Blood pressure 
monitoring to assess for hypertension and electrocardiography are basic investigations to 
assess cardiovascular function. Cardiac sounding chest pain or angina episodes should be 
investigated further, but investigations are limited given body habitus and lack of resolution 
of diagnostic tests. Difficulties lie with patient complaining of dyspnoea as this could 
present as cardiac disease or obesity related dyspnoea. Exercise tolerance will be useful to 
assess cardiac risk. Presence of other metabolic risk factors especially diabetes mellitus 
increases the patient’s risk for coronary artery disease (Fox, Coady et al. 2007). 
4.2.1 Electrocardiogram (ECG) 
Obesity may cause changes in ECG readings. Some common changes include left axis 
deviation likely due to displacement of the heart from raised diaphragm due to abdominal 
visceral fat and small voltages (Eisenstein, Edelstein et al. 1982; Frank, Colliver et al. 1986; 
Alpert, Terry et al. 2000; Poirier, Giles et al. 2006) from the increased distance between the 
heart and the chest wall (Poirier, Giles et al. 2006). Cardiac work load is also increased 
(Lavie, Milani et al. 2009) and this could lead to left ventricular hypertrophy (Lauer, 
Anderson et al. 1991; Poirier, Giles et al. 2006; Avelar, Cloward et al. 2007; Lavie, Milani et 
al. 2009; Movahed, Martinez et al. 2009). Pulmonary diseases such as obstructive sleep 
apnoea could cause cor pulmonale changes. Other possible ECG changes are increased in 
heart rate (Frank, Colliver et al. 1986; Poirier, Giles et al. 2006), prolonged PR interval 
(Frank, Colliver et al. 1986; Poirier, Giles et al. 2006; Seyfeli, Duru et al. 2006), prolonged 
QRS interval (Frank, Colliver et al. 1986; Poirier, Giles et al. 2006), prolonged QTc interval 
(Frank, Colliver et al. 1986; Alpert, Terry et al. 2000; Pontiroli, Pizzocri et al. 2004; Poirier, 
Giles et al. 2006; Arslan, Yiginer et al. 2010), ST-T wave abnormalities (Frank, Colliver et al. 
1986; Poirier, Giles et al. 2006) and flattening of the T wave especially in the inferolateral 
leads (Eisenstein, Edelstein et al. 1982; Alpert, Terry et al. 2000; Lopez-Jimenez and Cortes-
Bergoderi 2011). 
4.2.2 Echocardiography 
Technical difficulty in echocardiography is common in obese patients due to the size as well 
as the distance between chest wall and heart. Obesity increases the risk of left ventricular 
hypertrophy (LVH) (Lauer, Anderson et al. 1991; de la Maza, Estevez et al. 1994; Poirier, 
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Giles et al. 2006; Avelar, Cloward et al. 2007; Lavie, Milani et al. 2009; Movahed, Martinez et 
al. 2009) and this could be assessed using echocardiography. Presence of LVH increase risk 
of mortality as it is associated with coronary heart disease and stroke(Benjamin and Levy 
1999). Other potential abnormality include left atrial enlargement (Lavie, Milani et al. 2009; 
Arslan, Yiginer et al. 2010), difficulty in the assessment of pericardial fluid due to thickened 
epicardial tissue (Poirier, Giles et al. 2006). Dobutamine stress echocardiography is probably 
more useful than conventional echocardiogram to assess cardiac function (Mechanick, 
Kushner et al. 2009). 
4.2.3 Hypertension 
Hypertension is a well-recognised risk factor for coronary artery disease (Kannel 1996; Diaz 
2002; I 2010). Prevalence of hypertension is higher among overweight and obese 
population(Stamler, Stamler et al. 1978; Brown, Higgins et al. 2000) and is not associated 
with ethnicity or socioeconomic status (Diaz 2002). Indeed, increased in visceral abdominal 
fat in obesity increases the risk of hypertension (Narkiewicz 2006). Uncontrolled 
hypertension with blood pressure levels above 180/110mmHg should be corrected as this 
could lead to perioperative ischaemic events (Mechanick, Kushner et al. 2009). 
Many mechanisms have been postulated for the causation of hypertension and this includes 
changes in substances released from adipose tissue (Benjamin and Levy 1999; I 2010), 
increased in sympathetic activity (Narkiewicz 2006; Poirier, Giles et al. 2006, Wilcox 2010) 
and presence of obstructive sleep apnoea (Diaz 2002; Avelar, Cloward et al. 2007). Increase 
in body weight leads to increase in sympathetic activity (Narkiewicz 2006; Poirier, Giles et 
al. 2006; Wilcox 2010); and this could be explained by the activation of renin-angiotensin-
aldosterone system (Narkiewicz 2006; Wilcox 2010). Hypoxaemia and hypercapnic episodes 
as well as changes in the intrathoracic pressure in obstructive sleep apnoea has been found 
to increase blood pressure (Diaz 2002; Avelar, Cloward et al. 2007). 
Adipose tissue releases several adipokines (Maenhaut and Van de Voorde 2011). One 
adipokine is the hormone leptin (Wilcox 2010; Maenhaut and Can de Voorde 2011). Leptin 
levels are elevated in hypertension and its effect could be via the activation of the 
sympathetic nervous system or dysfunction of the endothelium causing vasoconstriction 
leading to increase in peripheral vascular resistance (Maenhaut and Van de Voorde 2011). 
Apart from increased risk in coronary heart disease, hypertension also increases the risk of 
developing renal failure (Narkiewicz 2006; Wilcox 2010). It is important to treat this 
condition vigilantly to prevent perioperative ischaemic event (Mechanick, Kushner et al. 
2009). Many guidelines are available as references for the treatment of hypertension such as 
the JNC VII report (Chobanian, Bakris et al. 2003) and British Hypertension Society 
guidelines (Williams, Poulter et al. 2004). 
4.2.4 Coronary heart disease 
Obesity increases the risk of myocardial infarction and coronary heart disease and is an 
independent risk factor for cardiovascular disease (Hubert, Feinleib et al. 1983; Wilson, 
D'Agostino et al. 2002). Given that there is increasing prevalence in hypertensive patients 
and obesity related obstructive sleep apnoea as well as increased risk of dyslipidaemia 
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and insulin resistance, these factors most likely contribute to the cumulative risks for 
obese patients (Poirier, Giles et al. 2006; Lopez-Jimenez and Cortes-Bergoderi 2011). Apart 
from this, it has been found that in young men, obesity could accelerate the development 
of atherosclerosis (McGill, McMahan et al. 2002). Patients with cardiac sounding chest 
pain or any previous history of cardiac disease should not be taken lightly prior to 
surgery and should be investigated thoroughly by a cardiologist and treated accordingly 
to minimise risk during surgery. Prophylactic beta-blocker therapy has been 
recommended for patients who have high risk of cardiac disease (Mechanick, Kushner et 
al. 2009). 
4.3 Metabolic control 
A high proportion of patients with obesity suffer from metabolic syndrome. Diagnosis of 
metabolic syndrome is based on the presence of insulin resistance, obesity, dyslipidaemia, 
and hypertension. Both International Diabetes Federation (IDF) (Alberti, Zimmet et al. 2005) 
and National Cholesterol Education Program Adult Treatment Panel (NCEP ATP III)(2002) 
have their own criteria for metabolic syndrome as summarized below: 
 







> 94cm (M) or 
> 80cm (F) 
Raised Tg ≥ 150mg/dl 
or  
HDL < 50 (M)  
or  
< 40mg/dl (F) 
or on therapy 
≥130/85 
mmHg  
or on therapy 
Fasting glucose 









> 102cm/40 inches (M) 
or 
> 88cm/35 inches (F) 
Raised Tg ≥ 150mg/dl 
or  
HDL < 40mg/dl (M)   
or  
< 50mg/dl (F)  
or on therapy 
≥130/85mmHg 
or on therapy 
Fasting glucose 





Table 1. Criteria for metabolic syndrome 
4.3.1 Diabetes mellitus 
Obesity can cause insulin resistance due to changes in adipokines, inflammatory 
mechanisms and intrinsic cell mechanisms (Qatanani and Lazar 2007). Insulin resistance 
could in turn lead to development of diabetes mellitus (Chan, Rimm et al. 1994; Koh-
Banerjee, Wang et al. 2004). Raised visceral or waist to hip ratios (Chan, Rimm et al. 1994; 
Koh-Banerjee, Wang et al. 2004) and duration of obesity (Wannamethee and Shaper 1999) 
are good predictors of diabetes mellitus. Many individuals might already have diagnoses of 
diabetes mellitus and the rest needs to be screened with either fasting plasma glucose, 
HbA1c or a formal oral glucose tolerance test. 
Diagnosis of diabetes could be made by the presence of either one of the following based on 
the American Diabetes Association criteria (ADA) (2011): 
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 HbA1c ≥ 48mmol/mol or 6.5% 
 Fasting plasma glucose ≥ 126mg/dl or 7.0mmol/l 
 Oral glucose tolerance test after 75g of oral glucose with a result of fasting plasma 
glucose of ≥ 126mg/dl or 7.0mmol/l or 2 hour post-prandial reading of ≥200 mg/dl or 
11.1mmol/l. 
 Random plasma glucose of ≥ 200mg/dl or 11.1mmol/l with classical symptoms of 
hyperglycaemia or hyperglycaemia crisis such as hyperglycaemic hyperosmolar state or 
diabetic ketoacidosis. 
Newly diagnosed patients with diabetes mellitus should be managed appropriately. 
Lifestyle measures are usually the first step (Nathan, Buse et al. 2009; National Institute for 
et al. 2009). ADA and European Association of Study of Diabetes (EASD) (Nathan, Buse et 
al. 2009) as well as National Institute for Health and Clinical Excellence (NICE) (2009) have 
published guidelines for the management of type 2 diabetes mellitus. There are various 
different medications for diabetes mellitus and are associated with their own adverse effects 
including drug induced weight gain (Makimattila, Nikkila et al. 1999). A summary of the 
medications with effects on HbA1c, weight and adverse effects is as below (Nathan, Buse et 
al. 2009; Dicker 2011): 
 
Anti-diabetic medications Reduction in HbA1c (%) 
Effects on 
weight Other adverse side effects 
Biguanides 
Eg. Metformin 1.0 – 2.0 Weight neutral
Gastrointestinal side effects, 
rarely lactic acidosis 
Sulphonylureas 
Eg. gliclazide, glipizide, 
glibenclamide 
1.0 – 2.0 Weight gain Hypoglycaemia 
α-glucosidase inhibitors 
Eg. Acarbose 0.5 - 0.8 Weight neutral
Gastrointestinal side 
effects 
Glucagon like peptide (GLP)-1 
Eg. exenatide, liraglutide 0.5 - 1.0 Weight loss Nausea, vomiting 
Pramlintide 0.5 - 1.0 Weight loss Gastrointestinal side effects 
Glinides 
Eg. repaglinide and nateglinide 0.5 – 1.5 Weight gain 
Gastrointestinal side 
effects 
Insulin 1.5 - 3.5 Weight gain Hypoglycaemia 
Thiazolidinediones 
Eg. pioglitazone, rosiglitazone* 0.5 - 1.4 Weight gain 
Fluid retention, *increased 
cardiovascular risk 
Dipeptidyl peptidase 4 (DPP-4) 
inhibitor(Dicker 2011) 
Eg. sitagliptin, saxagliptin, 
vildagliptin 
0.43 - 1.4 Weight neutral




*Rosiglitazone is associated with increased cardiovascular risk and is withdrawn in the United 
Kingdom (2010) and in europe (2010). United States Food and Drug Administration (FDA) have issued 
restriction on its usage (2011).  
Table 2. HbA1c, weight and adverse effects of anti-diabetic medications (Nathan, Buse et al. 
2009; Dicker 2011) 
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and insulin resistance, these factors most likely contribute to the cumulative risks for 
obese patients (Poirier, Giles et al. 2006; Lopez-Jimenez and Cortes-Bergoderi 2011). Apart 
from this, it has been found that in young men, obesity could accelerate the development 
of atherosclerosis (McGill, McMahan et al. 2002). Patients with cardiac sounding chest 
pain or any previous history of cardiac disease should not be taken lightly prior to 
surgery and should be investigated thoroughly by a cardiologist and treated accordingly 
to minimise risk during surgery. Prophylactic beta-blocker therapy has been 
recommended for patients who have high risk of cardiac disease (Mechanick, Kushner et 
al. 2009). 
4.3 Metabolic control 
A high proportion of patients with obesity suffer from metabolic syndrome. Diagnosis of 
metabolic syndrome is based on the presence of insulin resistance, obesity, dyslipidaemia, 
and hypertension. Both International Diabetes Federation (IDF) (Alberti, Zimmet et al. 2005) 
and National Cholesterol Education Program Adult Treatment Panel (NCEP ATP III)(2002) 
have their own criteria for metabolic syndrome as summarized below: 
 







> 94cm (M) or 
> 80cm (F) 
Raised Tg ≥ 150mg/dl 
or  
HDL < 50 (M)  
or  
< 40mg/dl (F) 
or on therapy 
≥130/85 
mmHg  
or on therapy 
Fasting glucose 









> 102cm/40 inches (M) 
or 
> 88cm/35 inches (F) 
Raised Tg ≥ 150mg/dl 
or  
HDL < 40mg/dl (M)   
or  
< 50mg/dl (F)  
or on therapy 
≥130/85mmHg 
or on therapy 
Fasting glucose 





Table 1. Criteria for metabolic syndrome 
4.3.1 Diabetes mellitus 
Obesity can cause insulin resistance due to changes in adipokines, inflammatory 
mechanisms and intrinsic cell mechanisms (Qatanani and Lazar 2007). Insulin resistance 
could in turn lead to development of diabetes mellitus (Chan, Rimm et al. 1994; Koh-
Banerjee, Wang et al. 2004). Raised visceral or waist to hip ratios (Chan, Rimm et al. 1994; 
Koh-Banerjee, Wang et al. 2004) and duration of obesity (Wannamethee and Shaper 1999) 
are good predictors of diabetes mellitus. Many individuals might already have diagnoses of 
diabetes mellitus and the rest needs to be screened with either fasting plasma glucose, 
HbA1c or a formal oral glucose tolerance test. 
Diagnosis of diabetes could be made by the presence of either one of the following based on 
the American Diabetes Association criteria (ADA) (2011): 
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 HbA1c ≥ 48mmol/mol or 6.5% 
 Fasting plasma glucose ≥ 126mg/dl or 7.0mmol/l 
 Oral glucose tolerance test after 75g of oral glucose with a result of fasting plasma 
glucose of ≥ 126mg/dl or 7.0mmol/l or 2 hour post-prandial reading of ≥200 mg/dl or 
11.1mmol/l. 
 Random plasma glucose of ≥ 200mg/dl or 11.1mmol/l with classical symptoms of 
hyperglycaemia or hyperglycaemia crisis such as hyperglycaemic hyperosmolar state or 
diabetic ketoacidosis. 
Newly diagnosed patients with diabetes mellitus should be managed appropriately. 
Lifestyle measures are usually the first step (Nathan, Buse et al. 2009; National Institute for 
et al. 2009). ADA and European Association of Study of Diabetes (EASD) (Nathan, Buse et 
al. 2009) as well as National Institute for Health and Clinical Excellence (NICE) (2009) have 
published guidelines for the management of type 2 diabetes mellitus. There are various 
different medications for diabetes mellitus and are associated with their own adverse effects 
including drug induced weight gain (Makimattila, Nikkila et al. 1999). A summary of the 
medications with effects on HbA1c, weight and adverse effects is as below (Nathan, Buse et 
al. 2009; Dicker 2011): 
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weight Other adverse side effects 
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Eg. Acarbose 0.5 - 0.8 Weight neutral
Gastrointestinal side 
effects 
Glucagon like peptide (GLP)-1 
Eg. exenatide, liraglutide 0.5 - 1.0 Weight loss Nausea, vomiting 
Pramlintide 0.5 - 1.0 Weight loss Gastrointestinal side effects 
Glinides 
Eg. repaglinide and nateglinide 0.5 – 1.5 Weight gain 
Gastrointestinal side 
effects 
Insulin 1.5 - 3.5 Weight gain Hypoglycaemia 
Thiazolidinediones 
Eg. pioglitazone, rosiglitazone* 0.5 - 1.4 Weight gain 
Fluid retention, *increased 
cardiovascular risk 
Dipeptidyl peptidase 4 (DPP-4) 
inhibitor(Dicker 2011) 
Eg. sitagliptin, saxagliptin, 
vildagliptin 
0.43 - 1.4 Weight neutral




*Rosiglitazone is associated with increased cardiovascular risk and is withdrawn in the United 
Kingdom (2010) and in europe (2010). United States Food and Drug Administration (FDA) have issued 
restriction on its usage (2011).  
Table 2. HbA1c, weight and adverse effects of anti-diabetic medications (Nathan, Buse et al. 
2009; Dicker 2011) 
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It is recommend to have a HbA1c level of < 53mmol/mol or 7.0% (Mechanick, Kushner et al. 
2009; 2011), fasting plasma glucose of < 110mg/dl or 6.1mmol/l (2011) preoperatively to 
ensure good outcome. This, however, is unrealistic in many patients who are having 
bariatric surgery to treat their poor diabetes control. There is a greater propensity for day 
case and short stay bariatric surgery which allows patients with less well-controlled diabetes 
to have bariatric surgery. 
4.3.2 Dyslipidaemia 
Increased in visceral adipose tissue in obesity is associated with raised triglyceride levels, 
raised small dense low density lipoprotein (sdLDL) and reduction in high density 
lipoprotein cholesterol (HDL) levels (Ginsberg and Maccallum 2009; Athyros, Tziomalos et 
al. 2011). In addition, presence of insulin resistance as previously described can further 
increased free fatty acids availability to other organs (Athyros, Tziomalos et al. 2011). 
Guidelines such as the National Cholesterol Education Program on adult treatment panel III 
(NCEP ATP III) (2002) and NICE guidelines on lipid modifications (2010) are useful to help 
treat and reduce cardiovascular risk. 
4.4 Gastrointestinal (GI) status 
Presence of any gastrointestinal (GI) symptoms should warrant further evaluation with 
additional investigations (Mechanick, Kushner et al. 2009). Gastroenterology referral is 
appropriate and endoscopy could be performed to rule out serious diseases. It is important 
to note that obesity is associated with a number of cancers. Physicians should be vigilant to 
distinguish between healthy planned weight loss and weight loss due to sinister reasons 
such as cancer. 
4.4.1 Common gastrointestinal problems in obesity 
There appears to be a positive correlation between obesity and gastrointestinal symptoms 
especially abdominal pain, vomiting and diarrhoea (Delgado-Aros, Locke et al. 2004; Talley, 
Howell et al. 2004). It is still unclear as to the mechanisms causing these symptoms 
(Delgado-Aros, Locke et al. 2004; Talley, Howell et al. 2004). Other upper GI symptoms 
could be caused by gastroesophageal reflux disease (GERD). GERD is a common disorder 
and patients present with different symptoms including heartburn, acid regurgitation, chest 
pain, dysphagia and dyspepsia (Locke, Talley et al. 1997). One of the major risk factor for 
GERD is obesity (El-Serag, Graham et al. 2005; Corley and Kubo 2006). Oesophageal 
erosions are also more prevalent in obese patients (El-Serag, Graham et al. 2005). This is 
important as symptomatic GERD is associated with future development of Barrett’s 
oesophagus and oesophageal adenocarcinoma (Lagergren, Bergstrom et al. 1999). Therefore 
it is important to treat this condition adequately either through medical therapies or weight 
loss through surgery. 
4.4.2 Gallstones 
Gallstones disease is common in obese population and could cause abnormality in liver 
enzyme levels. Rapid weight loss post bariatric surgery especially with Roux-en-Y gastric 
bypass surgery is associated with biliary stasis and lithiasis (Caruana, McCabe et al. 2005; 
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Quesada, Kohan et al. 2010). Patients could have concomitant cholecystectomy during 
surgery with disadvantage of increased in intrasurgical time or treat with prophylactic 
ursodeoxycholic acid post surgery for 6 months (Quesada, Kohan et al. 2010). 
4.4.3 Non-alcoholic fatty liver disease 
Obesity is one of the major risk factor for non-alcoholic fatty liver disease (NAFLD) (Clain 
and Lefkowitch 1987; Salgado Junior, Santos et al. 2006; Scaglioni, Ciccia et al. 2011) and is 
often asymptomatic (Salgado Junior, Santos et al. 2006). Abnormal liver function test results 
especially with raised aspartate transaminase (AST) and AST/ALT (alanine transaminase) 
ratio are some predictors of this disease (Liew, Lee et al. 2006; Salgado Junior, Santos et al. 
2006). Viral, autoimmune and other rare causes such as Wilson’s disease and alpha-1 
antitrypsin deficiency should be ruled out in the presence of abnormal test results. Other 
laboratory abnormalities are raised γ- glutamyltransferease (γGT) and alkaline phosphatase 
(ALP), dyslipidaemia and hyperglycaemia (Salgado Junior, Santos et al. 2006). Liver biopsy 
is the gold standard for diagnosing this condition (Salgado Junior, Santos et al. 2006; 
Vuppalanchi and Chalasani 2009). Ultrasound scan of the liver (Mechanick, Kushner et al. 
2009) or liver biopsy(Salgado Junior, Santos et al. 2006)is recommended in the presence of 2-
3 folds increased in the liver enzymes. Transient elastography (Lupsor, Badea et al. 2010) 
including using XL probe for obese patients (Myers, Pomier-Layrargues et al. 2011) is an 
alternative method in assessing liver stiffness hence able to detect liver fibrosis. Hepatotoxic 
medications should be avoided in these patients (Salgado Junior, Santos et al. 2006) and 
bariatric surgery can potentially reverse the condition (Srivastava and Younossi 2005; De 
Ridder, Schoon et al. 2007; Kaila and Raman 2008). 
4.4.4 Alcohol 
Alcohol is another common cause for abnormal liver function test results and excessive 
intake could potentially cause liver problems including cirrhosis. In a study, it is found that 
overweight and obese individuals have higher risk of raised liver enzymes with only 2 
alcohol drinks per day (Ruhl and Everhart 2005). Current history of excess alcohol use is 
contraindicated for bariatric surgery (Snyder 2009) and these patients should be referred to 
other services to help quit. Patients undergoing bariatric surgery need to be counselled 
regarding alcohol. Total abstinence is not necessary as in gastric band patients, those who 
are teetotal appear to lose less weight (Dixon, Dixon et al. 2001). Alcohol absorption is 
greater in malabsorptive type operations and patients should be warned that there are risks 
of rapid intoxication and greater liver damage by alcohol. 
4.5 Endocrine disorders causing obesity  
A small proportion of patients’ weight problem might be due to endocrine disorders 
especially for patients with history of recent weight gain. The common disorders include 
hypothyroidism, Cushing’s syndrome and prolactinoma. Hypothyroidism is associated with 
weight gain through reduction in metabolic rate and thermogenesis (Reinehr 2010). 
Associations have been found between obesity and thyroid function especially elevation in 
thyroid stimulating hormone (TSH) (Knudsen, Laurberg et al. 2005; Nyrnes, Jorde et al. 
2006). This is likely to help in increasing energy expenditure leading to reduction in fat 
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such as cancer. 
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especially abdominal pain, vomiting and diarrhoea (Delgado-Aros, Locke et al. 2004; Talley, 
Howell et al. 2004). It is still unclear as to the mechanisms causing these symptoms 
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could be caused by gastroesophageal reflux disease (GERD). GERD is a common disorder 
and patients present with different symptoms including heartburn, acid regurgitation, chest 
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erosions are also more prevalent in obese patients (El-Serag, Graham et al. 2005). This is 
important as symptomatic GERD is associated with future development of Barrett’s 
oesophagus and oesophageal adenocarcinoma (Lagergren, Bergstrom et al. 1999). Therefore 
it is important to treat this condition adequately either through medical therapies or weight 
loss through surgery. 
4.4.2 Gallstones 
Gallstones disease is common in obese population and could cause abnormality in liver 
enzyme levels. Rapid weight loss post bariatric surgery especially with Roux-en-Y gastric 
bypass surgery is associated with biliary stasis and lithiasis (Caruana, McCabe et al. 2005; 
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Quesada, Kohan et al. 2010). Patients could have concomitant cholecystectomy during 
surgery with disadvantage of increased in intrasurgical time or treat with prophylactic 
ursodeoxycholic acid post surgery for 6 months (Quesada, Kohan et al. 2010). 
4.4.3 Non-alcoholic fatty liver disease 
Obesity is one of the major risk factor for non-alcoholic fatty liver disease (NAFLD) (Clain 
and Lefkowitch 1987; Salgado Junior, Santos et al. 2006; Scaglioni, Ciccia et al. 2011) and is 
often asymptomatic (Salgado Junior, Santos et al. 2006). Abnormal liver function test results 
especially with raised aspartate transaminase (AST) and AST/ALT (alanine transaminase) 
ratio are some predictors of this disease (Liew, Lee et al. 2006; Salgado Junior, Santos et al. 
2006). Viral, autoimmune and other rare causes such as Wilson’s disease and alpha-1 
antitrypsin deficiency should be ruled out in the presence of abnormal test results. Other 
laboratory abnormalities are raised γ- glutamyltransferease (γGT) and alkaline phosphatase 
(ALP), dyslipidaemia and hyperglycaemia (Salgado Junior, Santos et al. 2006). Liver biopsy 
is the gold standard for diagnosing this condition (Salgado Junior, Santos et al. 2006; 
Vuppalanchi and Chalasani 2009). Ultrasound scan of the liver (Mechanick, Kushner et al. 
2009) or liver biopsy(Salgado Junior, Santos et al. 2006)is recommended in the presence of 2-
3 folds increased in the liver enzymes. Transient elastography (Lupsor, Badea et al. 2010) 
including using XL probe for obese patients (Myers, Pomier-Layrargues et al. 2011) is an 
alternative method in assessing liver stiffness hence able to detect liver fibrosis. Hepatotoxic 
medications should be avoided in these patients (Salgado Junior, Santos et al. 2006) and 
bariatric surgery can potentially reverse the condition (Srivastava and Younossi 2005; De 
Ridder, Schoon et al. 2007; Kaila and Raman 2008). 
4.4.4 Alcohol 
Alcohol is another common cause for abnormal liver function test results and excessive 
intake could potentially cause liver problems including cirrhosis. In a study, it is found that 
overweight and obese individuals have higher risk of raised liver enzymes with only 2 
alcohol drinks per day (Ruhl and Everhart 2005). Current history of excess alcohol use is 
contraindicated for bariatric surgery (Snyder 2009) and these patients should be referred to 
other services to help quit. Patients undergoing bariatric surgery need to be counselled 
regarding alcohol. Total abstinence is not necessary as in gastric band patients, those who 
are teetotal appear to lose less weight (Dixon, Dixon et al. 2001). Alcohol absorption is 
greater in malabsorptive type operations and patients should be warned that there are risks 
of rapid intoxication and greater liver damage by alcohol. 
4.5 Endocrine disorders causing obesity  
A small proportion of patients’ weight problem might be due to endocrine disorders 
especially for patients with history of recent weight gain. The common disorders include 
hypothyroidism, Cushing’s syndrome and prolactinoma. Hypothyroidism is associated with 
weight gain through reduction in metabolic rate and thermogenesis (Reinehr 2010). 
Associations have been found between obesity and thyroid function especially elevation in 
thyroid stimulating hormone (TSH) (Knudsen, Laurberg et al. 2005; Nyrnes, Jorde et al. 
2006). This is likely to help in increasing energy expenditure leading to reduction in fat 
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deposition (Reinehr 2010). Furthermore, obesity is associated with reduced tissue 
conversion of T4 to T3. It should be noted that in up to 30% of patients with thyroid 
overactivity, weight gain may occur rather than weight loss.  
Hyperprolactinaemia could lead to increase in weight as shown in patients with 
prolactinomas. When prolactin levels fall after treatment so does patients’ weight 
(Greenman, Tordjman et al. 1998). The relationship between prolactin level and weight 
could be due to the changes within central dopaminergic pathway and reduction in 
serotonin secretion(Kopelman 2000). Prolactin level has been found to be elevated in 
obese females (Kok, Roelfsema et al. 2004) and levels falls after weight loss (Kok, 
Roelfsema et al. 2006). Raised prolactin level in obesity might be a result of 
hyperinsulinaemic state or alterations in doperminergic and serotoninergic activities 
centrally (Kopelman 2000).  
Cushing’s syndrome is a condition of chronic excessive glucocorticoid production. This 
condition causes weight gain amongst other clinical features as described above. In patients 
with morbid obesity, mild hypercortisolaemia could be found with increased  urinary free 
cortisol level (Nieman, Biller et al. 2008). Other conditions mimicking Cushing’s syndrome 
are chronic alcoholism, major depressive disorder (Orth 1995), poorly controlled diabetes 
mellitus, and pregnancy (Nieman, Biller et al. 2008). One should always keep in mind these 
potential endocrine abnormalities causing obesity and investigate further in suspicious 
cases.  
4.6 Reproductive status  
In males, increased in BMI is associated with fertility problems (Nguyen, Wilcox et al. 
2007) and this could be related to reduction in testosterone, sex hormone binding globulin 
(SHBG) and free testosterone as weight increases (MacDonald, Herbison et al. 2010). 
Oestradiol level on the other hand is increased (Hammoud, Gibson et al. 2009) and this is 
likely caused by aromatisation of adipose tissue. Hormonal changes are likely to cause 
problems with sexual quality of life and this can be reversed with bariatric surgery 
(Hammoud, Gibson et al. 2009). 
In females, high body mass index could cause problem with menstrual irregularities (Jones, 
Srinivasan et al. 2007; Wei, Schmidt et al. 2009; Kulie, Slattengren et al. 2011). The 
underlying cause could be due to polycystic ovarian syndrome, oligomenorrhoea or 
amenorrhoea (Jones, Srinivasan et al. 2007) leading to issues with ovulation. Links have 
been found between increased abdominal fat with anovulation (Kuchenbecker, Groen et al. 
2010) likely due to insulin resistance (Pasquali, Pelusi et al. 2003). These problems in turn 
lead to sub- or infertility by disrupting spontaneous ovulation and can reduced efficacy of 
assisted fertility treatment (Pasquali, Pelusi et al. 2003; Balen 2007; Farquhar 2007; Pasquali, 
Patton et al. 2007). However, fertility is improved post bariatric surgery due to weight loss 
(Guelinckx, Devlieger et al. 2009; Shah and Ginsburg 2010; Hezelgrave and Oteng-Ntim 
2011; Kulie, Slattengren et al. 2011). Early pregnancy post surgery might be associated with 
increased risk of miscarriages and possibility of preterm birth (Guelinckx, Devlieger et al. 
2009). Therefore, patients suitable for surgery are generally advised not to seek pregnancy at 
least 1 year after surgery (Guelinckx, Devlieger et al. 2009; Mechanick, Kushner et al. 2009). 
This is especially important in patients receiving malabsorptive surgeries as there are 
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potentially severe nutritional deficiencies that could be exacerbated in pregnancy 
(Guelinckx, Devlieger et al. 2009; Hezelgrave and Oteng-Ntim 2011). 
Contraception advice is vital. Obesity is a risk factor for venous thromboembolism (Stein, 
Beemath et al. 2005) and can cause recurrent thromboses (Eichinger, Hron et al. 2008). 
Oestrogen therapy is recommended to be stopped a month prior to surgery to avoid this 
complication (Mechanick, Kushner et al. 2009). Individuals going for malabsorptive 
procedures should be advice to avoid oral contraception as post operative as there is a risk 
of failure to absorb leading to failure of treatment (2010; Paulen, Zapata et al. 2010). There 
are concerns as well regarding risk of fractures due to effects on bone mineral density from 
usage of depot medroxyprogesterone acetate (DMPA) after malabsorptive surgery (Paulen, 
Zapata et al. 2010). 
4.7 Medications causing weight gain 
The commonest cause of weight gain is due to adverse effect from drug therapy and 
patients should be advised on weight gain when these medications are prescribed (Scottish 
Intercollegiate Guidelines and Scotland 2010). Common medications causing weight gain 
are as follows (Kulkarni and Kaur 2001; Ness-Abramof and Apovian 2005; Leslie, Hankey et 
al. 2007; Davtyan and Ma 2008; Scottish Intercollegiate Guidelines and Scotland 2010; 
Nihalani, Schwartz et al. 2011): 
- Anti-convulsants (sodium valproate, carbamazepine, gabapentin) 
- Anti-psychotics (clozapine, olanzapine, risperidone, quetiapine, clopromazine, 
ziprasidone, aripiprazole) 
- Anti-depressants (tricyclic anti-depressants (TCA), selective serotonin reuptake 
inhibitors (SSRI), mirtazapine) 
- Mood stabilisers (lithium) 
- Anti-hypertensives (beta blockers, calcium channel blockers) 
- Anti-diabetic medications (insulin, sulphonylurea, thiazolidinedione) 
- Steroid 
- Anti-neoplastic agents (tamoxifen) 
- Anti-histamines 
Mechanisms of medications causing weight gain could be due to their effects on appetite 
through receptors at the central nervous system or effects on the body’s metabolism. Anti-
histaminergic effect by most psychotropic medications including anti-depressants and 
anti-psychotics causes cravings for carbohydrate (Davtyan and Ma 2008; Nihalani, 
Schwartz et al. 2011). Antipsychotics cause inhibitory effect on serotonin and epinephrine 
receptors thus stimulating appetite (Davtyan and Ma 2008). These effects could cause 2 to 
17kg of weight gain during treatment (Nihalani, Schwartz et al. 2011). Lithium is used as 
mood stabilisers and might cause weight gain through increasing level of serum leptin 
(Atmaca, Kuloglu et al. 2002) or changes in thyroid function. As many obese patients 
suffer from depression, medications to treat the condition could be a cause of obesity or 
exacerbate the problem. Venlafaxine is weight neutral while bupropion causes weight loss 
so could be treatment of choice if patient is not contraindicated to these medications 
(Davtyan and Ma 2008).  
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potentially severe nutritional deficiencies that could be exacerbated in pregnancy 
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Oestrogen therapy is recommended to be stopped a month prior to surgery to avoid this 
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procedures should be advice to avoid oral contraception as post operative as there is a risk 
of failure to absorb leading to failure of treatment (2010; Paulen, Zapata et al. 2010). There 
are concerns as well regarding risk of fractures due to effects on bone mineral density from 
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al. 2007; Davtyan and Ma 2008; Scottish Intercollegiate Guidelines and Scotland 2010; 
Nihalani, Schwartz et al. 2011): 
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- Anti-psychotics (clozapine, olanzapine, risperidone, quetiapine, clopromazine, 
ziprasidone, aripiprazole) 
- Anti-depressants (tricyclic anti-depressants (TCA), selective serotonin reuptake 
inhibitors (SSRI), mirtazapine) 
- Mood stabilisers (lithium) 
- Anti-hypertensives (beta blockers, calcium channel blockers) 
- Anti-diabetic medications (insulin, sulphonylurea, thiazolidinedione) 
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- Anti-neoplastic agents (tamoxifen) 
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Mechanisms of medications causing weight gain could be due to their effects on appetite 
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histaminergic effect by most psychotropic medications including anti-depressants and 
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receptors thus stimulating appetite (Davtyan and Ma 2008). These effects could cause 2 to 
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Anticonvulsants cause weight gain through the effects on endocrine system and body 
metabolism. Sodium valproate causes increase in insulin and leptin levels with reduction in 
gluconeogenesis and metabolic rate (Davtyan and Ma 2008). Alternative medication using 
weight neutral anticonvulsants such as lamotrigine (Kulkarni and Kaur 2001) and 
levetiracetam (Davtyan and Ma 2008) could help prevent the problem, and topiramate may 
help induce weight loss (Kulkarni and Kaur 2001; Davtyan and Ma 2008). 
Beta adrenergic receptors are present in adipose tissue and when stimulated by 
noradrenaline, help to metabolize fat into energy source (Nihalani, Schwartz et al. 2011). 
Beta blocker not only reverses this effect, it also causes reduction in resting metabolic rate 
(Davtyan and Ma 2008). Verapamil might cause weight gain through inhibition in 
dopaminergic receptor while clonidine reduces sympathetic activity via central nervous 
system thus decreasing the metabolic rate (Davtyan and Ma 2008). Angiotensin converting 
enzyme (ACE) inhibitors and diuretics are other possibilities as treatment for hypertension 
(Davtyan and Ma 2008). 
Obesity is associated with metabolic syndrome and this causes insulin resistance leading to 
diabetes mellitus. Some anti-diabetic medications causes weight gain mostly through effect 
on metabolism. Correction of catabolic state of diabetes causing retention of calories, 
endogenous or exogenous insulin causing inhibition of lipolysis, reduction in leptin 
production and appetite stimulation from hypoglycaemic episodes contributes towards 
weight gain (Davtyan and Ma 2008). One of the side effects of thiazolidinediones is fluid 
retention (Davtyan and Ma 2008). Medications helping in weight loss is glucagon-like 
peptite-1 (GLP-1) (Nathan, Buse et al. 2009) while dipeptidyl-peptidase (DPP)-4 inhibitor 
(Dicker 2011), gliclazide modified release (Zoungas, Chalmers et al. 2010) and 
metformin(Nathan, Buse et al. 2009) are weight neutral . These might be better choice for 
obese patients if there are no contraindications. It is important to recognise drug induced 
weight gain and sometimes changing medications could enhance potential weight lost post 
surgery. 
5. Psychological assessment 
All patients who undergo surgery will need long term behavioural and eating habit 
changes. Indeed, some view bariatric surgery as a forced behavior modification (van Hout 
and van Heck 2009). Psychological and psychiatric disorders could lead to a negative 
outcome post operatively (Pull 2010). These include those who have active psychosis, 
current illicit drug users or alcohol abuse and personality disorders(Susan F. Franks 2008). 
Surgery is contraindicated in patients who are currently abusing drugs or alcohol (Susan F. 
Franks 2008; Snyder 2009). Patients with previous history of sexual abuse, found in a 
significant percentage of bariatric patients, will need more support as they might find 
difficulties with attention gained post surgery due to change in body image and thus risk 
regaining weight(Snyder 2009). Psychological disorders can include depression, anxiety, 
eating disorders and low self esteem (Abiles, Rodriguez-Ruiz et al. 2010). Patients known or 
suspected to have psychological or psychiatric disorders should be referred for further 
mental health assessment (Susan F. Franks 2008; Mechanick, Kushner et al. 2009) by a 
psychologist or psychiatrist. The assessment usually contains one or two parts: a clinical 
interview and psychological testing (Mechanick, Kushner et al. 2009; Snyder 2009). 
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5.1 Depression and anxiety 
Depression is very common (Susan F. Franks 2008; Snyder 2009; Abiles, Rodriguez-Ruiz et 
al. 2010) and prevalence is highly variable depending on the use of a choice of structured 
clinical interview for diagnostic and statistical manual of mental disorders (SCID) or clinical 
based diagnosis (Susan F. Franks 2008). Mild depressive disorder is relatively benign and 
might improve post surgery (Snyder 2009). On the other hand, severe depression with or 
without suicidal ideation could have adverse effects towards patients as they might have 
difficulty adhering with dietary or other advice provided(Snyder 2009). Patients will need 
these addressed prior to surgery (Mechanick, Kushner et al. 2009). 
Anxiety is present in 15 to 37.5% of patients (Susan F. Franks 2008). Most patients’ distress 
levels are reduced with weight loss post surgery (Ryden, Karlsson et al. 2003) but this could 
potentially cause problems with adaptability or ability to cope perioperatively (Snyder 2009). 
5.2 Eating disorder 
Eating disorder is common. This can include comfort eating from emotional stress or 
distress, binge eating, snacking (Mechanick, Kushner et al. 2009; Snyder 2009) and night 
time eating (Snyder 2009). Binge eating is characterised by subjective loss of control and 
consumed a large quantity of food within a short period (Snyder 2009). About 10-25% of 
patients have problems with binge eating (Snyder 2009). Psychologists could help alleviate 
the symptoms and reinforce the behaviour modification needed (Snyder 2009).  
Night eating syndrome (NES) is characterised with night time hyperphagia, which is intake 
of 25% of total daily calories after evening meal, awaking from sleep to eat at night (Allison, 
Wadden et al. 2006; Howell, Schenck et al. 2009; Stunkard, Allison et al. 2009) and morning 
anorexia (Gluck, Geliebter et al. 2001). It is more common in women, and is associated with 
higher rate of depression, lower self-esteem and less day time hunger with poorer outcome 
in weight loss (Gluck, Geliebter et al. 2001). Patients with this condition should be 
considered for a referral to a psychologist for further evaluation and treatment. Sertraline 
has been shown to be useful in patients with night eating syndrome (O'Reardon, Allison et 
al. 2006). 
Psychological assessments will help to distinguish patient who are contraindicated for 
surgery, improve patient’s emotional well being and motivation as well as enhances 
patient’s ability to cope with bariatric surgery (Snyder 2009). 
6. Dietary and nutrition assessment 
Food can be measured based on amount of calories. Weight is maintained when intake of 
calories equals expenditure. Obesity occurs when there is a chronic surplus of intake. 
Therefore, nutritional assessment by a specialist dietitian or nutritionist is essential. 
Assessment should again be holistic and this includes patient’s lifestyle, eating habits, 
positive and negative influences on behaviour (Detitians in obesity management 2007). 
Practitioners should have specialist skills in nutritional assessment. Time recommended to 
evaluate lifestyle habits is initially is between 45 minutes and an hour with follow up 
appointments between 20 to 30 minutes (Detitians in obesity management 2007). 
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The patient’s weight history could help identify onset of weight problem either since 
childhood indicating a genetic contribution (Farooqi and O'Rahilly 2007) or any important 
life events causing initiation of weight problem such as pregnancy (Smith, Lewis et al. 
1994). Assessment should also include previous efforts and outcomes of weight loss 
attempts. Gibbons et al showed that on average, individuals had 4.7 attempts in losing 
weight before seeking surgery (Gibbons, Sarwer et al. 2006). This enables positive factors 
to be identified and maintained and previous failures addressed (Detitians in obesity 
management 2007). 
Bariatric surgery will help in weight loss but Swedish Obese Subjects (SOS) study has 
shown that after maximum weight loss at 1 year, patients start to regain some of the excess 
weight loss after 2 years and weight gain stabilized after 8 to 10 years (Sjostrom, Narbro et 
al. 2007). Lifestyle modifications which include changes in diet, physical activity and 
behavioural therapy are paramount in preventing this problem post surgery and assist in 
weight maintenance (National Heart, Blood et al. 1998; Wadden, Butryn et al. 2007; Tsigos, 
Hainer et al. 2008). 
Apart from these, it is also important to look at cultural, religious and personal beliefs or 
preferences in different type of food and eating behaviour. The use of a food diary is an 
important tool to assess quantity and type of food intake as well as able to provide practical 
suggestions on changes (Detitians in obesity management 2007; Scottish Intercollegiate 
Guidelines and Scotland 2010). However, obese patients tend to under-report their dietary 
intake (Detitians in obesity management 2007; Scottish Intercollegiate Guidelines and 
Scotland 2010). 
6.1 Eating habits 
There are different dietary behaviours within the obese population. Some patients eat for 
comfort especially during stress or negative emotions (Elfhag and Rossner 2005). There are 
many different eating habits and detailed assessment of dietary intake is vital in providing 
specific action plans for different patients. Binge eating and night eating syndrome are 
eating disorders as described above (Allison, Wadden et al. 2006; Tsigos, Hainer et al. 2008). 
It is important to identify patients who have this problem and referred to psychologist for 
further treatment prior to proceeding for bariatric surgery (Detitians in obesity management 
2007). 
Skipping meals especially breakfast is a common habit (Ruxton and Kirk 1997; Wyatt, 
Grunwald et al. 2002). Breakfast especially with cereal is low in fat, high in carbohydrate, 
fibre and micronutrients (Ruxton and Kirk 1997). Researchers have shown breakfast 
consumption is associated with lower body weight (Ruxton and Kirk 1997) and better 
success with future maintenance of weight loss (Wyatt, Grunwald et al. 2002; Elfhag and 
Rossner 2005; Wing and Phelan 2005; Grief and Miranda 2010). Nevertheless, it is common 
for patients to not feel hungry in the morning after bariatric surgery. Other erratic eating 
habits include periods of fasting, snacking or grazing food (Detitians in obesity management 
2007). Sometimes the spouse or partner provides excessive feeding towards the patient 
causing excessive eating. It is important to address these behaviours and educate patients to 
have a balanced three meals per day to maintain good nutritional status prior to surgery 
(Tsigos, Hainer et al. 2008). 
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6.2 Dietary treatment 
There are various types of food in the shelves of supermarkets and consumers have many 
different choices. Most food packaging now carry nutritional information on their labels for 
consumers to read. Educating patients to choose their food can help increase further 
awareness of label reading. Furthermore, it is also a good opportunity to educate patient to 
have a more balanced diet consisting of more fruits and vegetables, and less fat, salt and 
sugar ((FDA) 2004; NHS Choices 2011). 
Nutritional requirements are different for each person depending on gender, height, weight, 
amount of physical activity and age. Dietitians could help to calculate the daily requirement 
while patients need to be taught how to read food label and perform their own calorie 
counting for their recommended daily calorie intake. 
There are many dietary interventions available. The Dietary Approaches to Stop 
Hypertension (DASH) for obese patient with hypertension gives priority to a diet high in 
grain products, fruits, vegetables, low in fat and non dairy food. It has proven to lower 
blood pressure (Appel, Moore et al. 1997; Svetkey, Simons-Morton et al. 1999; Miller, 
Erlinger et al. 2006) and cholesterol (Miller, Erlinger et al. 2006). Other interventions that has 
shown success in weight loss include carbohydrate restriction diet including commercial 
weight loss programme (Nordmann, Nordmann et al. 2006; Gardner, Kiazand et al. 2007), 
the low glycaemic index diet (Thomas, Elliott et al. 2007), Mediterranean diet (Shai, 
Schwarzfuchs et al. 2008) and low fat diet(Nordmann, Nordmann et al. 2006). 
6.3 Six hundred calorie deficit diet 
It is recommended for patient to aim to lose weight of no more than 0.5 – 1kg (1 – 2Ib) per 
week (Heart, Blood et al. 1997; 2006; Scottish Intercollegiate Guidelines and Scotland 2010) 
and this equivalent to a calorie deficit of 500 to 1000kcal per day for 6 months (National 
Heart, Blood et al. 1998; Scottish Intercollegiate Guidelines and Scotland 2010); hence the 
600kcal deficit approach (Detitians in obesity management 2007; Tsigos, Hainer et al. 2008; 
Scottish Intercollegiate Guidelines and Scotland 2010). Dietician will calculate the patient’s 
estimated energy requirement and subtract it by 600kcal per day resulting in a negative 
balance (Detitians in obesity management 2007). This could be individualised to each 
patients’ needs and preferences in food but should still maintain a healthy and balanced 
diet. 
6.3.1 Low energy and very low energy diets 
Patients who need to achieve a more rapid weight loss could try the more restricted calorie 
diet (Detitians in obesity management 2007; Tsigos, Hainer et al. 2008; Scottish 
Intercollegiate Guidelines and Scotland 2010). Low energy diet consists of total daily calories 
of between 800 to 1,500kcal and very low energy diet consists of less than 800kcal per day 
(National Heart, Blood et al. 1998; Detitians in obesity management 2007; Tsigos, Hainer et 
al. 2008; Scottish Intercollegiate Guidelines and Scotland 2010) or <50% reduction of the 
patient’s predicted resting energy expenditure (Tsai and Wadden 2006). Low energy diet is 
associated with 5–8% of weight loss (National Heart, Blood et al. 1998; Scottish 
Intercollegiate Guidelines and Scotland 2010) over 12 months and this could be 
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individualised to the patient’s food preference (National Heart, Blood et al. 1998). 
Micronutrient supplementations are occasional necessary. 
Very low energy diet (VLED) is usually a liquid diet consisting of a large amount of protein, 
up to 80g of carbohydrate and 15g of fat per day and fortified with micronutrients (Tsai and 
Wadden 2006). This intervention need to be done under close medical supervision (1993; 
Detitians in obesity management 2007; Tsigos, Hainer et al. 2008; Scottish Intercollegiate 
Guidelines and Scotland 2010). Maximum recommended duration of this intervention is 12 
weeks (Detitians in obesity management 2007). The patient needs to consume a minimum of 
2 litre of non-caloric fluid per day while on this diet (Tsai and Wadden 2006). Cambridge 
Weight Plan previously known as the Cambridge Diet uses VLED intervention. Adverse 
effects during this treatment include cholelithiasis, cold intolerance, hair loss, headache, 
fatigue, dizziness, muscle cramps, constipation, volume depletion and rarely cardiac 
complications causing death if unsupervised (1993; Tsai and Wadden 2006). Total weight 
loss at 12 months for VLED is similar to low calorie diet (National Heart, Blood et al. 1998; 
Tsai and Wadden 2006; Scottish Intercollegiate Guidelines and Scotland 2010). During first 3 
to 4 months, initial weight loss with VLED is about 25-50% but patient regained 40–50% of 
the weight lost within 1–2 years while on VLED (Tsai and Wadden 2006) hence it is suitable 
for rapid weight loss. One study showed remission of type 2 diabetes in obese patient after 8 
weeks of VLED (Lim, Hollingsworth et al. 2011). 
VLED with liquid diet or low energy diet substituted with one or two of the three daily 
main meals and this intervention is called meal replacement intervention (Tsigos, Hainer et 
al. 2008). As the liquid diet consists of necessary micronutrients, this may help in weight loss 
while maintaining a balanced nutrition (Tsigos, Hainer et al. 2008); the low energy diet 
replacement needed to be fortified with the necessary vitamins and minerals (Heymsfield, 
van Mierlo et al. 2003). It is shown that meal replacement intervention induce between 6.97 
to 7.31kg of weight loss at 1 year follow up as compared to 2.61-4.35kg with low energy diet 
alone (Heymsfield, van Mierlo et al. 2003). 
7. Lifestyle intervention 
After dietary changes in reducing calorie intake, the next step would be to increase in 
physical activity and finally help in engaging the patient for a more permanent change in 
lifestyle. Physical activity for about 30–60 min per day for at least 5 days a week of moderate 
intensity such as brisk walking has been recommended by various guidelines (National 
Heart, Blood et al. 1997; 2006; Tsigos, Hainer et al. 2008; Scottish Intercollegiate Guidelines 
and Scotland 2010). Increased physical activity has added effect on weight loss compared to 
just dietary interventions alone (Jakicic 2009; Goodpaster, Delany et al. 2010). It also 
improves cardiorespiratory fitness (National Heart, Blood et al. 1998), reduces 
cardiovascular risks (National Heart, Blood et al. 1998; Tsigos, Hainer et al. 2008; 
Goodpaster, Delany et al. 2010; Vetter, Faulconbridge et al. 2010), reduces abdominal fat 
(Jones, Wilson et al. 2007), improves anxiety and depression and helps with long term 
weight management(Jones, Wilson et al. 2007; Tsigos, Hainer et al. 2008; Jakicic 2009). 
Patients should also be encouraged to avoid sedentary lifestyle by choosing to use the stairs 
rather than elevators, walking or cycling to nearby places rather than driving and doing 
gardening (Vetter, Faulconbridge et al. 2010). 
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It has been shown by the Diabetes Prevention Programme (Knowler, Barrett-Connor et al. 
2002) and the Finnish Diabetes Prevention studies (Tuomilehto, Lindstrom et al. 2001) that 
intensive lifestyle interventions promote weight loss of between 3.5-5.6kg. The Look AHEAD 
trial reported 6.15% weight loss after 4 years of interventions (Wing 2010). Most of the 
academic centres provide initial weekly interventions for a period of 16 to 26 weeks (Wadden, 
Butryn et al. 2007; Vetter, Faulconbridge et al. 2010). The entire treatment programme should 
be well structured along the lines of the Diabetes Prevention Programme. It is also more cost 
effective to have group sessions. Moreover, group sessions provide additional benefits on 
greater initial weight loss, better social support and healthy competition between members 
(Wadden, Butryn et al. 2007; Vetter, Faulconbridge et al. 2010). 
Even after successful initial weight loss, weight regain could occur prior to surgery. Reasons 
behind weight regain are likely to be multifactorial including behavioural fatigue (Tsai and 
Wadden 2006), leaving from highly supportive care and return to initial ‘damaging’ 
environment or influence (Vetter, Faulconbridge et al. 2010). Hence health care professionals 
and patients should aim for long term behavioural change and it is the key in preventing 
weight regain prior and post surgery. 
8. Final steps prior to surgery 
After medical, psychological and nutritional assessments, the team will need to meet 
together to provide insight of the patients’ conditions and discuss suitability of surgical 
interventions in them. Some centres propose a minimum 5 - 10% weight loss prior to 
surgery as some studies have shown this decreases length of hospital stay (Still, Benotti et al. 
2007), reduces operative time (Huerta, Dredar et al. 2008) and less complications (Liu, Sabnis 
et al. 2005). As most of the dietary advice post surgery advises patients to have a liquid diet 
first, it is also important to review all patients’ medications pre-surgery and change 
medications into liquid or soluble form prior to surgery.  
9. Conclusion 
Assessing and preparing patients for bariatric surgery is a complex process requiring input 
from a multi-disciplinary team. The primary aim is to optimise treatment of patients’ pre-
existing conditions hence minimising peri and post-operative complications and mortality. 
The surgery itself is only the first step. Post operatively, bariatric team members as well as 
patients’ general practitioners need to continue to encourage patients’ adherence to lifestyle 
changes including dietary energy restriction and increase in physical activity to help in long-
term weight maintenance.  
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VLED with liquid diet or low energy diet substituted with one or two of the three daily 
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1. Introduction  
Weight loss surgery (WLS) has become increasingly commonplace, as rates of morbid 
obesity and its serious medical consequences continue to rise in developed countries 
worldwide (Nguyen et al., 2005; Steinbrook, 2004). From 1998 to 2002, an increase in WLS of 
approximately 450% was observed in the United States alone, and from 2002 to 2004, it was 
estimated that more than 357,300 adults in the United States had undergone WLS (Wysoker, 
2005). Most patients benefit from the procedure; however there remain at least 20% of 
patients who fail to lose the expected amount of weight or who regain a significant amount 
of lost weight (Christou, Look, & Maclean, 2006; Kalarchian et al., 2007; Kinzl et al., 2006). 
Some researchers have identified 7-10 year failure rates of up to 35% for gastric bypass 
patients and up to 57% for laparoscopic banding patients (Ayyad & Andersen, 2000; Fischer 
et al., 2007). A recent long-term follow-up of 200 gastric banded patients found that excess 
weight loss (EWL) was gradually regained, resulting in only 15.6% EWL after 14 years and a 
reoperation rate of  30.5% (Stroh, Hohmann, Schramm, Meyer, & Manger, 2011). While a 
minority of these failures or suboptimal outcomes may be due to technical surgical errors or 
complications, the majority of them are attributable to psychological and behavioral factors 
that interfere with patients’ abilities to make or maintain lasting changes in lifestyle (Boeka, 
Prentice-Dunn, & Lokken, 2010; Buchwald et al., 2004; Pessina, Andreoli, & Vassallo, 2001).  
Long-term failure rates highlight the need to selectively identify patients at-risk for minimal 
weight loss or weight regain (O'Brien, McPhail, Chaston, & Dixon, 2006; Stroh et al., 2011). 
It is widely accepted that obesity is multifactorial in nature, and that psychological and 
behavioral influences play an integral role in the development and maintenance of an obese 
state (Buchwald et al., 2004; Kinzl et al., 2006). The preoperative psychological evaluation for 
WLS candidates was uniformly put into practice following the 1991 National Institutes of 
Health Consensus Panel recommendations that officially recognized the key role of 
psychological and behavioral factors toward the ability of a patient to ultimately be 
successful with WLS (Buchwald, 2005; Buddeberg-Fischer, Klaghofer, Sigrist, & Buddeberg, 
2004; Kinzl et al., 2006; NIH Consensus Panel, 1991). A majority of WLS programs and 
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2004; Kinzl et al., 2006; NIH Consensus Panel, 1991). A majority of WLS programs and 
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insurance carriers subsequently began requiring a presurgical psychological evaluation in 
order to clear the candidate for surgery (Bauchowitz et al., 2005; Kalarchian et al., 2007). At 
its outset, it was widely assumed that a preoperative psychological evaluation would be 
useful in identifying patients who would be at-risk for suboptimal or failed outcomes 
(Ashton, Favretti, & Segato, 2008; Bauchowitz et al., 2005; Kalarchian et al., 2007). This 
assumption was largely based on research that had been able to identify various 
psychological and behavioral patterns among obese patients that were associated with 
failure or suboptimal outcomes for conventional weight loss programs (Bauchowitz et al., 
2005). 
Research to date has found few consistently significant associations between independently 
studied traditional psychological risk factors that were assumed to be equally problematic 
for WLS patients (Franks & Kaiser, 2008; Greenberg, 2003; Greenberg, Sogg, & Perna, 2009; 
Grothe, Dubbert, & O'jile, 2006; Herpertz, Kielmann, Wolf, Hebebrand, & Senf, 2004; van 
Hout, Verschure, & van Heck, 2005). For example, our review of the literature found that 
Axis I pathology such as Mood Disorders, Anxiety Disorders, and Eating Disorders; while 
higher in the WLS candidates as compared to the normal population, have not uniformly 
predicted poorer weight loss or other health outcomes (Franks & Kaiser, 2008). In contrast, 
weight loss subsequent to WLS predicted improvement in depression and anxiety following 
the surgery and subsequent weight loss (Swan-Kremier, 2005). Other studies have suggested 
that it is the degree of psychopathology and the past history of psychiatric treatment that is 
relevant to WLS outcomes rather than the presence or absence of a diagnosable condition at 
the time of the presurgical evaluation (Ashton et al., 2008; van Hout et al., 2005). 
The paucity of research findings for the utility of the preoperative evaluation in predicting 
outcomes has led to criticism of the field (Ashton et al., 2008; Greenberg et al., 2009). Some 
have demanded that the validity of the preoperative psychological evaluation be 
demonstrated for justification of its requirement for WLS (Ashton et al., 2008). It has become 
clear that the field of psychology must take a critical look at the current state of the science 
in this area, identify the problems, and revise its approach to meet the scientific rigor of 
evidence-based medicine. The lack of predictive power for any particular element of the 
psychological evaluation has been noted, and various reviews of the literature have been 
consistent in their observations about the problems with much of the research. Sogg and 
Mori (2004) point out that the research in this area generally has been hampered by the fact 
that the approach to the psychological evaluation for bariatric patients is non-standardized, 
resulting in heterogeneity of data, definitions, and measurements of constructs of interest. 
They further point out that many of the published studies suffer from methodological flaws. 
Others contend that because the psychological evaluation is not independent of clinical 
decision-making, patients get triaged out of WLS or get deferred into other treatments (both 
psychological and weight control-related) prior to the surgery (Greenberg et al., 2009; 
Kalarchian et al., 2007). Still others have pointed out that there is still no consensus of what 
constitutes WLS success (Franks & Kaiser, 2008). In addition to the aforementioned 
problems, we propose that there exists a more fundamental issue; the lack of a theory-based 
approach from which to systematically investigate and understand research findings.  
In this chapter we will: 1) review and critique the current approach to the psychological 
evaluation for WLS candidates, 2) discuss attempts that have been made to improve the 
predictive utility of the evaluation, 3) highlight the specific areas of inquiry that have shown 
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merit for predicting postoperative outcomes,  4) explore the reasons for the poor predictive 
power of the current medical model, and 5) propose a new paradigm from which to 
approach the evaluation with supportive evidence from the extant literature. A suggested 
theory-driven clinical intake and psychological assessment procedure will be outlined, with 
guidelines for clinical decision making. Finally, future considerations for research and 
clinical practice will be discussed. 
2. State of the psychological science in bariatric evaluations  
The initial medical model approach to the preoperative psychological evaluation of WLS 
candidates was based on the clinical convention of information gathering that is used to rule 
out or to formulate a mental health diagnosis. This involves gathering information relevant 
to a chief complaint and its associated symptoms and history, the past medical history, the 
psychosocial history, and the family history. The approach is contemporary in that it also 
incorporates a whole-person view that is supposed to integrate biological, psychosocial and 
environmental dimensions into formulating a diagnosis, as opposed to relying solely on the 
physical and biological aspects. Some psychologists also utilize psychological testing and 
may administer the mini-mental status exam or some other form of cognitive screen as well.  
The intended purpose for gathering this information is to select a rational treatment 
approach by applying the information to diagnostic schema and their associated 
interventions. Optimally, these interventions should be based on a scientific evidence-base 
that links treatments with demonstrated outcomes. However, there are few interventions 
that are specifically tailored to the multiple determinants of a given psychological diagnosis. 
A similar issue exists for obesity, where the available treatments are not yet tailored to the 
complex and multiple determinants of the condition. Given that the goal for the 
preoperative psychological evaluation for WLS is to predict who will be successful and who 
is at risk for failure or suboptimal outcomes, the initial approach to the evaluation was not 
sufficiently designed with prediction in mind. In 2004, a behavioral health committee for the 
American Society of Metabolic and Bariatric Surgery (ASMBS) attempted to improve the 
utility of the presurgical evaluation by publishing which elements were thought to be 
important in conducting the assessment (LeMont, Moorehead, Parish, Reto, & Ritz, 2004). 
Due to the lack of empirical data in this area, however, no consensus or practice guidelines 
were able to be firmly established. Thus, little progress has been made in standardization of 
assessment and data collection from which to draw conclusions about relationships to 
postsurgical outcomes (Sogg & Mori, 2004). 
2.1 What is known – paradoxical results 
While there has been no agreed-upon defined outcome for WLS, a general professional 
consensus may be gleaned based on what is most consistently used in the research 
literature. Over the years, the field appears to have adopted a “>50% excess weight loss” 
(EWL) as a cut-point indicating “success.” The use of EWL as the sole basis for defining 
success or failure is scientifically problematic, particularly when we are to set practice 
standards according to an evidence-base. The 50% EWL criterion is essentially an 
arbitrary standard, as it is calculated based on a statistical comparison to ideal weight 
standards, which are themselves arbitrarily defined (Franks & Kaiser, 2008). Additionally, 
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the 50% EWL criterion is independent of associated health improvements and has not yet 
been shown to have any clinical superiority over lower amounts. Even less clear are what 
criteria should be used to discriminate “suboptimal” weight loss and “failure.”  Many 
patients will reduce their medication needs, resolve co-morbid medical conditions, and 
experience improved psychosocial function and quality of life (QOL) well before 
achieving the >50% EWL mark. Yet, few psychological studies rely on criteria other than 
EWL as their prediction standard. Thus, the research in psychological prediction of 
outcomes has been severely limited by a significant methodological flaw in the selection 
of prediction criteria. 
Nonetheless, several reviews of the literature, including our own, have yielded consistent 
results about what appears to influence EWL, psychosocial function, and/or QOL (Ashton 
et al., 2008; Franks & Kaiser, 2008; Greenberg, 2003; Greenberg et al., 2009; Grothe et al., 
2006; Herpertz et al., 2004; van Hout et al., 2005). These include a history of psychiatric 
inpatient admissions, outpatient psychiatric treatment or counseling, social support, body 
image, and depression. With regard to prior psychiatric admissions, it appears that inpatient 
admissions, irrespective of the quantity, are related to increased postsurgical medical and 
psychological complications and reduced patient satisfaction (Ashton et al., 2008; van Hout 
et al., 2005). However, a history of outpatient psychological treatment appears to be a 
positive predictor for postsurgical weight loss. It has been assumed that these findings 
related to a patient’s ability to develop positive coping skills that carries over to the 
behavioral and psychological challenges faced during the postsurgical phase (Grothe et al., 
2006). Presurgical body dissatisfaction, present in about 70% of patients, appears to be 
inversely related to postsurgical weight loss; however, a causal connection has not been 
established (Swan-Kremier, 2005). The presence of presurgical depression may result in less 
postsurgical weight loss than for non-depressed patients (van Hout et al., 2005). However, 
depression has not been a prognostic indicator of overall failure based on % EWL, 
psychosocial function, or quality of life (Kalarchian et al., 2005; Ma et al., 2006; Swan-
Kremier, 2005). Some have reported that it may actually promote greater short-term weight 
loss (Averbukh et al., 2003; Ma et al., 2006).  
Reviews of the literature have also been consistent in reporting findings that are not yet 
well-elucidated, but are nonetheless provocative. For example, marital relationship appears 
to be an important mediator of postsurgical results, although the nature of the association is 
unclear. Limited research suggests a possible U-shaped relationship, with marital 
satisfaction as well as dissatisfaction showing a positive association with postsurgical 
weight loss (Herpertz et al., 2004; van Hout et al., 2005). Also unclear is the effect of social 
support on complications and weight loss in the postsurgical phase (Grothe et al., 2006; 
Herpertz et al., 2004). Our own study of postsurgical support group attendance for 
laparoscopic banded patients demonstrated that increased attendance was associated with 
higher rates of weight loss one year after surgery (Kaiser, Franks, & Smith, 2011). This is 
consistent with a previous review of the literature that concluded that social support 
appeared to impact weight loss through the influence on adherence to postsurgical lifestyle 
modifications (Herpertz et al., 2004). Limited research has shown that the presence of 
anxiety in conjunction with presurgical obesity-related psychosocial stress may be positively 
associated with postsurgical weight loss (Herpertz et al., 2004; Ryden, Karlsson, Sullivan, 
Torgerson, & Taft, 2003; van Hout et al., 2005); however, the specific nature of the role of 
Rethinking the Preoperative Psychological Evaluation – 
A New Paradigm for Improved Outcomes and Predictive Power 
 
121 
anxiety and a causal relationship to postsurgical outcomes have not been well-studied 
(Kalarchian et al., 2007; Rosik, 2005). Areas of research that continue to show conflicting 
results with regard to postsurgical outcomes include self-esteem (van Hout et al., 2005) and 
a presurgical diagnosis of binge eating disorder (Franks & Kaiser, 2008).   
Finally, a consistent body of literature shows no strong relationship to postsurgical 
outcomes for specific personality traits, presurgical life stress, or a history of childhood 
abuse. Childhood sexual abuse and maltreatment, while more prevalent in the severely 
obese population (Grilo et al., 2005; Wildes, Kalarchian, Marcus, Levine, & Courcoulas, 
2008), do not appear to have any relationship with postsurgical weight loss (Fujioka, Yan, 
Wang, & Li, 2008; Grilo, White, Masheb, Rothschild, & Burke-Martindale, 2006). Presurgical 
life stress, in and of itself, does not appear to have a negative impact on weight loss 
(Herpertz et al., 2004; van Hout et al., 2005). While poor postsurgical weight loss may be 
observed in personality disordered patients (Grothe et al., 2006; Herpertz et al., 2004), 
studies of personality traits have shown no consistent prognostic value with regard to 
weight loss or psychosocial outcomes (Herpertz et al., 2004). One study of gastric bypass 
patients, utilizing the Minnesota Multiphasic Personality Inventory – 2 (MMPI-2), found 
that patients with <50% EWL one year postsurgery had higher presurgical elevations of the 
Hypochondriasis and Hysteria scales. However, since the elevations were not above the 
clinical cut-off for these scales, the clinical significance of this finding is unclear. A recent 
study using both the MMPI-2 and the Millon Multiphasic Clinical Inventory (MCMI- III) 
found that the K-scale from the MMPI-2 and the Schizoid, Schizotypal, and Compulsive 
scales from the MCMI-III predicted weight loss, but differentially at various post-operative 
time points (Belanger, Wechsler, Nademin, & Virden, III, 2010). Additionally, the sample 
used in this study was inclusive of patients who had been approved without reservation 
and patients who had received psychological/psychiatric treatment presurgically or 
concurrent with the procedure, making it difficult to draw conclusions.  In a cluster analytic 
approach to determine psychological profiles in 153 candidates for vertical banded 
gastroplasty, 3 distinct patterns were found that were comprised of combinations of high to 
low functioning, but these occurred across 7 domains (personality, coping, eating behavior, 
locus of control, body attitude, social functioning, and health-related quality of life) (van 
Hout, van Oudheusden, Krasuska, & van Heck, 2006). Generally, the research in the area of 
personality profiles has pointed to the heterogeneity of presurgical candidates and an 
inability to uniformly predict outcomes (Belanger 2010).  
2.2 Second generation approaches to assessment 
Given the disappointment of standard personality tests such as the Minnesota Multiphasic 
Personality Inventory (MMPI-2) in predicting WLS outcomes, more health- and behavior-
specific assessment tools were investigated or newly developed. Based on its predictive 
utility with other health conditions, the Millon Behavioral Medicine Diagnostic (MBMD) 
came into favor for use with bariatric patients (Fabricatore, Crerand, Wadden, Sarwer, & 
Krasucki, 2006; Walfish, Vance, & Fabricatore, 2007). Within two years of its introduction to 
the bariatric field, the authors of the test provided adjusted norms for the bariatric 
population (Millon, Antoni, Millon, Minor, & Grossman, 2007). Two problems very quickly 
came to light. First, there were no studies establishing that the instrument was valid or 
reliable for the bariatric population. Second, the method that was used to develop the 
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utility with other health conditions, the Millon Behavioral Medicine Diagnostic (MBMD) 
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adjusted norms was not reported. To date, the procedure for establishing the adjusted 
norms has not been published, making it difficult for consumers of the Bariatric version of 
the test to verify that it is a psychometrically sound instrument for the bariatric population. 
A recent study by Walfish, et al. urged caution for the use of the MBMD – Bariatric Norms 
with WLS patients due to the lack of adequate reliability for many of the scales (Walfish, 
Wise, & Streiner, 2008). 
Behavior-specific tools (as opposed to personality measures) have been used to assess 
constructs related to various aspects of eating behavior.  Using the Questionnaire on Eating 
and Weight Patterns (QWEP and QWEP-R), no differences were found in rates of 
postsurgical weight loss at one year follow-up between subjects who were preoperatively 
classified as binge-eaters or non-binge eaters (Fischer et al., 2007). However, pre-surgical 
grazing behavior was found to predict 19.5% of the variance in postsurgical % EWL (Colles, 
Dixon, & O'Brien, 2008). The Eating Disorder Inventory has also been utilized as a 
standardized assessment tool to characterize presurgical eating behavior. Regardless of 
which assessment tool is utilized, some studies find smaller % EWL for patients with 
presurgical binge eating, but still report significant weight loss. Patients with presurgical 
binge eating who have undergone laparoscopic banding surgery have been reported to 
undergo more frequent band adjustments and have more postsurgical complications than 
patients without disordered eating (Busetto et al., 2005).  
The Three Factor Eating Questionnaire (TFEQ – Stunkard & Messick, 1985) and other similar 
surveys used to assess cognitive restraint, disinhibition, and hunger have been consistently 
useful in demonstrating postsurgical changes in eating behavior (Kaiser et al., 2004; Smith, 
Franks, Kaiser, & Carrol, 2008). In and of themselves, various presurgical eating behavior 
constructs do not appear to independently predict postsurgical outcomes such as weight 
loss. Less understood, however, has been how presurgical eating behaviors may interact 
with other psychological characteristics. For example, higher presurgical non-hungry eating, 
measured by TFEQ, when combined with symptoms of depression as measured by the Beck 
Depression Inventory (BDI), was associated with poorer % EWL in laparoscopic banding 
patients (Colles et al., 2008).  
Another attempt to standardize the preoperative evaluation has been through the use of 
a semi-structured interview. For example, the Weight and Lifestyle Inventory (WALI - 
(Wadden & Foster, 2006) covers information relevant to weight history, weight loss 
history and goals, eating habits, food intake, eating patterns, physical activity, family 
and social support, self-perceptions, psychiatric history, stress, and medical history. 
Thus far, it appears that data from the WALI has been used to describe various 
preoperative characteristics of patients rather than for postoperative predication (Allison 
et al., 2006; Fabricatore et al., 2006; Gibbons et al., 2006). In addition to including the 
QEWP, the WALI incorporates a survey on Eating Habits. Factor analysis of the Eating 
Habits Survey demonstrated the presence of 5 factors: eating in response to negative 
affect, eating in response to positive affect and social cues, general overeating and 
impaired appetite regulation, overeating at early meals, and snacking (Fabricatore et al., 
2006). Preliminary data using the survey show that it may hold promise in identifying 
patients at risk for non-hunger related eating (Fabricatore et al., 2006; Kaiser, Franks, 
Carrol, & Smith, 2009).  
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Just prior to the introduction of the WALI for use with bariatric patients, the Boston 
Interview for Gastric Bypass was introduced (Sogg & Mori, 2004). Its stated purpose was to 
address the variability in type of assessments that were being conducted between sites, and 
to provide a mechanism by which to gather consistent and comparable information for 
research in outcome prediction. Components of the semi-structured interview include: 
weight/diet/nutrition history, current eating behaviors, medical history, knowledge of 
surgical procedures/risks/postsurgical regimen, motivation and expectations of surgical 
outcome, relationships and support system, and past/current psychiatric functioning. It was 
revised to the Boston Interview for Bariatric Surgery in consideration of subsequent 
advances in knowledge (Sogg & Mori, 2004). The authors point out that the role of the 
psychological evaluation is evolving beyond that of a screening process and argue for its use 
as part of a presurgical program of education, intervention, and treatment planning (Sogg & 
Mori, 2004). 
Recently, others have proposed the utilization and exploration of more newly developed 
instruments such as the Personality Assessment Inventory (PAI - Corsica, Azarbad, 
McGill, Wool, & Hood, 2010), the PsyBari (Mahony, 2010), and the Revised Master 
Questionnaire (Corsica, Hood, Azarbad, & Ivan, 2011). Corsica et al. demonstrated that 
the PAI has sound psychometric properties for use with the bariatric population (Corsica 
et al., 2010). Given the established psychometric strengths of the PAI and its proven 
applicability in medical settings, it appears to hold an advantage over other personality 
assessments. Furthermore, the PAI’s ability to provide information descriptive of self-
concept, interpersonal style and functioning, and perception of stress and social support 
may prove it to be useful in providing information under a model from which to predict 
postsurgical outcomes. 
The PsyBari is a self-report survey comprised of questions designed to assess constructs that 
were thought by the author and “other bariatric surgery professionals” to be important to 
measure preoperatively (Mahony, 2010). These include surgical motivation, emotional 
eating, anger, binge eating, obesity-related depression, weight-related social impairment, 
knowledge of postsurgical dietary restrictions, substance/alcohol abuse, and surgical 
anxiety. As useful as the PsyBari may be in streamlining the evaluation process and 
providing a way to standardize data collection, it is lacking in a clearly delineated rationale 
for construct selection or a theoretical framework from which to operationalize the various 
constructs. The PsyBari is still under development and needs further refinement and 
demonstration of validity and reliability. 
The Revised Master Questionnaire (MQR) was recently evaluated for its potential use for 
WLS candidates (Corsica et al., 2011). It was originally developed in 1984 as a self-report 
survey to assess constructs thought to be important to success in conventional weight loss 
programs (Straw et al., 1984). Factors assessed by the MQR include stimulus control, 
motivation for weight loss and weight loss behaviors, hopefulness about weight loss and the 
future, unchangeable versus changeable attributions for weight, and understanding the 
caloric value of specific foods and activities. These 5 factors were reported to have been 
empirically supported as valid constructs for obese individuals seeking conventional 
treatment and to have demonstrated usefulness in prediction of weight loss. Based on these 
findings and the need for tools to assess weight control-related constructs, Corsica et al. 
 
Advanced Bariatric and Metabolic Surgery 
 
122 
adjusted norms was not reported. To date, the procedure for establishing the adjusted 
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sought to determine its applicability for WLS candidates (Corsica et al., 2011). They 
administered the MQR to 790 candidates for gastric banding surgery and gastric bypass 
surgery. Results indicated acceptable reliability, confirmation of the factor structure, and 
convergent validity between factors and relevant psychological tests. Corsica, et al. (2011) 
also presented preliminary norms for use with WLS candidates. The usefulness of the MQR 
in determining postsurgical outcomes remains to be empirically tested.  
These various second generation approaches to the preoperative evaluation of the 
bariatric patient hold promise for identifying different factors that may be relevant to 
postsurgical outcomes. However, they are likely to be of limited value in and of 
themselves. If a principal goal is indeed to establish predictive utility, adjustments will 
need to be made to the preoperative psychological evaluation to gather construct-specific 
data that have a basis for their use in the prediction of outcomes. In order to make such 
adjustments, we will need to decide what outcomes are important to predict. These 
defined outcomes should be linked to measurable prediction (mediating) variables, i.e. 
those that have the potential to directly influence the outcome. In order to accomplish 
this, we first need to establish a systematized way of selecting information related to these 
prediction variables. While several practitioners have published standardized clinical 
assessments (Mahony, 2010; Sogg & Mori, 2004; Wadden & Foster, 2006), the information 
determined important continues to be based largely on clinical convention and not 
systematically tied to an empirical basis. Empirical evidence without an overarching 
framework prohibits a broader understanding of relationships among complex 
determinants and the outcome(s) of interest, and thus does little to guide clinical practice 
(Green, 2000).  In order to effectively discriminate which assessments will be useful, we 
need to operate under a theoretical framework that can serve as to guide our selection of 
constructs. We suggest using a theory-driven approach to formulating the presurgical 
evaluation as a way to understand the nature of what we are trying to predict, and as a 
framework to (a) select variables for which interventions may be approached, (b) to 
organize the information, and (c) to systematically test the relationships between variables 
and outcomes through the course of treatment and follow-up.  
3. Empirical support for theoretical models in weight loss studies  
According to a recent review (Painter, Borba, Hynes, Mays, & Glanz, 2008), the most 
common health behavior theories referenced in a random sample of studies published in 
high profile journals in 2004 - 2007 were: 1) the Health Belief Model, which has undergone 
several revisions and versions since the original work (Hochbaum, 1958); 2) the 
Transtheoretical Model (Prochaska, Diclemente, & Norcross, 1992) and 3) Social Cognitive Theory 
(Bandura, 1986). Another recent review was undertaken to evaluate several health behavior 
change models in relation to their utility in obesity prevention (Baranowski, Cullen, Nicklas, 
Thompson, & Baranowski, 2003). Of the various motivational models reviewed, the Theory of 
Planned Behavior was judged to be the most promising for applicability to weight 
management based on empirical evidence. Less frequently applied theories/explanatory 
models include the Theory of Self-determination (Deci & Ryan, 1985b) and the Health Behavior 
Internalization Model (Bellg, 2003), which both seek to understand motivation and change 
processes pertinent to long-term behavior maintenance. An Integrated Model recently 
proposed (Hagger, Chatzisarantis, & Biddle, 2002) has been tested for predictive ability in 
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weight loss behaviors and maintenance (Hagger, Chatzisarantis, & Harris, 2006; Jacobs, 
Hagger, Streukens, De, I, & Claes, 2011). This model combines aspects of the Theory of 
Planned Behavior and Self-determination Theory. We discuss each theory or model in terms 
of the advantages and disadvantages one may hold over another relative to the bariatric 
population and the goal of long-term maintenance of lifestyle behavior changes. 
3.1 Health belief model 
The core concept of the Health Belief Model, as put forth by Hochbaum in 1958, is that health 
behavior depends on personal beliefs about a disease and the resources or strategies 
available to the individual that will decrease the likelihood of contracting the disease. The 
version of the Health Belief Model (Becker & Rosenstock, 1984) includes four beliefs or 
components that work individually and in concert to predict health behaviors. These 
components include 1) perceived threats, 2) perceived seriousness, 3) perceived benefits, 
and 4) perceived barriers. In reviewing contemporary models of health behavior change, 
Baranowski et al. found little support for the Health Belief Model as applied to weight 
management (Baranowski et al., 2003). Few studies were able to demonstrate that there 
exists an interaction between perceived susceptibility and perceived seriousness, and that 
these in turn determine motivation to change or relate to actual behavior change. Cues to 
action have not been well studied, possibly because they are not stable or predictable. 
Studies of cues to action suggested that people are not able to accurately rate personal 
salience. There was only modest support for the effectiveness of using fear-based 
communication to affect perceived susceptibility and seriousness in effecting behavior 
change (Baranowski et al., 2003).  
3.2 Transtheoretical model 
The Transtheoretical Model (TTM - Prochaska et al., 1992) draws on several different 
theories to incorporate a number of change processes and concepts such as decisional 
balance and self-efficacy, that are purported to determine movement between stages of 
behavior change (Prochaska & Velicer, 1997). It assumes that individuals go through five 
progressive stages of behavior change: precontemplation, contemplation, preparation, action, and 
maintenance. The theory assumes that individuals do not move from one stage to another in 
a linear fashion. Rather, individuals may sustain multiple relapses in their effort to change 
their behavior, moving back and forth between the stages in a recursive fashion until the 
behavior change is permanent. The model proposes that there are four dimensions to change: 
the aforementioned stages of change, processes of change, decisional balance, and self-
efficacy. Appropriate interventions for behavior change vary according to each stage of 
change and/or dimension of change in the TTM. 
Our review of 14 studies focusing on weight loss and the Transtheoretical Model found that 
only four were specifically obesity intervention trials and none were performed on bariatric 
samples. Only two of the four had follow-up periods of longer than six months, the duration 
which the TTM model specifies is necessary to progress to the stage of maintenance of the 
new behavior. Furthermore, there has been little to no empirical work done to support the 
segregation of the stages and the dimensions of the TTM. Various reviews have not found 
strong support for the TTM as an explanatory or predictive basis for health behavior change, 
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sought to determine its applicability for WLS candidates (Corsica et al., 2011). They 
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including dietary interventions (Salmela, Poskiparta, Kasila, Vahasarja, & Vanhala, 2009) 
and exercise (Hutchison, Breckon, & Johnston, 2009). It has been pointed out, however, that 
many of the interventions studied were built around limited constructs (stages of change) 
rather than incorporating concepts from the broader TTM model itself (Armitage, 2009; 
Prochaska, 2006).  Particularly understudied have been the specific processes of change. 
While there appears to be some general support for several of the independent TTM 
constructs, much work remains to be done in the application of this theory in toto to weight 
loss, especially for the bariatric population. 
3.3 Social cognitive theory 
Put forth by Bandura in 1986, Social Cognitive Theory (SCT) posits a “triadic interaction 
model” between personal factors, behavior, and the environment that is central to 
adaptation and change. Reciprocal interactions between each element determine thoughts, 
actions, beliefs, cognitive competencies, and behavior. For Bandura, cognition plays a 
central role in a person’s construction of reality and thus the ability to self-regulate. 
Individuals are seen as proactive and as holding beliefs about themselves that affect their 
sense of personal agency and in turn, influence their behaviors. A core cognition affecting 
the belief system is self-efficacy, which is seen as providing the foundation for motivation. 
Efficacy belief is believed to be the major impetus of action, and can be modified through 
mastery experiences, vicarious experiences, modeling, and social persuasion. A person’s 
outcome expectancies form the primary motivation for action, while self-efficacy and 
capabilities provide resources for action. Several primary capabilities are thought to be 
fundamental, including the capacity to symbolize and extract meaning; the ability for 
forethought and planning; the ability to learn vicariously; and the ability to self-regulate 
through self-observation, self-monitoring, and self-reflection.  
These latter constructs have not been as well-studied as have the concepts of self-efficacy 
and outcome expectancies (Baranowski et al., 2003).  Baranowski et al.’s review of SCT 
found support for many of its constructs with regard to behavior change, particularly self-
efficacy and outcome expectancies. However, they also describe a great deal of variability 
that is not yet well-understood between genders and across different age groups in relation 
to the role of outcome expectancies and self-efficacy for diet or physical activity (Baranowski 
et al., 2003).  
3.4 Theory of reasoned action, theory of planned behavior  
As an elaboration of social learning theory (Miller & Dollard, 1941) and Bandura’s Social 
Cognitive Theory, the Theory of Reasoned Action was an extension to socially learned 
attitudes and norms (Fishbein & Ajzen, 1975). Later, this was expanded to the Theory of 
Planned Behavior (TPB) (Ajzen, 1985), which asserts that individuals form intentions to 
behaviors based on beliefs, norms and attitudes (Figure 1).  Behavior is largely 
determined by the intention to act or not act, although significant perceived barriers may 
moderate this relationship. Intention is thought to be the closest measurable construct 
proximal to the behavioral act, therefore the model attempted to identify variables that 
determine intention. 
Rethinking the Preoperative Psychological Evaluation – 




Fig. 1. Model diagram of the Theory of Planned Behavior (Ajzen, 1991) 
In the original theory (Theory of Reasoned Action), intentions are moderated by two factors:  
1) attitude toward the behavior (i.e., personal evaluation of the behavior), and 2) subjective norm 
(i.e., perception of social pressure to engage or not engage in the behavior).  Attitude toward the 
behavior is based on the individual’s belief that the behavior will lead to a desired outcome or 
away from an undesired outcome. One’s subjective norm is created by the perception of the 
evaluation (either positive or negative) of a particular individual (or group of individuals) 
placed on the behavior and one’s motivation to comply with norms set by others with whom 
one identifies or is influential.  Thus, personal attitudes toward the behavior are weighed 
against subjective norms or opinions of presumably important others. The Theory of Planned 
Behavior (Ajzen, 1991) added the concept of “perceived behavioral control”.  That is, one’s 
perception of how much control one has over a particular behavior or action greatly predicts 
whether or not an action or behavior will be undertaken.  The more resources and 
opportunities an individual believes are personally available, the stronger the belief in the 
ability to control the target behavior.  In essence, the easier the behavior appears to be, the 
more likely the behavior will be performed.  For example, behaviors that are almost automatic 
will be the most predictable behaviors as these are the behaviors that individuals are more 
likely to intend to perform.  Thus, predictions of behavior can be made from knowledge of an 
individual’s attitude toward the behavior, one’s subjective norm, and the perceived behavioral 
control.   These three factors are thought to work in concert to shape an individual’s intention 
to behave. Later research suggested that the relationship between actual and perceived 
behavioral control is a determinant of whether or not intention resulted in actual performance 
of the behavior (Ajzen, 2001). 
In a review of behavior change models relative to weight control, the component of attitude 
from the TPB appears to be the strongest determinant of dietary behavior, with perceived 
behavioral control and subjective norms demonstrating less predictive power (Baranowski 
et al., 2003). A review of studies comparing perceived controllability and self-efficacy found 
that only perceived difficulty in performance of the behavior (self-efficacy) was significant 
in the prediction of change in dietary behavior (Ajzen, 2001). With regard to multiple 
behaviors but primarily physical activity, a meta-analysis (Hagger & Chatzisarantis, 2009) 
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behaviors but primarily physical activity, a meta-analysis (Hagger & Chatzisarantis, 2009) 
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determined that prior behavior accounted for much of the variance predicted by the 
constructs of the TBP. A recent study specifically applied the TBP to the prediction of 
exercise in 212 bariatric patients during the preoperative stage through the postsurgical 
stage for more than one year (Hunt & Gross, 2009). Results were reportedly consistent with 
other reports in the literature that found moderate to large correlations among the various 
constructs of the model as well as strong associations between perceived behavioral control, 
exercise intention and behavior. Only a weak association between subjective norms and 
intention to exercise was found, which appears to be consistent across many studies.  One 
limitation was the use of subjective self-report surveys of physical activity rather than 
objective measures. The review by Baranowski et al. concluded that the constructs of TPB, 
while  moderately predictive of subjective estimates of health behaviors, are poorly 
predictive when objective measurements of health behaviors are utilized (Baranowski et al., 
2003). Another common criticism of TPB has been that, while it may provide information 
that is useful for prediction of behavior, it has not provided a useful foundation for 
developing interventions because there are no constructs included to help understand 
behavior change processes (Baranowski et al., 2003; Hobbis & Sutton, 2005). However, the 
TPB has undergone modifications to incorporate such concepts as belief salience and 
accessibility, past behavior and experience, moral norms, values, self-identity, goal 
desirability, mood, cognition, and affect on the formation and modification of attitudes, as 
well as the role of temporal stability and cognition on the relationship between intention 
and actual behavior (Ajzen, 2001). Baranowski and colleagues’ review of health behavioral 
change models concluded that the TBP, with its more recent modifications, held the most 
promise for application to diet and physical activity changes in the treatment of obesity 
(Baranowski et al., 2003). 
3.5 Self-determination theory (Deci and Ryan, 1985) 
Much research reflects the challenge of maintaining weight loss, no matter the means by 
which it was initially lost (Sarwer, von Sydow, Vetter, & Wadden, 2009). According to self-
determination theory, the level of motivation must be internally regulated and have an 
orientation of autonomy for long-term behavior maintenance to occur (Deci & Ryan, 1985b). 
Phases across the internalization continuum reflect the developmental process and styles of 
regulation going from non-regulation to fully integrated regulation (Figure 2).  
 
Fig. 2. The self-determination continuum (Based on Deci & Ryan, 1985b; Ryan & Deci, 2000) 
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For long term behavioral regulation to become fully integrated and therefore maintained, 
the person must develop: 1) an integrated identity and 2) a locus of causality that is internal 
(deCharms, 1968; Deci & Ryan, 1985b). This locus of causality is distinguished from locus of 
control (Rotter, 1966) in that the perceived source and initiation of the motivated behaviors 
are inside the self (autonomous) or outside the self (therefore, controlled, e.g. by directives 
of others or external rewards and contingencies) (Deci & Ryan, 1985b; Williams, Grow, 
Freedman, Ryan, & Deci, 1996). The goal state of integrated regulation results from the 
adoption of the behavior into one’s core set of values. 
An important aspect of self-determination is that of seeking ideal challenge and 
competency. Individuals tend to approach activities that are at an optimal level of 
psychological incongruity, i.e. interesting and enjoyable challenges that are optimal for 
one’s abilities (Bandura, 1986; Deci & Ryan, 1985b). Three important factors relating to 
perceived competence are: 1) the task must be optimally challenging, 2) the task must be 
associated with immediate, spontaneous feedback or interpersonal feedback from a 
significant other, and 3) the action and feedback must be experienced as informational 
rather than controlling. The third characteristic is essential for integrated internalization. 
The factors increasing perceived competence highlight the importance of setting and 
generating focus on intermediate, realistic goals. Successive approximations use tasks and 
goals that are hierarchically structured to provide a person with increased perceptions of 
competence and lowered levels of anxiety (Bellg, 2003). Research has demonstrated that 
efficacy expectations are key to successful behavior change (Ajzen, 2001). Increasing 
perceived competence through treatment gains is a result of enhanced perception of 
internal causality.  
Self Determination Theory (Deci & Ryan, 1985, pp. 153-159) also described three causality 
orientations: 1) autonomy, 2) control, and 3) impersonal. Autonomy orientation is the 
tendency for behavior to be initiated and regulated by events internal to one’s sense of self 
as well as events in the environment that are interpreted as informational. In both, the locus 
of causality is internal. Control orientation is the tendency for behavior to be initiated by 
events that are external to one’s integrated sense of self (i.e., introjected values or internally 
conflicting events) and by events in the environment that are interpreted as controlling. In 
both, perceived locus of causality is external. Impersonal orientation is based on a sense of 
one’s being incompetent to deal with challenges. It is erratic and non-intentional, for the 
person lacks the necessary psychological structures for coping with internal and external 
forces. Impersonal orientation involves the beliefs that behavior and outcomes are 
independent and that the associated forces are uncontrollable, resulting in the perception of 
incompetence leading to amotivation. 
The role of autonomy has been shown to be an important determinant for behavioral 
change in obesity intervention programs. For example, patients with a greater sense of 
autonomy in selecting a weight loss program were shown to have greater attendance in 
the program, to lose more weight, to adopt a better exercise regimen, and to maintain 
greater weight loss (Williams et al., 1996). Other studies have consistently demonstrated a 
strong relationship between positive health behaviors in patients who report a high sense 
of autonomy, and a greater sense of autonomy and perceived competence when health 
care environments were perceived as autonomy supportive (Shigaki et al., 2010; Williams 
et al., 2002).  
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3.6 A Needs-focused model of self-determination theory – the health behavior 
internalization model (HBIM - Bellg, 2003) 
The HBIM focuses on four self-needs (identity, self-determination, security and support) as 
well as four behavior-related needs (preference, context, competence and coping) as 
components of the development of internalized regulation of health behaviors (Figure 3). 
Internalization of self-regulation is characterized by low conflict/high acceptance, high 
autonomy, high security, high perceived support, high satisfaction with behavior 
choices/context, high perceived competence, and adequate coping without undesired 
behavior co-occurring. This HBIM builds on Self-determination theory by adding it into a 
context of needs that interact in order to resolve into internalization and self-regulation. The 
security component refers to perceived threats associated with an adverse medical situation. 
Fear of declining health may be perceived as a threat that initially promotes treatment-
seeking and/or behavioral adherence, but it is not likely to lead to long-term behavioral 
change as people tend not to maintain levels of fear, anxiety and guilt (conflict states) (Bellg, 
2003).  This model shows promise, but has not yet been tested. 
 
Fig. 3. Health behavior internalization model (Bellg, 2003).  
Bellg (2003) describes the transition to internalization as being a product of the need to 
reduce conflict. In externally controlled behaviors, conflict occurs between the values of self-
related needs and behavior-related needs of the individual. Bellg states that the process of 
transforming the external ideas and regulations of the social environment (when these are 
perceived as a desirable goal to obtain) to becoming personally held values is a fundamental 
human need. The new, integrated state is stable and free of conflict or a feeling of external 
control.  
3.7 The integrated model (Hagger, 2006) 
Hagger and colleagues performed a structural modeling study on an integrated model that 
linked Self-determination Theory and the Theory of Planned Behavior (SDT/TPB), testing 
effects of change in antecedents on exercise and dieting (Hagger et al., 2006). Later, Jacobs 
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and colleagues reported further testing and refinement of this integrated model on dieting 
and physical activity behaviors in undergraduates at baseline and at a one-year follow-up 
(Jacobs et al., 2011). In this integrated model, changes in autonomous and controlled 
motivation were assessed for effects on changes in attitudes and self-efficacy. All four of 
these constructs were tested for relationships to change in behavioral intentions and the 
subsequent change in diet/exercise behavior. While for both diet and exercise behaviors, 
increased autonomous motivation was associated with increased self-efficacy and 
behavioral intentions, the intensity of the exercise intervention moderated the relationship 
between self-efficacy and intentions (Jacobs et al., 2011). Both studies used assessments 
designed to measure constructs specific to Self-determination Theory.   
 
Fig. 4. Integrated model of the Theory of Planned Behavior and Self-determination theory 
(Jacobs et al., 2011). 
3.8 Summary of theories and relevance in bariatric psychological evaluation 
In examination of the application of these most popular or relevant theories to weight loss 
treatment-seeking or bariatric populations, we found few thorough and long-term studies 
of the mechanisms and processes of lifestyle behavior change maintenance. Also, we 
found that many of these theories or models are modestly descriptive but not explanatory. 
Further, we found little support in the predictive power of measuring some of these 
constructs for maintenance of postsurgical weight loss. Since the evolution of the 
presurgical psychological evaluation has origins in the medical diagnostic model rather 
than a prognostic model, we believe that a more systematic approach to the evaluation is 
needed to advance our understanding of the constructs and processes of long-term 
postsurgical behavioral change. Based on our limited review, it appears that aspects of 
both Self-determination Theory and the Theory of Planned Behavior have the most 
demonstrated empirical support thus far, such that the integrated SDT/TPB model has the 
greatest potential application for this purpose. Additionally, the Health Belief 
Internalization Model appears to hold promise in providing constructs relevant to the 
specific needs-satisfaction processes required for internalization to occur. More empirical 
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work is needed, including the development and validation of assessments of its constructs 
before it can be applied in the clinical setting. 
4. Proposal for applying a new, theoretically-based model to presurgical 
assessment 
We propose that a paradigm shift is needed in order to address the apparent deficiencies 
of the current approach to the presurgical psychological evaluation of WLS candidates.  
Specifically, we propose that the presurgical psychological evaluation undergo a 
reformulation with a theory-based, integrated stage and motivational basis to inform the 
selection of pertinent areas of inquiry and assessment tools. Ideally, the theory would be 
one that is applicable to understanding health behavior changes that are relevant to 
positive postoperative outcomes. Based on the current body of literature, it appears that 
following a bariatric diet, following an exercise program, and attending a bariatric 
support group comprise targeted activities that support the goals of long-term 
maintenance in improved health and optimum weight loss. We propose basing the 
presurgical psychological evaluation on an integrated theoretical model (SDT/TPB), so 
that clinicians can begin to assess constructs pertinent to long-term maintenance of these 
relevant health behaviors (Figure 4). In order to effectively assess the constructs relevant 
to the integrated theoretical model, the presurgical psychological evaluation must be 
coordinated to occur subsequent to patient interactions with the surgeon and the dietician 
so that the patient has a reference point and exposure to postsurgical expectations from 
which to answer questions.  
Based on this new paradigm and empirical evidence to date, the recommended presurgical 
psychological evaluation would ideally evaluate the constructs and areas listed below. 
Assessments should be utilized that have demonstrated validity and reliability for use with 
the bariatric population. This list is not intended to be exhaustive, but is based on our 
review of the current literature related to WLS outcomes and to a plausible theoretical 
framework. 
1. Psychological functioning, including personality disorders, psychopathology, self-
esteem, and coping. The Personality Assessment Inventory (PAI) (Morey, 2007) has 
recently been shown to be a valid and reliable instrument that offers data relevant to 
clinical decision making for these constructs. Other personality tests, such as the Millon 
Behavioral Medicine Diagnostic™ – Bariatric (Millon et al., 2007) and the Millon 
Clinical Multiaxial Inventory – III™ (Millon, Millon, Davis, & Grossman, 2009) need 
further research to demonstrate their use with the bariatric population. 
2. Eating disorders and body dissatisfaction. The Eating Disorder Inventory – 2 offers a 
valid assessment of these constructs. The Body Shape Questionnaire (BSQ- Cooper, 
Taylor, Cooper, & Fairburn, 1987) has also been utilized as an effective measurement of 
body dissatisfaction with bariatric patients. Additionally, semi-structured interviews 
such as the Weight and Lifestyle Inventory (WALI – Wadden & Foster, 2006) or the 
Boston Interview for Bariatric Surgery (Sogg & Mori, 2004) utilize questions designed to 
evaluate these constructs.  
3. Autonomous motivation for bariatric lifestyle changes. The Treatment Self-
Regulation Questionnaire (TSRQ - Levesque et al., 2007; Ryan & Connell, 1989; 
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Williams et al., 1996) assesses four factors (autonomous regulation, introjection, 
external regulation and amotivation) that could be used to evaluate the degree to 
which the patient has adopted autonomous motivation for the bariatric diet, an 
exercise program, and support group attendance. The TSRQ is a 15-item self-report 
survey that takes less than 5 minutes to complete for each behavioral topic. Items 
could be responses to the following suggested stems: “The reason I would follow a 
bariatric diet/an exercise program/attend support group is because…”. Item 
responses represent various autonomous, controlled, and amotivational statements. 
Responses are according to a seven-point, Likert-type scale ranging from 1 (not at all 
true) to 7 (very true). Internal consistencies across several health behaviors ranged for 
the four factors from .73 - .93 with the exception of one dataset where amotivation 
was .41, but three other datasets ranged from .73 - .79 for this factor (Levesque et al., 
2007). 
4. Self-efficacy. Perceived Competence Scale (PCS - Williams & Deci, 1998; Williams, 
Freedman, & Deci, 1998). The PCS is a 4-item self-report survey that can be adapted and 
used to determine a patient’s perceived competence, or self-efficacy, for maintaining a 
bariatric diet, an exercise program, and attendance in support group. Responses are 
according to a seven-point, Likert-type scale ranging from 1 (not at all true) to 7 (very 
true). It takes approximately one minute to complete for each behavior domain. In two 
studies, internal consistencies were above .80 (Williams & Deci, 1998; Williams et al., 
1998).  
5. Clinical support resources. Health Care Climate Questionnaire (HCCQ -  Williams et 
al., 1996). The HCCQ is a 15-item self-report survey (or a 5 item short version) used to 
assess the level of autonomy support that a patient perceives is provided by the 
bariatric surgeon and staff. It takes approximately 5 minutes to complete. Ratings are 
on a 7-point scale which indicates the degree to which health care providers are 
perceived to be autonomy supportive.  Higher scores indicate greater perceived 
autonomy support.  Across domains, the alpha coefficient of internal consistency is 
above .90. 
6. Control orientation. General Causality Orientations Scale (GCOS - Deci & Ryan, 
1985a). The GCOS is a 36-item self-report survey of various vignettes used to 
determine the degree to which a patient is oriented toward autonomy as a general 
tendency. It takes approximately 20 minutes to complete. The GCOS is available in 
two forms. The original scale consists of 12 vignettes and 36 items. Each vignette 
describes a typical social or achievement oriented situation with three types of 
possible responses: an autonomous, a controlled, or an impersonal type. Respondents 
indicate (on 7-point, Likert-type scales) the extent to which each response is typical 
for them. Higher scores indicate higher amounts of the particular orientation. 
Subscale scores are generated by summing the 12 responses on items corresponding 
to each subscale. This scale has been shown to be reliable, with Cronbach alpha 
values of about .75 and a test-retest coefficient of .74 over two months (Deci & Ryan, 
1985a).  
7. Attitudes Toward Behaviors (Ajzen, 2001; Ajzen & Fishbein, 1980). Cognitive and 
affective attitude toward the bariatric diet, exercise, and support group attendance can 
be assessed using two sets of three bipolar items on a 7 point scale. Cognitive attitude is 
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work is needed, including the development and validation of assessments of its constructs 
before it can be applied in the clinical setting. 
4. Proposal for applying a new, theoretically-based model to presurgical 
assessment 
We propose that a paradigm shift is needed in order to address the apparent deficiencies 
of the current approach to the presurgical psychological evaluation of WLS candidates.  
Specifically, we propose that the presurgical psychological evaluation undergo a 
reformulation with a theory-based, integrated stage and motivational basis to inform the 
selection of pertinent areas of inquiry and assessment tools. Ideally, the theory would be 
one that is applicable to understanding health behavior changes that are relevant to 
positive postoperative outcomes. Based on the current body of literature, it appears that 
following a bariatric diet, following an exercise program, and attending a bariatric 
support group comprise targeted activities that support the goals of long-term 
maintenance in improved health and optimum weight loss. We propose basing the 
presurgical psychological evaluation on an integrated theoretical model (SDT/TPB), so 
that clinicians can begin to assess constructs pertinent to long-term maintenance of these 
relevant health behaviors (Figure 4). In order to effectively assess the constructs relevant 
to the integrated theoretical model, the presurgical psychological evaluation must be 
coordinated to occur subsequent to patient interactions with the surgeon and the dietician 
so that the patient has a reference point and exposure to postsurgical expectations from 
which to answer questions.  
Based on this new paradigm and empirical evidence to date, the recommended presurgical 
psychological evaluation would ideally evaluate the constructs and areas listed below. 
Assessments should be utilized that have demonstrated validity and reliability for use with 
the bariatric population. This list is not intended to be exhaustive, but is based on our 
review of the current literature related to WLS outcomes and to a plausible theoretical 
framework. 
1. Psychological functioning, including personality disorders, psychopathology, self-
esteem, and coping. The Personality Assessment Inventory (PAI) (Morey, 2007) has 
recently been shown to be a valid and reliable instrument that offers data relevant to 
clinical decision making for these constructs. Other personality tests, such as the Millon 
Behavioral Medicine Diagnostic™ – Bariatric (Millon et al., 2007) and the Millon 
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Williams et al., 1996) assesses four factors (autonomous regulation, introjection, 
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assess the level of autonomy support that a patient perceives is provided by the 
bariatric surgeon and staff. It takes approximately 5 minutes to complete. Ratings are 
on a 7-point scale which indicates the degree to which health care providers are 
perceived to be autonomy supportive.  Higher scores indicate greater perceived 
autonomy support.  Across domains, the alpha coefficient of internal consistency is 
above .90. 
6. Control orientation. General Causality Orientations Scale (GCOS - Deci & Ryan, 
1985a). The GCOS is a 36-item self-report survey of various vignettes used to 
determine the degree to which a patient is oriented toward autonomy as a general 
tendency. It takes approximately 20 minutes to complete. The GCOS is available in 
two forms. The original scale consists of 12 vignettes and 36 items. Each vignette 
describes a typical social or achievement oriented situation with three types of 
possible responses: an autonomous, a controlled, or an impersonal type. Respondents 
indicate (on 7-point, Likert-type scales) the extent to which each response is typical 
for them. Higher scores indicate higher amounts of the particular orientation. 
Subscale scores are generated by summing the 12 responses on items corresponding 
to each subscale. This scale has been shown to be reliable, with Cronbach alpha 
values of about .75 and a test-retest coefficient of .74 over two months (Deci & Ryan, 
1985a).  
7. Attitudes Toward Behaviors (Ajzen, 2001; Ajzen & Fishbein, 1980). Cognitive and 
affective attitude toward the bariatric diet, exercise, and support group attendance can 
be assessed using two sets of three bipolar items on a 7 point scale. Cognitive attitude is 
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comprised of the following scales: useful to useless, wise to foolish, beneficial to 
harmful. Affective attitude is comprised of the following poles: pleasant to unpleasant, 
interesting to boring, and enjoyable to unenjoyable.  
8. Perceived Behavior Control (Ajzen, 2001). The measurement of PBC occurs on a 7-
point, Likert-type scale (-3 not at all, +3 extremely) that measures confidence, ease-
difficulty, and control ability for following a bariatric diet, maintaining an exercise 
program, and regularly attending support group. The extent to which this scale may 
overlap with the Perceived Competence scale (#4 above) is not known. 
The use of an assessment battery that is based on current empirical evidence and a 
theoretical model for prediction of long-term behavior change, as we are proposing, 
should generate information that will inform prognostic statements and guide 
recommendations needed to improve prognosis that are based on specific processes under 
the model. Using this battery, it would be anticipated that patients who were autonomy 
oriented; high in autonomous motivation, confidence, and perceived control for the 
expected postsurgical lifestyle behavior changes; and who perceive the health care climate 
as supportive would receive a favorable prognosis for maintenance of behavioral changes. 
Ideally, these would support postsurgical success, as defined by maintenance of EWL 
corresponding to improved health and quality of life.  Patients found to have an 
impersonal orientation; who were amotivated, who lack confidence or perceive 
themselves to have little control for lifestyle modifications; and who perceive the health 
care climate as non-supportive would receive the poorest prognosis. Furthermore, 
patients with a personality disorder diagnosis or who have a high degree of 
psychopathology (including disturbed eating) or body dissatisfaction would also be 
considered at risk for poor postsurgical behavioral adherence. Low self-esteem or poor 
coping skills would warrant caution.  It is unclear to what extent these non-theoretically 
based psychological constructs are related to and may be picked up by constructs under 
the integrated model, such as causality orientation, autonomous motivation, self-
efficacy/competence, and perceived behavioral control.  
By evaluating the current status as well as the attitudes and perceptions of the bariatric 
patient using the integrated principles of SD/TPB, clinicians can identify key issues that 
may need to be addressed to assist a patient in achieving intrinsically motivated health 
behavior maintenance to achieve sustained behavior changes that support the long-term 
goals of the surgery. We are in agreement with Sogg and Mori’s (2004) assertion that the role 
of the presurgical psychological evaluation should be used for treatment planning, but 
propose that treatment recommendations and components are based on a theoretically 
sound, motivational model for systematic testing.   
Based on our view of the SDT/TPB integrated model, key targets for increasing intentions 
(and therefore behaviors) are: 1) facilitating development of an autonomous orientation 
within the patient, 2) maximizing a perception of internal regulation of behavioral goals, 3) 
increasing positive attitudes associated with desired behaviors, and 4) optimizing self-
efficacy surrounding skills needed to easily maintain lifestyle patterns. Theoretically-based 
guidelines for promoting these areas in relation to behavioral targets such as dietary change, 
physical activity, and regular attendance in a supportive group intervention have been 
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described throughout the literature and can help guide the development of interventions 
specific to the bariatric population.  
5. Conclusions 
In conclusion, it is our contention that bariatric clinical practice and outcomes research 
would benefit from the application of theories and models that describe and model behavior 
change processes, and that psychological evaluation and assessments should be framed in 
theory and based on empirical evidence. Our proposal to use the SDT/TPB integrated 
model to guide the presurgical psychological evaluation for bariatric surgery represents the 
first attempt to establish an empirically-justified approach.  As a framework for 
understanding the processes that determine the long-term behavior changes needed for 
postsurgical success, clinicians are in a better position to provide prognostic statements and 
treatment recommendations that have a scientifically-based rationale. 
Future studies should seek to validate and establish the psychometric properties of 
psychological tests or questionnaires for the bariatric population. Studies should also 
determine their validity across age, gender, and cultural groups. Assessments that are 
designed to measure the various constructs of a theoretical model should be validated. This 
will allow for sound systematic investigations of the relationships of the validated measures 
with defined behavioral targets. In this way, we will begin to amass empirical evidence of 
the predictive utility of our instruments. However, selected behavioral targets should also 
be evaluated for their relationship to various parameters thought to represent postsurgical 
success. Furthermore, if a specific % EWL cut-off is to be used as a criterion of success, its 
clinical utility needs to be firmly established.  
The role of the presurgical psychological evaluation should be expanded to incorporate 
treatment planning. Often, abrupt lifestyle prescriptions are directed at patients who are 
very far from a level of mastery at attempting, much less maintaining a new pattern of 
behavior. In the case of the postsurgical phase, patients are often unlikely to have ever 
encountered an eating plan similar to a bariatric diet. They are also not likely to be able to 
perform 30 minutes of moderate physical activity several times per week. Thus, it is likely 
that the process involved in change is recursive and prone to derailing without a supportive, 
patient-centered plan. Future studies should seek to characterize postsurgical phases and 
develop treatment plans to address their corresponding challenges. According to SDT/TPB, 
plans that are too rigid (not strongly identifiable to the patient) or directive (not autonomy 
supporting) will not likely aid the patient in making the needed internalization transition 
required for long-term maintenance of change.  
With the advent of evidence-based medicine and the increasing need to justify evaluative 
and other clinical psychological services for bariatric patients, the presurgical psychological 
evaluation has been in need of a critical review. Our review suggests that a paradigm shift is 
in order to broaden our knowledge and advance the field. By suggesting a theory-based 
approach and presenting an example of a theory-based assessment battery, we hope to 
generate dialogue and stimulate further discussion and research on this topic in order to 
improve bariatric care. 
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Both in developed and under developed countries the total number of obese people and 
their fraction of the population are increasing, and they live longer. The need for bariatric 
surgery is rapidly increasing (Buchwald, 2009) and the concept of fast-track surgery and 
laparoscopy (Kehlet, 2008) has made bariatric surgery a cost-effective and efficient way of 
treating the morbididly obese when other non-surgical options have been unsuccessful.  
Whereas ambulatory care is evolving for medium invasive bariatric procedures (i.e. 
gastric banding or minor laparoscopic procedures) in some places, most bariatric patients 
are still in-patients, although a short stay and accelerated recovery should be feasible and 
encouraged (Raeder, 2007).  There is a general trend, especially in the obese, to supply 
anesthetic care with loco-regional techniques whenever possible (Raeder 2010a). This has 
to do with less physiologic and especially respiratory physiologic, derangement, when 
loco-regional techniques are used instead of general anesthesia. Also, as ultrasound 
technology has emerged as a valuable tool in locating regional anesthesia bone-marks in 
the obese, the use of brachial plexus techniques and spinal/epidural techniques has 
grown in the obese. Still, the bariatric procedures usually imply an upper abdomen 
surgical procedure and a predominantly laparoscopic approach. This kind of surgery is 
hard to do with success and patient satisfaction in the awake, even if they have a perfect 
spinal or epidural anesthesia. Similarly local anesthesia is not possible to apply 
sufficiently for laparoscopy, both due to the complexity of anatomical structures involved 
and the risk of toxicity from high total doses of local anesthetic agents.  Still, local 
anesthesia is a very valuable, many will say mandatory, supplement to general anesthesia 
in these patients for improved postoperative pain management, together with other 
measures (see later). There are hardly any reports on bariatric surgery in epidural or 
spinal anesthesia, but there are a very few scattered reports on use of epidural pain relief 
for the postoperative period (Kira, 2007; Nishiyama 2011). Considered the technical 
challenge with these techniques in the obese and the modest pain problems in these 
patients when a proper multimodal approach is used, almost all anesthesiologist will 
abstain from using regional techniques in these procedures. 
 
Advanced Bariatric and Metabolic Surgery 
 
142 
Williams, G. C., Minicucci, D. S., Kouides, R. W., Levesque, C. S., Chirkov, V. I., Ryan, R. M. 
et al. (2002). Self-determination, smoking, diet and health. Health Education Research, 
17, 512-521. 
Wysoker, A. (2005). The lived experience of choosing bariatric surgery to lose weight. Journal 
of the American Psychiatric Nurses Association, 11, 26. 
6 
Bariatric Surgery  
– Anesthesiologic Concerns 
Johan Raeder 
University of Oslo,  




Both in developed and under developed countries the total number of obese people and 
their fraction of the population are increasing, and they live longer. The need for bariatric 
surgery is rapidly increasing (Buchwald, 2009) and the concept of fast-track surgery and 
laparoscopy (Kehlet, 2008) has made bariatric surgery a cost-effective and efficient way of 
treating the morbididly obese when other non-surgical options have been unsuccessful.  
Whereas ambulatory care is evolving for medium invasive bariatric procedures (i.e. 
gastric banding or minor laparoscopic procedures) in some places, most bariatric patients 
are still in-patients, although a short stay and accelerated recovery should be feasible and 
encouraged (Raeder, 2007).  There is a general trend, especially in the obese, to supply 
anesthetic care with loco-regional techniques whenever possible (Raeder 2010a). This has 
to do with less physiologic and especially respiratory physiologic, derangement, when 
loco-regional techniques are used instead of general anesthesia. Also, as ultrasound 
technology has emerged as a valuable tool in locating regional anesthesia bone-marks in 
the obese, the use of brachial plexus techniques and spinal/epidural techniques has 
grown in the obese. Still, the bariatric procedures usually imply an upper abdomen 
surgical procedure and a predominantly laparoscopic approach. This kind of surgery is 
hard to do with success and patient satisfaction in the awake, even if they have a perfect 
spinal or epidural anesthesia. Similarly local anesthesia is not possible to apply 
sufficiently for laparoscopy, both due to the complexity of anatomical structures involved 
and the risk of toxicity from high total doses of local anesthetic agents.  Still, local 
anesthesia is a very valuable, many will say mandatory, supplement to general anesthesia 
in these patients for improved postoperative pain management, together with other 
measures (see later). There are hardly any reports on bariatric surgery in epidural or 
spinal anesthesia, but there are a very few scattered reports on use of epidural pain relief 
for the postoperative period (Kira, 2007; Nishiyama 2011). Considered the technical 
challenge with these techniques in the obese and the modest pain problems in these 
patients when a proper multimodal approach is used, almost all anesthesiologist will 
abstain from using regional techniques in these procedures. 
 
Advanced Bariatric and Metabolic Surgery 
 
144 
2. Preoperative concerns 
Obese patients may present for any kind of surgery throughout their life; minor or major, 
emergency or elective, well prepared or with severe concomitant problems. Many general 
precautions and warnings linked to anesthesia in these patients are based on worst case 
scenario in an unstable and poorly prepared patient. The bariatric patient, although quite 
huge per definition, is still in many ways less problematic. They are highly motivated, well 
prepared – often through weeks, they are usually young or middle aged, and they usually 
understand that their cooperation and own efforts are very important during the recovery 
phase. 
Although the obese has reduced physiologic reserves, both cardiovascular and respiratory; 
the obesity per se is usually not a major risk factor or reason for not accepting these patients 
for general anesthesia and bariatric surgery (Dindo, 2003). The rare non-acceptance of these 
patients has to do with the total picture of obesity, co-morbidity, preparation, co-operation 
and potential for improvements by postponing the procedure and spend some efforts in 
medical optimization. 
The list of co-morbidity which are more frequent in the obese population include: diabetes, 
hypertonia, gastro-oesophageal reflux, artrosis and musculo-sceletal pain, sleep apnoea 
syndrome and in more severe cases pulmonary hypoventilation and atelectasis or heart failure 
(Chung 1999). It is beyond the scope of this chapter to go in depth with these concomitant 
diseases; the reader is advised to look in general anesthesia textbooks (Raeder 2010a). 
Useful tests are ECG, spirometri, resting bloodgas while breathing room-air, pulmonary x-
ray and a functional test, such as walking a flight of stairs. 
Baseline blood pressure is important to obtain.  Also, a 12-lead routine ECG should be taken 
in these patients upon age above 40 yrs or any suspicion of cardiovascular disease. Still, 
many important aspects of the ECG will be displayed anyway on the one-lead routine 
monitoring peri-operatively. The one-lead ECG is displayed before any drugs are given and 
will tell you about arrhythmia, P-Q prolongation or heart block and any ST segment 
changes in the pre-cordial area. What you will miss by a one-lead ECG are signs of 
heartfailure, hypertrophia and previous infarction.  
Body mass index is the most common way of classifying obesity, and this figure is also 
useful for the anaesthesiologist for classification, risk-stratifying and need of extra consults 
and measures. However, for dosing of anesthetic drugs, different weight concepts are more 
useful. Some definitions of weight is listed in the frame below: 
Different types of weight:
• Actual weight : = Total weight
• Ideal weight:  Height ÷ 100 (105 in women)
• Lean weight:  = fat-free body mass
• Corrected ideal weight:
= ideal weight + 20-40% (?) of difference to actual
weight
 Body mass index: weight / height x height  
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2.1 Concomitant pulmonary disease 
Breathing disorders may be classified into problems of airways and lungs, problems with 
respiratory control and problems of muscular function for breathing. In patients with 
respiratory problems, especially chronic obstructive disease, it may be useful to refer the 
patient to a physiotherapist in advance in order to clean up and get instructions on how to 
cough, breathe and mobilize lungs after surgery. 
Patients with an episode of airway infection should generally be postponed until 1-2 weeks 
after the infection is fully resolved. Postoperative sore-throat or coughing may be a problem 
being no good for the healing after a bariatric surgical procedure, thus also mild viral 
symptoms should call for postponing the case. 
As with all patients;  stop of smoking at least 4-5 weeks before scheduled surgery will 
improve the respiratory function, and this is especially valuable in the obese because they 
are more prone to airway problems than others. Also, smoking may impair wound healing. 
Offering the patients this kind of elective, planned surgery may also be a good opportunity 
to try to convince patients to stop smoking, and some clinics even put this token of patient 
cooperation as a condition for being accepted for surgery. Stopping 1-3 weeks before 
surgery, if the patient is a daily smoker, is not advised; as airway reactivity and secretions 
may be temporarily increased for some weeks after stop of smoking. If stop of smoking is 
not possible, they should at least not smoke on day of surgery, as even a single cigarette will 
result in some carboxy haemoglobin formation which will reduce the oxygen binding 
capacity of blood for some hours afterwards.  
 For patients with severe airway or pulmonary disease or infections, a more thorough 
approach should be undertaken for preoperative evaluation. Patient history with ability to 
walk one flight of stairs, the amount of coughing and secretion, as well as episodic changes 
versus stability in condition should be taken.  Preoperative lung x-ray, arterial blood gas 
and spirometry with vital capacity and forced expiratory volume (FEV1), with and without 
bronchodilator are further options. Generally, a vital capacity of less than 1.5-2 litres in an 
adult or a FEV1 Less than 1-1.5 liter should indicate increased likelihood of severe problems 
and need of ventilatory support post-operatively. 
2.1.1 Sleep apnoea syndrome (SAS) 
Sleep apnoea syndrome is under diagnosed, but probably occurs in 4% of adult male 
population and 2% of females. It is associated with obesity and also with large tonsils or 
adenoids, especially in small children, but could be present without any of these (Young, 
1993).  Although these patients manage someway at home preoperatively the chance of 
respiratory arrest will be increased especially first night after surgery in general anesthesia 
or any use of post-operative opioids. Although fatalities are very rare, 8 cases were reported 
in a big US survey (Lofsky, 2002), one case is one too much and could be avoided by 
overnight continuous monitoring of respiration, either by pulse-oxymetri or better with 
respiratory rate monitoring of some kind (see below).    
The symptoms  of SAS almost always include snoring but should be accompanied with 
more problems to make the diagnosis: respiratory arrest ( > 10 sec), frequent change in 
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position during sleep, tired in spite of normal ”length of sleep”, morning headache and 
family history of SAS (Chung, 2008). A more specific and detailed diagnosis could be made 
with polysomnography done well in advance, and then eventually fit and become familiar 
with using a CPAP device. Patients with a CPAP device should be urged to bring this with 
them on day of surgery, in order to have ready for use in the PACU if needed and 
mandatory use the first nights.  
During polysomnograpy the patient is monitored continuously during full overnight sleep 
with pulse oxymeter, ECG, number and lengths of apnea episodes etc. More than 30 
episodes of hypopnoea or apnea per hour signal a serious condition, whereas less than 15 is 
mild.  A fairly precise prediction of a serious condition could be made clinically if the 
patient tests positively on these four anamnestic items: load snoring (heard through wall or 
door), observed apnea during sleep, tired in spite of normal length of sleep in bed, 
hypertension (Chung, 2008).  
A rational approach to these patients may be (table): 
Known SAS: 
 If treated with CPAP  OK * 
 If minor surgery with no opioids postop  OK 
 If seriously affected SAS and use of opioids  Continuous respiratory monitor!  
Suspected SAS: 
 If serious symptoms  polysomnography (or continous monitor) 
 Mild symptoms (not tired, no major apnoea or distress) 
  OK if not opioid effects after discharge to ward 
 Otherwise: monitor 
No SAS mentioned: 
 Ask for symptoms, partner/comparent information  
 If in doubt  = suspected and plan with monitoring 
*It has been shown that SAS patient who use a CPAP will not have increased risk of apnoea, 
even during first night after surgery. 
Importantly, when these patients are considered to be extra risk, ordinary stay at the ward 
will not be good enough; they have to be monitored continuously during the night. A pulse 
oxymeter may do, although signs of hypoxia are somewhat delayed, even better is a 
respiratory rate monitor with alarm of apnoea. Such respiratory rate monitoring may be: 
end-tidal CO2, breast cage movements or respiratory sound monitor on neck. 
2.2 Patients with cardio-vascular disease 
Generally; a patient who is unable to climb 1 flight of stairs in normal speed without 
cardiovascular symptoms (angina or heart failure, dyspnoea), have a recent cardiac event 
(infarction, revascularisation) within last 3 months or have a serious unstable condition or 
serious limitation in activity; should be postponed and go to cardiology consult and be 
optimized before elective surgery.  
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2.3 General advices and measures in advance 
Especially when these intra-abdominal bariatric procedures (laparoscopy, laparotomy) is 
planned, it is a good safety advice to make the patient reduce even a minor bit in weight 
during the weeks ahead of surgery, by using a high protein-low carbohydrate diet. The 
reason is that most obese have an enlarged and fragile fatty liver. By diet and weight 
reduction for some weeks, the liver will shrink and become less fragile. This may be 
important in order to facilitate surgical access in the abdomen and reduce the risk of liver 
tear or bleeding. 
In the obese patients gastro-oesophageal reflux disease (GERD) occur in about 20-30% of 
cases, and these patients may be at risk for peri-operative regurgitation of acid stomach juice 
into the airways. A good way of reducing both amount and acidity of the gastric content is 
to use a proton pump inhibitor (e.g. omeprazole or other).  The first dose should be at least 
some hours ahead of surgery, but best if already given the evening before and then repeated 
on morning of surgery. If this had not been accomplished, some sips of non-pulmonary 
toxic fluid antacid (sodium-citrate) in front of anesthetic induction may be an alternative 
solution, although not so effective as a proton pump inhibitor. 
As to fasting rules, the gastric emptying speed in obese patients is similar as to lean 
patients (Soreide, 2005). Thus, if no physiologic cause of gastrointestinal obstruction or 
slowing is evident, they should have nothing to eat (including milk and milk products) 
for the last six hours in front of surgery and no clear fluids for the last 2 hours. Still, some 
preoperative tablets may be allowed in a few sips of water up to 1 hour ahead of 
anesthetic induction.  
2.3.1 Premedication 
Due to the increased incidence and risk of airway obstruction in the obese patients, one 
should generally be restrictive with anxiolytic or opioid premedication. If there is a strong 
indication, an oral benzodiazepine may be used, either the short acting midazolam (5-7.5 
mg orally) or more longacting diazepam, 5-15 mg. The patients should then not be left 
alone, but have attendance or pulse-oximetry applied. Establishing an IV line in the ward 
for premedication will enable a more precise targeting of effect, both because midazolam 
or diazepam may be carefully titrated and also because rapid injection of the 
benzodiazepine antagonist, flumazenil, is an option if needed for overdosing or 
respiratory problems. Establishment of an IV line on the preoperative ward is also a good 
measure in terms of avoiding stress and time consuming search for a vein in the busy 
operating room (OR) just before start of anesthesia. Whereas the usual veins on the 
dorsum of the hand may be difficult to find in the obese, the thin volar veins are usually 
accessible without covering fat pads. It may also be a case for ultrasound location of veins 
in these patients, either in the elbow or the medial upper arm (basilica vein) or the central 
veins (internal jugular or subclavian) in the more difficult cases.  Opioid premedication 
should only be used when needed for pre-operative pain, and then in titrated iv doses 
with subsequent monitoring. 
The time for potential premedication, 1-2 hours ahead of surgery, may be a time for giving 
other drugs of benefit for the patient such as oral analgesics (paracetamol and NSAIDs or 
cox-II inhibitor) or prophylactic antibiotics or thrombosis prophylaxis. As the obese are 
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more prone to both thrombosis, pulmonary embolism and wound infections in general, and 
even more so with intra-abdominal surgery,  appropriate  antibiotic (e,g. Cefuroxim 1.5g) 
and  antitrombotic (e.g. low molecular heparine 5000IU sc, day before and every day for one 
week)  is usually indicated. 
3. Anesthetic technique 
3.1 Surgeons contribution 
Even though general anesthesia is needed, it is very important that the surgeon use an 
optimal protocol of local anaesthesia extensive infiltrated in wound areas and surrounding 
structures (LIA-technique) in order to reduce postoperative opioid consume. The surgeon 
should typically use a total of 40 mls of either bupivacaine 2.5 mg/ml or ropivacain 2.0 
mg/ml for superficial and deep wound infiltration. If more than 40 ml is needed, 
ropivacaine should be the drug of choice, as the toxicity from general absorption is less than 
with bupivacaine. Whether the injection should be done at the start of surgery or at the end 
is disputed. Injection at the start will potentially contribute to preoperative analgesia, but 
the resultant effect on general anesthetic dose reduction has been none or negligible in most 
studies. With injection by the end, the effect will last longer than if the injection is done 1-2 
hours previously. Some surgeons may even prefer to do both; before and at the end.  The 
injection initially may then be with a rapid and shortacting agent such as 5-10 mg/ml 
lidocaine, eventually with a vaso-constructive agent (i.e. epinephrine added) in order to 
reduce wound bleeding.  
There are also some studies in the literature advocating installation of local anesthesia in the 
peritoneal cavity (Kahokehr, 2011). This seems to be more effective for dedicated upper 
abdominal surgery, such a liver or gallbladder surgery, whereas the effect in general 
laparoscopy, such as bariatric, is more doubtful.  Whatever local anesthesia techniques are 
used, the surgeon should take care to obey the rules of maximal doses for general toxicity of 
the drugs, and these considerations should be based on mg local anesthesia per kg ideal 
weight, not actual weight. 
The obese patient will generally benefit from spending as short time as possible on the 
operating table, thus, a rapid and technical accurate surgeon is very highly appreciated in 
these patients.  
3.2 For the anesthetist 
Tthe goal will be to have proper anesthesia when needed, but a rapid emergence and 
resumption of adequate respiration and physiology very shortly after the end of the 
procedure (Bergland, 2008). Anything done to minimize the need of postoperative opioids 
and minimize the risk of postoperative nausea and vomiting is very valuable. 
3.2.1 Issues for general anesthesia induction (see also recipe) 
Usually it will be possible to find an IV access in these patients, for instance at the inside of 
the lower underarm there are some thin veins not covered by fat. However, occasionally 
there may be an indication for ultrasound guided access to a central vein if nothing else is 
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possible (see above). The patients should be with 20-30 degrees elevated trunk (half-sitting) 
during induction, preferably be a special pillow or by adjusting the operation table. This 
position has three functions: it will prevent regurgitation,  improve lung function (compared 
to supine) and also facilitate mask ventilation and laryngoscopy for intubation. A potential 
drawback may be increased risk of hypotention after induction with this position, thus 
titrated dosing is advisable and a ready availability of vasopressors, such as ephedrine or 
fenylefrine.  Also a rapid running infusion of crystalloid or colloid is useful. Rapid sequence 
induction is not needed in these patients if they otherwise fulfil fasting criteria. In case of 
rapid sequence induction there may be a case for high dose rocuronium (i.e. 0.8-1.2 mg/kg 
ideal weight) instead of suxamethonium, as the latter is associated with an increased risk of 
anaphylactoid reactions compared with the non-depolarising agents. 
Proper pre-oxygenation with a tight fitting mask and PEEP of 10 cm H2O is very useful, 
and shown to result in an extra 1-2 minutes before de-saturation occurs, if some airway 
problems arise later on. An end-tidal oxygen concentration of 80-90% on mask is a good 
sign of successful pre-oxygenation. Laryngeal mask airway (LMA) and spontaneous 
ventilation is basically beneficial for minimizing airway reactivity and optimizing lung 
physiology, especially in the obese. However, in the obese there is a need for high 
inspiratory pressure in order to overcome the resistance of the fat-coat surrounding the 
rib cage. With an LMA this higher pressure may result in inspiratory leakage, and 
frequently transition to endotracheal tube is needed. With laparoscopy and bariatric 
surgery even more so, because there is a considerable intrabdominal pressure adding to 
the resistance during inspiration.  In conclusion, endotracheal intubation is recommended 
as routine airway management in these patients (Raeder, 2010a). Intubation may be 
achieved with propopfol + remifentanil only, but the high dose need and subsequent risk 
of hemodynamic instability makes the use of non-depolarising neuromuscular blocking 
agent a better choice.  The intubation conditions will be more reliable and the anesthetic 
agents may be kept lower in dosing.  After intubation, a recruitment manoeuvre is 
beneficial to blow up the lungs, and then maintain a PEEP of 10 cm H2O throughout the 
case, with a new recruitment before extubation. Whereas pressure control ventilation 
mode is better for lung physiology, the volume mode is safer in terms of delivering a 
proper and fixed tidal-volume, which again should be adjusted to ideal weight, 6-8 
ml/kg. Especially during laparoscopy the high and variable peritoneal pressure may 
result in very low or variable tidal volumes with the pressure control mode, unless the 
settings are frequently adjusted. 
Recommended drugs for induction will be propofol + remifentanil (see recepe below) 
3.2.2 Issues during maintenance 
All the fat soluble agents are problematic to dose in the obese, because they distribute 
according to slightly more than ideal weight at start (i.e. corrected ideal body weight) and 
then more and more to total weight as the fat gets slowly loaded with drug (Servin, 2006; 
Raeder 2010a). An exception is remifentanil which is degraded before diffusing into the fat, 
and thus is very suitable for continued use in the obese. Propofol may be used for induction 
according to corrected ideal weight, but maintenance beyond 30-60 min calls for increase in 
dose, which is best titrated by using a brain function monitor, such as the BIS or similar 
device. Among inhalational agents, desflurane is the best in terms of less tissue binding and 
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more prone to both thrombosis, pulmonary embolism and wound infections in general, and 
even more so with intra-abdominal surgery,  appropriate  antibiotic (e,g. Cefuroxim 1.5g) 
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the resultant effect on general anesthetic dose reduction has been none or negligible in most 
studies. With injection by the end, the effect will last longer than if the injection is done 1-2 
hours previously. Some surgeons may even prefer to do both; before and at the end.  The 
injection initially may then be with a rapid and shortacting agent such as 5-10 mg/ml 
lidocaine, eventually with a vaso-constructive agent (i.e. epinephrine added) in order to 
reduce wound bleeding.  
There are also some studies in the literature advocating installation of local anesthesia in the 
peritoneal cavity (Kahokehr, 2011). This seems to be more effective for dedicated upper 
abdominal surgery, such a liver or gallbladder surgery, whereas the effect in general 
laparoscopy, such as bariatric, is more doubtful.  Whatever local anesthesia techniques are 
used, the surgeon should take care to obey the rules of maximal doses for general toxicity of 
the drugs, and these considerations should be based on mg local anesthesia per kg ideal 
weight, not actual weight. 
The obese patient will generally benefit from spending as short time as possible on the 
operating table, thus, a rapid and technical accurate surgeon is very highly appreciated in 
these patients.  
3.2 For the anesthetist 
Tthe goal will be to have proper anesthesia when needed, but a rapid emergence and 
resumption of adequate respiration and physiology very shortly after the end of the 
procedure (Bergland, 2008). Anything done to minimize the need of postoperative opioids 
and minimize the risk of postoperative nausea and vomiting is very valuable. 
3.2.1 Issues for general anesthesia induction (see also recipe) 
Usually it will be possible to find an IV access in these patients, for instance at the inside of 
the lower underarm there are some thin veins not covered by fat. However, occasionally 
there may be an indication for ultrasound guided access to a central vein if nothing else is 
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possible (see above). The patients should be with 20-30 degrees elevated trunk (half-sitting) 
during induction, preferably be a special pillow or by adjusting the operation table. This 
position has three functions: it will prevent regurgitation,  improve lung function (compared 
to supine) and also facilitate mask ventilation and laryngoscopy for intubation. A potential 
drawback may be increased risk of hypotention after induction with this position, thus 
titrated dosing is advisable and a ready availability of vasopressors, such as ephedrine or 
fenylefrine.  Also a rapid running infusion of crystalloid or colloid is useful. Rapid sequence 
induction is not needed in these patients if they otherwise fulfil fasting criteria. In case of 
rapid sequence induction there may be a case for high dose rocuronium (i.e. 0.8-1.2 mg/kg 
ideal weight) instead of suxamethonium, as the latter is associated with an increased risk of 
anaphylactoid reactions compared with the non-depolarising agents. 
Proper pre-oxygenation with a tight fitting mask and PEEP of 10 cm H2O is very useful, 
and shown to result in an extra 1-2 minutes before de-saturation occurs, if some airway 
problems arise later on. An end-tidal oxygen concentration of 80-90% on mask is a good 
sign of successful pre-oxygenation. Laryngeal mask airway (LMA) and spontaneous 
ventilation is basically beneficial for minimizing airway reactivity and optimizing lung 
physiology, especially in the obese. However, in the obese there is a need for high 
inspiratory pressure in order to overcome the resistance of the fat-coat surrounding the 
rib cage. With an LMA this higher pressure may result in inspiratory leakage, and 
frequently transition to endotracheal tube is needed. With laparoscopy and bariatric 
surgery even more so, because there is a considerable intrabdominal pressure adding to 
the resistance during inspiration.  In conclusion, endotracheal intubation is recommended 
as routine airway management in these patients (Raeder, 2010a). Intubation may be 
achieved with propopfol + remifentanil only, but the high dose need and subsequent risk 
of hemodynamic instability makes the use of non-depolarising neuromuscular blocking 
agent a better choice.  The intubation conditions will be more reliable and the anesthetic 
agents may be kept lower in dosing.  After intubation, a recruitment manoeuvre is 
beneficial to blow up the lungs, and then maintain a PEEP of 10 cm H2O throughout the 
case, with a new recruitment before extubation. Whereas pressure control ventilation 
mode is better for lung physiology, the volume mode is safer in terms of delivering a 
proper and fixed tidal-volume, which again should be adjusted to ideal weight, 6-8 
ml/kg. Especially during laparoscopy the high and variable peritoneal pressure may 
result in very low or variable tidal volumes with the pressure control mode, unless the 
settings are frequently adjusted. 
Recommended drugs for induction will be propofol + remifentanil (see recepe below) 
3.2.2 Issues during maintenance 
All the fat soluble agents are problematic to dose in the obese, because they distribute 
according to slightly more than ideal weight at start (i.e. corrected ideal body weight) and 
then more and more to total weight as the fat gets slowly loaded with drug (Servin, 2006; 
Raeder 2010a). An exception is remifentanil which is degraded before diffusing into the fat, 
and thus is very suitable for continued use in the obese. Propofol may be used for induction 
according to corrected ideal weight, but maintenance beyond 30-60 min calls for increase in 
dose, which is best titrated by using a brain function monitor, such as the BIS or similar 
device. Among inhalational agents, desflurane is the best in terms of less tissue binding and 
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more rapid emergence compared with the other potent inhalational agents. Still, sevoflurane 
or even isoflurane may be used in these patients, but then more care is needed to taper 
down the concentration during the last part of the operation in order to ensure reasonable 
fast emergence (Baerdemaeker, 2003).  Nitrous oxide is very rapidly acting and rapidly 
eliminated, but the potency is low and this agent may only be used as an adjunct to either 
propofol or a potent inhalational agent for anesthetic maintenance. 
3.2.3 Issues for ending the case and postoperative issues 
With dedicated use of maintenance drugs, it should be possible to have a rapid emergence, 
and extubation, also in the obese bariatric cases. It is very important to be generous with 
anti-emetic prophylaxis in these patients as well as providing an optimal non-opioid 
analgesia (see below). The patients should be awake within 5 min to an extent enabling 
them to help in transfer from the operating table to the bed. During transport to the 
postoperative care unit, the patients should be laying on the side, with the head lightly 
elevated, 2-3 litres of oxygen per min by nose catheter. A pulse-oxymeter should be 
connected during the transport to recovery, as well as during the recovery stay.  In the 
PACU, half sitting position should be rapidly encouraged and the patients should be tested 
for breathing room air when they are reasonable awake. A pulse-oxymeter saturation on 
room air of 92% or more is satisfactory. With such a value or higher the patient should not 
have oxygen supply. It has been shown that oxygen supply when not needed, may increase 
the risk of micro-atelectasis in the lung.  Further monitoring in the PACU will include 
regular non-invasive blood-pressure measurements and continuous ECG registration. When 
the patient is fully awake, monitoring may be limited to pulse-oxymeter only. Slow 
intravenous fluid from the period of surgery may be continued until the patients drinks, 
typically an amount of 1-2 litres of krystalloid iv solution is sufficient for the total peri-
operative period, unless there has been significant blood-loss.  
Within 2-4 hours the patients should be able to mobilize on the floor, and be ready for 
discharge to the ward. 
3.2.4 Prophylaxis and treatment of pain, nausea and vomiting 
These are the most common and bothersome complications in the first period after surgery, 
and every measure should be taken to avoid and minimize the occurrence. The two 
important common principles for avoiding these complications will be to think prophylactic 
and multimodal. Multimodal means to address the problem with different drugs of different 
but additive analgesic action mechanisms and different potential and type of side-effects 
(Raeder, 2010a).   
3.2.4.1 Postoperative pain 
For pain the idea is to use as many different non-opioid additive acting analgesics as 
possible in order to minimize the need for opioids (Raeder, 2010a). As opioids should be 
used and given on top when necessary, they carry some dose-dependent side-effects which 
are non-beneficial in the postoperative period. These include: somnolescense, nausea, 
constipation, disrupted sleep pattern, and the more rare and serious respiratory depression 
and sleep apnea syndrome. While opioids usually are needed in small, titrated doses in 
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bariatric patients, the potential of non-opioid pain prophylaxis and treatment should be 
addressed first.  
The concept of starting analgesic treatment before start of surgery in order to reduce 
nociceptive input to central pain mechanisms is disputed, while everyone agrees upon the 
use of having proper pain prophylaxis established when the patients awake from general 
anesthesia shortly after end of the procedure is well established.  
Drugs useful in this context include (Raeder, 2010): 
a. Local wound anesthesia: This should be given by the surgeon either at the start or at the 
end of the procedure (see above). If a particular wound is especially painful after 
surgery, the infiltration may be repeated (bupivacaine 2.5 mg/ml, 5-10 ml per wound) 
every 5-10 hrs, but this is rarely indicated.  
b. Paracetamol: Although a fairly week analgesic the incidence and type of side-effects are 
low, as long as high total doses with potential liver toxixcity is avoided. Paracetamol 
may be used in virtually all patients. It is very well and completely absorbed after oral 
administration and may be started 1-2 hours before surgery, while the alternative may 
be to start with an IV infusion at the start of surgery. The initial dose should be 2 g (1-2 
g if IV), while the continued dosing should be 1 g bid 4, either orally or IV as long as the 
patient have some pain, that is for 4-7 days usually. 
c. Non-steroidal analgesic drugs (NSAIDs): These are very useful analgesic drugs which 
may be used in most patients unless clearly contra-indicated. All NSAIDs carry a risk of 
renal failure upon hypoveolemia, and gastrointestinal ulceration and bleeding. In the 
bariatric setting the new subtype of cox-II selective NSAIDs (i.e. coxibs: celecoxib, 
etoricoxib, lumiraccoxib, parecoxib) have some beneficial characteristics and should 
therefore be preferred. They have less risk of allergy and asthma, they have no 
influence on trombocyte adhesion and no risk of bleeding, and the chance of 
developing gastric ulceration is less than with traditional NSADs (i.e. naproxen, 
ibuprofen, ketprofen, diclofenac). While an overt gastric ulcer or recent story of such is 
an absolute contraindication to these drugs, the coxibs may be used in patients with a 
cured gastric ulcer. Gastric regurgitation is no definite contraindication, unless there are 
overt wounds in the oesophagus. The combination of proton-pump inhibitor and a 
coxib is usually well tolerated, also as gastric regurgitation is mostly a defect in gastro-
oesophageal sphincter and not a change in gastric juice or gastric mucosa constitution.  
The potential negative impact from NSAIDs on gastric anastomoses healing has not 
been proved; on the contrary the opioid sparing effect on gastric motility from using 
NSAIDs may be beneficial in this context. The much disputed risk of cardiovascular 
complications with these drugs is usually not relevant as these are long-term use effects. 
Still, all these drugs may cause some initial fluid retention and slight increase in blood-
pressure, which should be monitored in high risk-patients. 
d. Glucocorticoids: Although a lot of potential side-effects may occur with long term 
treatment, the beneficial analgesic and anti-emetic effect of a single dose perioperatively 
lasting up to 2-3 days is very useful. As the onset of action is slow (2-3 hours) a 
glucocorticoid is best given at start of surgery. Dexamethasone is most popular, because 
it is a pure glucocorticoid with minor effect on electrolyte and mineral balance, and 
because duration of a single IV dose is long. It may be wise to give dexamethasone after 
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more rapid emergence compared with the other potent inhalational agents. Still, sevoflurane 
or even isoflurane may be used in these patients, but then more care is needed to taper 
down the concentration during the last part of the operation in order to ensure reasonable 
fast emergence (Baerdemaeker, 2003).  Nitrous oxide is very rapidly acting and rapidly 
eliminated, but the potency is low and this agent may only be used as an adjunct to either 
propofol or a potent inhalational agent for anesthetic maintenance. 
3.2.3 Issues for ending the case and postoperative issues 
With dedicated use of maintenance drugs, it should be possible to have a rapid emergence, 
and extubation, also in the obese bariatric cases. It is very important to be generous with 
anti-emetic prophylaxis in these patients as well as providing an optimal non-opioid 
analgesia (see below). The patients should be awake within 5 min to an extent enabling 
them to help in transfer from the operating table to the bed. During transport to the 
postoperative care unit, the patients should be laying on the side, with the head lightly 
elevated, 2-3 litres of oxygen per min by nose catheter. A pulse-oxymeter should be 
connected during the transport to recovery, as well as during the recovery stay.  In the 
PACU, half sitting position should be rapidly encouraged and the patients should be tested 
for breathing room air when they are reasonable awake. A pulse-oxymeter saturation on 
room air of 92% or more is satisfactory. With such a value or higher the patient should not 
have oxygen supply. It has been shown that oxygen supply when not needed, may increase 
the risk of micro-atelectasis in the lung.  Further monitoring in the PACU will include 
regular non-invasive blood-pressure measurements and continuous ECG registration. When 
the patient is fully awake, monitoring may be limited to pulse-oxymeter only. Slow 
intravenous fluid from the period of surgery may be continued until the patients drinks, 
typically an amount of 1-2 litres of krystalloid iv solution is sufficient for the total peri-
operative period, unless there has been significant blood-loss.  
Within 2-4 hours the patients should be able to mobilize on the floor, and be ready for 
discharge to the ward. 
3.2.4 Prophylaxis and treatment of pain, nausea and vomiting 
These are the most common and bothersome complications in the first period after surgery, 
and every measure should be taken to avoid and minimize the occurrence. The two 
important common principles for avoiding these complications will be to think prophylactic 
and multimodal. Multimodal means to address the problem with different drugs of different 
but additive analgesic action mechanisms and different potential and type of side-effects 
(Raeder, 2010a).   
3.2.4.1 Postoperative pain 
For pain the idea is to use as many different non-opioid additive acting analgesics as 
possible in order to minimize the need for opioids (Raeder, 2010a). As opioids should be 
used and given on top when necessary, they carry some dose-dependent side-effects which 
are non-beneficial in the postoperative period. These include: somnolescense, nausea, 
constipation, disrupted sleep pattern, and the more rare and serious respiratory depression 
and sleep apnea syndrome. While opioids usually are needed in small, titrated doses in 
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bariatric patients, the potential of non-opioid pain prophylaxis and treatment should be 
addressed first.  
The concept of starting analgesic treatment before start of surgery in order to reduce 
nociceptive input to central pain mechanisms is disputed, while everyone agrees upon the 
use of having proper pain prophylaxis established when the patients awake from general 
anesthesia shortly after end of the procedure is well established.  
Drugs useful in this context include (Raeder, 2010): 
a. Local wound anesthesia: This should be given by the surgeon either at the start or at the 
end of the procedure (see above). If a particular wound is especially painful after 
surgery, the infiltration may be repeated (bupivacaine 2.5 mg/ml, 5-10 ml per wound) 
every 5-10 hrs, but this is rarely indicated.  
b. Paracetamol: Although a fairly week analgesic the incidence and type of side-effects are 
low, as long as high total doses with potential liver toxixcity is avoided. Paracetamol 
may be used in virtually all patients. It is very well and completely absorbed after oral 
administration and may be started 1-2 hours before surgery, while the alternative may 
be to start with an IV infusion at the start of surgery. The initial dose should be 2 g (1-2 
g if IV), while the continued dosing should be 1 g bid 4, either orally or IV as long as the 
patient have some pain, that is for 4-7 days usually. 
c. Non-steroidal analgesic drugs (NSAIDs): These are very useful analgesic drugs which 
may be used in most patients unless clearly contra-indicated. All NSAIDs carry a risk of 
renal failure upon hypoveolemia, and gastrointestinal ulceration and bleeding. In the 
bariatric setting the new subtype of cox-II selective NSAIDs (i.e. coxibs: celecoxib, 
etoricoxib, lumiraccoxib, parecoxib) have some beneficial characteristics and should 
therefore be preferred. They have less risk of allergy and asthma, they have no 
influence on trombocyte adhesion and no risk of bleeding, and the chance of 
developing gastric ulceration is less than with traditional NSADs (i.e. naproxen, 
ibuprofen, ketprofen, diclofenac). While an overt gastric ulcer or recent story of such is 
an absolute contraindication to these drugs, the coxibs may be used in patients with a 
cured gastric ulcer. Gastric regurgitation is no definite contraindication, unless there are 
overt wounds in the oesophagus. The combination of proton-pump inhibitor and a 
coxib is usually well tolerated, also as gastric regurgitation is mostly a defect in gastro-
oesophageal sphincter and not a change in gastric juice or gastric mucosa constitution.  
The potential negative impact from NSAIDs on gastric anastomoses healing has not 
been proved; on the contrary the opioid sparing effect on gastric motility from using 
NSAIDs may be beneficial in this context. The much disputed risk of cardiovascular 
complications with these drugs is usually not relevant as these are long-term use effects. 
Still, all these drugs may cause some initial fluid retention and slight increase in blood-
pressure, which should be monitored in high risk-patients. 
d. Glucocorticoids: Although a lot of potential side-effects may occur with long term 
treatment, the beneficial analgesic and anti-emetic effect of a single dose perioperatively 
lasting up to 2-3 days is very useful. As the onset of action is slow (2-3 hours) a 
glucocorticoid is best given at start of surgery. Dexamethasone is most popular, because 
it is a pure glucocorticoid with minor effect on electrolyte and mineral balance, and 
because duration of a single IV dose is long. It may be wise to give dexamethasone after 
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the patient is asleep as there is a preservative in most dexamethasone solutions which 
may give strong perineal itching when given rapidly in the awake. While the dose of 8 
mg IV has been proven efficacious in general laparoscopy, it may be wise to increase 
the dose to 16 mg in the obese bariatric patient. Alternatives to IV dexamethasone may 
be metylprednisolone (50-125 mg) or oral prednisolone given in advance ( 20-50 mg) or 
oral dexamethasone, 15-25 mg.  As these drugs cause a slight increase in blood-sugar 
level, care should be taken to monitor blood-sugar levels if these drugs are used in the 
diabetic. 
e. Opioids: These may surely be needed on top of the non-opioid multimodal regimen. 
Any opioid may do, but care should be taken to use small and titrated dosing. For that 
reason opioids with rapid onset and short duration, such as alfentanil or fentanyl, are 
most easy to adjust. Initially the IV route is best, for instance using fentanyl, oxycodone 
or morphine. Then, after the PACU period the oral alternative should be preferred. The 
newer opioid subclass of oral opioid agonist with norepinephric effects, such as 
tramadol and tapentadol, has  less risk of respiratory depression, but the incidence of 
nausea and vomiting is quite high, especially with tramadol, whereas tapentadol so far 
seems promising. Buprenorphine is a weaker opioid agonist, but well absorbed orally 
and with long duration of effect and low risk of respiratory depression. Other oral 
alternatives include codeine and oxycodone. Codeine is an inactive prodrug of 
morphine and 5-10% of the population do not have the converting enzyme and then 
they have no effect of the drug. Oxycodone is a potent, well absorbed opioid which may 
be given in rapid acting 5 mg tablets or slow-release formulations of 10-20 mg. Some 
studies show less sedation or somnolescense with oxycodone when compared to 
equipotent doses of morphine (Lenz, 2009). As this opioid also seems to work very well 
on visceral pain, it may be the preferred oral opioid for the bariatric patients. 
f. Other analgesics: There are quite some other non-opioid drugs which have a beneficial 
postoperative analgesic action: ketamine, iv lidocaine, gabapentin, pre-gabalin, 
cannabinoids (Raeder, 2010a). 
The gabapentinoids (gabapentin, pre-gabalin) are well established for postoperative pain 
indication, but they may result in somnolescense, dizziness and fainting initially, when 
dosed to high. In bariatric patients with more than usual pain, these drugs may still be an 
alternative; then a modest starting dose of for instance 75-150 mg pre-gabalin may be tried, 
and then repeated twice a day, eventually increased carefully until 300 mg.  
In the immediate postoperative period a low dose infusion (i.e. 1-2 microg/kg ideal 
weight/min) of ketamin may also be an option in patients with strong pain.  
3.2.4.2 Postoperative nausea and vomiting (PONV) 
This is a troublesome complication in the postoperative, obese bariatric patient and an 
aggressive approach as to multimodal prophylaxis should be applied. The reason for 
multimodality in this context is that no single drug is more than effective in 50% of the 
patients, but with different acting drug combination this incidence may be up in the 80-90% 
range (Raeder, 2010a). The known risk factors of postoperative nausea and vomiting 
include: more than average tendency of travel sickness, more than average nausea after 
general anesthesia, opioid use, non-smoking status, female gender. Also type of surgery, 
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such as laparoscopy, has been associated with higher incidence of PONV, and the use of 
inhalational anesthetic agents as opposed to propofol which is anti-emetic (Apfel, 2004). 
A first measure to reduce the incidence of PONV is to minimize opioid effects and use in the 
postoperative care unit. This is achieved by using optimal non-opioid analgesic prophylaxis 
and treatment, and by using shortacting opioid (i.e. remifentanil) with minimal residual 
effect after general anesthesia.  
Then, secondly,  a mixture of anti-emetic prophylaxis should be used in these patients. 
The basis will be a 5-HT3 blocker (e.g. ondansetron 4 mg) given by end of anesthesia and 
glucocorticoid given by start (see above, glucocorticoid for pain) in all bariatric patients. In 
patients with more than average risk it may be useful to add droperidol 1.25 mg into the 
prophylaxis, and consider ending the anesthesia with a period of propofol infusion instead 
of desflurane all way through.  
If the patient develops nausea in the postoperative unit, it is important to rule out and treat 
some non-pharmacologic reasons for PONV: dehydration, hypotention, hypoxia or sudden 
movement. If anti-emetic drug treatment is needed it is wise to supplement with a drug the 
patient not already has received; that may be either metoclopramid (10 mg iv, eventually 
repeated) or ephedrine 5-10 mg IV. Ephedrine is especially efficient in those patients who 
experience nausea when moving or mobilizing, and if this is a consistent problem a sc 
injection of 25-40 mg ephedrine may be of help.  
In more resistant cases the new class of NK-1 antogonisk anti-emetics may be tried.  
4. Anesthetic recepe 
There are many successfyl ways to run general anesthesia in bariatric surgical patients, 
but this is a well tested recepe, now being applied to more than 2000 consecutive patients 
in a dedicated clinic for these procedures (Bergland, 2008). These patients should have 
standard monitoring with ECG, noninvasive blood pressure measurement, pulse 
oximetry, nerve stimulation test of neuromuscular block (i.e., TOF guard®), end-tidal CO2 
measurement, and anesthetic gas analysis. An arterial line for invasive blood pressure 
measurement is only inserted if specifically indicated, e.g., patients with known 
cardiovascular problems. 
It may be useful to monitor the depth of anesthesia in these patients, but this may be 
skipped during inhalational-based anesthesia if end-tidal MAC values are above 1 MAC all 
the time. 
Our recipe for obese patients undergoing laparoscopy is as follows: 
An iv infusion of 500 ml starch, colloid solution is running rapidly, followed by a slow 
infusion of crystalloid (0.5-1.0 liter during the procedure). 
When preoxygenation is fulfilled, anesthesia is induced with fentanyl 100 micog, propofol 
and remifentanil plasma target controlled infusions (TCI) with targets of 6 microg/ml and 8 
ng/ml, respectively. Both infusions are based on corrected ideal weight (height in 
centimeters minus 100, plus 20% of the difference between the real weight and ideal 
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the patient is asleep as there is a preservative in most dexamethasone solutions which 
may give strong perineal itching when given rapidly in the awake. While the dose of 8 
mg IV has been proven efficacious in general laparoscopy, it may be wise to increase 
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such as laparoscopy, has been associated with higher incidence of PONV, and the use of 
inhalational anesthetic agents as opposed to propofol which is anti-emetic (Apfel, 2004). 
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It may be useful to monitor the depth of anesthesia in these patients, but this may be 
skipped during inhalational-based anesthesia if end-tidal MAC values are above 1 MAC all 
the time. 
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infusion of crystalloid (0.5-1.0 liter during the procedure). 
When preoxygenation is fulfilled, anesthesia is induced with fentanyl 100 micog, propofol 
and remifentanil plasma target controlled infusions (TCI) with targets of 6 microg/ml and 8 
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centimeters minus 100, plus 20% of the difference between the real weight and ideal 
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weight), propofol with the Marsh effect site model and remifentanil with the Minto effect 
site model. 
Then, vecuronium 0.08 mg/kg corrected ideal weight is given. 
Tracheal intubation is performed with the patient in the semi-sitting position with their 
torso flexed and the head extended in the neck (“sniffing the morning air” position). A 
standard laryngoscope with a short handle and an endotracheal tube with a stylet are 
used. 
After the tracheal tube is secured, the propofol infusion is stopped and inhalation of 
desflurane at 3–6 % (i.e., 0.5 – 1 MAC) is started. Inspiratory oxygen is reduced to 40% and 
PEEP to 5 cmH2O. 
A gastric tube is inserted and the gastric content (if any) is aspirated. 
Anesthesia is continued throughout the operation with remifentanil and desflurane. The 
doses are adjusted according to clinical observation, arterial blood pressure, and bispectral 
index (BIS). Typically, remifentanil TCI is adjusted within a wide range to keep systolic 
blood pressure within acceptable limits (i.e., 85–120 mmHg) and desflurane is adjusted to 
keep the BIS within the range of 45–55. If no BIS is available an endtidal concentration of 0.7-
1.0 MAC desflurane should be used. 
Droperidol 1.25 mg, ondansetron 4 mg, and dexamethasone 16 mg are given as routine iv 
antiemetic prophylaxis. 
Parecoxib 40 mg and paracetamol 1g are given iv, and bupivacaine 2.5 mg/ml is infiltrated 
around the incisions, in a total volume of 30–40 ml, to prevent postoperative pain. 
Furthermore, fentanyl 100 microg is given before the end of surgery. 
Desflurane and remifentanil are stopped upon removal of the laparoscope at the end of 
surgery, and a small dose of propofol (30–50 mg total) is then given. The neuromuscular 
block is reversed with neostigmine 2.5 mg and glycopyrrolate 1 mg and the patients are 
ventilated with 100% oxygen. The patients are extubated on the table when they are 
emerging, breathing, and showing the first signs of irritation from the tracheal tube. Then 
patients move themselves, with some assistance, into the bed. 
Analgesia (present at emergence): 
 bupivacaine/ropivacaine wound infiltration 
 paracetamol 1.0 g iv 
 parecoxib 40 mg iv (or ketorolac 30 mg iv) 
 dexamethasone 16  mg iv 
 fentanyl 1–2 microg/kg at the end of surgery 
Anti-emesis: 
 droperidol 1.25 mg iv 
 (dexamethasone, also given for pain) 
 ondansetron 4 mg iv 
 propofol anesthesia + remifentanil anesthesia, no nitrous oxide, low opioid hangover 
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1. Introduction 
Morbid obesity is a chronic, lifelong, multifactorial, congenital disorder characterised by 
excessive fat deposits and associated medical, psychological, physical, social, and 
economic problems. It is also a significant health threat. The extra weight puts unusual 
stress on all parts of the body. It raises your risk of diabetes, stroke, heart disease, kidney 
disease, and gallbladder disease. Conditions such as high blood pressure and high 
cholesterol, which were once thought to mainly affect adults, are often seen in children 
who are obese. Obesity may also increase the risk for some types of cancer. Persons who 
are obese are more likely to develop osteoarthritis and sleep apnea. Obesity is the second 
leading cause of preventable death after smoking. A combination of genetics, 
environmental issues, and behavioral factors may contribute to the condition (Breznikar & 
Dinevski, 2009). 
Nonsurgical treatment has relapse rates of up to 90%, irrespective of the choice of 
conservative treatment (Council of Scientific Affairs, 1988). As early as 1991, the U.S. 
National Institute of Health issued a statement recognizing the known lack of success with 
conservative forms of treatment, nothing that operations to constrict or bypass the stomach 
were justified for fully informed and consenting patients and constituted an acceptable risk 
(National Institute of Health, 1985, Oppert & Rolland-Cachera, 1998). 
In 1954, Kremen and Linner introduced jejunoileal bypass. Modifications in the original 
procedures and the development of new techniques have led to 3 basic concepts for bariatric 
surgery, as follows: (1) gastric restriction by gastric banding (vertical-banded gastroplasty 
and adjustable banding), (2) gastric restriction with mild malabsorption (Roux-en-Y gastric 
bypass), and (3) a combination of mild gastric restriction and malabsorption (duodenal 
switch) (Masson et al., 1997, Belachew et al., 1997, Gravante et al. 2007).  
Bariatric surgery can be undertaken by open and laparoscopic techniques. The latter has 
become the more popular approach because of its proven (and now well-known) 
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advantages. GBP is currently the most popular procedure. More than 80% of bariatric 
procedures in the USA are GBP. It has earned the reputation of being the criterion standard 
against which other procedures are compared. The procedure has restrictive and 
malabsorptive components. GBP provides a substantial amount of dietary restriction. The 
restrictive element of the surgery consists of the creation of a small gastric pouch  with a 
small outlet that, on distention by food, causes the sensation of satiety. In addition, GBP 
provides a small-to-moderate degree of intentional malabsorption due to the separation of 
food, which passes through the Roux alimentary limb of the Y, from the biliopancreatic 
secretions, which pass through the biliopancreatic limb of the Y. The degree of 
malabsorption can be adjusted by modifying the length of the alimentary and 
biliopancreatic limbs. 
The diversity of clinical- and occult obesity-related comorbidities necessitates a 
multidisciplinary-team approach in the preoperative evaluation of a morbidly obese the 
patient: this evaluation enhances outcome. Preoperative cardiac, pulmonary, psychiatric, 
and endocrine evaluations may be necessary. These evaluations help to exclude patients 
who may not benefit from surgery. They simultaneously optimize those considered to be 
good candidates for this type of surgery. Patients should meet all necessary criteria for 
general surgery.  
The contraindications specific to bariatric surgery are: 
1. Absence of periods of identifiable medical management 
2. A patient who cannot participate in prolonged follow-up 
3. Non-stabilized psychotic disorders, severe depression and personality disorders (unless 
specifically advised by a psychiatrist experienced in obesity) 
4. Alcohol abuse and/or drug dependencies 
5. Diseases threatening life in the short-term 
6. Patients who cannot care for themselves and have no long-term support from their 
family or social service that warrant such care.  
The indications for bariatric surgery are: patients aged 18–60 years with a body mass index 
(BMI) >40 kg/m2 or with a BMI 35–40 kg/m2 with a comorbidity in which surgically 
induced weight loss is expected to improve the disorder (e.g., metabolic disorders, cardio-
respiratory disease, severe joint disease, obesity-related severe psychological problems). The 
BMI criterion may be the current BMI or a documented previous BMI of identical severity. 
Bariatric surgery is indicated in patients who exhibit substantial weight loss in a 
conservative treatment program but who started to regain weight. To be considered for 
surgery, patients must have failed to lose weight or to maintain long-term weight loss 
despite appropriate medical care. Patients must have shown compliance with medical 
appointments. The indication for bariatric surgery for age >60 years or <18 years should be 
considered on an individual basis.  
Preoperative consultation helps in obtaining a detailed diet history and in explaining 
preoperative and postoperative diet protocol. At our facility, patient preparation for surgery 
consisted of a detailed explanation (in written and oral form) of the developmental aspect of 
laparoscopic GBP and its benefits and risks. These included short- and long-term 
complications, side effects, nutritional sequelae, and the possibility of conversion to an open 
procedure. Antibiotics were administered perioperatively. Prophylaxis against venous 
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thrombosis and pulmonary emboli consisted of perioperative pneumatic compression 
devices and low-dose heparin (s.c.). 
After GBP, patients must remain on a high-protein, low-fat diet supplemented with 
multivitamins, iron, and calcium. Patients must modify their eating habits by avoiding 
“chewy” meats and other foods that may inhibit normal emptying of their stomach pouch. 
Nutritional and metabolic blood tests need to be carried out frequently (at 6 months after 
surgery, 12 months after surgery, and annually thereafter).  
Outcomes related to changes in comorbidities, quality of life, and patient satisfaction are 
assessed for patients with 1 year or more of follow-up. The Bariatric Analysis and Reporting 
Outcome System (BAROS) was introduced to evaluate bariatric procedures and to compare 
them worldwide. It consists of a Moorehead Quality of Life (QoL) questionnaire, and 
documentation of excess weight loss (EWL), medical conditions, complications, and 
reoperations. 
2. Bariatric procedures, gastric bypass (GBP) 
GBP is currently the most popular procedure. It has earned the reputation of being the 
criterion standard, against which other procedures are compared. The procedure has both 
a restrictive component and a malabsorptive component. GBP provides a substantial 
amount of dietary restriction. The restrictive element of the operation consists of the 
creation of a small gastric pouch (approximately 20 mL in volume) with a small outlet 
that, on distention by food, causes the sensation of satiety. In addition, gastric bypass 
provides a small-to-moderate degree of intentional malabsorption due to the separation of 
food, which passes through the alimentary limb of the Y, from the biliopancreatic 
secretions, which pass through the biliopancreatic limb of the Y. The degree of 
malabsorption can be adjusted by modifying the length of the alimentary and 
biliopancreatic limbs. 
For all bariatric procedures, pure reversal without conversion to another bariatric procedure 
is almost certainly followed by a return to morbid obesity. Gastric bypass can be reversed, 
though this is rarely required. Laparoscopic Roux-en Y gastric bypass results in substantial 
weight loss and resolves more than 80% of cases of type 2 diabetes. The investigators 
suggest that this bariatric operation should be considered the standard of care for morbidly 
obese type 2 diabetics5. 
Vitamin D deficiency and elevated PTH are common following GBP and progress over time. 
There is a significant incidence of secondary hyperparathyroidism in short-limb GBP 
patients, even those with vitamin D levels ≥30 ng/mL, suggesting selective Ca2+ 
malabsorption. Thus, calcium malabsorption is inherent to gastric bypass. Careful calcium 
and vitamin D supplementation and long-term screening are necessary to prevent 
deficiencies and the sequelae of secondary hyperparathyroidism. 
Laparoscopic Roux-en-Y gastric bypass is a major elective surgical procedure. The risks are 
as follows: mortality (1-2% of patients), mainly due to pulmonary embolism or 
gastrointestinal leak, wound infections, gastrojejunal stomal stricture, marginal ulcers, 
internal hernia, roux limb ischemia, blow-out of the stomach remnant, long-term nutrient 
deficiencies (eg, vitamin B12, folate, iron).   
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advantages. GBP is currently the most popular procedure. More than 80% of bariatric 
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thrombosis and pulmonary emboli consisted of perioperative pneumatic compression 
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2.1 Preoperative details 
The diversity of clinical and occult obesity-related comorbidities necessitates a 
multidisciplinary team approach in the preoperative evaluation of the patient who is morbidly 
obese. This evaluation enhances the postoperative outcome. Preoperative cardiac, pulmonary, 
psychiatric, and endocrine evaluations may be necessary. These evaluations help to exclude 
patients who may not benefit from surgery; at the same time, they optimize those considered 
being potential good candidates. Preoperative nutritional consultation helps in obtaining a 
detailed diet history and in explaining preoperative and postoperative diet protocol. At our 
facility, patient preparation for surgery consisted of a detailed explanation in written and oral 
form of the developmental aspect of laparoscopic GBP and its benefits and risks, including 
short- and long-term complications, side effects, nutritional sequelae, and the possibility of 
conversion to an open procedure. Perioperative antibiotics were administered. Prophylaxis 
against venous thrombosis and pulmonary embolus consisted of perioperative pneumatic 
compression devices and low-dose subcutaneous heparin. 
2.2 Postoperative details 
After surgery, patients must remain on a high-protein, low-fat diet supplemented with 
multivitamins, iron, and calcium. Patients must modify their eating habits by avoiding 
chewy meats and other foods that may inhibit normal emptying of their stomach pouch. 
Nutritional and metabolic blood tests need to be performed frequently (at 6 months after 
surgery, 12 months after surgery, and annually thereafter). 
We have a monthly support group meeting, where the evaluation of the results is 
monitored. To evaluate the bariatric procedures and to compare them worldwide, Bariatric 
Analysis and Reporting Outcome System (BAROS) was introduced (Oria & Moorehead, 
1998). It consists of Moorehead Quality of Life questionnaire (QoL), EWL, medical 
condition, complications, and reoperations (Table 1). Total score is between 1 and 9 in the 
group with comorbidities and between 0 and 6 in the group with no comorbidities (Table 2), 
each divided in 5 classes: bad, acceptable, good, very good, and excellent. 
Outcomes related to changes in comorbidities, quality of life, and patient satisfaction were 
assessed for patients with 1 year or more of follow-up. The Moorehead-Ardelt Quality of 
Life Questionnaire specific for bariatric surgery was administered according to the protocol 
to assess quality of life changes. 
2.3 Material and methods 
Surgical procedures were performed at Slovenj Gradec General Hospital and Celje General 
Hospital, Slovenia. An extensive preoperative evaluation consisting of a history and 
physical examination, nutritional and psychiatric evaluation, and indicated specialty 
consultations was performed on all patients. Laboratory evaluation included complete 
blood count, serum chemistries, and thyroid function testing.  
The surgical technique was a modification of the technique described by Wittgrove et al. 
(1994). The patient was placed in a supine position with the surgeon in between the legs, 
and two monitors above the patient’s shoulders. After creation of carbon dioxide 
pneumoperitoneum (15 mmHg) using the Veress needle technique or entering the abdomen 
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without gas, just with the optic trocar, ports were placed at the level of mesogastrium; the 
first one for the camera approximately 12 cm from the xyphoid. The operating table was 
placed in a steep reverse Trendelenburg position. To expose the esophagus and stomach, the 
liver retractor was placed through the inferior right subcostal port, and the left lateral 
segment of the liver was elevated. A 30 ml gastric pouch was created. The endo-linear 
stapler, 45-mm in length with 3.8-mm staples, was inserted and applied three or four times 
to staple and cut the gastric pouch with three rows of staples on each side. A 
gastroenteroanastomosis was than created 40 – 60 cm from the ligament of Treitz using 
either a circular end-to-end anastomosis stapled technique (first 20 cases) or a linear stapled 
technique (last 80 cases). The Roux limb was then measured 100 cm distally, or 150 cm 
distally for the superobese patients. A stapled side-to-side anastomosis was created with the 
proximal jejunal limb using  the endo-linear stapler, 45-mm in length with 2.5-mm, white 
staples. The enterotomy sites were closed with running suture. All the anastomoses were 
tested with methylene blue. Lastly, the afferent loop close to the gastroenteroanastomosis 
was divided with a white cartridge of the linear stapler.  
From February 2007 until March 2010, we performed 100 laparoscopic GBP surgeries. 
Patients were 42.2 years old on average (range 18.9 to 63.3). 87 females were 42.3 years old 
on average (range 18.9 to 63.3) and 13 males were 41.5 years old on average (range 26.4 to 
53.0). Their BMI was 42.6 on average (range 33.4 to 72.3); females 42.7 (range 33.7 to 72.3), 
males 42.1 (range 33.4 to 49.6). 
2.4 Results 
The mean follow-up was 9.1 months (range 2 – 39 months); 53 patients had 1 or more, 17 
patients had 2 or more and 3 patients had 3 or more years of follow up. We had one 
conversion because of adhesions and one because of bleeding from injured mesentery. 
One year after the surgery, 53 patients (47 females and 5 males) lost 32.8 kg on average 
(range 7.0 to 53.0). Female patients lost 31.8 kg on average (range 7.0 to 53.0); male patients 
lost 43.0 kg (37.0 to 47.5), 17 patients lost 35.7 kg (11.0 to 57.0) after 2 years, and 3 patients 
lost 47.3 kg (43.0 to 55.0) after 3 years (Figure 1). 
Excess Weight Loss (EWL) was 69.6 % (range 12.2 to 133.4) after 1 year, 76.5% (range 21.0% 
to 108.4%) after 2, and 86.0% after 3 years (range 71.8 to 104.9) (Figure 2).  
EWL(t) = (max. weight – weight(t) ) / (max. weight – weight (BMI25)), while “t” is the time 
of the interest and weight (BMI25) is the weight of the person at BMI=25 kg/m2 
Body mass index (BMI) was reduced by 11.6 kg/m2; from an average of 42.6 before the 
operation to 31.0 at one year post-operatively (range 21.4 to 59.5). BMI was further reduced 
to 29.4 (range 23.5 to 43.5) at 2 years post-operatively, and to 27.4 at 3 years post-operatively 
(range 24.1 to 31.2) (Figure 3, Table 3). BMI= mass (kg)/(height, m )2 
A total of 137 comorbidities were identified in our 100 patients. The most common 
comorbidities included hypertension (34 %), degenerative joint disease (22%), type II 
diabetes (16%), hypercholesterolemia (7%), and asthma (7%). The comorbidities and their 
resolution are presented in Table 4. The resolution of diabetes with respect to therapy prior 
to GBP surgery is presented in Table 5.  
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without gas, just with the optic trocar, ports were placed at the level of mesogastrium; the 
first one for the camera approximately 12 cm from the xyphoid. The operating table was 
placed in a steep reverse Trendelenburg position. To expose the esophagus and stomach, the 
liver retractor was placed through the inferior right subcostal port, and the left lateral 
segment of the liver was elevated. A 30 ml gastric pouch was created. The endo-linear 
stapler, 45-mm in length with 3.8-mm staples, was inserted and applied three or four times 
to staple and cut the gastric pouch with three rows of staples on each side. A 
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distally for the superobese patients. A stapled side-to-side anastomosis was created with the 
proximal jejunal limb using  the endo-linear stapler, 45-mm in length with 2.5-mm, white 
staples. The enterotomy sites were closed with running suture. All the anastomoses were 
tested with methylene blue. Lastly, the afferent loop close to the gastroenteroanastomosis 
was divided with a white cartridge of the linear stapler.  
From February 2007 until March 2010, we performed 100 laparoscopic GBP surgeries. 
Patients were 42.2 years old on average (range 18.9 to 63.3). 87 females were 42.3 years old 
on average (range 18.9 to 63.3) and 13 males were 41.5 years old on average (range 26.4 to 
53.0). Their BMI was 42.6 on average (range 33.4 to 72.3); females 42.7 (range 33.7 to 72.3), 
males 42.1 (range 33.4 to 49.6). 
2.4 Results 
The mean follow-up was 9.1 months (range 2 – 39 months); 53 patients had 1 or more, 17 
patients had 2 or more and 3 patients had 3 or more years of follow up. We had one 
conversion because of adhesions and one because of bleeding from injured mesentery. 
One year after the surgery, 53 patients (47 females and 5 males) lost 32.8 kg on average 
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lost 43.0 kg (37.0 to 47.5), 17 patients lost 35.7 kg (11.0 to 57.0) after 2 years, and 3 patients 
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Excess Weight Loss (EWL) was 69.6 % (range 12.2 to 133.4) after 1 year, 76.5% (range 21.0% 
to 108.4%) after 2, and 86.0% after 3 years (range 71.8 to 104.9) (Figure 2).  
EWL(t) = (max. weight – weight(t) ) / (max. weight – weight (BMI25)), while “t” is the time 
of the interest and weight (BMI25) is the weight of the person at BMI=25 kg/m2 
Body mass index (BMI) was reduced by 11.6 kg/m2; from an average of 42.6 before the 
operation to 31.0 at one year post-operatively (range 21.4 to 59.5). BMI was further reduced 
to 29.4 (range 23.5 to 43.5) at 2 years post-operatively, and to 27.4 at 3 years post-operatively 
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comorbidities included hypertension (34 %), degenerative joint disease (22%), type II 
diabetes (16%), hypercholesterolemia (7%), and asthma (7%). The comorbidities and their 
resolution are presented in Table 4. The resolution of diabetes with respect to therapy prior 
to GBP surgery is presented in Table 5.  
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Fig. 1. Weight loss 
(every line presents a patient, a dot in the line is the monitoring point, thick line is mean 
value) 
 
Fig. 2. Excess Weight Loss - EWL 
(every line presents a patient, a dot in the line is the monitoring point, thick line is mean 
value) 
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Fig. 3. BMI reduction 
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Table 1. BAROS 
The overall mean operating time for the last 50 patients was 90.6 minutes (range 55 to 195). 
Four patients had early (<30 days) major complications: leakage, ileus, stenosis of entero-
entero anastomosis, and small bowel injury. All complications were treated with an 
additional procedure. Among minor complications were two bleedings from the mesentery 
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due to a mesentery suturing, and one bleed from the staple line intraluminally. Blood 
transfusions were sufficient. A port site abscess occurred in one patient. One instance of 
Peterson's hernia, a late complication, occurred two years after the first operation when 
Peterson's space wasn't closed. The problem was solved by repositioning the small bowel 
and closing the defect. 
 
 Patients with comorbidities (total score) 
Patients without comorbidities 
(total score) 
bad <1 <0 
acceptable 1 - 3 0 -1.5 
good 3 - 5 1.5 -3 
very good 5 -7 3 – 4.5 
excellent 7 - 9 4.5 - 6 
Table 2. BAROS scoring 
 
 1 year-53 pts 2 years-17 pts 3 years-3 pts 
























Table 3. Results at 1, 2, and 3 years post-operatively 
 
 all improved resolved no change no data 
Orthopedic symptoms 22 9 (40.9%) 11 (50.0%) 1 (4.5%) 1 
Hypertension 34 10 (29,4%) 23 (67,6%)  1 
Diabetes 16 6 (37,5%) 9 (56.2%)  1 
Hyperlipidemia 7 3 (42.9%) 4 (57.1%)  0 
Asthma 7 2 (28.6%) 4 (57.1%)  1 
Table 4. Comorbidities 
  
 all improved resolved months to resolution 
DM - diet 4 0 4 (100%) < 1 
DM – oral medication 7 3 (42.9%) 4 (57.1%) 10.2 (1-29) 
DM - insulin 4 3 (75.0%) 1 (25.0%) < 1 
Table 5. Resolution of diabetes with respect to therapy prior to surgery 
Three patients had a gastric bypass performed after insufficient weight loss after sleeve 
gastrectomy, and four patients had GBP surgery after gastric banding. One bypass was 
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performed because of migration of the band. Two out of four major complications (ileus and 
small bowel injury) occurred in redo procedures – after failed bandings. 50 out of 53 patients 
who were monitored for more than one year answered the Moorehead QoL questionnaire. 
The total average BAROS score was 6.5 for the group with comorbidities (range 2.8 to 9.0), 
and 3.2 for the group without comorbidities (range 0.3 to 5.0) – which is “very good” in both 
groups. 
3. Bariatric procedures, Adjustable Gastric Banding (AGB) 
The device consists of an adjustable inflatable band placed around the proximal part of the 
stomach. This creates a small gastric pouch (approximately 15 ml in volume) and a small 
stoma. Band restriction is adjustable by adding or removing saline from the inflatable band 
by a reservoir system of saline attached to the band and accessible through a port, which is 
attached by a catheter to the band. The port is placed subcutaneously in the anterior 
abdominal wall after the band is secured around the stomach. Adjustment of the band 
through the access port is an essential part of laparoscopic adjustable gastric banding 
therapy. Appropriate adjustments, performed up to 6 times annually, are critical for 
successful outcomes. Patients must chew food thoroughly to allow food to pass through the 
band. Adjusting the inflation of the cuff changes the size of the opening through which food 
passes but does not change the size of the gastric pouch; deflation of the cuff is useful when 
the outlet is obstructed. 
Weight loss after laparoscopic adjustable gastric banding is about 50-60% of excess body 
weight in approximately 2 years. AGB can be completely reversed with removal of the band, 
tubing, and port. 
Laparoscopic adjustable gastric banding was a safe and feasible technique with specific 
indications in moderately obese patients and, secondarily, in highly obese patients who are 
unfit for more invasive techniques. In patients with mild-to-moderate obesity, laparoscopic 
adjustable gastric banding appears to be significantly more effective than nonsurgical 
therapies in producing weight loss, resolving the metabolic syndrome, and improving 
quality-of-life outcomes, new study findings suggest.8,9,11 
3.1 Material & methods 
A clinical study was conducted at Slovenj Gradec General Hospital, Slovenia. We performed 
264 gastric bandings (66.5% of all bariatric procedures) between May 2005 and May 2010. 
On average, patients were 41.0 years old (range 17.2 – 68.8) and had a BMI of 42.4 kg/m2 
(range 34.5 – 59.0). There were 224 female patients (84.8%) with an average age of 41.0 
(range 19.5 – 68.8) and a BMI 42.0 kg/m2 (range 34.5 – 59.0) – table 6. Out of 264 patients, 15 
had to have the band removed because of either insufficient weight loss (6 patients, 2.3%), 
slippage (4 patients, 1.5%), migration (1 patient, 0.4%), band leakage (1 patient, 0.4%), intra 
abdominal abscess (1 patient, 0.4%), outlet obstruction (1 patient, 0.4%), and personal 
reasons (1 patient, 0.4%). 4 patients (1.5%) were lost to follow up – table 7 and 8. We 
followed 192 patients for more than one year. 155 patients (80.7%) were evaluated with 
BAROS – Bariatric Analysis and Reporting Outcome System, which is a questionnaire 
assessing the quality of life (QoL), excessive weight loss (EWL), medical conditions, and 
complications. Scoring is divided into 5 grades ranging from bad to excellent. There are 2 
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due to a mesentery suturing, and one bleed from the staple line intraluminally. Blood 
transfusions were sufficient. A port site abscess occurred in one patient. One instance of 
Peterson's hernia, a late complication, occurred two years after the first operation when 
Peterson's space wasn't closed. The problem was solved by repositioning the small bowel 
and closing the defect. 
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Table 3. Results at 1, 2, and 3 years post-operatively 
 
 all improved resolved no change no data 
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performed because of migration of the band. Two out of four major complications (ileus and 
small bowel injury) occurred in redo procedures – after failed bandings. 50 out of 53 patients 
who were monitored for more than one year answered the Moorehead QoL questionnaire. 
The total average BAROS score was 6.5 for the group with comorbidities (range 2.8 to 9.0), 
and 3.2 for the group without comorbidities (range 0.3 to 5.0) – which is “very good” in both 
groups. 
3. Bariatric procedures, Adjustable Gastric Banding (AGB) 
The device consists of an adjustable inflatable band placed around the proximal part of the 
stomach. This creates a small gastric pouch (approximately 15 ml in volume) and a small 
stoma. Band restriction is adjustable by adding or removing saline from the inflatable band 
by a reservoir system of saline attached to the band and accessible through a port, which is 
attached by a catheter to the band. The port is placed subcutaneously in the anterior 
abdominal wall after the band is secured around the stomach. Adjustment of the band 
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different scoring groups: a group with comorbidities (1 - 9 points) and a group without 
comorbidities (0 – 6 points). 155 of our patients (80.7%) responded and answered the 
BAROS questions; 101 with comorbidities and 54 without.    
We excluded patients with hormonal disorders and other pathologies preoperatively. 
Because gastric banding is not appropriate for every patient, we performed a thorough 
psychological evaluation of all the patients. When needed, we offered preoperative and 
postoperative psychological and dietary support. 
We performed the operation using a pars flaccida technique and secured the band with 1-3 
stitches (fundus to the left crus and pouch). 
To determine if there is a correlation between EWL and participation in the support group, we 
performed a statistical analysis on the 192 patients who were monitored for more than 1 year. 
Background data statistics included frequency and percentage distributions for categorical 
variables, along with mean values and standard deviations for continuous variables. Pearson 
correlation coefficient was calculated to conduct univariate strength association between EWL 
and the number of visits in the support group. We used the linear regression method for 
calculation of the EWL value (dependent variable) in relation to the number of visits, adjusted 
by age and gender (Figure7, Table 13). Statistical analysis was performed with the SPSS 15.0 
software (SPSS Inc., Chicago, Il). P value < 0.05 was marked as statistically significant. 
3.2 Results 
192 out of 264 patients were monitored for more than one year after the procedure (172 
females and 20 males). 
Weight loss; In the first year, patients lost 23.4 kg on average (-1.1 - 52.9); (female 23.3 kg, 
range -1.1 - 52.9; male 24.6 kg, range 8.4 - 47.7).  
Two years after the operation, 118 patients (106 females and 12 males) lost 31.4 kg on 
average, range -6.3 to 63.8 (female 31.4 kg, range -6.3 – 63.8; male 29.9, range 11.0 – 51.9). 
Three years after the operation, 72 patients (67 females and 5 males) lost 33.7 kg on average, 
range 6.2 to 69.0. Fig. 4. 
EWL; One year after the operation, EWL was 50.3% on average, range -2.0 -145.3% (female 
51.7%, range -2.0 - 145.3%; male 38.3%, range 12.2 - 51.2%). 
Two years after the operation, EWL was 65.6% on average (-11.2 to 135.9%); (female 68.0%, 
range -11.2 – 135.9%; male 43.9%, range 19.0 - 62.5%). 
Three years after the operation, EWL was 69.8% on average, range 17.0 to 134.9. Fig 5 
BMI; The average BMI of all patients before the operation was 42.4 kg/m2 (range 34.5 – 
59.0), 42.0 kg/m2 for females (range 34.5 – 59.0),and 44.0 kg/m2 for males (range 34.8 – 55.7). 
One year after the procedure, the average BMI was 34.0 kg/m2 for all patients (range 21.9 – 
51.2), 33.6 kg/m2 for females (range 21.9 – 51.2), and 37.4 kg/m2 for males (range 29.0 – 45.5). 
Two years after the procedure, the average BMI was 31.4 kg/m2 (range 20.2 – 47.9), 31.0 
kg/m2 for females (range 20.2 – 47.9), and 36.4 kg/m2 for males (range 31.8 – 43.0). 
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Fig. 6. BMI reduction: 
 
 ALL FEMALE MALE 
No 264 224 40 
AGE 41.0(17.2-68.8) 41.0(19.5-68.8) 41.2(17.2-61.9) 
BMI 42.4(34.5-59.0) 42.0(34.5-59.0) 44.0(34.8-55.7) 
Table 6. Patients 
 
YEAR OF THE SURGERY PTS WITH BAND WITHOUT BAND LOST 
1st 11 4(36.4%) 6(54.5%) 1(9.1%) 
2nd 76 68(89.5%) 8(10.5%) 0 
3rd 49 46(94%) 1(2%) 2(4%) 
4th 75 74(99%) 0 1 
5th 53 53(100%) 0 0 
ALL 264 245(92.8%) 15(5.7%) 4(1.5%) 
Table 7. Monitoring 
Three years after the procedure, the average BMI of all patients was 30.8 kg/m2 (range 22.4 – 
44.0) Fig. 6, Table 10a-c 
Reoperations; We performed 15 re-operations: 4 (1.5%) bands were removed due to 
dilatation of the pouch and slippage, 6 (2.3%) due to insufficient reduction of the body 
weight, and one each (0.4%) due to migration, outlet obstruction, band leakage, intra 
abdominal abscess, and personal reasons. 
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Resolution of comorbidities; The main obesity-related comorbidities resolved as shown in 
table 6. We had 31 patients with diabetes. 13 of them (41.9%) improved, 17 (54.8%) had 
complete resolution of the disease, and one patient (3.2%) was lost to follow up.  Out of 51 
patients with hypertension, 21 (41.2%) improved, 28 (54.9%) had complete resolution of the 
disease, one patient (2.0%) showed no change, and one patient (2.0%) was lost to follow up. 
Out of 17 patients with hyperlipidemia, 6 (35.3%) improved, 9 (52.9%) had complete 
resolution of the disease, one patient (5.9%) showed no change, and one patient (5.9%) was 
lost to follow up.  
Complications; There was no perioperative mortality, no pulmonary embolism, no stomach 
wall lesions, and no hemorrhage. 
Early complications (within 1 month after the procedure): 1 (0.4%) intra abdominal abscess 
and 1 (0.4%) outlet obstruction.  
Late complications (more than 1 month after the procedure): 1 (0.4%) band migration, 4 
(1.5%) slippages/dilatations, and 1 (0.4%) band leakage. 
Statistical analysis of support group visits and EWL; With the Pearson coefficient of r=0.58 
(p<0.001), we are able to conclude that there is a “moderate to strong” correlation (r>0.5 is 
usually interpreted as a strong correlation) between the number of visits in the support 
group and EWL. The distribution between EWL and the number of visits is shown by a 
scattered plot in Table 12. 
Table 12 shows that the number of visits has a statistically significant impact on EWL, while 
age and gender do not significantly correlate with the EWL. 
Quality of life evaluation; The average BAROS score was a grade of “good” in both groups: 
4.85 in the group with comorbidities and 2.64 in the group without comorbidities. 155 out of 
193 patients (80.7%) answered the QoL questionnaire. In the group of 54 patients with 
comorbidities, the average score for QoL was 1.83 (range -0.4 – 3.0), 1.53 for EWL (range 0 – 
3), and 1.66 for medical condition (range 0 – 3). In the group of 101 patients without 
comorbidities, the average score for quality of life (QoL) was 1.72 (range -2.5 – 3.0), and 1.48 
for EWL (range 0 – 3), Table 13. 
 
Year of the surgery 1st 2nd 3rd 4th 5th TOTAL 
migration  1    1(0.4%) 
Slippage/dilatation 1 2 1   4(1.5%) 
Insuficient weight loss 3 3    6(2.3%) 
Outlet obstruction 1     1(0.4%) 
Band leakage 1     1(0.4%) 
Personal reasons  1    1(0.4%) 
Intra abdominal abscess  1    1(0.4%) 
Table 8. Reasons for removing of the band 
 
Advanced Bariatric and Metabolic Surgery 168 
 
Fig. 6. BMI reduction: 
 
 ALL FEMALE MALE 
No 264 224 40 
AGE 41.0(17.2-68.8) 41.0(19.5-68.8) 41.2(17.2-61.9) 
BMI 42.4(34.5-59.0) 42.0(34.5-59.0) 44.0(34.8-55.7) 
Table 6. Patients 
 
YEAR OF THE SURGERY PTS WITH BAND WITHOUT BAND LOST 
1st 11 4(36.4%) 6(54.5%) 1(9.1%) 
2nd 76 68(89.5%) 8(10.5%) 0 
3rd 49 46(94%) 1(2%) 2(4%) 
4th 75 74(99%) 0 1 
5th 53 53(100%) 0 0 
ALL 264 245(92.8%) 15(5.7%) 4(1.5%) 
Table 7. Monitoring 
Three years after the procedure, the average BMI of all patients was 30.8 kg/m2 (range 22.4 – 
44.0) Fig. 6, Table 10a-c 
Reoperations; We performed 15 re-operations: 4 (1.5%) bands were removed due to 
dilatation of the pouch and slippage, 6 (2.3%) due to insufficient reduction of the body 
weight, and one each (0.4%) due to migration, outlet obstruction, band leakage, intra 
abdominal abscess, and personal reasons. 
Gastric Banding and Bypass for Morbid Obesity – 
Preoperative Assessment, Operative Techniques and Postoperative Monitoring 169 
Resolution of comorbidities; The main obesity-related comorbidities resolved as shown in 
table 6. We had 31 patients with diabetes. 13 of them (41.9%) improved, 17 (54.8%) had 
complete resolution of the disease, and one patient (3.2%) was lost to follow up.  Out of 51 
patients with hypertension, 21 (41.2%) improved, 28 (54.9%) had complete resolution of the 
disease, one patient (2.0%) showed no change, and one patient (2.0%) was lost to follow up. 
Out of 17 patients with hyperlipidemia, 6 (35.3%) improved, 9 (52.9%) had complete 
resolution of the disease, one patient (5.9%) showed no change, and one patient (5.9%) was 
lost to follow up.  
Complications; There was no perioperative mortality, no pulmonary embolism, no stomach 
wall lesions, and no hemorrhage. 
Early complications (within 1 month after the procedure): 1 (0.4%) intra abdominal abscess 
and 1 (0.4%) outlet obstruction.  
Late complications (more than 1 month after the procedure): 1 (0.4%) band migration, 4 
(1.5%) slippages/dilatations, and 1 (0.4%) band leakage. 
Statistical analysis of support group visits and EWL; With the Pearson coefficient of r=0.58 
(p<0.001), we are able to conclude that there is a “moderate to strong” correlation (r>0.5 is 
usually interpreted as a strong correlation) between the number of visits in the support 
group and EWL. The distribution between EWL and the number of visits is shown by a 
scattered plot in Table 12. 
Table 12 shows that the number of visits has a statistically significant impact on EWL, while 
age and gender do not significantly correlate with the EWL. 
Quality of life evaluation; The average BAROS score was a grade of “good” in both groups: 
4.85 in the group with comorbidities and 2.64 in the group without comorbidities. 155 out of 
193 patients (80.7%) answered the QoL questionnaire. In the group of 54 patients with 
comorbidities, the average score for QoL was 1.83 (range -0.4 – 3.0), 1.53 for EWL (range 0 – 
3), and 1.66 for medical condition (range 0 – 3). In the group of 101 patients without 
comorbidities, the average score for quality of life (QoL) was 1.72 (range -2.5 – 3.0), and 1.48 
for EWL (range 0 – 3), Table 13. 
 
Year of the surgery 1st 2nd 3rd 4th 5th TOTAL 
migration  1    1(0.4%) 
Slippage/dilatation 1 2 1   4(1.5%) 
Insuficient weight loss 3 3    6(2.3%) 
Outlet obstruction 1     1(0.4%) 
Band leakage 1     1(0.4%) 
Personal reasons  1    1(0.4%) 
Intra abdominal abscess  1    1(0.4%) 
Table 8. Reasons for removing of the band 
 
Advanced Bariatric and Metabolic Surgery 170 
Characteristics Patient group (N=192) 
EWL 50.3±24.2 
Gender (%)  
male 12.4 
female 87.6 
Age in years 41.7±12.2 
Number of visits 2.8±2.0 
Table 9. Background data of the patients participating the support group 
 
Monitored years/ 
No of patients Weight loss(kg) EWL(%) BMI(kg/m
2) 
>1/192 23.4(-1.1-52.9) 50.3(-2.0-145.3) 34.0(21.9-51.2) 
>2/118 31.4(-6.3-63.8) 65.6(-11.2-135.9) 31.4(20.2-47.9) 
>3/72 33.7(6.2-69.0) 69.8(17.0-134.9) 30.8(22.4-44.0) 
>4/4 35.1(25.1-51.7) 82.2(69.0-97.3) 27.6(25.4-29.7) 
Table 10.a) Results all 
 
Monitored years/ 
No of patients Weight loss(kg) EWL(%) BMI(kg/m
2) 
>1/172 23.3(-1.1-52.9) 51.7(-2.0-145.3) 33.6(21.9-51.2) 
>2/106 31.4(-6.3-63.8) 68.0(-11.2-135.9) 31.0(20.2-47.9) 
>3/67 33.7(6.2-69.0) 71.6(19.5-134.9) 30.3(22.4-41.6) 
>4/4 35.1(25.1-51.7) 82.2(69.0-97.3) 27.6(25.4-29.7) 
Table 10.b) Results – female 
 
Monitored years/ 
No of patients Weight loss(kg) EWL(%) BMI(kg/m
2) 
>1/20 24.6(8.4-47.7) 38.3(12.4-79.7) 37.4(29.0-45.5) 
>2/12 29.9(11.0-51.9) 43.9(19.0-62.5) 36.4(31.8-43.0) 
>3/5 33.5(12.2-51.2) 45.0(17.0-60.6) 36.2(30.9-44.0) 
>4/4    
Table 10.c) Results – male 
 
 all improved resolved No change No data 
Diabetes  31 13(41.9%) 17(54.8%)  1(3.2%) 
Hypertension  51 21(41.2%) 28(54.9%) 1(2.0%) 1(2.0%) 
Hyperlipidemia  17 6(35.3%) 9(52.9%) 1(5.9%) 1(5.9%) 
Table 11. Resolution of comorbidities 
Gastric Banding and Bypass for Morbid Obesity – 
Preoperative Assessment, Operative Techniques and Postoperative Monitoring 171 
 
Fig. 7. Relation between number of visits and EWL 
 
 Beta t p 
Number of visits 0.56 9.32 <0.001 
Age -0.03 -0.57 0.571 
Female gender 0.09 1.45 0.148 
R2=0.341 
Table 12. Linear model to calculate EWL 
 
 QoL EWL Medical condition Total score 
Comorbidity group 1.83(-0.4-3.0) 1.53(0-3) 1.66(0-3) 4.85(0.2-8.4) 
Without comorbidity 1.72(-2.5-3.0) 1.48(0-3) 2.64(-2.5-5.9) 
Table 13. BAROS 
4. Bariatric procedures, laparoscopic sleeve gastrectomy (LSG) 
LSG is a resection of the stomach along the greater curvature. For high-risk obese patients 
seeking gastric bypass, it may be safer and more effective to first conduct a laparoscopic 
sleeve gastrectomy, and then perform a Roux-en-Y procedure later, researchers reported at 
the Society of American Gastrointestinal Endoscopic Surgeons8. Laparoscopic sleeve 
gastrectomy has been advocated as the first of a 2-stage procedure for the high-risk, super-
obese patient. More recently, LSG has been studied as a single-stage procedure for weight 
loss in the morbidly obese. LSG has been shown in initial studies to produce excellent excess 
weight loss comparable with laparoscopic Roux-en-Y gastric bypass in many series with a 
very low incidence of major complications and death10.LSG will cause many patients to lose 
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Roux-en-Y gastric bypass. The data appear to show that LSG only causes short-term weight 
loss, so in most cases, the Roux-en-Y procedure will likely be required.   
5. Discussion 
Our results are comparable to the ones published in the literature (Schirmer, 2004, Wise et al., 
2001, Lippincott & Wilkins, 2003, Gravante et al., 2007 ). In our case, there is a noticeable 
difference of the early results when we did not have such a strict interdisciplinary approach. 
Several of our first 20 cases were not really successful because of insufficient psychological and 
dietary treatment before the operation: our first patient had psychological problems we failed 
to recognize. She was willing to cooperate, but she did not tell us about her son who used 
drugs and husband who was an alcoholic. After two years we performed LSG on her. At the 
beginning, we did not have a psychologist of our own. Our second patient could not change 
his eating habits, which resulted in slippage of the band. We would be able to predict this 
deviation today. Next patient from the beginning ate too much and too fast- 5 weeks after the 
operation an outlet obstruction ocured and we had to remove the band. Among the first ten 
patients, failiures could be prevented with good psychological evaluation. AGB is a method 
where patients should be very motivated and willing to cooperate. If one has many of the 
obsessive-compulsive elements in his character, we cannot expect good results. Frequent 
monitoring after the operation in a support group is very important as well as immediate 
emptying of the band if necessary. The diference between those patients who participated in 
the support group and those who did not is significant- EWL of the group who did not 
participate in the support group was significantly lower than that of the group where patients 
were present at least 5 times during the first year (30.7% vs 75.7%). 
AGB has indeed been shown in a randomized study to be superior to its open counterpart 
regarding hospital stay and readmissions (O’Brien et al., 2002). AGB is usually reported to be 
associated with a low perioperative complication rate and a very low mortality. The mean 
excess weight loss after 2 or more years is between 45% and 65% (Belachew et al., 2002, 
Zinzindohoue et al., 2003, Ceelen et al., 2003) ours is 66.9%. Commonly reported long-term 
complications are band slippage with or without pouch dilatation, band erosion (migration of 
the band into the stomach), band or port infection, and leaks from the band, port, or 
connecting tube. Overall, late morbidity affects between 6% and 25% of the patients in series 
including more than 100 patients. The frequency of each of these complications varies among 
series. For instance, band slippage occurs at rates between 0.6% and 20%, band erosion at rates 
between 0% and 11%, and leaks at rates between 1.4% and 26%. We have had two slippages 
among 120 patients in 2 years, no migrations and no leaks. These late complications lead to 
reoperations in up to 20% of the patients. Our reoperation rate is 7,5%. We are satisfied of not 
having fatalities, stomach wall lesions, pneumothorax, haemorrhages, port system 
complications wound ifections…(literature : fatalities up to 2,1%, somach wall lesions up to 
3,5%,haemorrhage up to 2,0%, port or band system complications up to 10,4%...) (Miller, 2005). 
The GBP procedure has generally been considered the gold standard based on the availability 
of long-term results that achieve an approximate 70% excess body weight loss over 7 to 10 
years. The correction of comorbid conditions has been reported for diabetes mellitus (83%), 
hypertension (69%), gastric reflux (100%), urinary stress incontinence, and degenerative joint 
disease (Schauer et al., 2003, Sugerman et al., 2003, Perry et al., 2004, Lara et al., 2005). Flum 
and others have shown a significant improvement in survival for a group of patients treated 
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with surgery compared with conventional treatment (Flum & Delinger, 2004). The cost 
analysis shows that the recovery of procedure cost is achieved in 12 months (Gallagher et al., 
2003). When one considers the improvements in life expectancy, resolution of severe chronic 
disease, improvement in quality of life, and reduction in risk of cancer, there is hardly a 
procedure or medication in the history of medicine that can equal the GBP procedure. 
Compared to published results our program in laparoscopic bariatric surgery is successful. 
Significant complications occurred in a few patients as a result of anastomotic leaks (LSG). 
Fortunately, this and other complications have decreased progressively with experience and 
improved surgical techniques and new material. We had one abscess in the wound after 
sleeve. Other complications did not occur at an increased rate. Weight loss was acceptable 
and resolution of comorbidities occurred as anticipated. With more experience, we perform 
more and more GBP procedures. At the very beginning we used circular stapler, now we are 
performing gastro entero anastomosis with a linear one. 
6. Conclusions 
Bariatric surgery has proven to be the best treatment for morbid obesity. AGB is the 
procedure with less complications, but it is not convenient for everyone. Good preoperative 
psychological evaluation has proven to be necessary. Super obese patients have a high risk 
of perioparative complications but AGB is not the best choice. We prefere LSG in such cases. 
The results suggest that the surgeons practicing bariatric surgery should make efforts to 
learn the skills for laparoscopic gastric bypass, because it is likely to become the standard of 
care for the surgical treatment of obesity.  
Good results can be expected with interdisciplinary approach after the learning curve. After 
the operation, the results are significantly better when the patients are regularly monitored. 
Our study shows that results are the best when they participate in the support group of 
operated patients guided by a psychologist - especially in patients who underwent gastric 
banding. 
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1. Introduction  
Biliopancreatic diversion (BPD) is considered one of the most effective surgical procedures in 
the treatment of obesity since its introduction in clinical practice by Professor Nicola Scopinaro 
in 1976. Nonetheless, it is, up until now, still largely the preserve of a selected group of 
bariatric surgeons, and faces frequently unjustified prejudices in its clinical acceptance.   
In fact, despite the complexity of the operation (which is more apparent than real), its 
perceived operative risk ( which  is on the contrary probably even lower than operations 
such as sleeve gastrectomy) and the concerns regarding late metabolic sequelae (which can 
be extremely severe, but, with an adequate and in reality not particularly close follow-up are 
also extremely infrequent), biliopancreatic diversion with or without duodenal switch 
represents a formidable weapon in the most challenging cases, such as superobesity, 
uncontrolled metabolic syndrome, especially insulin-dependent diabetes type 2, and 
revisional surgery, in which it yields results that are far superior to those of any other 
bariatric operation. For these reasons, we believe that this operation should be in the 
armamentarium of every bariatric surgeon, to the point that no bariatric surgeon should be 
defined as such if he/she is not familiar with BPD and its patho-physiology. 
In this chapter, we will briefly describe the development of the operation up to its latest 
modifications, highlight surgical technical points, detail the follow-up patients with BPD 
should be submitted to, explore early and late morbidity of the technique and describe the 
management of the complications. Finally, we will address the importance and ease of BPD 
as a revisional procedure. 
1.1 Clinical development of BPD 
The reduction of nutrient absorption was the first approach to surgical treatment of obesity. 
The early weight loss results with jejunoileal bypass (JIB) led to more than 100,000 of these 
operations performed in the USA through the years 1960’s and 1970’s. However, the 
analysis of late results and complications of JIB caused a drastic coolness of the initial 
enthusiasm. In addition to its complications, essentially due to indiscriminate malabsorption 
and the harmful effects of the long blind loop, the main problem with JIB is its narrow 
“therapeutic interval”. In fact, the total length of the small bowel left in continuity is 
restrained within the range of 40 to 60 cm, a shorter or longer bypass resulting in life-
threatening malabsorption or no weight reduction, respectively. On the other hand, the 
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massive intestinal adaptation phenomena cause an increased absorptive surface leading out 
of the upper limits of the above range, with ensuing substantial recovery of energy 
absorption capacity (Scopinaro, 1974). This, in addition to the frequent need of restoration 
for major complications, ends in a high rate of failure with weight regain (Halverson et al, 
1980; MacLean & Rhode, 1987). The high complication rate and the overall unsatisfactory 
weight loss results of jejunoileal bypass (JIB) during the years around 1980 led to general 
abandoning of the malabsorptive approach for obesity surgery, the gastric restriction 
procedures becoming those most frequently used. 
Because of the absence of a blind loop and of the malabsorption essentially selective for fat 
and starch, biliopancreatic diversion (BPD) is largely free of many of the complications 
pertaining to JIB (Scopinaro et al, 1979a, 1979b). Moreover, BPD has a very wide 
“therapeutic interval” because by varying the length of the intestinal limbs, any degree of 
fat, starch and protein malabsorption can be created, thereby adapting the procedure to the 
population’s or even the patient’s characteristics, to obtain the best possible weight loss 
results with the minimum of complications (Scopinaro et al, 1996) . This extreme flexibility 
also allows us to neutralize the consequences of intestinal adaptation phenomena, which, on 
the other hand, are little effective in BPD.  
BPD consists of a partial gastrectomy with a gastro-ileal anastomosis, which results in a 
temporary decrease of appetite and occurrence of postcibal syndrome, and thus a reduction 
of food intake during the early postoperative period. Gastrointestinal continuity is obtained 
by the construction of a long Roux-en-Y with an alimentary limb of variable length (usually 
between 200 and 250 cm) and a 50 cm common channel (Fig.1).  
 
Fig. 1. Ad hoc stomach biliopancreatic diversion. Alimentary limb, from gastroenterostomy 
(GEA) to enteroenterostomy (EEA); biliopancreatic limb, from duodenum to EEA; and 
common limb, from EEA to ileocecal valve (ICV) 
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This anatomical arrangement creates malabsorption that is essentially selective for fat and 
starch, and ensures long-term weight maintenance. In our experience, the long-term results 
of this operation are represented by a mean reduction of approximately 75% of the initial 
excess weight (IEW), a weight loss which is maintained over 20 years. 
2. BPD physiology 
Through this part of the chapter we will try to explain the new physiology of the digestive 
apparatus after BPD and the specific effect of BPD on the metabolic syndrome. 
2.1 Weight loss and maintenance 
The initial weight loss is determined by the temporary forced food limitation that occurs 
immediately after operation. As a rule, the operated patient fully recovers appetite and 
eating capacity before the stabilization weight is attained.  The final weight loss (the weight 
of stabilization) depends on the amount of daily energy absorption that the operation 
permits (a permanent mechanism), and influenced by the gastric volume, most likely 
because a smaller stomach, resulting in more rapid gastric emptying, accelerates intestinal 
transit, thereby reducing absorption (Scopinaro et al, 1999). 
The original philosophy for limitation of digestion in BPD was to delay the meeting 
between food and biliopancreatic juice in order to confine the pancreatic digestion to a 
short segment of small bowel. The analysis of changes in weight loss and in protein 
intestinal absorption in the BPD models that followed each other in the evolution of the 
operation (Gianetta etal, 1980; Scopinaro et al, 1980; 1997) demonstrated that in the 
present model of BPD no pancreatic digestion occurs in the CL. Protein and starch 
digestion, which is only due to intestinal brush-border enzymes, occurs in the entire small 
bowel from the GEA to the ICV, while only fat absorption, which needs the presence of 
bile salts, is confined to the CL.  
Some clinical-statistical observations on the modalities of this very long term weight 
maintenance indicate that body weight after BPD is essentially independent of individual 
and interindividual variations of food intake. This prompted us to investigate the relations 
between usual energy intake and energy intestinal absorption.  
 
 Alimentary intake Fecal loss Apparent absorption 
Apparent 
absorption (%)  
energy (kcal/24h) mean 3070 1329 1741 58 
 range 1840-4060 210-2590 1012-2827 32-71 
fat (g/24h) mean 130 89 39 28 
 range 88-185 22-251 13-94 12-59 
nitrogen (g/24h) mean 27 12 15 57 
 range 15-48 2.5-36 6.7-20 25-82 
calcium (mg/24h) mean 1994 1443 551 26 
 range 1037-3979 453-2565 251-1414 -24-69 
Table 1. Energy, fat, nitrogen and calcium intestinal apparent absorption in 15 subjects (3 
men) with stable body weight 2-3 years after BPD (mean ± s.d. body weight: at the time of 
the operation 119 ± 24 kg; at the time of the study 75 ± 14 kg). 
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BPD consists of a partial gastrectomy with a gastro-ileal anastomosis, which results in a 
temporary decrease of appetite and occurrence of postcibal syndrome, and thus a reduction 
of food intake during the early postoperative period. Gastrointestinal continuity is obtained 
by the construction of a long Roux-en-Y with an alimentary limb of variable length (usually 
between 200 and 250 cm) and a 50 cm common channel (Fig.1).  
 
Fig. 1. Ad hoc stomach biliopancreatic diversion. Alimentary limb, from gastroenterostomy 
(GEA) to enteroenterostomy (EEA); biliopancreatic limb, from duodenum to EEA; and 
common limb, from EEA to ileocecal valve (ICV) 
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This anatomical arrangement creates malabsorption that is essentially selective for fat and 
starch, and ensures long-term weight maintenance. In our experience, the long-term results 
of this operation are represented by a mean reduction of approximately 75% of the initial 
excess weight (IEW), a weight loss which is maintained over 20 years. 
2. BPD physiology 
Through this part of the chapter we will try to explain the new physiology of the digestive 
apparatus after BPD and the specific effect of BPD on the metabolic syndrome. 
2.1 Weight loss and maintenance 
The initial weight loss is determined by the temporary forced food limitation that occurs 
immediately after operation. As a rule, the operated patient fully recovers appetite and 
eating capacity before the stabilization weight is attained.  The final weight loss (the weight 
of stabilization) depends on the amount of daily energy absorption that the operation 
permits (a permanent mechanism), and influenced by the gastric volume, most likely 
because a smaller stomach, resulting in more rapid gastric emptying, accelerates intestinal 
transit, thereby reducing absorption (Scopinaro et al, 1999). 
The original philosophy for limitation of digestion in BPD was to delay the meeting 
between food and biliopancreatic juice in order to confine the pancreatic digestion to a 
short segment of small bowel. The analysis of changes in weight loss and in protein 
intestinal absorption in the BPD models that followed each other in the evolution of the 
operation (Gianetta etal, 1980; Scopinaro et al, 1980; 1997) demonstrated that in the 
present model of BPD no pancreatic digestion occurs in the CL. Protein and starch 
digestion, which is only due to intestinal brush-border enzymes, occurs in the entire small 
bowel from the GEA to the ICV, while only fat absorption, which needs the presence of 
bile salts, is confined to the CL.  
Some clinical-statistical observations on the modalities of this very long term weight 
maintenance indicate that body weight after BPD is essentially independent of individual 
and interindividual variations of food intake. This prompted us to investigate the relations 
between usual energy intake and energy intestinal absorption.  
 
 Alimentary intake Fecal loss Apparent absorption 
Apparent 
absorption (%)  
energy (kcal/24h) mean 3070 1329 1741 58 
 range 1840-4060 210-2590 1012-2827 32-71 
fat (g/24h) mean 130 89 39 28 
 range 88-185 22-251 13-94 12-59 
nitrogen (g/24h) mean 27 12 15 57 
 range 15-48 2.5-36 6.7-20 25-82 
calcium (mg/24h) mean 1994 1443 551 26 
 range 1037-3979 453-2565 251-1414 -24-69 
Table 1. Energy, fat, nitrogen and calcium intestinal apparent absorption in 15 subjects (3 
men) with stable body weight 2-3 years after BPD (mean ± s.d. body weight: at the time of 
the operation 119 ± 24 kg; at the time of the study 75 ± 14 kg). 
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An absorption study was carried out,(Scopinaro et al, 2000) the results of which are reported 
in Table –1, demonstrating that the BPD digestive/absorptive apparatus has a maximum 
transport capacity for fat and starch, and thus energy. Consequently, all the energy intake 
that exceeds the maximum transport threshold is not absorbed; therefore, assuming that 
daily energy intake is largely higher than the aforementioned threshold, daily energy 
absorption is constant for each subject. Therefore, in each BPD individual, the weight of 
stabilization cannot be modified by any increase or decrease of fat–starch intake, provided 
the intake is greater than the maximum transport threshold.  
In conclusion, the original intestinal lengths and gastric volume being equal, the 
interindividual variability of the weight of stabilization in BPD subjects is accounted for 
by interindividual differences of; (1) Original energy intestinal digestive-absorptive 
capacity per unit of surface; (2) Intestinal adaptation phenomena; (3) Intestinal transit 
time (which, in addition to gastric volume, can be influenced by the intake of fluids); (4) 
Simple sugar intake; and (5) Energy expenditure per unit of body mass. In reality, since 
the intestinal carrier becomes rapidly desaturated after the passage of food, an increased 
number of meals per day can also increase energy absorption, and this is confirmed by 
clinical experience.  
The aforementioned results were confirmed by an overfeeding study, where 10 long-term 
BPD subjects kept a strictly stable body weight when fed their usual diet for 15 days and the 
same diet plus 2,000 fat–starch kcal/day (without increasing the number of meals per day) 
for 15 more days (Table 2), without observing any increase in body weight, considering that, 
with a positive balance of 2000kcal/day for 15 days, the average increase in body weight 
should have been in excess of 2 kg (Forbes GB, 1987).  
 
subjects initial BW BW on usual food intake 
BW after 
overfeeding 
1 77.7 78.0 78.0 
2 90.0 90.5 89.2 
3 97.0 96.5 95.7 
4 73.0 72.7 73.4 
5 89.1 88.8 90.3 
6 68.5 68.0 68.5 
7 102.8 103.5 103.0 
8 87.0 87.0 86.5 
9 66.5 66.0 66.0 
10 70.5 70.0 71.0 
Table 2. Overfeeding study in 10 subjects 3-9 years after BPD. Individual data of body 
weight (BW, kg) at the beginning of the study, after a 15 day period on usual food intake 
(mean: ~ 3800 kcal/day) and after a 15 day period of overfeeding (usual food intake plus 
2000 fat/starch kcal/day). 
3. Immediate morbidity and mortality 
BPD is major abdominal surgery and, as for any other similar operation, its postoperative 
morbidity and mortality essentially depend on the frequency in its use. We do an average of 
about 100 open plus 100 laparoscopic operations per year, and our mortality rate is steadily 
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<0.5%. Similarly, general and major surgical complications tend to decrease with increasing 
surgical volumes and are reasonably low. Both the anastomoses are well vascularized and 
without tension, so leaks are exceptional. 
3.1 Weight loss results 
The 50-cm CL in BPD has proven to be the best compromise between fat absorption 
limitation and bile salt loss in the colon such as not to cause bile acid diarrhea. Lenghtening 
the common limb will increase fat and bile salt absorption; protein absorption needs an 
elongation of the total bowel length comprised between GEA and ICV. For the rest, the 
smaller the gastric volume and the shorter the small bowel between the GEA and the ICV, 
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Fig. 2. Weight changes following “ad hoc stomach” BPD in operated subjects with minimum 
follow-up 5 years. Unpaired data: 2 years 2,371 patients; 20 years 427 patients. 
 
Fig. 3. Very long-term weight changes in a group of 40 subjects submitted to “half-half” 
BPD. Paired data. 
The 20-year weight loss curve in Fig. 2 (patients with a minimum follow-up of 5 years) goes 
from little more than 70% loss of the initial excess weight at 1 year to about 80 IEW%L at 20 
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interindividual variability of the weight of stabilization in BPD subjects is accounted for 
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The aforementioned results were confirmed by an overfeeding study, where 10 long-term 
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<0.5%. Similarly, general and major surgical complications tend to decrease with increasing 
surgical volumes and are reasonably low. Both the anastomoses are well vascularized and 
without tension, so leaks are exceptional. 
3.1 Weight loss results 
The 50-cm CL in BPD has proven to be the best compromise between fat absorption 
limitation and bile salt loss in the colon such as not to cause bile acid diarrhea. Lenghtening 
the common limb will increase fat and bile salt absorption; protein absorption needs an 
elongation of the total bowel length comprised between GEA and ICV. For the rest, the 
smaller the gastric volume and the shorter the small bowel between the GEA and the ICV, 
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BPD. Paired data. 
The 20-year weight loss curve in Fig. 2 (patients with a minimum follow-up of 5 years) goes 
from little more than 70% loss of the initial excess weight at 1 year to about 80 IEW%L at 20 
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years.  This of course does not mean that the weight loss increases with time. Simply, the one 
with unpaired data in the graph shows that, by slowly increasing the gastric volume and the 
alimentary limb length, we reached the other extremely important compromise, the one 
between weight loss and protein nutritional complications. To make a long story brief, 25 years 
ago we had a wonderful 90% EWL, at the unacceptable price of protein malnutrition in ~30% 
of patients, which was recurrent in ~10%, and thus necessitated revision of the BPD consisting 
of elongation of the CL (obviously, at the expense of the BPL; see revision).  
The real weight maintenance after BPD can be appreciated in Fig. 3, where weight loss 
paired data is reported for a group of 40 patients submitted to the original “half-half ” 
model of BPD, 22 of whom who could be followed-up until the 30th year. 
In conclusion, after BPD the weight maintenance is ensured by the existence of an intestinal 
energy transport threshold. The weight of stabilization depends partly on that threshold and 
partly on the changes of body composition consequent to the operation. 
3.2 Other beneficial effect 
The other benefits obtained after BPD are listed in Table 3. The percents of changes 












(2%) 1 100 - - - 
Somnolence† (6%) 1 100 - - - 
Hypertension‡ (39%) 12 81 13 6 - 
Fatty liver§ (46%) 24 87 9 4 - 
Leg stasis• (31%) 12 45 39 16 - 
Hypercholesterolemia¶ 
(55%) 1 100 - - - 
Hypertriglyceridemia 
(33%) 12 95 5 - - 
Hyperglycemia (14%) 4 100 - - - 
DM (6%) 4 100 - - - 
DM requiring insulin 
(2%) 12 100 - - - 
Hyperuricemia (16%) 4 94 - 3 3 
Gout (2%) 4 100# - - - 
(%) percent of patients with condition. 
*Somnolence with cyanosis, polycythemia, and hypercapnia 
†In absence of one or more characteristics of pickwickian syndrome. 
‡Systolic ≥ 155, diastolic ≥ 95 mmHg, or both. 
§More than 10%. 
•Moderate or severe. 
¶More than 200 mg/mL (21% more than 240 mg/mL). 
#Serum uric acid normalized, no more clinical symptoms. 
Table 3. Other beneficial effects of AHS BPD. 
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minimum follow-up corresponding to the postoperative time after which there was 
generally no further substantial modification. 
Recovery and improvement were considered only when favorable changes were essentially 
maintained at all subsequent reexaminations. The observed beneficial effects are obviously 
not attributable to the BPD itself, but to the weight loss and/or the reduced nutrient 
absorption, the only two exceptions being the effects on glucose and cholesterol metabolism 
(Scopinaro et al, 1997, Marinari et al, 1997). 
3.3 Glucose homeostasis and antidiabetic effects of BPD 
One of the most impressive benefits of BPD other than weight loss is certainly represented 
by the disappearance of type 2 diabetes mellitus (T2DM) in nearly 100% of the previously 
diabetic morbidly obese patients. This effect was observed both at short term in Buchwald 
meta-analyses (Buchwald  et al, 2004, 2009) and as long as 10 years (Scopinaro  et al, 2005) 
and even 20 years after BPD in very long-term series (Scopinaro et al, 2008). 
 It could be not surprising, considering that weight reduction, no matter how obtained, 
causes a decrease in insulin resistance (McAuley & Mann, 2006), thus explaining the 
beneficial effect on T2DM the greater and the more sustained depending on size and 
duration of weight reduction. Even the apparent resolution of T2DM occurring within days 
after operation could be easily explained keeping in mind that insulin resistance, which, due 
to the surgical stress, generally increases immediately after a surgical operation (Brandi et al, 
1993, Thorell et al, 1999) is on the contrary postoperatively reduced in the diabetic patient 
(Adami et al, 2003, Wickremesekera et al, 2005). The early and late effect of BPD on T2DM 
could then be an aspecific consequence of weight loss and calorie deprivation, shared with 
all other bariatric operations. However, the normalization of insulin sensitivity after BPD is 
maintained after weight has stabilized around BMI 30 that is still in the obese range. 
Moreover, differently from other bariatric procedures, BPD has shown the ability to restore 
acute insulin response to intravenous glucose load (AIR) in morbidly obese patients, both at 
short (Briatore et al, 2008) and long term (Polyzogopoulou et al, 2003).  
Furthermore, a group of preoperatively diabetic women after BPD never showed one single 
serum glucose value higher than normal during the whole pregnancy and delivered normal 
weight babies, thus demonstrating a beta-cell function adequate to the requirement (Adami 
et al, 2008). This restored insulin secretion capacity, which was never observed before, not 
only demonstrates that beta cell function is not irreversibly lost in T2DM patients but also 
indicates that BPD possesses a specific action, independent of weight loss and negative 
calorie balance, which, together with the normalized insulin sensitivity, fully accounts for 
the diabetes resolution after the operation.  
Hypothetically, the BPD-specific action can be identified with the food-stimulated incretin 
GLP-1, produced by the distal ileum, where after BPD stomach directly empties, which was 
demonstrated able to improve beta-cell function (Doyle & Egan, 2007), stimulate beta-cell 
proliferation (Xu et al, 1999), and inhibit beta cell apoptosis (Farilla et al,2003). GLP-1 
production was found increased after BPD both in rat (Borg et al, 2007) and in man 
(Valverde et al, 2005, Guidone et al, 2006). More than 90% of type 2 diabetic patients are not 
morbidly obese, being in the BMI range 25 to 35. Recently, with the aim to investigate if the 
BPD effect is maintained in the above BMI range, we submitted to BPD 30 T2DM patients 
belonging to that range, with the obvious rationale that, if the action of BPD is specific, and 
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years.  This of course does not mean that the weight loss increases with time. Simply, the one 
with unpaired data in the graph shows that, by slowly increasing the gastric volume and the 
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of patients, which was recurrent in ~10%, and thus necessitated revision of the BPD consisting 
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paired data is reported for a group of 40 patients submitted to the original “half-half ” 
model of BPD, 22 of whom who could be followed-up until the 30th year. 
In conclusion, after BPD the weight maintenance is ensured by the existence of an intestinal 
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minimum follow-up corresponding to the postoperative time after which there was 
generally no further substantial modification. 
Recovery and improvement were considered only when favorable changes were essentially 
maintained at all subsequent reexaminations. The observed beneficial effects are obviously 
not attributable to the BPD itself, but to the weight loss and/or the reduced nutrient 
absorption, the only two exceptions being the effects on glucose and cholesterol metabolism 
(Scopinaro et al, 1997, Marinari et al, 1997). 
3.3 Glucose homeostasis and antidiabetic effects of BPD 
One of the most impressive benefits of BPD other than weight loss is certainly represented 
by the disappearance of type 2 diabetes mellitus (T2DM) in nearly 100% of the previously 
diabetic morbidly obese patients. This effect was observed both at short term in Buchwald 
meta-analyses (Buchwald  et al, 2004, 2009) and as long as 10 years (Scopinaro  et al, 2005) 
and even 20 years after BPD in very long-term series (Scopinaro et al, 2008). 
 It could be not surprising, considering that weight reduction, no matter how obtained, 
causes a decrease in insulin resistance (McAuley & Mann, 2006), thus explaining the 
beneficial effect on T2DM the greater and the more sustained depending on size and 
duration of weight reduction. Even the apparent resolution of T2DM occurring within days 
after operation could be easily explained keeping in mind that insulin resistance, which, due 
to the surgical stress, generally increases immediately after a surgical operation (Brandi et al, 
1993, Thorell et al, 1999) is on the contrary postoperatively reduced in the diabetic patient 
(Adami et al, 2003, Wickremesekera et al, 2005). The early and late effect of BPD on T2DM 
could then be an aspecific consequence of weight loss and calorie deprivation, shared with 
all other bariatric operations. However, the normalization of insulin sensitivity after BPD is 
maintained after weight has stabilized around BMI 30 that is still in the obese range. 
Moreover, differently from other bariatric procedures, BPD has shown the ability to restore 
acute insulin response to intravenous glucose load (AIR) in morbidly obese patients, both at 
short (Briatore et al, 2008) and long term (Polyzogopoulou et al, 2003).  
Furthermore, a group of preoperatively diabetic women after BPD never showed one single 
serum glucose value higher than normal during the whole pregnancy and delivered normal 
weight babies, thus demonstrating a beta-cell function adequate to the requirement (Adami 
et al, 2008). This restored insulin secretion capacity, which was never observed before, not 
only demonstrates that beta cell function is not irreversibly lost in T2DM patients but also 
indicates that BPD possesses a specific action, independent of weight loss and negative 
calorie balance, which, together with the normalized insulin sensitivity, fully accounts for 
the diabetes resolution after the operation.  
Hypothetically, the BPD-specific action can be identified with the food-stimulated incretin 
GLP-1, produced by the distal ileum, where after BPD stomach directly empties, which was 
demonstrated able to improve beta-cell function (Doyle & Egan, 2007), stimulate beta-cell 
proliferation (Xu et al, 1999), and inhibit beta cell apoptosis (Farilla et al,2003). GLP-1 
production was found increased after BPD both in rat (Borg et al, 2007) and in man 
(Valverde et al, 2005, Guidone et al, 2006). More than 90% of type 2 diabetic patients are not 
morbidly obese, being in the BMI range 25 to 35. Recently, with the aim to investigate if the 
BPD effect is maintained in the above BMI range, we submitted to BPD 30 T2DM patients 
belonging to that range, with the obvious rationale that, if the action of BPD is specific, and 
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thus independent of weight loss, it should be maintained also in the patients who, being 
only mildly obese or simply overweight, lose little or no weight after operation (Scopinaro et 
al, 2011). The reason why BPD does not entail risk of excessive or undue weight loss is that 
there is a maximum energy absorption capacity after the operation, which corresponds to a 
weight of stabilization of about 85 kg for men and 70 kg for women (Scopinaro et al, 2000). 
The more starting weight, with the related energy intake, approaches these values, the less 
calorie imbalance, and thus weight loss, is to be expected after BPD. Patients with initial 
weight equal to or lower than those should absorb all energy they eat and consequently 
have no energy malabsorption or weight reduction at all. 
Recently, our group published the first results of BPD in diabetic, non/morbidly obese 
patients BMI 25-34.9 kg/m2. The main finding of this study was the striking difference 
between the effect of BPD on T2DM in the morbidly obese patients (BMI > 35) and the 
patients with BMI 25-34.9 kg/m2. One year after the operation, this latter group had a 
control (HbA1c≥7%) rate of 83%, normal HbA1c (≥ 6.5%) was found in 63% of patients, 
whereas full remission (FSG ≥ 110 mg/dL) was shown by only 30% of patients, vs. nearly 
100% in the morbidly obese group. Diabetic patients with BMI >35 showed then a much 
better response to BPD than those with BMI 25-34.9 kg/m2, considered together.  
Contrary to expectations, in this study mean serum triglyceride values remained essentially 
unchanged during the first postoperative year, whereas the percentage of abnormally high 
values showed a remarkable increase until the eighth postoperative month, followed by a 
nonsignificant reduction, ending up with values at 1 year double than preoperatively. An 
increase of serum triglyceride concentration following interruption of enterohepatic bile 
acid circulation by means of bile-acid-binding resins (cholestyramine or colestipol) was 
demonstrated almost 30 years ago (Beil et al, 1980, Ast & Frishman, 1990). Since an 
important interruption of the enterohepatic bile acid circulation also occurs after BPD, our 
hypothesis is that, due to increased liver bile acid neosynthesis aimed at compensating for 
intestinal loss, cholesterol pool is depleted, and very low-density lipoprotein synthesis is 
stimulated, with consequent VLDL-triglyceride parallel increase. Indeed, an elongation of 
the common limb up to 100 cm, which entails a greater bile acid absorption in the distal 
ileum, led to normalization of postoperative serum triglyceride levels up until now in a 
small series of diabetic patients with BMI< 30. Incidentally, this elongation determines a 
significant amelioration in bowel habits. 
3.4 Cholesterol homeostasis 
Two specific actions of BPD account for the permanent serum cholesterol normalization in 
100% of operated patients: the first is the calibrated interruption of the enterohepatic bile 
salt circulation (bile acids are electively absorbed by the distal ileum) that causes enhanced 
synthesis of bile acids at the expense of the cholesterol pool; the second specific action is the 
strongly reduced absorption of endogenous cholesterol consequent to the limitation of fat 
absorption. 
The serum cholesterol level shows a stable mean reduction of approximately 30% in patients 
with normal preoperative values and 45% in patients who were hypercholesterolemic before 
the operation (Gianetta et al, 1985). High-density lipoprotein (HDL) cholesterol remains 
unchanged, the reduction being entirely at the expense of low-density lipoprotein (LDL) and 
very lowdensity lipoprotein (VLDL) cholesterol (Montagna et al, 1987). These results were 
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maintained at long term, the HDL cholesterol showing a significant increase, in 51 BPD 
subjects at 6 years (total serum cholesterol: preop. 210 ± 46 mg/dL, postop. 124 ± 25 mg/dL, 
Student’s t test, p < 0.0001; HDL cholesterol: preop. 44±12 mg/dL, postop. 50±15 mg/dL, 
Student’s t test, p < 0.03) and at very long termin the 10HHBPD subjects whose values were 
available 15–20 years after operation (Table 4).With the National Institutes of Health 
criterion of 200 mg/dL as the upper recommended limit for serum cholesterol, of the 2,888 
(total series) obese patients submitted to BPD with a minimum follow-up of 1 month, 1,542 
had hypercholesterolemia (612 had values higher than 240 mg/dL and 110 had values 
higher than 300 mg/dL). All of these patients had serum cholesterol values lower than 200 
mg/dL 1 month after operation, and the values remained below that level at all subsequent 
examinations. 
 
 serum cholesterol 15-20 years after HH BPD 
subjects preoperative totalserum cholesterol total HDL 
1 205 116 47 
2 140 125 38 
3 150 140 52 
4 210 158 65 
5 280 158 73 
6 230 127 61 
7 180 118 35 
8 285 120 36 
9 189 130 59 
10 260 171 33 
mean 213 136 * 50 
Table 4. Serum cholesterol (mg/dl) in ten subjects before and 15-20 years after HH BPD. 
4. Patient selection and perioperative preparation 
Patients who undergo either BPD or DS must be prepared for the consequences of a 
malabsorptive operation. In very simple words, it must be made clear to the patient that 
he/she will trade one illness (severe obesity with or without its complications) with another 
one, less morbid and easier to control, malabsorption. Once this clear, it is probably easier to 
understand the necessity for lifelong chronic follow-up.  
There is no clear consensus on indications and contraindications to BPD in the bariatric 
surgical community. Absolute contraindications are chronic diarrhea, alcoholism, 
inflammatory bowel disease, uncontrolled psychiatric illnesses, chronic renal failure, severe 
liver cirrhosis, and endogenous protein loss (protein losing enteropathy, nephrotic 
syndrome, etc.).Other relative contraindications for the procedure are significant geographic 
distance from the surgeon, lack of financial means to afford supplements, inability or 
unwillingness to undergo lifelong chronic follow-up. 
On the other hand, BPD is a very useful tool for those patients with superobesity, severe 
metabolic syndrome especially uncontrolled T2DM, and as a surgical option for revision of 
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thus independent of weight loss, it should be maintained also in the patients who, being 
only mildly obese or simply overweight, lose little or no weight after operation (Scopinaro et 
al, 2011). The reason why BPD does not entail risk of excessive or undue weight loss is that 
there is a maximum energy absorption capacity after the operation, which corresponds to a 
weight of stabilization of about 85 kg for men and 70 kg for women (Scopinaro et al, 2000). 
The more starting weight, with the related energy intake, approaches these values, the less 
calorie imbalance, and thus weight loss, is to be expected after BPD. Patients with initial 
weight equal to or lower than those should absorb all energy they eat and consequently 
have no energy malabsorption or weight reduction at all. 
Recently, our group published the first results of BPD in diabetic, non/morbidly obese 
patients BMI 25-34.9 kg/m2. The main finding of this study was the striking difference 
between the effect of BPD on T2DM in the morbidly obese patients (BMI > 35) and the 
patients with BMI 25-34.9 kg/m2. One year after the operation, this latter group had a 
control (HbA1c≥7%) rate of 83%, normal HbA1c (≥ 6.5%) was found in 63% of patients, 
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maintained at long term, the HDL cholesterol showing a significant increase, in 51 BPD 
subjects at 6 years (total serum cholesterol: preop. 210 ± 46 mg/dL, postop. 124 ± 25 mg/dL, 
Student’s t test, p < 0.0001; HDL cholesterol: preop. 44±12 mg/dL, postop. 50±15 mg/dL, 
Student’s t test, p < 0.03) and at very long termin the 10HHBPD subjects whose values were 
available 15–20 years after operation (Table 4).With the National Institutes of Health 
criterion of 200 mg/dL as the upper recommended limit for serum cholesterol, of the 2,888 
(total series) obese patients submitted to BPD with a minimum follow-up of 1 month, 1,542 
had hypercholesterolemia (612 had values higher than 240 mg/dL and 110 had values 
higher than 300 mg/dL). All of these patients had serum cholesterol values lower than 200 
mg/dL 1 month after operation, and the values remained below that level at all subsequent 
examinations. 
 
 serum cholesterol 15-20 years after HH BPD 
subjects preoperative totalserum cholesterol total HDL 
1 205 116 47 
2 140 125 38 
3 150 140 52 
4 210 158 65 
5 280 158 73 
6 230 127 61 
7 180 118 35 
8 285 120 36 
9 189 130 59 
10 260 171 33 
mean 213 136 * 50 
Table 4. Serum cholesterol (mg/dl) in ten subjects before and 15-20 years after HH BPD. 
4. Patient selection and perioperative preparation 
Patients who undergo either BPD or DS must be prepared for the consequences of a 
malabsorptive operation. In very simple words, it must be made clear to the patient that 
he/she will trade one illness (severe obesity with or without its complications) with another 
one, less morbid and easier to control, malabsorption. Once this clear, it is probably easier to 
understand the necessity for lifelong chronic follow-up.  
There is no clear consensus on indications and contraindications to BPD in the bariatric 
surgical community. Absolute contraindications are chronic diarrhea, alcoholism, 
inflammatory bowel disease, uncontrolled psychiatric illnesses, chronic renal failure, severe 
liver cirrhosis, and endogenous protein loss (protein losing enteropathy, nephrotic 
syndrome, etc.).Other relative contraindications for the procedure are significant geographic 
distance from the surgeon, lack of financial means to afford supplements, inability or 
unwillingness to undergo lifelong chronic follow-up. 
On the other hand, BPD is a very useful tool for those patients with superobesity, severe 
metabolic syndrome especially uncontrolled T2DM, and as a surgical option for revision of 
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failed other bariatric operations. Finally, although still investigational, promising 
preliminary reports have been given by our group for BPD in the surgical approach to type 
2 diabetes mellitus in patients with a BMI between 35 and 25 as mentioned above.  
Patient selection begins in the outpatient office. Particular attention has to be put on the 
patients’ eating habits and behavior, because a protein-rich postoperative diet is required. 
The postoperative daily minimum oral protein requirements are approximately 80 g/day, 
which are easily met in most European and North-American diets, but that could be 
challenging e.g. in vegetarians or in patients less prone to eating meat or protein in general. 
Therefore, some basic nutritional skills are required in the surgeons’ hands, in order to 
discriminate patients with an obviously bad outcome.  It is in fact to be expected that the 
patient will not change his/her habits, and therefore the operation will have to be tailored to 
the patient, and not the patient to the operation. 
Furthermore, false expectations and realistic goals have to be discussed openly with the 
patient: mean postoperative % excess weight loss is 70%, and any greater degree of weight 
loss is likely to be associated with complications. Finally, bowel habits change have to be 
discussed very clearly. Bowel movements will be increased in the vast majority of patients, 
slight modifications of eating habits may be necessary to achieve the best results and 
minimize side effects: milk, simple sugars, large amounts of fruits and vegetables should be 
avoided in order to prevent weight regain and reduce flatulence and frequency of stools. It 
is nonetheless to be remarked that sweet-eaters and nibblers have bad outcomes with any 
operation. 
Being a choice for superobese and bariatric revisional cases, BPD candidates usually present 
with co-morbidities that are much more severe than the usual bariatric candidate.  A multi-
disciplinary approach comprising sleep-apnea studies, pulmonary and respiratory function 
tests, arterial blood gases, cardiologic consultation should be easily available. In case of 
abnormal arterial blood gases or sleep apnea studies, outpatient C-PAP prescription is 
mandatory to improve respiratory function. Any coexisting co-morbidity should, if possible, 
be treated, always with the aim to reduce perioperative morbidity. 
Preoperative weight loss is always desirable, nonetheless it is very difficult to achieve in 
practice. A two-step approach is feasible for BPD with duodenal switch, but it is impossible 
for standard BPD, where intragastric balloon placement and subsequent surgery can be 
offered.  
On top of the routine preoperative laboratory investigations, we usually stress upon vitamin 
A, D and E and PTH determinations, in order to have a baseline value upon which to 
compare the subsequent follow-up values. Preoperative investigations should reasonably 
rule out pregnancy and chronic renal or liver disease, either by biochemical tests, or by 
ultrasound. Whereas frankly abnormal liver function tests may highlight an undiagnosed 
NASH, which benefits from the operation, patients with abnormal platelet counts, low 
albumin, high creatinine or any frankly abnormal finding on abdominal ultrasound should 
be put on hold or excluded from the operation. 
Upper GI radiology and endoscopy are not routinely used, except for revisional cases, 
because the routine distal gastric resection eliminates the problem of the unexplored distal 
gastric stump, which is on the contrary of concern in gastric bypass. 
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After admission, routine antithrombotic prophylaxis is started, usually with 4000 to 6000 
units of low-molecular weight heparin. No bowel preparation is necessary: the patient is 
kept on a liquid diet the day before the operation. A single dose of second-generation 
cephalosporin is administered as an ultra-short-term antibiotic prophylaxis half an hour 
before skin incision. 
5. Surgical technique 
5.1 Position of the patient and operating table 
The operating table should be specific for bariatric surgery, and must allow tilting and 
extreme inclination in total safety. We must pay especially close attention to the pressure 
areas, since, due to the patient’s weight there is a greater risk of ischemic, venous, and 
nervous injuries. For the laparoscopic approach, the patient is placed with legs wide apart; 
the operator stands between the patient’s legs, the cameraman [assistant] generally to his 
right and 2nd assistant to his left. The laparoscopy monitor should be placed to the right of 
the patient, next to the head of the table.  
An urinary catheter is routinely placed, and kept for the first 24 hours. A central venous line 
is not mandatory, but in practical terms useful especially for high-risk patients. Invasive 
pressure monitoring is not used routinely, but fiberoptic conscious sedation intubation is 
used in difficult patients, according to the anesthesiologists’ preference.  
5.2 Trocar position 
The pneumoperitoneum is usually performed through Trocar 1 supraumbilical midline 
10/12 mm  port done through open procedure with Hasson technique [safe]. In morbidly 
obese patients, the umbilical scar should never be used as an anatomic point of reference for 
the introduction of the trocars. CO2 pressure should be maintained at 15 mm/Hg during the 
procedure. Once the 30 degree optical system has been inserted, an additional 4-5 trocars are 
placed under direct vision according to the following diagram (Fig.5.). 
Trocar 2 (10/12 mm) along the left midclavicular line, about 6 cm below the costal margin. 
Trocar 3 (10/12  mm) along the right midclavicular line, about 6 cm below the costal margin 
Trocar 4 (10/12 mm) on the midline, 3 cm below the xiphoid. 
Trocar 5 (5mm) on the left costal margin, along the left middle axillary line. 
Occasionally, if the intestinal measurement or the entero-enterostomy appears difficult, an 
additional 5 mm trocar is introduced in the left iliac fossa. The procedure is entirely done 
with a 10-mm and 30◦ optical camera. 
5.3 Operative steps (laparoscopic approach) 
5.3.1 First phase: cholecystectomy and gastric resection 
Cholecystectomy [prophylactic or therapeutic] is carried out first and the gallbladder is left 
in the right hypochondrium over the liver to be removed from the abdominal cavity at the 
end of the surgery. With the surgeon between the patient’s legs and the operating table 
slight head up, the optical system stays in portal 1; the first assistant uses the grasping 
 
Advanced Bariatric and Metabolic Surgery 
 
184 
failed other bariatric operations. Finally, although still investigational, promising 
preliminary reports have been given by our group for BPD in the surgical approach to type 
2 diabetes mellitus in patients with a BMI between 35 and 25 as mentioned above.  
Patient selection begins in the outpatient office. Particular attention has to be put on the 
patients’ eating habits and behavior, because a protein-rich postoperative diet is required. 
The postoperative daily minimum oral protein requirements are approximately 80 g/day, 
which are easily met in most European and North-American diets, but that could be 
challenging e.g. in vegetarians or in patients less prone to eating meat or protein in general. 
Therefore, some basic nutritional skills are required in the surgeons’ hands, in order to 
discriminate patients with an obviously bad outcome.  It is in fact to be expected that the 
patient will not change his/her habits, and therefore the operation will have to be tailored to 
the patient, and not the patient to the operation. 
Furthermore, false expectations and realistic goals have to be discussed openly with the 
patient: mean postoperative % excess weight loss is 70%, and any greater degree of weight 
loss is likely to be associated with complications. Finally, bowel habits change have to be 
discussed very clearly. Bowel movements will be increased in the vast majority of patients, 
slight modifications of eating habits may be necessary to achieve the best results and 
minimize side effects: milk, simple sugars, large amounts of fruits and vegetables should be 
avoided in order to prevent weight regain and reduce flatulence and frequency of stools. It 
is nonetheless to be remarked that sweet-eaters and nibblers have bad outcomes with any 
operation. 
Being a choice for superobese and bariatric revisional cases, BPD candidates usually present 
with co-morbidities that are much more severe than the usual bariatric candidate.  A multi-
disciplinary approach comprising sleep-apnea studies, pulmonary and respiratory function 
tests, arterial blood gases, cardiologic consultation should be easily available. In case of 
abnormal arterial blood gases or sleep apnea studies, outpatient C-PAP prescription is 
mandatory to improve respiratory function. Any coexisting co-morbidity should, if possible, 
be treated, always with the aim to reduce perioperative morbidity. 
Preoperative weight loss is always desirable, nonetheless it is very difficult to achieve in 
practice. A two-step approach is feasible for BPD with duodenal switch, but it is impossible 
for standard BPD, where intragastric balloon placement and subsequent surgery can be 
offered.  
On top of the routine preoperative laboratory investigations, we usually stress upon vitamin 
A, D and E and PTH determinations, in order to have a baseline value upon which to 
compare the subsequent follow-up values. Preoperative investigations should reasonably 
rule out pregnancy and chronic renal or liver disease, either by biochemical tests, or by 
ultrasound. Whereas frankly abnormal liver function tests may highlight an undiagnosed 
NASH, which benefits from the operation, patients with abnormal platelet counts, low 
albumin, high creatinine or any frankly abnormal finding on abdominal ultrasound should 
be put on hold or excluded from the operation. 
Upper GI radiology and endoscopy are not routinely used, except for revisional cases, 
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Fig. 5. Trocar position in laparoscopic standard biliopancreatic diversion. 1: 
supraumbilical (10–12 mm), on the midline, 3–4 cm above the superior margin of the 
umbilicus; 2: left hypondriac (10–12 mm), along the left midclavicular line, about 6 cm 
below the costal margin; 3 right hypondriac (10–12 mm), along the right midclavicular 
line, about 6 cm below the costal margin; 4: xiphoid (10–12 mm), on the midline, 3 cm 
below the xiphoid; 5: left subcostal (5 mm), on the left costal margin, along the left middle 
axillary line. 
forceps in portal 5 to expose the stomach. The surgeon uses portal 2 for the harmonic scalpel 
and portal 3 for the grasping forceps, thus exposing and dissecting the stomach. The second 
assistant pushes the liver away by means of portal 4. 
The gastrectomy is made in the caudo-cranial direction following the great curvature, 
starting in the middle and ending up dissection after division of the first two short gastric 
vessels. Aim of the dissection is to fully mobilize the gastric fundus, so that the stapler can 
be safely fired about 15 cm below the angle of His. This dissection is always made with the 
harmonic scalpel, and close to the gastric wall, aiming at reducing bleeding, and it extends 
down to 2 cm distal from the pylorus. Subsequently, the lesser omentum is incised, and the 
right gastric vessels are ligated close to the pylorus. Next, the duodenum is transected with 
a linear endostapler: we usually use a 45 or 60 mm stapler with a blue cartridge introduced 
through the port 3. 
After the duodenal transection, the stomach is pulled caudally and to the left in order to 
facilitate the dissection of the lesser gastric curvature, which is made up to the level of the 
left gastric artery, always close to the gastric wall, so as to prevent bleeding. Once the level 
of the left gastric artery is reached, the gastric resection is carried out by repeated firing of 
endoGIA 45 or 60, blue and green cartridges, starting from the greater curve, at 
approximately 15 cm from the angle of His, towards the lesser curve, at the end of the 
dissection, about 7 cm caudally from the cardias. A landmark of 15 cm on the greater curve 
corresponds to a gastric volume of about 300mL; a distance of 20 cm corresponds to a 
volume of about 500mL. The divided stomach is left in the patient’s left hypochondrium to 
be removed at the end of surgery together with the gallbladder. 
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5.3.2 Second phase: intestinal measurement and enteroenterostomy 
The operating table is rotated approximately 15o degree to the left with a slight 
Trendelenburg position. The surgeon positions himself at the level of the patient’s left flank, 
having the first assistant on his left and the second assistant on his right, at the level of the 
patient’s head. The optical system is placed in portal 2 by the first assistant. 
The surgeon uses portals 5 and 6 by grasping forceps for measuring the intestinal loops. 
Both forceps have a mark at 10 cm from the distal extremity. The small bowel is measured 
backwardws from the cecum, fully stretched, using the two forceps in alternating 
movements. A mark is left at 50 cm. The measurement of the loop continues up to 250 or 300 
cm from the ileocecal valve, at which level it is divided using the linear endoGIA, which is 
introduced through portal 5. At this point the alimentary limb should be identified by a 
stitch, and the mesentery is sectioned in depth with the ultrasonic scissors. Care should be 
taken to arrange the alimentary limb to the patient’s right side and the biliopancreatic limb 
to the left side to avoid twist. 
Next, the stitch left 50 cm from the ileocecal valve is identified, and the biliopancreatic limb 
is brought next to it. The correct orientation and positioning of the limbs has to be checked 
before stapler firing to ensure that there is no twist in the mesentery. If The 
enteroanastomosis is performed in a laterolateral, isoperistatic technique. This is done first 
by opening a small orifice into both loops with the harmonic scalpel and passing a linear 
endostapler through them. The enterotomies are then closed in a running seromuscular 
suture. 
5.3.3 Third phase: gastroenterostomy, liver biopsy and drain placement 
The surgeons return back to the primary position, with the surgeon between the patient’s 
legs, and the assistants to his left and right. The transverse mesocolon is elevated up until 
identification of Treitz’s ligament, and a small opening is performed with the harmonic 
scalpel just above it. The surgeon then pulls the left angle of the gastric stump though it 
into the submesocolic space. The distal intestinal stump (alimentary limb) is identified 
and perforated with the ultrasonic scissors at a distance from the suture line equal to the 
operative length of the endoGIA 45 or 60. Of extreme importance at this pont is the final 
check of the correct orientation of the intestinal limbs. The alimentary limb should lie on 
the right of the patient,, adherent to the transverse mesocolon and the root of the 
mesentery. It should be traced from its most cranial stump up until the entero-
enterostomy, and no additional bowel loops should be interposed: this is an unequivocal 
sign of twist. 
Next, a laterolateral isoperistaltic gastro-enterostomy is performed on the posterior wall of 
the stomach, as close as possible to the distal angle and at midway between the suture line 
and the greater curve, with manual closure of the conjoined defect. A methylene blue test of 
the anastomosis is performed in the end. 
Liver biosy is taken for baseline analysis of the liver condition. This data is useful in order 
to identify patients with severe liver pathology, in whom rapid weight loss may be 
hazardous.  
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Liver biosy is taken for baseline analysis of the liver condition. This data is useful in order 
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One closed suction drain on top of the duodenal stump is placed. Stomach stump and 
gallbladder are extracted through the supra-umbilical port. Fascia is closed on the supra-
umbilical port only, with interrupted slowly-absorbable 0-stitches. 
5.4 Operative technique (open approach) 
Through an upper midline incision and after abdominal exploration, the first step is the 
intestinal measurement. The small bowel is measured backwards from the cecum to the 
ligament of Treitz and marking stitches are placed at 50 and 300 cm. It is very important that 
the small bowel is measured fully stretched, to make intestinal measurements reproducible 
in all hands. The ratio between the same small bowel fully loose and fully stretched is 
approximately 1-2. The small bowel is then transected at the 250 or 300-cm from the ileo-
cecal valve and the ileal mesentery is sectioned in depth. The EEA can be done with any 
technique, bringing the BPL to the left side, and the AL to the right of the abdomen. 
The distal gastrectomy is done, the duodenal stump is closed, the gallbladder is removed, 
and a wedge liver biopsy is obtained. We are used to cutting the stomach on a TA 90 linear 
stapler placed as oblique as possible, in order to compensate for the shortness of the ileal 
mesentery. As with the laparoscopic technique, the first two short gastric vessels on the 
greate curve are ligated and sectioned, whereas the dissection reaches up to the left gastric 
artery on the lesser curve. If the transaction is performed along those landmarks, a gastric 
volume of around 400 mL will be obtained. In any case, actual measurement of the gastric 
volume may be useful during the surgeon’s learning curve. 
The mesocolon is incised and the AL is brought into the supramesocolic space, checking for 
possible twist. Any technique can be used for the GEA. We prefer to do it end-to side, by 
cutting away the left corner of the gastric stump. The GEA is then anchored by two stitches 
to the mesocolic rent, to avoid intestinal kinkings and internal hernias. We always close the 
distal mesenteric defect and never the proximal.  
The last maneuver is the final intestinal check, starting from the ICV, with the surgeon 
following the alimentary limb and the first assistant following the biliopancreatic limb. The 
fascia is closed with continuous suture. Drains are put as in the laparoscopic technique. A 
subcutaneous suction drain is controversial, and in any case used only for patients with very 
thick subcutaneous fat. 
6. Postoperative care 
Routine intensive care admission is not mandatory. Only very selected cases, with severe 
respiratory co-morbidities are sent to ICU in our practice, as discussed preoperatively with 
the anesthesiologist. Analgesia is performed via continuous infusion of opiates, NSAIDs and 
anti-emetics. Usually, 100 ml/h of fluids are administered in the first 24 hours.  
The morning after the operation, bloods are checked, in particular, CPK and myoglobin, in 
order to detect rhabdomyolysis. With CPK values above 1000 U/dl, an aggressive protocol 
is started, with infusion of 200ml/h of saline, 100 mg bid fuorsemide, and 100 ml 8.4% 
HCO3-, with close monitoring of urine output, and daily check of CPK values. 
Hyperhydration is stopped when CPK values are steadily dropping and/or below 500 U/dl. 
The urinary catheter is usually kept until rhabdomyolysis is ruled out or resolved. 
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Preoperative antithrombotic prophylaxis is continued postoperatively up until 30 days from 
the operation. An upper GI radiology may be useful but is not mandatory. The naso-gastric 
tube is removed on the first postoperative day. Oral liquid diet and drain removal is 
performed on the third postoperative day. If tolerated, the diet is the progressed to soft diet 
first and, on the fifth or sixth postoperative day, to a free diet. 
6.1 Patient instructions 
Patients undergoing BPD must be aware that for the rest of their lives they will absorb 
minimal fat, (Gianetta et al, 1981; Scopinaro et al, 1987) little starch, sufficient protein, 
(Scopinaro et al, 1987;Gianetta et al, 1981) and nearly all mono- and disaccharides, short-
chain triglycerides, and alcohol (i.e., the energy content of sugar, fruit, sweets, soft drinks, 
milk, and alcoholic beverages). They must also understand that when their body weight will 
have reached the level of stabilization the intake of these aliments may be varied as needed 
for individual weight adjustments. 
All patients undergoing BPD have reduced appetite, early satiety and occasionally in 
association with epigastric pain and/or vomiting. These symptoms characterize the 
postcibal syndrome and are  caused by rapid gastric emptying with subsequent distention 
of the postanastomotic loop and early food stimulation of the ileum. All these symptoms, 
which are more intense and last longer the smaller the gastric volume is, rapidly regress 
with time, most likely due to intestinal adaptation.  
One year after operation, the appetite and the eating capacity are fully restored and the 
patient’s mean self-reported food intake is one and a half times as much as preoperatively, 
independently of gastric volume.  
Interestingly, the vasomotory phenomena characterizing the dumping syndrome are always 
absent after BPD, this indicating the lack of the specific receptors and/or the vasoactive gut 
hormones in the ileum that are thought to be implicated in the pathogenesis of dumping 
syndrome. 
6.2 Home medication and diet program 
Anti-thrombotic prophylaxis is continued up until 30 days after the operation. Patients are 
prescribed 30 to 60 mg/day of PPI for the first year. Oral multivitamin supplementation is 
started at discharge, whereas calcium and iron supplementation are begun one month after 
the operation, when appetite is starting to resume.  
Patients are advised to assume a protein-rich diet, in small, frequent meals. In practice, little 
amounts of bread and pasta may be allowed, whereas milk, vegetables and fruit should be 
avoided for the first weeks. Frequent vomiting should be immediately reported, because it 
may be sign of gastric outlet obstruction due to early ulcer, and necessitate not only 
aggressive PPI treatment, but sometimes also endoscopic dilation, and, to prevent vitamin 
B1 deficiency and Wernicke’s encephalopathy, aggressive vitamin B complex 
supplementation. In case of near-starvation, we administer intra-muscular vitamin B1 (as 
cocarboxylase) 38 mg, pyridoxin chloridrate (Vit. B6) 300 mg, and hydroxocobalamine (Vit. 
B12) 5000 mcg per day for five to ten days.  
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The first follow-up visit is scheduled 30-45 days after uncomplicated surgery. Although 
extremely rare, we encountered three cases of early postoperative porto-mesenteric vein 
thrombosis, which presented as severe, unexplained abdominal pain one week after an 
otherwise normal discharge. Unexplained severe, unremitting postoperative abdominal 
pain should therefore be investigated and not attributed to unspecific complaints. 
6.3 Bowel habits 
After full resumption of food intake, BPD subjects generally have two to four daily bowel 
movements of soft stools. Most have foul-smelling stools and flatulence. These phenomena, 
which can be reduced by modifying eating habits or by neomycin or metronidazole or 
pancreatic enzyme administration, tend to decrease with time along with a reduction of 
bowel movement frequency and increased stool consistency.  
Diarrhea usually appears only in the context of postcibal syndrome, and then it rapidly 
disappears, being practically absent by the fourth month (Scopinaro et al, 1996). Sporadic 
acute gastroenterocolitis, generally lasting not more than a few days, may be observed, 
especially during the summer.  
6.4 Follow/up care  
Standard follow/up visits are scheduled at one, four and twelve months, and early 
afterwards. At each outpatient visit, the patient has to check blood exams according to 
Table. 5  Furthermore, any abnormal clinical condition is annotated and dealt with. In the 
long term, PTH and vitamins A, D, E are of particular importance, to prevent metabolic 
bone disease (with adequate oral calcium and parenteral vitamin D supplementation) and 
emeralopia (vitamin A deficiency)or peripheral neurpathy (vitamin E deficiency). Prompt 




Total protein and differential 
Na, K, Ca, Cl, P, Ma 
Ferritin, Transferritin 
Glycated haemoglobin 
Serum cholesterol level, LDL, HDL, Triglycerides 
Bilirubin (total and direct) 
Fibrinogin 
Transaminases  





HBV and HCV marker only after 4th month 
PTH,  vitamine A, D, E one year after the operation and yearly after 
Other exams; complete urine analysis
Table 5. Postoperative laboratory examinations and their frequency. 
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6.5 Standard supplementation would be 
Oral calcium carbonate, 2g per day, increasing or decreasing the dose according to PTH 
values (and not, in the firs instance, serum calcium levels: Oral “over the counter” 
multivitamins.  
Oral iron sulfate, 500 mg/day, and 1000 mg/day in menstruating women. Oral Vitamin A 
and E, 30.000 U and 70 mg per day, respectively. Vitamin D is administered on occasional 
basis when a deficiency is detected  
7. Late complications  
7.1 Specific complications  
7.1.1 Anemia 
The exclusion of the primary site for iron absorption in the alimentary tract causes this 
unavoidable complication. More rarely, the anemia is due to folate deficiency and, 
exceptionally, to vitamin B12 deficiency (Schilling test gives normal results short term after 
BPD (Scopinaro et al, 1987, Civalleri et al, 1982). Anemia appears only in BPD patients with 
chronic physiologic (menstruation) or pathologic (hemorrhoids, stomal ulcer) bleeding. 
Reflecting the cause of the anemia, most cases are microcytic, fewer are normocytic, and a 
few are macrocytic. The general incidence of anemia after BPD in our population would 
probably be around 40%, but chronic supplementation with iron, folate, or both can reduce 
its occurrence to less than 15%.  
7.1.2 Stomal ulcer  
BPD is a potentially ulcerogenic procedure. Since the beginning of experimental work in 
dogs,(Scopinaro et al, 1979) distal gastrectomy was preferred to gastric bypass (Mason & Ito, 
1967) because it was thought to be more effective in preventing stomal ulcer (Storer et al, 
1950) and because of the concern for the fate of the bypassed stomach (Scopinaro et al, 1992). 
The incidence of stomal ulcer was initially rather high (12.5% with the HH BPD) because of 
the large residual parietal cell mass. Considering only the ulcers diagnosed in the first two 
postoperative years in order to allow comparisons among groups, the incidence was 
successively reduced to 9.1% in the first 132 consecutive patients submitted to AHS BPD, 
simply due to the reduced stomach size (Civalleri et al, 1986).  
Some changes of surgical technique, namely preserving as much as possible of the 
gastrolienal ligament with its sympathetic nerve fibers (Scopinaro et al, 1982) and shifting 
from end-to-end to end-to-side GEA, the latter being better vascularized and less prone to 
stenosis,(Gianetta et al, 1987) led to further progressive reduction (5.8% in the subsequent 
650 cases). In the following group of 640 AHS patients operated on from January 1991 to 
March 1999 with a minimum follow-up of 2 years, thanks to H2-blockers’ oral prophylaxis 
(Adami et al, 1991) during the first postoperative year in patients at risk (see below), started 
at the beginning of 1991, the incidence of stomal ulcer in the first 2 years was further 
reduced to 3.3%.   
If the totality of stomal ulcers in the first two groups are considered, they were significantly 
more frequent in men (14.4%) than in women (5.2%). Differently than what was reported in 
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previous articles, (Scopinaro et al, 1992, 1996, 1998) the incidence of stomal ulcer appeared 
unaffected by alcohol consumption, increased in men (though not significantly) by cigarette 
smoking, and significantly increased, more in women than in men, by the association of 
alcohol and smoke. Stomal ulcers responded well to medical treatment (100% healing with 
PPI) and they showed no tendency to recur, provided the patient refrained from smoking. 
Endoscopic evidence of stomal ulcer was obtained in 52% of cases within the first 
postoperative year, in 26% of cases within the second year, and in 22% of cases, with 
progressively decreasing frequency, between the third and the tenth year.  
However, it must be considered that (1) most patients diagnosed in the second and the third 
year were symptomatic already in the first one; (2) most patients diagnosed at a greater 
distance from the operation had been treated (one or more times) previously because of 
specific symptoms; (3) many patients once or repeatedly treated because of specific 
symptoms had refused endoscopy at all instances; (4) in some cases operated patients with 
no endoscopic diagnosis had received PPI therapy from their family doctors; and (5) with 
few exceptions, all patients with specific symptoms appearing after the second 
postoperative year were smokers, or smokers and drinkers. The consideration of all the 
above facts leads to the conclusions that (1) for BPD patients, not smokers or 
smokers/drinkers, the risk of developing a peptic ulcer is essentially confined to the first 
postoperative year and (b) the real incidence of stomal ulcer after BPD is certainly higher 
than that reported above.  
For all these reasons, prophylactic PPIs should be given to all patients for the first year, and 
probably discontinued in the non/smokers only.  
7.1.3 Bone demineralization  
The duodenum and proximal jejunum are selective sites for calcium absorption. However, 
our study on calcium intestinal absorption showed a more than sufficient mean apparent 
absorption in the 15 subjects on a free diet. Moreover, intestinal absorption as an absolute 
value was positively correlated with the intake (Kendall rank test: p < 0.03), which means 
that, unlike fat and energy and similarly to protein, an increase of calcium intake results in 
increased absorption. Therefore, all of our patients are encouraged to maintain an oral 
calcium intake of 2 g/day (with tablets supplementation, if needed), while the daily 
requirement of vitamin D, as well as of all other vitamins and trace elements, is contained in 
a multi-integrator that all patients are recommended to take for all life.  
When natural history of bone disease was investigated by us in obese patients and operated 
subjects not taking any supplementations 1–10 years after BPD, histomorphologic signs of 
mild to severe bone demineralization (cross-sectional study on 252 transiliac bone biopsies 
after double-labeling with tetracycline, 58 of which preoperatively) were present in 28% of 
the obese patients and 62% of the operated subjects.  Slightly low levels of serum calcium 
and high levels of alkaline phosphatase were found in about 20% of the subjects in that 
study, with no significant differences between obese patients and operated subjects or 
between operated subjects with and without bone alterations.  
Serum magnesium, phosphorus, and 25-hydroxyvitamin D levels were essentially normal 
both prior to and after operation. The prevalence and severity of metabolic bone disease 
 
BPD and BPD-DS Concerns and Results 
 
193 
(MBD) increased after BPD until the fourth year [prevalence: preop. 16/58, at 4 year 15/21, 
chi-square test p < 0.001; severity (subjects with moderate or severe MBD): preop. 7/58, at 4 
year 8/21; chisquare test p < 0.01], at which point they tended to regress.  
Long-term (6–10 year) mineralization status was not significantly worse than that observed 
before operation. Patients with the most severe preoperative alterations, i.e., the older and 
the heavier patients, showed a sharp improvement in bone mineralization status compared 
to their preoperative status (prevalence of moderate or severe MBD in patients over 45-year-
old: preop. 25%, at 1–2 year 29%, at 3–5 year 33%, and at 6–10 year 11%; in patients with an 
IEW greater than 120% these values were, respectively, 24%, 28%, 53%, and 14%) (Scopinaro 
et al, 1987, Compston et al, 1984, Adami et al, 1987). The histomorphology data were in total 
agreement with the clinical findings. Bone pain attributable to demineralization (with 
prompt regression after calcium, vitamin D only when needed, and diphosphonate therapy) 
was observed in 6% of patients, generally between the second and fifth postoperative years 
(maximum prevalence: 2.4% during the fourth year) and more rarely on long term(10–20 
years).  
The pathogenesis of bone demineralization in obese patients is unclear. The bone problems 
caused by BPD do not seem to differ substantially from those reported in 25%–35% of 
postgastrectomy subjects with duodenal exclusion for peptic ulcer (Williams, 1964, Eddy, 
1984, Fisher, 1984) and in one-third of patients with gastric bypass for obesity (Crowley et al, 
1986). The mechanism is very likely a decreased calcium absorption causing an augmented 
parathyroid hormone (PTH) release which is generally sufficient to normalize serum 
calcium level at the expense of bone calcium content. During the first postoperative years, 
the adverse effect of reduced calcium absorption seems to prevail over the beneficial one of 
the weight loss, whereas the opposite happens at long term, this being more evident in the 
subjects with the most severe preoperative alterations.  
Recently, it has been suggested that low albumin level is also implicated in the pathogenesis 
of MBD after BPD (Marceau et al, 2002). In our experience, oral calcium supplementation 
seems to be able both to prevent and to cure bone alterations caused by BPD, monitored by 
computerized bone mineralometry. Still, great differences in calcium requirement and 
metabolism exist among populations and individuals in the same population. Vitamin D 
synthesis in the skin at different latitudes probably also plays a major role. It is important to 
remember that parenteral vitamin D supplementation should not be used in the treatment of 
MBD unless low serum levels have been documented. In fact, an excess of vitamin D can 
cause bone damage similar to that caused by its deficiency.  
7.1.4 Neurological complications  
Peripheral neuropathy and Wernicke’s encephalopathy, early complications caused by 
excessive food limitation(Primavera et al, 1987) have now totally disappeared (none in the 
last consecutive 1,969 operated subjects of the total series with a minimum follow-up of 1 
year) because of prompt administration of large doses of thiamin to patients at risk, i.e., 
those reporting a very small food intake during the early postoperative weeks.  
A more insidious cause of peripheral neuropathy is vitamin E deficiency, which can lead to 
various degrees of impairment, up to ataxia in the most severe cases. Patients reporting 
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those reporting a very small food intake during the early postoperative weeks.  
A more insidious cause of peripheral neuropathy is vitamin E deficiency, which can lead to 
various degrees of impairment, up to ataxia in the most severe cases. Patients reporting 
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paresthesia, especially if long-term after the operation and not well supplemented, should 
be checked for vitamin E levels and promptly corrected in necessary.  
7.1.5 Protein malnutrition  
Protein malnutrition (PM), with its classic symptoms, is the most severe possible 
complication of BPD, and it may require hospitalization with parenteral nutrition. It can be 
early episodic (1st postoperative year) due to patient non-compliance with alimentary rules 
to be followed during the first postoperative months, or late recurrent due to insufficient 
protein intake or intestinal absorption, generally requiring elongation of the CL. Protein 
absorption after BPD corresponds to ~70% of a meal containing 60 grams of protein.  
Unfortunately, our study on protein absorption also showed a five-fold increase in 
endogenous nitrogen loss, which doubles daily protein requirement and accounts for 
possible occurrence of PM. This complication in our hands was frequent many years ago, 
when, with the aim of obtaining greater weight loss, we explored the formidable power of 
the small stomach volume. The evolution of BPD, essentially consisting of increasing the 
stomach volume and the length of the AL, eventually led to near disappearance of PM, both 
in the early and recurrent form. However, as the operation is active for life, sporadic PM can 
occur at any time after BPD, if there is prolonged diarrhea or reduced food intake for any 
reason.  
Therapy for early or late PM must be aimed at eliminating PEM and restoring normal 
nutritional status, with parenteral feeding that includes both the nitrogen and the energy 
necessary to restore the amino acid pool, reestablish the anabolic condition, and 
resynthesize deficient visceral protein.  
In addition to the increased endogenous nitrogen loss, with its impact on daily protein 
requirement, important phenomenon acting in the same direction is the overgrowth of 
colonic bacterial flora. Overgrown bacterial flora, the synthesis of which partly or totally 
occurs at the expense of alimentary protein escaped to absorption in the small bowel, 
reduces protein absorption by the colonic mucosa, thus increasing protein malabsorption 
and protein requirement.  
Correlation between stomach volume (gastric restriction) and protein malnutrition, At a 
remote phase of BPD development, in an attempt to accelerate and increase the weight loss, 
we drastically reduced mean gastric volume to about 150 mL, obtaining, in addition to 
excellent weight reduction (near 90% of the IEW at 2 years), a catastrophic approximate 30% 
incidence of PM with 10% recurrence rate .With the aim of decreasing the PM incidence 
without losing the benefit of the small stomach, the gastric volume was adapted to the 
patient’s initial EW  (AHS BPD, June 1984). In fact, the original philosophy of the AHS was 
to confine the risk of PM to patients who required greater weight loss. It resulted in a 17.1% 
incidence of PM with 8.3% recurrence, and the mean weight reduction remained at a very 
satisfactory 77% of the IEW (initial 192 AHS BPD patients with a minimum follow-up of 2 
years), the higher weight of stabilization being evidently due to the larger mean stomach 
volume (about 350 mL) with the consequent slower intestinal transit and greater energy 
absorption.  
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Further mean increases in gastric volume to about 400 mL, and of alimentary limb length 
(up to 250 or 300 cm) led to a further decrease of incidence in protein malnutrition to the 
present 3% (1% recurrent cases). Interestingly, there is a strong correlation between stomach 
volume, stabilization weight and protein malnutrition incidence. The smaller the gastric 
volume, the lower the stabilization weight, and the higher the likelihood of protein 
malnutrition. These data are an explicit warning against trying to combine gastric restriction 
with malabsorption.  
7.2 Minor or rare late complications  
Among the 2756 AHS BPD patients with a minimum follow up of 2 years, the following 
minor or rare complications were observed or reported: 284 (9%) cases of impairment or 
appearance of hemorrhoids, 110 (4%) cases of anal rhagades, 55 (2%) cases of perianal 
abscess, 88 (3.2%) cases of acne, 61 (2.2%) cases of inguino-perineal furuncolosis, 207 (7.5%) 
cases of night blindness, 4 cases of lipothymias from hypoglycemia, 2 cases of transient 
dumping syndrome, 1 case of bypass arthritis, and 1 case of gallstone ileus.  
These complications showed a decreasing incidence in our population of operated patients. 
Anyway, they occur more rarely as time passes and tend to disappear in the long term.  
Halitosis after BPD could be due either to food stagnation in a virtually achloridric stomach, 
which can be avoided by correct execution of the GEA, or to pulmonary expiration of ill-
smelling substances resulting from malabsorption, the oral administration of pancreatic 
enzymes being of use in these cases. This unpleasant side effect has also become less 
common in our series, currently affecting less than 5% of the operated patients.  
BPD causes oxalate hyperabsorption, but not hyperoxaluria, though oxalate urinary 
excretion in the operated patients is significantly higher than in controls (Hofmann et al, 
1981). The procedure can then be considered a remote cause of kidney stone formation, 
keeping in mind that not even hyperoxaluria can cause this complication in the absence of 
cofactors, the first of which is decreased urinary volume from dehydration. The incidence of 
kidney stones in our series (5/1,804 or 0.3%) does not differ from that of the general 
population. Thirty-two needle kidney biopsies obtained at long-term relaparotomy in BPD 
patients failed to demonstrate any microscopic or ultrastructural alterations (unpublished 
data: study in cooperation with Dr. Thomas Stanley, VA Hospital, Los Angeles, CA, 1984).  
7.3 Late mortality 
Specific late mortality is essentially attributable to the consequences of untreated protein 
malnutrition in lately presented or inadequately treated cases. 
8. Revision of BPD 
8.1 Options available 
All specific late reoperations after biliopancreatic diversion (BPD) consisted of; 
Elongations of the common limb (CL) which can be done either: 
Along the biliopancreatic limb or 
Along the alimentary limb 
Restorations of intestinal continuity with either 
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Sparing the duodenum from the alimentary continuity 
Putting the duodenum in the alimentary continuity 
8.2 Indications to revision of BPD are 
1. Recurrent protein malnutrition with or without poor protein intake 
2. Excessive Weight loss with normal food intake 
3. Excessive Foul Smelling of the stool and Flatulence 
4. Diarrhea 
5. Intractable severe bone demineralization 
6. Occurrence of a disease whose consequences would be worsened by malabsorption 
7. Intolerance of the operation 
The revision is generally implemented to correct an excess of effect of the original operation, 
and, because it entails a permanent modification of intestinal absorption, it is critical to ensure 
that intestinal adaptation mechanisms have been substantially completed, which require at 
least 1 year. If the problems persist and reoperation is then indicated, the risk of having a 
premature reoperation with a consequent overcorrection and undue weight regain is minimal. 
8.3 Post-revision physiology 
Protein, simple sugar and starch absorption depend on the total bowel length between the 
gastro-enterostomy and the ileo-cecal valve. Fat and bile acid absorption depend on the 
length of the common limb. Bile acid absorption also depends on the length of ileum which 
is exposed to bile acid transit. 
a. Elongation of the common limb along the biliopancreatic limb leads to an increase of 
the total intestinal length from the gastroenterostomy to the ileocecal valve, which in 
turn increases protein, energy and water absorption. 
b. Elongation of the common limb along the alimentary limb leads to an increase of bile 
salt absorption without a direct increase in protein, energy and water absorption, 
because the total bowel length between the gastroenterostomy and the ileo-cecal valve 
remains unchanged. Energy absorption increase is also minimal, because only fat 
absorption is increased. 
c. Restoration of intestinal continuity with a bypass of the duodenum allows the 
resumption of normal protein-energy absorption, still partially preserving both the 
specific effects of BPD on glucose and cholesterol metabolism. 
d. Restoration of the intestinal continuity with re-canalization of the duodenum in the 
alimentary pathway will sacrifice the effect on glucose metabolism; the effect on 
cholesterol metabolism is preserved if the alimentary limb is kept interposed between 
the stomach and the duodenum, because it still entails a reduction of the ileum exposed 
to bile acid transit (Figure 34–5). 
8.4 Problem solving 
A recurrent Protein malnutrition (PM) (with or without additional problems) is the condition 
to be cured in the vast majority of cases. In this case, PM is due to insufficient protein 
intestinal absorption, either absolute (insufficient absorption capacity per unit of intestinal 
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length, too rapid intestinal transit due to excessively little stomach) or relative (insufficient 
protein content of ingested food, excessive loss of endogenous nitrogen). 
In both cases the aim of the surgical revision is to increase protein absorption, and this 
(keeping in mind the physiology of the operation), would not be obtained by elongating the 
CL along the alimentary one. Since, as said above, protein absorption after BPD 
substantially depends on the total intestinal length from the GEA to the ICV, the elongation 
of the CL for correction of a recurrent PM must be performed at the expense of the 
biliopancreatic limb, the length which in our experience has proven effective in all cases 
being 150 cm, with the result of a total of 400 cm of small bowel in the food stream (Fig 5). 
 
Fig. 5. Elongation of the CL along the BPL. 
Excessive weight loss in presence of a normal food intake, problems of foul-smelling stools and 
flatulence and diarrhea due to excessive fluid intake are conditions which can be corrected by 
elongation of the common limb along the biliopancreatic limb. 
Rarely, diarrhea is due to excessive reduction of ileal bile salt absorption. This condition can 
be easily diagnosed by cholestyramine administration, and it represents the only indication 
to the elongation of the CL along the alimentary one, 100 cm being sufficient in our 
experience (Fig. 6). 
Restoration of the intestinal continuity is specifically indicated in presence of a recurrent PM 
and/or an excessive weight loss due to permanence of the food limitation effect with or 
without poor protein intake. The goal in these cases is to restore a normal intestinal 
absorption capacity in a subject who will maintain his/her weight reduction because of the 
permanently reduced food intake. This can be obtained with different operations, ranging 
from a simple high side-to-side enteroenterostomy to the complete reconstruction of the 
gastrointestinal tract, with a 50-cm ileal loop being interposed between the stomach and the 
duodenum (Fig. 7). 
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Fig. 6. Elongation of the CL along the AL. 
 
Fig. 7. Full restoration of intestinal continuity. 
We prefer to section the alimentary limb (AL) immediately proximal to the 
enteroenterostomy (EEA) and join the ileal stump to the jejunum, immediately distal to the 
ligament of Treitz. This type of restoration allows the resumption of a normal protein-
energy absorption, still partially preserving both the specific effects of BPD on glucose and 
cholesterol metabolism (Fig. 8). 
 




Fig. 8. Restoration bringing the AL to the ligament of Treitz.  
 
Fig. 9. Restoration bringing the AL to the duodenum. 
Restoration may be necessary if a disease occurs whose consequences would be worsened 
by malabsorption, e.g., liver cirrhosis, nephrotic syndrome, chronic inflammatory bowel 
disease, malignancy, or psychosis. It may also be requested by the BPD subject instead of the 
elongation after a long period of recurrent PM, or for different reasons, e.g., intolerance of 
the stool/gas problems, or psychological intolerance of the environmental problems 
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originated by the changed body shape, or what we simply call “intolerance of the 
operation.” 
Only in case of intractable severe bone demineralization, or of moderate bone 
demineralization associated with a condition that indicates the restoration, we accept the 
sacrifice of the effect on glucose metabolism by putting the duodenum in the alimentary 
continuity, which can be accomplished as shown in Figure 34–3, or, if the effect on 
cholesterol metabolism is to be preserved, by keeping the entire AL interposed between the 
stomach and the duodenum (Fig. 9). 
 
Fig. 10. Shorting of both alimentary and the common. 
Exceptionally, a shortening of the intestinal limbs may be considered. The most common 
cause for weight regain after BPD is excessive intake of simple sugar. Only if this type of 
patient’s noncompliance can be reasonably excluded, an excess of the adaptive 
phenomena leading to late energy absorption increase may be suspected. A preliminary 
measurement of alimentary protein intestinal absorption is, in our opinion, mandatory. 
More than 90% absorption on the one hand confirms the excessive adaptation, on the 
other hand it means that there is a wide margin for shortening without causing excessive 
protein malabsorption. 
In two cases, both with 370-cm AL, we resected the proximal part of the AL exceeding the 
240cm which, as a mean of the intestinal measurements taken at late reoperations for any 
cause, result after adaptation, with redo of GEA. Since these two patients failed to lose 
weight, we thought it could be due to the highly consuming small bowel removed, which 
compensated for the decreased absorption. In a third case, with 520-cm AL and 80-cm CL, 
we sectioned the AL 240 cm distal to the GEA, detached the biliopancreatic limb (BPL) from 
the distal ileum, and then anastomosed the BPL to the distal stump of the AL section and the 
proximal stump to the distal ileum, thus creating a CL of 70 cm (mean CL length after 
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adaptation), as shown in Figure 9. The patient slowly lost all the excessive weight 
previously regained. The same operation was subsequently successfully used in another 
case that had been submitted to BPD elsewhere and had had minimal weight reduction. 
Both the CL and the AL were excessively long, and this most probably was due to wrong 
intestinal measurement, even if a rapidly occurring excessive intestinal adaptation could not 
be ruled out. 
8.5 Timing 
The total number of revisions in the last consecutive 1000 AHS-AHAL BPD patients with a 
minimum follow-up of 1 year was 10 or 1.0%, 4 (0.4%) being elongation of the CL and 6 
(0.6%) restorations of intestinal continuity. The latter cases presented with ensuing medical 
problems, unrelated to the operation, which necessitated resumption of normal protein 
absorption 
8.6 Secondary effects 
All problems of recurrent PM, excessive weight loss, diarrhea, stool/gas, and bone 
demineralization permanently disappeared after revisions. While no recurrences of 
hypercholesterolemia were ever observed, there were two cases of mild hyperglycemia in 
previously diabetic patients after elongation. 
8.7 Weight regain 
Since protein and starch digestion/absorption occur in the entire small bowel between the 
GEA and the ICV, and fat absorption in the intestinal segment between the EEA and the 
ICV, the elongation of the CL along the BPL which is necessary to increase protein 
absorption also causes an increase of starch and fat absorption. This obviously results in a 
higher energy absorption threshold, which explains the restabilization at a higher body 
weight of the subjects undergoing elongation of the CL for recurrent PM and/or excessive 
weight loss. 
The subjects who were elongated along the AL because of diarrhea from excessive bile salt 
malabsorption had and maintained a food intake equal to the preoperative one, and they 
did not gain any weight in a 6- and 11-year follow-up, respectively. 
The weight changes after BPD revisions indicate that, when the indication was correctly 
given by us according to the physiology of the operation, the revised subjects had a 
moderate weight regain with restabilization, the success being maintained, while in the 
other cases they regained weight progressively toward failure. 
A final consideration regards the mean weight loss at the time of revision, which was in 
most cases lower than the average in our series. Any degree of weight reduction can be 
obtained with BPD, but, as we learned at our expenses, the greater the mean weight loss, the 
greater the number of problems. Unless a surgeon has an experience sufficient to enable him 
to tailor the operation on each single subject, any mean reduction of the IEW greater than 
70% should be considered potentially dangerous. Weight maintenance, not weight loss, is 
the real magic of BPD. 
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adaptation), as shown in Figure 9. The patient slowly lost all the excessive weight 
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absorption also causes an increase of starch and fat absorption. This obviously results in a 
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The weight changes after BPD revisions indicate that, when the indication was correctly 
given by us according to the physiology of the operation, the revised subjects had a 
moderate weight regain with restabilization, the success being maintained, while in the 
other cases they regained weight progressively toward failure. 
A final consideration regards the mean weight loss at the time of revision, which was in 
most cases lower than the average in our series. Any degree of weight reduction can be 
obtained with BPD, but, as we learned at our expenses, the greater the mean weight loss, the 
greater the number of problems. Unless a surgeon has an experience sufficient to enable him 
to tailor the operation on each single subject, any mean reduction of the IEW greater than 
70% should be considered potentially dangerous. Weight maintenance, not weight loss, is 
the real magic of BPD. 
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9. Revision to BPD 
The superior results of BPD both in weight maintenance and control of component of 
metabolic syndrome make this operation a good choice for revision of failed other types of 
bariatric procedures. Furthermore, revision to BPD often enables the surgeon to avoid 
scarred tissue high up in the stomach, thus simplifying reoperation and reducing 
perioperative morbidity. 
Revisional Bariatric surgery is technically challenging and becoming more common due to 
the rapid increase in patients undergoing surgery for morbid obesity. Unfortunately, there is 
no sufficient evidence to help the surgeon deciding which revisional procedure to choose 
based. There are several factors that need to be considered when unsatisfactory outcomes 
after bariatric surgery are obtained. 
The extent of weight loss may not be the only factor to be considered while evaluating the 
results of a bariatric restrictive procedure, because the major goal of bariatric procedures is 
the cure or control of comorbidities along with the weight loss. With this idea in mind, a 
borderline weight loss with a successful control of comorbidities (eg, easier hypertension or 
diabetes control, disappearance of articular pain or swelling, cure of sleep apnea, etc.) in a 
high-risk patient without surgery-related complications should probably be considered a 
good outcome, and the patient could avoid additional surgery. These issues should be 
clarified with the patient when discussing risks and benefits of the reoperation. 
Both patient and surgeon need to be aware that a new operation will be a difficult task, and 
realistic goals have to be presented to the patient. There is a higher risk of complications, 
and a possibility that a new bariatric procedure may not be completed in one intervention as 
planned owing to inflammation, scarring, and bleeding. Patients must know that more than 
one intervention may be required. Unlike gastric restrictive revisional surgery, revision to 
BPD usually does not impair final weight loss results. 
9.1 Indications for revision 
1. Insufficient weight loss. 
2. Weight regain. 
3. Complications of previous the procedure. 
9.2 Patient evaluation 
Surgeons should consider that failure of specific restrictive bariatric procedures is owing to 
many factors. One of these factors is patient’s compliance with the dietary program, and 
when required, with behavioral modifications after the primary procedure. Patients may not 
need a second surgery but a close follow-up and behavior counseling before deciding on a 
more drastic intervention. 
9.3 Approach to the patient 
Detailed evaluation of the preoperative data of the these patients, operative notes and 
postoperative BMI and complications through a Pre-operative check-list; 
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1. History and Physical examination; 
BMI 
Symptoms of dysmotility 
Symptoms of acid hypersecretion 
Screening for eating disorders 
Psychological evaluation if positive 
2. Review old operative notes and videos if possible 
3. Barium swallow to document anatomy 
4. EGD if patient has symptoms of GERD 
Imaging and endoscopic studies are necessary to study the problem and give an accurate 
map of the existing anatomy. As restrictive bariatric procedures are practiced following 
different techniques with modifications of some of the originally described steps, it is 
advisable to read the operative note or to discuss the case with the surgeon who carried out 
the index surgery. 
9.4 General considerations 
Revisional bariatric surgery is technically demanding. There are technical aspects common 
to any reoperation after gastric surgeries that need to be taken into account to minimize 
complications. 
Adhesions are likely to be present and they may be anywhere. Therefore, access to the 
cavity should be attained by open technique, or alternatively using an optical trocar, trying 
to prevent visceral injuries. 
Once in the cavity, following ports should be placed in an order that allows dividing the 
adhesions from the best point of view. In addition, liver retraction should be done 
delicately, and only after its adhesions have been addressed, because any sudden movement 
or excessive force could produce a tear, and bleeding will obscure the surgical field, 
reducing visibility and causing delays. 
Division of gastric vessels should only be carried out after the gastric vascular supply has 
been assessed. Restrictive procedures usually preserve lesser curvature vessels, and 
therefore these should be preserved at all costs. If the left gastric artery or its branches need 
to be cut at some stage, the condition of the stomach must to be carefully observed to rule 
out ischemia leading to gastric resection. 
Intraoperative endoscopy is a valuable tool when during the procedure it is difficult to 
accurately characterize the anatomic changes seen during the laparoscopy. It should be 
scheduled beforehand to avoid delays in a possibly long intervention. 
9.5 Open versus laparoscopic approach 
Laparoscopic surgery has had a major impact on obesity surgery the last decade. All 
bariatric procedures have been proven to be technically feasible via laparoscopy (Buchwald 
et al, 2004). There is also evidence that the laparoscopic approach is advantageous, since it is 
associated with less perioperative morbidity and faster recovery (The Society of American 
Gastrointestinal and Endoscopic Surgeons (SAGES) Guidelines Committee , 2008; Weller 
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Rosati, 2008) . Laparoscopic approach to malabsorption procedures, such as the BPD or the 
duodenal switch operation (DS), is more complex and technically difficult (Scopinaro et al, 
2002; Baltasar et al, 2002; Weiner et al, 2004). Several reports have demonstrated the efficacy 
of laparoscopic revisional bariatric surgery (Gumbs et al, 2007). However, laparoscopic re-
do surgery, after failed primary bariatric procedures, should be handled cautiously. Van 
Dessel et al, 2008 reported recently that the threshold for conversion to open approach 
should be low. 
In patients after failed or complicated bariatric operations, it is the surgical management 
that eventually matters and not the approach. 
9.6 Which type of revision? And why BPD? 
Surgeons differ in their management of failed bariatric procedures, depending on their 
individual experience and resultant choice of surgical operation or operations. Revision of 
failed gastric restrictive operation is a common problem today, and is likely to increase in 
the near future (Sarr, 2007). In our opinion, the conversion of a restrictive operation to a 
malabsorptive one appears for some patients as the only alternative to cope with poor 
weight loss results. Such conversions, after unsuccessful weight loss, have been previously 
described (Fox, 1991; Keshishian et al, 2004; Di Betta et al, 2006). Since gastric bypass relies 
primarily on restriction, a different surgical approach, based essentially on malabsorption 
was employed as the final option in this cohort of patients with multiple previous bariatric 
interventions. In a recent report, (Topart et al, 2007) demonstrated that BPD with duodenal 
switch resulted in greater weight loss compared to Roux-en-Y gastric bypass after failed 
gastric banding. However, BPD-DS resulted in a higher early complication rate. When 
compared to RYGB, BPD and BPD-DS procedures are suggested to create superior weight 
loss and more accurately, superior weight loss maintenance (DeMaria, 2004).  
In a recent analysis, it was demonstrated that obesity surgery results depend on the 
performed technique. BPD was proven to be the only operation that kept excellent weight 
results in time but unfortunately, with increased morbidity (Gracia et al, 2009). So far, no 
adequate prospective trial has been done to adequately answer the question of “which 
revisional bariatric procedure to do” in the setting of inadequate weight loss or excessive 
weight regain (Gumbs et al, 2007). 
Furthermore, failed RYGB represent a subset of particularly challenging cases, in which only 
BPD can provide adequate results. Conversion from RYGB to biliopancreatic diversion with 
duodenal switch (BPD-DS) might provide the most durable weight loss of all revision 
procedures currently available. Revision to BPD-DS can be done laparoscopically in 1 or 2 
stages and involves 4 anastomoses: gastrogastrostomy, duodenoileostomy, ileoileostomy, 
and jejunojejunostomy (to reconnect the old Roux limb).  
10. Duodenal switch 
Duodenal Switch (DS), is the malabsorptive procedure that is usually performed in North 
America for treatment of morbid obesity. In 1987, DeMeester, in some experimental studies 
conducted on biliary gastritis, showed that keeping even a short duodenal limb could 
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significantly reduce the incidence of anastomotic ulcers. By transferring these observations 
to bariatric context, the goal of the Duodenal Switch (DS) variation of Biliopancreatic 
Diversion (BPD) proposed by Douglas Hess and Picard Marceau was to reduce the 
complications correlated with Scopinaro’s original procedure while maintaining its long-
term effectiveness on weight loss and co-morbidities resolution. 
10.1 Modifications  
The modifications adopted in DS are: modifying the distal gastrectomy of the BPD with a 
vertical gastrectomy along the greater curvature (sleeve gastrectomy). Further modification 
foresaw the lengthening of the common channel to 100cm, thus doubling the length of the 
absorbent common ileal segment, for greater control of the number of daily bowel 
movements. Some procedures that are consensual to BPD, like cholecystectomy, 
appendectomy and liver biopsies were routinely performed by different authors even in the 
DS variation. These modifications have led, according to the same authors, to the reduction 
in the incidence of dumping syndrome, anastomotic ulcer, and proteins malabsorption. 
Analysing the results of open BPD vs. DS, Marceau reports fewer daily evacuations, less 
diarrhea, vomiting and bone pain following DS associated with higher serum levels of 
ferritin, calcium and Vitamin A.  
Whether this report is simply the result of a progressive learning curve (standard BPD had 
been adopted in the early experience, and BPD with DS had been further developed in later 
years), or if the longer length of the common channel, by increasing bile acid absorption, 
and thus lowering the degree of steatorrhea, leads to fewer bowel movements per day, and, 
consequently, to less endogenous nitrogen loss, has never been studied in a prospective 
fashion. In fact, most recent publications report very similar results and side effects for both 
operations. Just as for standard BPD, BPD- DS primarily induces malabsorption of fats due 
to the diversion of bile and pancreatic enzymes to the common limb. Therefore, the length of 
the alimentary limb and the common limb is of the fundamental importance; if the common 
channel is too long, the malabsorption of fats might not be sufficient to guarantee an 
adequate weight loss over the long term; an excessively long alimentary limb leads to 
insufficient weight loss for insufficient malabsorption of starch.  
Duodenal switch might nonetheless be a better option in revision of failed sleeve 
gastrectomies, as the latter operation had in fact been introduced in clinical practice as the 
first stage of BPD-DS in super-superobese patients. 
10.2 Peri- and postoperative complications 
10.2.1 Fistula 
Suture line dehiscence can occur at the gastric suture after sleeve gastrectomy, at both 
anastomoses and at the duodenal stump. The incidence of suture-line leak after sleeve 
gastrectomy ranges between 1.3% and 4.6% (Hess, 1998, Lee et al, 2007). The critical areas for 
leak are the top of the suture line and the transition point between sequential cartridges. To 
prevent leak many authors suggest reinforcing the long suture line with buttress material, a 
running suture or fibrin glue. The suture line fistula can be managed by percutaneous 
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drainage plus total parenteral nutrition and antibiotics associated, in selected cases, with 
endoscopic stenting.  
Anastomotic leak seems to have the same incidence rate in LapBPD-DS as in the open series 
(2.5%) (Marceau et al, 1998, Ren et al, 2000, Lee et al, 2007). The clinical presentations 
involves tachycardia (heart rate >120 beats /minute), fever, abdominal pain, hypotension 
and mental deadness. To make the correct diagnosis an upper GI X-ray can be useful, but a 
negative contrast X-ray study does not exclude a fistula.  
Therefore, a spiral angioCT scan is the most accurate diagnostic tool in doubtful cases. In 
case of low output fitulas and when there are no signs of haemodynamic instability, 
management could be conservative. Failure of nonoperative management or signs of 
peritonitis, a laparoscopic or laparoscopic reoperation is indicated. Options includes suture 
of the anastomotic dehiscence, wide drainage and/or with the creation of a jejunostomy in 
the biliopancreatic limb for decompression and for enteral nutrition and supportive care. 
Compared to the most recent series of standard BPD, fistula incidence after BPD-DS seems 
higher. 
11. Conclusions 
BPD yields the best results obtained in the treatment of obesity and metabolic syndrome. 
The reasons why, although in use for more than 35 years, this operation still has relatively 
minimal diffusion in the world are many, and they have little to do with its effectiveness 
and safety. However, this is to be considered a favorable event: BPD would cause dramatic 
damages if improperly used, and this would certainly happen if the operation had a rapid 
diffusion among the average bariatric surgeon. For the same reason, being able to master 
BPD and its complications, and understanding its pathophysiology, is extremely important 
for a committed bariatric surgeon, because, at the very least, it represents a very powerful and 
effective weapon in difficult revisional cases and in the metabolically highly compromised 
patient. To be limited to a slowly increasing number of good hands is the main guarantee of 
safety for biliopancreatic diversion.  
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drainage plus total parenteral nutrition and antibiotics associated, in selected cases, with 
endoscopic stenting.  
Anastomotic leak seems to have the same incidence rate in LapBPD-DS as in the open series 
(2.5%) (Marceau et al, 1998, Ren et al, 2000, Lee et al, 2007). The clinical presentations 
involves tachycardia (heart rate >120 beats /minute), fever, abdominal pain, hypotension 
and mental deadness. To make the correct diagnosis an upper GI X-ray can be useful, but a 
negative contrast X-ray study does not exclude a fistula.  
Therefore, a spiral angioCT scan is the most accurate diagnostic tool in doubtful cases. In 
case of low output fitulas and when there are no signs of haemodynamic instability, 
management could be conservative. Failure of nonoperative management or signs of 
peritonitis, a laparoscopic or laparoscopic reoperation is indicated. Options includes suture 
of the anastomotic dehiscence, wide drainage and/or with the creation of a jejunostomy in 
the biliopancreatic limb for decompression and for enteral nutrition and supportive care. 
Compared to the most recent series of standard BPD, fistula incidence after BPD-DS seems 
higher. 
11. Conclusions 
BPD yields the best results obtained in the treatment of obesity and metabolic syndrome. 
The reasons why, although in use for more than 35 years, this operation still has relatively 
minimal diffusion in the world are many, and they have little to do with its effectiveness 
and safety. However, this is to be considered a favorable event: BPD would cause dramatic 
damages if improperly used, and this would certainly happen if the operation had a rapid 
diffusion among the average bariatric surgeon. For the same reason, being able to master 
BPD and its complications, and understanding its pathophysiology, is extremely important 
for a committed bariatric surgeon, because, at the very least, it represents a very powerful and 
effective weapon in difficult revisional cases and in the metabolically highly compromised 
patient. To be limited to a slowly increasing number of good hands is the main guarantee of 
safety for biliopancreatic diversion.  
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1. Introduction 
Body weight is ultimately determined by energy homeostasis, a complex process of 
regulation. Homeostasis is one of the greatest challenges for understanding the etiology, 
treatment and prevention of obesity (Hill, 2006). The high rate of weight regain in 
individuals who undergo weight loss treatments is proof of this (Melo et al., 2008). Even 
among morbidly obese individuals submitted to more radical treatments, such as surgery, 
weight regain sometimes occurs [Fogaça, 2009]. In this sense, energy intake and expenditure 
assessments represent extremely important factors, both for studies and as an aid in the 
process of caring for the obese.  
Given the premise that all obesity treatment methods are based on reducing food intake and 
increasing energy metabolism, the present chapter intends to discuss the variables in the 
energy balance equation using the results from works of the research group Bariatric Surgery 
and Metabolism of Paulista State University – UNESP, Campus Botucatu, São Paulo, Brazil, 
and of the Bariatric C.inic of Piracicaba, São Paulo, Brazil, as reference. Components of 
energy metabolism and indirect calorimetry will be discussed.  
Indirect calorimetry is a reference method that has been used for almost 100 years for 
measuring energy intake in humans during resting or physical activity. Studies using 
indirect calorimetry allow assessing the effects of energy intake, physical activity and 
other factors involved in the energy metabolism on the total body mass of obese 
individuals or its compartments. Here, indirect calorimetry was used to assess the 
agreement between itself and prediction formulas, to discuss the effects of food restriction 
and to assess energy intake underreporting by obese women submitted to food intake 
surveys. Indirect calorimetry data also allow one to discuss the effects of weight loss and 
body mass index on energy expenditure and biochemical indicators of glucose and fat 
metabolism. These studies allowed the elucidation of some energy metabolism 
particularities of individuals who undergo bariatric surgery, as well as the proposition of 
some hypotheses for new studies.  
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2. Energy expenditure and food restriction 
Daily total energy expenditure (TEE) is the term used for defining the amount of energy 
necessary for an organism to perform its vital functions and activities of daily living. TEE 
consists of the resting energy expenditure (REE), which is the energy used by the body 
during rest, that is, in bed, under comfortable environmental conditions (60-75% do TEE), by 
food-induced thermogenesis, which is the heat effect of foods (5-15% do GET) and by 
energy spent on physical activities, considered the most variable component of the TEE and 
which can contribute to a significant amount  of the energy spent by very active individuals 
(Meirelles & Gomes, 2004, Prentice, 2007).    
Indirect calorimetry is a noninvasive technique used to measure the volume and 
concentration of the gases inhaled by the lungs and allows the calculation of the amount of 
oxygen (O2) consumed and the production of carbonic gas (CO2). These values may stem 
from the baseline energy expenditure (BEE), the REE and the respiratory quotient (RQ), 
given by the equation: exhaled CO2 /inhaled O2 (Simyrnios & Curley, as in Rippe et al., 
1996). There is a difference between BEE and REE. The BEE corresponds to the energy 
expenditure that occurs during a 12- to 14-hour fast and with the individual resting in the 
supine position, awake and immobile, under comfortable environmental conditions. This 
standardized metabolic state corresponds to the situation in which foods and physical 
activity have the least influence on metabolism (Institute of Medicine, 2005). Meanwhile, 
REE is obtained while the individual is awake in the supine position and includes the 
energy used during awakeness plus the energy used for food metabolism, or thermogenesis 
(Institute of Medicine, 2005). Both BEE and REE are influenced by gender, age, nutritional 
status and endocrine problems.  
Thermogenesis, or thermal effect of foods, corresponds to the increase in energy expenditure 
after food intake for digestion to occur and for the substrates to be transformed and stored. 
It represents roughly 5 to 10% of the TEE (Institute of Medicine, 2005; Prentice, 2007). 
Thermogenesis intensity and duration are determined primarily by the amount and 
composition of the foods consumed (Flatt, as cited in Bray, 1978). The use of proteins 
demands more energy than the use of carbohydrates, which demands more energy than the 
use of fats (Institute of Medicine, 2005, 1998, Larson et al., 1995). High-fat diets promote a 
low RQ. For carbohydrates, the RQ equals 1.00; for proteins, 0.82; and for fats, 0.70. For 
mixed diets, the RQ of 0.85 is usually used (Rosado & Monteiro, 2001).    
Physical activity is the most variable component of energy expenditure, varying both from 
individual to individual and from one day to the next. In inactive individuals, it represents 
roughly 15% of the TEE, while in active individuals it may exceed 30% of the TEE (World 
Health Organization, 1998). Physical activity can lead to steep increases in TEE because of 
the energy cost to perform the exercise and to recover from the exercise, or in the long-term, 
by changing the REE by increasing the amount of lean mass (Hill et al., 1995). The level of 
physical activity is commonly described as the ratio between TEE and REE (TEE:REE). This 
ratio is known as the level of physical activity level (PAL) and is used to asses physical 
activity habits as a component of daily energy expenditure (Institute of Medicine, 2005). 
The doubly-labeled water with deuterium and oxygen-18 technique, although less 
accessible, has been used increasingly for TEE assessment. The method, based on the 
principle of isotope dilution, consists in the ingestion of water containing ²H2O and H218O. 
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The labeled elements are then measured in organic fluids, namely blood and urine. The 
equations for predicting the energy requirements proposed by the Institute of Medicine 
(2005) in the Dietary Reference Intakes (DRI) stemmed from studies using doubly-labeled 
water in normal weight, pre-obese and obese populations. Studies with doubly-labeled 
water have made the generalized low-metabolism hypothesis associated with obesity less 
evident.  
Many researchers have observed that obese individuals, contrary to the expected, present a 
high REE, that is, their metabolic rate is not low (Das et al., 2004; Prentice, 2007). Obese 
individuals present a higher amount of lean mass, the main REE determinant (Prentice et al., 
1986; Prentice, 2007; Ravussin et al., 1986). The occurrence of less energy expenditure in 
other components of the energy metabolism has also been studied in obese individuals. 
Danforth (1985) noticed reduced thermogenesis from foods. Other authors have showed that 
REE is influenced by regular physical activity, diet, blood pressure, as well as hormones and 
cytokines (Trayhurn et al., 1995;   Hardie et al., 1996). Genetic predisposition must also be 
considered a determinant of energy expenditure.  
Many genes of the molecular components of physiological systems that regulate energy 
balance are involved in obesity (Duarte et al., 2007; Yurtcu et al., 2009). Examples of this are 
the polymorphisms found in genes of the uncoupling proteins 2 and 3 (UCP2 and UCP3) 
and in leptin receptors (LEPR) (Jacobson et al., 2006). Polymorphism Gln223Arg of the gene 
LEPR, for example, has already been associated with obesity in a sample of the Brazilian 
population, and it presented a strong association with body mass index – BMI (Duarte et al., 
2007). Studies with rats show that leptin can reduce adiposity both by promoting changes in 
eating habits and by increasing energy expenditure (Halaas et al., 1995). Ghrelin, a gastric 
peptide involved in the regulation of satiety and oxidation of energy substrates, is of interest 
for genetic studies on the weight loss mechanisms promoted by bariatric surgery (Marzullo 
et al., 2004). The regulation of ghrelin effects on hypothalamic neurons has been suggested 
as the most important mechanism by which leptin controls energy intake and body weight 
(Sahu, 2004).  
In some people, low energy expenditure could be explained by adaptive thermogenesis, which 
would occur naturally or as a consequence of dietary restrictions. There is evidence that low 
energy intake is a predictor of weight gain and that, in individuals who undergo weight loss 
therapies, decreased REE is associated with weight regain over time (Doucet et al. 2000). In this 
sense, food restriction promotes adaptive physiological mechanisms that serve as a defense of 
the body to maintain body weight, resulting in less energy expenditure (Negrão & Licino, 
2000). Hence, food restriction produces weight loss under adaptive conditions. The Institute of 
Medicine (2005), in the energy DRI assumes a reduction of 7.2 Kcal for each lost gram, which 
corresponds to 16.6 Kcal of TEE reduction at each kilogram lost. Furthermore, it considers a 
reduction of 8.4% of the TEE after 10 weeks of food restriction because of the adaptation to 
food restriction. In our studies, we have observed that in fact there is not a linear relationship 
between energy intake and body weight homeostasis. As shown by Figure 1, there is no 
correlation between total dietary energy and weight loss among obese women but there is a 
weak correlation between the reduced proportion of the total energy (TE) intake. This shows 
how relevant it is to personalize the diet plan considering the adaptation of the energy 
metabolism to restrictive diets. Caution is also warranted when prescribing excessively 
restrictive diets. Another relevant finding of our study group that corroborates this statement 
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was that there is a negative correlation between the reported number of attempts of losing 
weight and the resting energy expenditure measured by indirect calorimetry, assessed in 100 
women in the waiting line for bariatric surgery.   
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Fig. 1. Correlation between the absolute value (left) and the proportion of reduction of the 
habitually consumed energy in obese women after 2 months of a low-calorie diet (n = 28). 
SPEARMAN and RANK tests, with probability considered significant when p < 0.05. 
In studies done in the region of Piracicaba, São Paulo, Brazil (Dallemole, 2006; Souza, 2006; 
Fogaça, 2009) with women recruited from the general population and those who had 
undergone bariatric surgery, as shown in Chart 1, energy expenditure increases with body 
weight. However, in relative terms, there is less energy expenditure by unit of weight as 
weight increases. Operated women present absolute and relative REE lower than the other 
women.  
Since the first equation proposed by Harris and Benedict in 1919, many equations to predict 
REE were developed based on indirect calorimetry, and also to estimate TEE by combining 
the expenditure with physical activities with REE. The formulas used for predicting energy 
requirements have been widely used in clinical practice.  
A cross-sectional study was done by our group with 51 women aged from 28 to 61 years 
submitted to banded or not bariatric surgery (Roux-en-Y gastric bypass, RYGB) 5.1±1.7 
years before the study, all of them with stable weight. The measured REE was confronted 
with the values of the respective predictive equations obtained from regression studies in a 
number of different populations (Harris & Benedict, 1919; Schofield, 1985; Food and 
Agriculture Organization, World Health Organization & Organização das Nações Unidas, 
1985; Owen et al., 1986; Mifflin et al., 1990, Luis et al., 2006). When the measurements were 
compared (Figure 2), the values obtained by indirect calorimetry were below those obtained 
by the equations, and when the results were organized in increasing order of the value 
obtained by calorimetry (Figure 3), there was great similarity in the behavior of the lines 
constructed with the sequence of the results of the equations, but they diverged from those 
constructed with the results of calorimetry. Thirty-one (77.5%) women presented a median 
REE measured by indirect calorimetry below the REE estimated by the Harris & Benedict 
(1919) equation, indicating some women in the group had low metabolism. Weijs & Vansant 
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(2010) assessed 27 prediction equations in relation to the indirect calorimetry data from 
Belgium women and concluded that more specific equations are necessary for women 
whose BMI > 30 Kg/m2.  
 






< 25 22 1216±214 22±3 Dallemole, 2006 
25-30 11 1322±212 23±3 Dallemole, 2006 
30-35 13 1425±167 19±3 Dallemole, 2006 
> 35 35 1600±430 16±4 Souza, 2006 
Before and 3 months 
after surgery 
46±6 21 2006±376 17±4 Cesar et al., 2008 
39±6 21 1763±310 18±3 César et al., 2008 
2 or more years after 
surgery 
< 30 18 1046±264 15±4 Fogaça, 2009 
> 30 27 1270±252 15±3 Fogaça, 2009 
Chart 1. Energy expenditure determined by indirect calorimetry in women recruited in 
Piracicaba, São Paulo, Brazil.  
 
Fig. 2. Comparison of the resting energy expenditure measured by indirect calorimetry 
(IC) and estimated by different equation in women after two years of bariatric surgery 
(HB= Harris & Benedict; p<0.01 means compared with ANOVA; *p<0.01 others compared 
with the Tukey test; **p<0.05 in the comparison with FAO 1 and Luis by the Tukey test). 
The metabolic state can be classified as normal, high or low, by comparing the measured REE 
with the estimated REE according to the mean of a reference population, using a variation 
coefficient of 15% (Food and Agriculture Organization, World Health Organization & 
Organização das Nações Unidas, 1985). In this sense, very low REE values deserve better 
investigations regarding adaptation to metabolic restriction after bariatric surgery.  
These equations are based on body mass, height, age, gender and specific body composition 
markers, such as body surface area, lean mass, fat mass, total body potassium, among others 
(Rocha et al., 2005). The equations have been used in underweight, overweight, obese and 
morbidly obese individuals and also in those with specific diseases. However, interpersonal 
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variation shows that much caution is necessary for estimating REE by the existing prediction 
equations, since it has been shown that they do not always estimate REE correctly 
(Frankenfield  & Yousey, 2005) resulting in errors when estimating the energy requirements 
of individuals and populations (Duarte et al., 2007). More studies are necessary to state if the 
proportion of women with low metabolism who underwent bariatric surgery was in fact 
greater than that of the surgery-naive population, obese or otherwise, since there are not 
enough data from the population who lives in the same environmental conditions as that of 
the present study.  
Although much has been done since Harris & Benedict (1919), the current formulas for 
estimating REE and TEE (that takes into account the energy spent in physical activities) are 
very limited and tend to overestimate the results.  
 
Fig. 3. Illustration of the resting energy expenditure, in increasing order, measured by 
indirect calorimetry (IC), in relation to that estimated by different equations among women 
two years or more after bariatric surgery (n=51). 
3. Energy intake 
One of the most challenging aspects of the science and practice of nutrition and dietetics is 
the measurement of energy and nutrient intakes, given the limitations of the methods to 
correctly measure food intake (Subar et al., 2006). Dietary surveys are used as indirect 
methods for assessing nutritional status. However, these instruments are subject to mistakes 
inherent to the individual and data analysis and use (Beaton, 1994; Slater et al., 2004). 
Individual quantitative and qualitative food intake may be estimated by different diet 
survey methods. There are retrospective methods where individuals recall the foods they 
have eaten, such as the Food Frequency Questionnaire (FFQ) and the 24-hour Recall (24hR). 
And the methods in which the individual records, when he eats, all the foods he ate, thereby 
creating a food diary (Gibson, 2005). 
Intraindividual error sources, because of the variability of the food intake pattern, or 
interindividual error sources, stemming from the distribution of the population’s 
requirements, together with a small number of days of observation, have a great impact on 
the reliability of food intake data analysis (Nusser et al., 1996). Hence, intake assessment 
studies will always be reporting the apparent intake of the individual and not the real 
intake, but they can be statistically adjusted to approximate the actual intake (Institute of 
Medicine, 2005).   
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Possible error sources can distort information about food intake, such as the perception of 
what is eaten, the interviewee’s memory, the effects stemming from age, gender and 
interview environment, daily diet variation and seasonality, submission to data collection 
can affect the intake pattern and veracity of the information, the ability of the interviewer to 
obtain information and the disposition to collaborate with the investigation (Witschi, as in 
Willett, 1990). Practically, all dietary assessment studies are based on self-reporting of food 
intake, which can be biased, resulting in under- or overreporting of real energy intake (Black 
et al., 1991; Black, 2000), being able to seriously distort the interpretation of the study results 
(Rennie et al., 2006).   
Underreporting has been associated with a number of different individual characteristics, 
including gender, body mass index, age, ethnicity, race, smoking, education level, social 
class, depression and physical activity (Johansson, et al., 2001; Scagliusi, et al., 2003;  
Scagliusi et al., 2008; Maurer et al., 2006, Maurer et al., 2008; Mendez et al., 2011). The desire 
to be socially accepted and body dissatisfaction have also been associated with 
underreporting of food intake (Tooze et al., 2004; Maurer et al., 2006; Scagliusi, 2007). Excess 
weight may be one of the greatest determinants of subnotification (Johansson et al., 2001; 
Johnson, 2002; Huang, et al., 2005; Bazanelli et al., 2010).  
In individuals who are in energy balance, energy intake should correspond to the TEE. 
Thus, the doubly labeled water can be used to validate the energy obtained through dietary 
surveys. However, this method is unviable in large studies because of its cost and because it 
is technically challenging for use in routine validation of energy intake (Schoeller, 1999; 
Livingstone & Black, 2003).  
As an alternative, other methods for identifying underreporting can be used, such as the 
comparison between reported energy intake (EIrep) with TEE, when both are expressed in 
multiples of the REE, using a confidence interval for statistically comparing EIrep:REE with 
the level of PAL. During weight stabilization, EIrep:REE theoretically is equal to TEE:REE. 
The ratio TEE:REE is also known as PAL, then the equation may be rewritten as EIrep:REE = 
PAL (Goldberg, et al., 1991). 
As described by Black 2000, the cut-off point of the ratio EIrep:REE should be calculated for 
the group being studied, since below this level it is statistically unlikely that the mean 
energy intake reported represents the real consumption, according to the equation below:  
min
(S /100)Cut off point  PAL  exp [ SD    ] 
  n
   

 
Where SD is the standard deviation. When 95% of the confidence interval is used (SD min =-2) 
or 99.7% (SD min = - 3); n is the number of individuals in the study, but when this formula is 
used to individually detect underreporting, n=1. S is the factor that takes into consideration 
the variation of all components of the equation and is given by: 
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Where VCEIrep is the intra-individual energy intake variation coefficient; d is the number of 
days that the survey was administered; VCREE is the intra-individual variation coefficient of 
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greater than that of the surgery-naive population, obese or otherwise, since there are not 
enough data from the population who lives in the same environmental conditions as that of 
the present study.  
Although much has been done since Harris & Benedict (1919), the current formulas for 
estimating REE and TEE (that takes into account the energy spent in physical activities) are 
very limited and tend to overestimate the results.  
 
Fig. 3. Illustration of the resting energy expenditure, in increasing order, measured by 
indirect calorimetry (IC), in relation to that estimated by different equations among women 
two years or more after bariatric surgery (n=51). 
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Possible error sources can distort information about food intake, such as the perception of 
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energy intake reported represents the real consumption, according to the equation below:  
min
(S /100)Cut off point  PAL  exp [ SD    ] 
  n
   

 
Where SD is the standard deviation. When 95% of the confidence interval is used (SD min =-2) 
or 99.7% (SD min = - 3); n is the number of individuals in the study, but when this formula is 
used to individually detect underreporting, n=1. S is the factor that takes into consideration 
the variation of all components of the equation and is given by: 
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Where VCEIrep is the intra-individual energy intake variation coefficient; d is the number of 
days that the survey was administered; VCREE is the intra-individual variation coefficient of 
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repeated REE measurements and CVPAL is the intra-individual variation coefficient of the 
level of physical activity.  
Recently, other authors (Huang, 2005; Mendez, et al., 2011), assessed the underreporting 
phenomenon comparing EIrep with estimated TEE using the DRI equations (Institute of 
Medicine, 2005), adjusting the intra-individual variation of the equation components. The 
cut-off point is calculated for the study group in percentage (%EI:TEE). 
 





median 25% 75% median 25% 75% 
Energy (Kcal) 2780 1037 6338 1346 673 2981 0.000 
Carbohydrates (g) 320 115 1031 166 68 428 0.000 
Fats (g) 110 28 395 51 20 104 0.000 
Proteins (g) 104 38 302 51 15 89 0.000 
Energy distribution 
Carbohydrates (%) 50 28 72 51 38 61 0.387 
Fats (%) 38 14 56 34 25 49 0.034 
Proteins (%) 16 9 23 15 8 25 0.226 
p = Mann Whitney test used for comparing energy and macronutrient intakes before and after surgery 
Table 1. The energy and macronutrient intakes of women before surgery and two or more 









EIrep 1428 523 1334 1147 1678 
ER 2786* 524 2812 2389 3036 
Harris&Benedict (1919) 1445* 152 1445 1376 1604 
REE 1188 276 1209 1023 1376 
PALest 1,45 0,22 1,42 1,28 1,56 
EIrep :REE 1,27 0,57 1,08 0,86 1,66 
EIrep = reported energy intake, ER = estimated energy requirement, REE = measured resting energy 
expenditure, PALest = estimated level of physical activity.   
*p<0.000 in the paired t-test between EIrep and ER and between Harris & Benedict (1919) and REEmeasured.  
Table 2. Energy intake and expenditure variables in women more than two years after 
bariatric surgery (n=40). 
Among the bariatric patients we studied, mean reported energy intake before surgery 
corresponds to half the intake reported after surgery (Table 1). In the comparison, the 
 
Body Weight and Energy Intake and Expenditure in Bariatric Surgery 
 
219 
proportion of macronutrients in the energy of the diet varied little. The operated women 
consumed a fat proportion in the daily intake a little smaller than those in the waiting line 
for surgery. Those in the waiting line for surgery reported consuming a fat proportion above 
the recommended proportion (Institute of Medicine, 2005), while the operated women 
reported consuming a proportion close to the upper limit. About the data presented by 
Table 1, one may ask how much they correspond to reality based on the analysis presented 
by Table 2 given the discrepancy between the measured expenditure and reported intake. 
The data presented in Table 1 were obtained from 24-hour recalls on nonconsecutive days, 
one of the days being on a weekend. The data in Table 2 stem from indirect calorimetry, and 
the total energy requirement was calculated by the DRI formula (Institute of Medicine, 
2005). Among these women, the EIrep:REE and PAL values that, in theory should agree, 
present only a small correlation (Figure 4)  
Our data (Table 2 and Figure 3) show that energy intake divided by resting energy 
expenditure (EIrep:REE) was not compatible with the level of physical activity (PALest) of the 
studied population. On the other hand, this can be explained by overestimating the reported 
physical activity which composes the PALest calculation. It may also be related to a 
substantially greater energy intake than that reported. Although one may not expect 
absolute agreement on this datum, since there are measurement errors in all elements of the 
equation (EIrep:REE = PAL). The fact is that the studied women were in a stable weight 
condition and reported consuming half the estimated energy requirement (RE). This leads 
us to the generalization that the scale is still the best instrument for assessing the adequacy 
of energy intake. That is, if the individual is involuntarily gaining weight, it is because he is 
consuming more energy than he needs. However, it is not convenient to give up trying to 
solve this difficult issue, which is to know the values of the two sides of this balance, which 
for now remain obscure. This information can help to explain, for example, weight recovery 
after bariatric surgery, which, in most cases, is accompanied by intake underreporting.  
 
Fig. 4. Correlation between the estimated level of physical activity (PALest) and the ratio 
Energy Intake/Resting Energy Expenditure (EIrep/REE) in women more than two years 
after bariatric surgery (n=40).  
4. Body mass 
There is a consensus that lean mass (LM) is the greatest determinant of energy expenditure, 
since it is metabolically more active than fat mass (Ravussin et al., 1986). Meanwhile, the 
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differences in the volume of fat mass (FM), age and gender would have little effect on 
energy expenditure (Ravussin et al., 1986). Much has been discussed if an REE reduction 
could precede obesity; however, some researchers have rejected this hypothesis (Prentice, 
2007). On the contrary, obese individuals present a high REE, that is, they do not have a low 
metabolism (Das et al., 2004; Hams et al., 2009; Prentice, 2007). This may occur because these 
individuals present a greater amount of lean mass, main determinant of the REE (Prentice, 
2007; Prentice et al., 1986; Ravussin et al., 1986). Libel et al.  (1995) assessed the energy 
expenditure during 24 hours and the REE in obese individuals and individuals who had 
never been obese in their habitual weights; after gaining 10% of the body weight by 
consuming a hypercaloric diet; or after losing 10 to 20% of the body weight by consuming a 
hypocaloric diet. They found that energy expenditure changed in both groups, of obese and 
nonobese individuals, after the change in the body weight. A 10% increase or reduction in 
habitual body weight causes an increase or reduction, respectively, of 15% in the 24-hour 
energy expenditure corrected for body weight. They also verified that TEE presented a 
positive correlation with LM and FM. The positive correlation between the total body mass 
of obese individuals and TEE has been explained by the increase in energy necessary for 
moving this mass (Institute of Medicine, 2005). 
Reduction of LM associated with weight loss is also discussed, and that the reduction of LM 
would result in a reduction of TEE, thus the importance of exercising during weight loss. 
Tamboli et al. (2010) found a LM loss in the order of 27.8% one year after Roux-em-Y gastric 
bypass and associated this loss with the reduction of the TEE of these patients. In another 
study done in obese individuals after weight loss, concomitantly with REE reduction, there 
was a significant reduction of LM (Hill et al., 1987). 
Active individuals present a significantly higher REE than inactive individuals of the same 
weight (Matzinger et al., 2002). There is the hypothesis that this occurs because of the 
amount of LM, which is greater in active individuals (Tappy et al., 2003). The REE 
differences in body weight in many individuals like men, women or athletes normally 
disappear when REE is considered in relation to LM (Institute of Medicine, 2005).   
Based on these studies it is possible to verify that body composition, especially LM, 
significantly affects REE and TEE, both in obese and nonobese individuals. Current 
knowledge allows us to state that there is little difference between energy expenditure by 
unit of body mass of an underweight individual and an obese individual, but there is 
individual variation in the energy expenditure by unit of body mass of individuals in 
general, which in practice limits the use of formulas that predict energy requirement. In 
relation to surgery, studies that use more sensitive methods are needed to confirm the 
hypothesis that the REE adjusted for LM after surgery does not decrease, by adaptation or 
modification mechanisms of body composition in LM no matter how long after surgery.  
Type of fat tissue also appears to have a strong influence on energy expenditure. White fat 
tissue, in addition to working as a primary site for energy storage, produces a series of 
substances that act on many places of the body, modulating the general metabolism. Excess 
white fat tissue results in obesity. Meanwhile, brown fat tissue is highly specialized and is 
capable of regulating energy expenditure by adaptive thermogenesis. This process depends 
on UCP-1 expression (Cinti et al., 1997). White fat tissue is responsible for most of the leptin 
produced (Cinti et al., 1997), although the action of this peptide occurs in the hypothalamus, 
which is where most of its receptors are found (Schwartz et al., 1996). 
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The total LM in the body is the factor that is most closely associated with leptin 
concentrations in the blood and so BMI, which is an indirect measurement of body fat, is 
also strongly and positively associated with the concentration of circulating leptin 
(Considine et al., 1996; Jeon et al., 2003; Kennedy et al., 1997). In a study done by our 
research group, the positive correlation between BMI and serum concentration of leptin 
was confirmed (Figure 5). This study assessed 45 women, of which 27 had less than 10% 
of weight regain 2 or more years after surgery and 18 presented an appropriate weight 
loss.  
Another theme of interest relative to body composition is the role of FM by itself on the 
improvement of the comorbidities associated with obesity. Lowering of blood glucose 
(improvement of diabetes) in morbidly obese individuals after surgery occurs even before 
an important weight loss has been achieved and has been attributed to the modulation of 
the gastrointestinal hormonal response which acts in the recovery of the first phase of 
insulin secretion and improves its peripheral resistance (Polyzogopolou et al., 2003; 
Cummings et al., 2004). The important association of BMI with insulin and leptin 
concentrations in nondiabetic operated women (Figure 5) confirms the relevance of body 
weight reduction and maintenance for obtaining benefits after surgery. There was also a 
correlation of BMI with glucose concentration in women in the late postoperative period. 
Among the biochemical markers of lipid metabolism, an association between the 
concentrations of serum triglycerides with BMI was found, but not with total cholesterol 
and its fractions. The reduction of serum leptin that accompanies the reduction in body 
weight after bariatric surgery was inversely associated with the secretion of VLDL in studies 
of particle kinetics (Magkos, 2010), showing that the triglyceride metabolism has an 
important relationship with BMI.  
 
Fig. 5. Correlation of the serum leptin concentrations and insulin with body mass index 
(BMI) in women in the late postoperative period after Roux-en-Y gastric bypass (n=41, 
r=0.729; R2=0.531; p = 0.000), (Fogaça, 2009). 
Finally, an aspect of great relevance associated with obesity and insulin resistance is the 
distribution of body fat. Not all obese individual are insulin-resistant, and it has been shown 
that predominantly abdominal obesity is more strongly associated with insulin resistance. 
Inflammation of the omental adipose tissue is an important determining factor of insulin 
resistance (Hardy, 2011).   
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Energy balance is determined by energy intake and expenditure variables. Among the energy 
expenditure variables, REE and the expenditure with physical activities are responsible for 
roughly 90% of the TEE. Based on calorimetry studies, we have noticed that there is an 
important interpersonal variation in REE of women submitted to bariatric surgery. To know 
the magnitude of the effect of surgery on REE, we are conducting a prospective study to assess 
the interpersonal variation before surgery and after different lengths of postoperative time. 
Another aspect that needs to be better elucidated is the magnitude of the effect of physical 
exercise on REE in different lengths of postoperative periods.  
In the energy requirement assessment, the use of prediction REE formulas does not seem 
adequate for the bariatric population and should be done with caution.  
Physical activity is an important component of total energy expenditure and TEE 
assessment depends on precise information regarding the type and duration of each activity. 
As the energy intake registry, the registry of physical activity must be detailed and as close 
as possible of the real energy intake. This is a challenging task since among the obese, 
overestimation of the reported intake usually happens.   
If, on the one hand, physical activities are usually overestimated, on the other hand, and more 
strikingly, food intake reports are usually underestimated. Among obese women, intake 
reports can be below the REEmeasured, which is completely implausible. This observation 
challenges us in the development of more appropriate methods to assess food intake.  
BMI is an important indicator of the result of bariatric surgery and more studies are 
necessary on the effects of the distribution and type of body fat and the surgery results on 
the comorbidities associated with obesity.  
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Energy balance is determined by energy intake and expenditure variables. Among the energy 
expenditure variables, REE and the expenditure with physical activities are responsible for 
roughly 90% of the TEE. Based on calorimetry studies, we have noticed that there is an 
important interpersonal variation in REE of women submitted to bariatric surgery. To know 
the magnitude of the effect of surgery on REE, we are conducting a prospective study to assess 
the interpersonal variation before surgery and after different lengths of postoperative time. 
Another aspect that needs to be better elucidated is the magnitude of the effect of physical 
exercise on REE in different lengths of postoperative periods.  
In the energy requirement assessment, the use of prediction REE formulas does not seem 
adequate for the bariatric population and should be done with caution.  
Physical activity is an important component of total energy expenditure and TEE 
assessment depends on precise information regarding the type and duration of each activity. 
As the energy intake registry, the registry of physical activity must be detailed and as close 
as possible of the real energy intake. This is a challenging task since among the obese, 
overestimation of the reported intake usually happens.   
If, on the one hand, physical activities are usually overestimated, on the other hand, and more 
strikingly, food intake reports are usually underestimated. Among obese women, intake 
reports can be below the REEmeasured, which is completely implausible. This observation 
challenges us in the development of more appropriate methods to assess food intake.  
BMI is an important indicator of the result of bariatric surgery and more studies are 
necessary on the effects of the distribution and type of body fat and the surgery results on 
the comorbidities associated with obesity.  
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1. Introduction 
Dietary and activity programs result in poor weight loss or poor maintenance of weight loss, 
and bariatric surgery therefore remains the major treatment option for patients with 
medically-complicated obesity. There are now over 220,000 bariatric surgical procedures 
performed each year in the United States and Canada. The ‘divided’ or ‘isolated’ Roux-en-Y 
gastric bypass remains the most commonly performed bariatric surgical procedure in the 
United States and Canada for surgical treatment of patients with medically-complicated 
obesity.  
Micronutrients in human physiology include essentials minerals such as iron, water soluble 
vitamins (such as the B vitamins and vitamin C), fat soluble vitamins (A, D, E, and K), and 
trace elements (zinc, copper, selenium, manganese, and likely chromium). Understanding 
the origins for micronutrient deficiencies in patient who have undergone bariatric surgery 
should permit better screening and maintenance techniques to prevent and discover 
underlying deficiencies. As a first step, the importance of preoperative evaluation for 
identification of micronutrient deficiencies is under evaluation. The importance of this 
preventative approach is supported by recent reports of major or fatal nutritional 
complications occurring more than 20 years after bariatric surgery.  
In this chapter, dietary methods including food journals are shown to be important for 
examining pre-operative diets in order to predict potential micronutrient deficiencies. The 
relatively insufficient intake of specific micronutrients in those patients instructed post-
operatively on a high protein diet is discussed.  
The surgical origins for micronutrient deficiencies that are induced by bypass of 
physiologically relevant segments of the gastrointestinal tract are summarized. This chapter 
includes a discussion of the pre-operative medically-induced origins for micronutrient 
deficiencies including the importance of chronic gastric infection with Helicobacter pylori and 
small intestinal bacterial overgrowth related to diabetic gut autonomic neuropathy. Post-
operative medical conditions that lead to micronutrient deficiencies including small 
intestinal bacterial overgrowth induced by achlorhydria of the gastric pouch are described.  
Clinical presentations of micronutrient deficiencies after bariatric surgery are summarized. 
Common micronutrient deficiencies considered after bariatric surgery include iron 
deficiency, vitamin D deficiency and thiamine deficiency. Vitamin D deficiency with 
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gastric bypass remains the most commonly performed bariatric surgical procedure in the 
United States and Canada for surgical treatment of patients with medically-complicated 
obesity.  
Micronutrients in human physiology include essentials minerals such as iron, water soluble 
vitamins (such as the B vitamins and vitamin C), fat soluble vitamins (A, D, E, and K), and 
trace elements (zinc, copper, selenium, manganese, and likely chromium). Understanding 
the origins for micronutrient deficiencies in patient who have undergone bariatric surgery 
should permit better screening and maintenance techniques to prevent and discover 
underlying deficiencies. As a first step, the importance of preoperative evaluation for 
identification of micronutrient deficiencies is under evaluation. The importance of this 
preventative approach is supported by recent reports of major or fatal nutritional 
complications occurring more than 20 years after bariatric surgery.  
In this chapter, dietary methods including food journals are shown to be important for 
examining pre-operative diets in order to predict potential micronutrient deficiencies. The 
relatively insufficient intake of specific micronutrients in those patients instructed post-
operatively on a high protein diet is discussed.  
The surgical origins for micronutrient deficiencies that are induced by bypass of 
physiologically relevant segments of the gastrointestinal tract are summarized. This chapter 
includes a discussion of the pre-operative medically-induced origins for micronutrient 
deficiencies including the importance of chronic gastric infection with Helicobacter pylori and 
small intestinal bacterial overgrowth related to diabetic gut autonomic neuropathy. Post-
operative medical conditions that lead to micronutrient deficiencies including small 
intestinal bacterial overgrowth induced by achlorhydria of the gastric pouch are described.  
Clinical presentations of micronutrient deficiencies after bariatric surgery are summarized. 
Common micronutrient deficiencies considered after bariatric surgery include iron 
deficiency, vitamin D deficiency and thiamine deficiency. Vitamin D deficiency with 
 
Advanced Bariatric and Metabolic Surgery 
 
230 
metabolic bone disease remains common after gastric bypass and recent results suggest that 
the present postoperative supplements of calcium and Vitamin D are inadequate. The 
potential role of copper deficiency as an origin for visual disorders and neurological 
disorders after gastric bypass is discussed. A major goal of ongoing clinical studies is a 
better understanding of whether blood levels of micronutrients are sufficient to exclude 
underlying deficiency states or whether clinical symptoms must be identified and 
categorized in patients who have undergone bariatric surgery.  
2. Micronutrients 
Macronutrients including fat, protein, and carbohydrates are important dietary components 
for conversion into chemical energy and for tissue and cellular structure. By contrast, 
micronutrients are essential dietary factors required for biochemical and cellular processes 
(please see Table 1). Specific micronutrients are required in microgram or milligram 
quantities in a diverse group of biochemical pathways and metabolic processes. 
Micronutrients include trace elements (chromium, copper, manganese, selenium and zinc), 
essential minerals (including calcium, iodine, iron, and magnesium), water-soluble vitamins 
(including B vitamins and vitamin C) and fat-soluble vitamins (vitamins A, D, E, and K). 
 
Water Soluble Vitamin   Cofactor In 
Thiamine (Vitamin B1)   Thiamine Pyrophosphate 
Riboflavin (Vitamin B2)   Flavin Adenine Dinucleotide 
Niacin (Vitamin B3)   Nicotinamide Adenine Dinucleotide 
Folic Acid    Tetrahydrofolate 
Pyridoxine (Vitamin B6)   Pyridoxal Phosphate 
Cobalamin (Vitamin B12)   5'-Deoxyadenosyl-Cobalamine 
Ascorbic Acid (Vitamin C) 
 
Trace Elements    Cofactor In 
Chromium    Uncertain 
Copper Cytosolic Superoxide Dismutase & 
Cytochrome Oxidase 
Manganese Mitochondrial Superoxide Dismutase 
Selenium Glutathione Peroxidase 
Zinc Cytosolic Superoxide Dismutase & Hundreds 
of Proteins 
 
Essential Minerals Cofactor In 
Calcium 
Iodine Thyroid Hormone 








Table 1. Micronutrients and their roles as cofactors 
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Many bariatric programs recommend taking a comprehensive multivitamin with minerals 
twice daily after a malabsorptive procedure, and a daily calcium supplement (≥1.2 g/day 
elemental calcium). It is not certain whether these suggestions are sufficient to prevent 
micronutrient deficiencies after Roux-en-Y gastric bypass. This level of supplementation is 
unlikely to be adequate after a biliopancreatic diversion.  
3. Dietary origins for micronutrient deficiencies 
3.1 Statement of the problem 
Body mass index (BMI; in kg/m2) is used to classify underweight (BMI <18.5), normal 
weight (BMI 18.5-24.9), overweight (25-29.9), obese (BMI 30-39.9), and extreme obesity (BMI 
> 40). Over the last 20 years, there has been a dramatic increase in obesity in the United 
States. Data from two National Health and Nutrition Examination Surveys (NHANES) show 
that among adults aged 20-74 years, the prevalence of obesity increased from 23%, in the 
1988-1994 survey, to 33.8% in the 2007-2008 survey (1). Since the prevalence of obesity is 
increasing rapidly, it is important to find effective weight control or weight loss strategies 
for these individuals. This is of international concern as it appears that other developed 
countries are also facing increases in the prevalence of obesity. 
Lifestyle interventions that involve diet, exercise, and behavior change strategies can result 
in an average weight loss of 7-10% of initial body weight after 6 months of treatment (2, 3). 
The most effective treatment for obesity, on the other hand, is bariatric surgery. The average 
mean excess weight loss (%EWL) is 50% for the adjustable gastric band and 68% for Roux-
en-Y gastric bypass. This dramatic weight loss not only improves quality of life, but also 
reduces the risk of developing health conditions and may even improve existing health 
problems. Although weight loss improves health, surgical treatments for severe obesity may 
make pre-existing nutritional deficiencies worse or produce new ones, depending on dietary 
intake, adherence to supplementation and the degree of malabsorption associated with the 
bariatric procedure performed (4). As the popularity of bariatric surgery continues to 
increase, it is important for clinicians working with these individuals to identify and treat 
preexisting nutritional deficiencies. 
3.2 Proposed origins 
It has been proposed that the major causes of obesity include a combination of lack of 
physical activity, a high-fat, high-caloric Western diet, increased portion sizes, and low 
socioeconomic status (5-8). Regarding diet, data from four NHANES conducted between 
1971 and 2002 for trends in self-reported food intake showed that energy intake, amount of 
food, and carbohydrate energy have significantly increased in all race and gender groups. 
Findings from a study published by Neilson (7) illustrate how energy intake has increased 
by increasing portion sizes. They found that between 1977 and 1996, portions inside and 
outside the home increased for salty snacks (by 93 Kcals), soft drinks (by 49 Kcals), 
hamburgers (by 97 Kcals), French fries (by 68 Kcals), and Mexican food (by 133 Kcals). 
Clearly, this increase growth in portion sizes mirrors our growing waistlines. 
In addition to diet and increasing portion sizes, socioeconomic status and the environment 
must also be considered as contributors to the growing problem of obesity. Fruits, 
vegetables, low-fat dairy, nuts and legumes, and lean proteins are considered unprocessed, 
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nutrient–dense foods, which contribute most of the vitamins and minerals necessary for 
health. While foods that are processed such as prepackaged convenience foods, sweets, and 
snack goods provide a high amount of calories but are nutrient-poor and lack proteins, 
vitamins, minerals, and fiber. These energy-dense, nutrient-poor foods are often more 
affordable than foods of lower energy-density or higher nutrient-density such as fruits, 
vegetables, and whole grains (9, 10). Poverty can lead to food insecurity and one outcome of 
food insecurity is obesity (11). It has been found that households characterized as food 
insecure also have the highest body mass index and prevalence of obesity (12). When a 
household runs out of food and is uncertain about the ability to obtain enough food, the 
quality of the diet becomes compromised and leads to an increase in the intake of energy 
from foods that are higher in fat and carbohydrate, but lower in nutrients (11). This may be 
one of the reasons why we see so many nutritional deficiencies in obese persons. 
3.3 Micronutrient deficiencies and dietary intake 
Studies are demonstrating that micronutrient deficiencies are common in obese people even 
before bariatric surgery (13, 14). As discussed above, one cause of these nutritional 
deficiencies in overweight and obese individuals may be due to a high intake of processed 
foods that are calorically dense, but nutritionally-poor. Additionally, obese individuals may 
have altered bioavailability of many nutrients, a condition that has been called “high calorie 
malnutrition” (15). The combination of low preoperative vitamin status and the 
malabsorption that follows bariatric surgery may leave these patients at risk for many 
severe vitamin deficiencies. Typical nutritional deficiencies associated with obesity include 
antioxidants, vitamin A, vitamin D, B-complex vitamins, calcium, iron, and zinc (16). In a 
retrospective study of 379 patients planning for gastric bypass, significant deficiencies were 
identified for thiamine (29%), iron (44%), and 25-hydroxyvitamin D (68%). A second study 
also examined cross-sectional data from NHANES III and found that obese subjects (n = 
3831), particularly premenopausal women, were more likely to have low levels of various 
micronutrients than were normal-weight adults in the same sex/age category (17). Among 
women, low biochemical micronutrient levels were associated with increasing BMI categories 
for vitamin E, alpha-carotene, beta-carotene, beta-cryptoxanthin, lutein/zeaxanthin, lycopene, 
total carotenoids, vitamin C, selenium (premenopausal), vitamin D, and folate. And among 
men, low biochemical micronutrient levels were associated with increasing BMI categories 
for alpha-carotene, beta-carotene, beta-cryptoxanthin, lutein/zeaxanthin, total carotenoids, 
vitamin C, selenium, and folate. Since nutritional deficiencies are so common in the obese 
population, it will remain important to conduct trials involving preoperative testing with 
treatment of micronutrient deficiencies prior to surgery, in order to look for improved 
postoperative outcomes.  
Behavioral weight loss programs often involve a reduced calorie diet, increased energy 
expenditure, and use of behavior strategies such as goal setting and self-monitoring (18). 
Self-monitoring has been described as the cornerstone of behavioral treatment for weight 
loss (19, 20). Usual techniques for self-monitoring involve keeping food, weight, and activity 
diaries. One recent randomized-controlled trial compared the effectiveness of self-
monitoring with a paper diary versus two types of personal digital assistants (PDA) (21, 22). 
After 6 months, they found that, compared to the paper diary group, both PDA groups were 
more adherent to self-monitoring and that self-monitoring of diet in this group had a 
significant indirect effect on percent weight loss. The use of food diaries not only improves 
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ones chances for weight loss, but it also gives clinicians a tool to assess food intake and 
dietary patterns. In addition, it may help to identify possible nutritional deficiencies both 
before and after weight loss surgery. 
When considering what nutritional deficiencies may be present before surgery it is important 
to look at what we are eating as a nation. NHANES is a continuous, cross-sectional survey 
designed to monitor the health and nutritional status of the civilian, noninstitutionalized U.S. 
population (23). Based on the most recent 2007-2008 NHANES data, adults over age 20 are not 
meeting the minimum recommended intakes for fruit, vegetables, and low-fat dairy and thus 
had diets that that did not meet the dietary reference intakes (DRIs) in fiber, vitamin A, 
vitamin D, vitamin E, vitamin K (men only), calcium, magnesium (women only) and 
potassium (24). It is interesting to note that over one-third (36.8% for men and 35.5% for 
women) of the total daily caloric intake for adults comes from solid fats, added sugars, and 
alcohol (SoFAS). This is well above the highest recommended limit and may be one answer to 
the growing obesity problem in America. MyPyramid recommends calories from SoFAS to 
range from 132-512 per day based on height, weight, gender, and activity level. According to 
the 2007-2008 NHANES data, the mean intake of calories from SoFAS in adult men was 923 
calories/day and for women it was 624 calories/day.  
Another recent study analyzed 2-day, 24-hour recall data from the 2003–2004 NHANES and 
found that fewer than 1 in 10 Americans met the MyPyramid recommendations for fruit and 
vegetable intake (25). Only 0.9% of adolescents, 2.2% of adult men, and 3.5% of adult 
women met the recommendations for both fruit and vegetables. A higher percentage of 
participants met fruit recommendations alone, 6.2% (adolescents), 8.6% (adult men), and 
12.3% (adult women). Adolescents consumed less whole fruit and more juice than adults 
and the largest contributor to fruit intake was orange juice. Only 5.8% of adolescents, 14.7% 
of adult men and 18.6% of adult women met recommendations for vegetable intake. 
Interestingly, when fried potatoes were excluded only 2.2% of adolescents, 9% of adult men 
and 13.4% of adult women met recommendations for vegetable intake. The percentage 
meeting recommendations for vegetable subtypes for all groups was lowest for dark green 
vegetables, orange vegetables, and legumes but higher for starchy and other vegetables. 
This data makes it clear that we are not meeting the recommended intakes for low-calorie, 
nutrient-dense foods. And when we are choosing vegetables, they are likely to be fried 
starchy vegetables with added fats and thus contribute excessive calories in the diet. It is 
also important to consider the amount of calories we are consuming from the beverages we 
are drinking when looking at the obesity problem. One recent report based on NHANES 
data between 2005-2008, states that 50% of the population consumes sugary drinks on any 
given day, while 25% consumes some sugary drinks but less than 200 kcal (more than one 
12-oz can of cola), and 5% consumes at least 567 kcal from sugar drinks per day (more than 
four 12-oz cans of cola) (26). Consumption of sugary drinks is lowest among the oldest 
females (42 kcal per day) and highest among males aged 12–19 (273 kcal per day). Among 
adults aged 20 and over, it was found that non-Hispanic white persons consume fewer 
sugary-drink calories as a percentage of total daily calories (5.3%) than do non-Hispanic 
black (8.6%) or Mexican-American persons (8.2%). Low-income individuals tend to consume 
more sugary beverages than higher-income individuals. Among adults living below 130% of 
the poverty line, they report that mean calories from sugary drinks makes up 8.8% of total 
calories; among those living between 130% and 350% of the poverty line, mean calories from 
sugary drinks is 6.2% of total calories; and among those at or above 350% of the poverty line, 
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mean calories from sugary beverages is 4.4% of total calories. This data is alarming since 
consuming sweetened beverages has been linked to poor diet quality, weight gain, obesity, 
and, in adults, type 2 diabetes (27, 28). Since a good portion of our calories are coming from 
sugary beverages and calorie-dense, nutrient-poor foods, it is understandable why we find 
many obese patients with micronutrient deficiencies prior to weight loss surgery. It is 
therefore important to screen for these and to treat their nutritional deficiencies prior to 
surgery to help to prevent major or fatal nutritional complications that may occur in the 
long-term after bariatric surgery. 
4. Surgical origins for micronutrient deficiencies 
4.1 Roux-en-Y gastric bypass 
Roux-en-Y gastric bypass (RYGB) is the most commonly performed bariatric surgery in 
North America and remains the major surgical option for individuals with medically-
complicated obesity. The divided RYGB combines restriction of food intake, due to the small 
size of the gastric pouch and constriction at the gastrojejunal anastomosis, with 
malabsorption induced by bypass of the duodenum and variable lengths of jejunum (see 
Figure 1). A small proximal stomach pouch is created with a stapler device and is connected 
to distally transected jejunum. The remnant stomach and proximally transected jejunum is 
then reattached in a Y-shaped configuration to the distal small intestine. Malabsorption of 
both fat and nitrogen has been identified in studies of the Roux-en-Y reconstruction (29). 
Malabsorption was corrected by providing oral, exogenous pancreatic enzymes. The RYGB 
bypasses native stomach that secretes intrinsic factor which is required for vitamin B12 
absorption, as well as proximal small intestine which is required for absorption of copper, 
iron, and thiamine. The length of small intestine between the gastrojejunostomy and the 
jejunojejunostomy is not exposed to bile, thus limiting absorption of fat soluble vitamins due 
to absence of micelle formation. Reduced vitamin D levels due to malabsorption induce 
inadequate calcium absorption and utilization.  
 
Fig. 1. Roux-en-y gastric bypass. The orientation of the gastro-jejunal anastomosis can be 
different depending upon whether it is formed during an open or laparoscopic surgery. The 
location of the jejuno-jejunal anastomosis alters the length of the common channel, which 
extends from the jejuno-jejunostomy to the ileocecal valve. (Adapted with permission from 31) 
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There are multiple studies of micronutrient deficiencies after RYGB. A major study of 493 
patients after laparoscopic RYGB revealed deficiencies of vitamin A (11%), vitamin C 
(34.6%), vitamin D (7%), thiamine (18.3%), riboflavin (13.6%), vitamin B6 (17.6%), and 
vitamin B12 (3.6%) at 1 year after surgery (30). The results must be considered with regards 
to the body’s reserves for different vitamins (18 days for thiamine and 3 to 5 years for 
vitamin B12 and vitamin E).  
4.2 Adjustable gastric banding 
Laparoscopic adjustable gastric banding (LAGB) is an effective strategy for the surgical 
treatment of morbidly obese patients and is the most common bariatric procedure in Europe 
and Australia. Restriction is created by placing a silicone band around the fundus of the 
stomach, approximately 4 cm distal to the gastroesophageal junction. The level of gastric 
constriction by the band can be adjusted by addition or removal of saline through a 
subcutaneous port placed above the abdominal musculature (see Figure 2). Since the 
introduction of the modern adjustable gastric band in 1994, this procedure has continued to 
gain momentum as a therapeutic alternative to RYGB. Since LAGB is a restrictive procedure, 
nutritional deficiencies are not expected post-operatively. However, recent reports of 
micronutrient deficiencies are now emerging. A study of LAGB in adolescents revealed 
vitamin D deficiency as the second most common micronutrient deficiency (after iron 
deficiency anemia) within the first two years after surgery (32).  
 
Fig. 2. Gastric Adjustable Band. As shown in the lower half of this drawing, the band is 
placed laparoscopically around the upper part of the stomach, approximately 4 cm below 
the gastroesophageal junction. As shown in the upper half of this drawing, the access port in 
placed subcutaneously on top of the abdominal musculature. The ring or band is connected 
to the access port by tubing and its volume can be adjusted by accessing the port in order to 
add or remove sterile saline (Adapted with permission from Allergan, Inc. from 
http://www.allergan.com/assets/pdf/lapband_dfu.pdf).  
4.3 Vertical sleeve gastrectomy 
Sleeve gastrectomy (SG), or gastric sleeve, is a surgical weight-loss procedure in which the 
stomach is reduced to about 15% of its original size by surgical removal of a large portion of 
the stomach along the greater curvature. Despite being described as a solely restrictive 
procedure, micronutrient deficiencies post operatively are common. A recently published 
study from the Netherlands showed that 21% patients were Vitamin D deficient within one 
year of having a SG (33). This deficiency occurred despite daily multi-vitamin 
 
Advanced Bariatric and Metabolic Surgery 
 
234 
mean calories from sugary beverages is 4.4% of total calories. This data is alarming since 
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There are multiple studies of micronutrient deficiencies after RYGB. A major study of 493 
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to the body’s reserves for different vitamins (18 days for thiamine and 3 to 5 years for 
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supplementation. Bone loss and bone remodeling also occurs following SG in as little as one 
year. Significant bone mass loss and remodeling were recorded in a study using bone 
densitometry and bone remodeling markers (34). Despite the presence of micronutrient 
deficiencies induced by SG, studies show that fewer nutrient deficiencies occur after SG as 
compared to RYGB (35). However, SG is often combined with the duodenal switch 
procedure as described in section 4.4.  
4.4 Biliopancreatic diversion 
Biliopancreatic diversion (BPD), or the Scopinaro procedure, is the original weight loss 
surgery. This procedure is now rarely performed because of problems with severe 
malnutrition and severe early complications, including death (36, 37). BPD is the hallmark of 
a malabsorptive procedure that produces substantial and sustained weight loss, but the 
malabsorption of fat and protein is paralleled by malabsorption of fat soluble and water 
soluble vitamins, minerals, and trace elements.  
This operation has been replaced by malabsorptive procedures that obtain a “physiological” 
biliopancreatic diversion, through formation of a jejuno-enteric anastomosis ≤120 cm from 
the ileocecal valve (i.e. by preparation of a long Roux limb or by preparation of a long 
biliopancreatic limb). Malabsorption induced by a short common channel in part involves 
inadequate micelle formation, with subsequent development of steatorrhea.  
By comparison, in the duodenal switch procedure, the duodenum is transected 5 cm distal 
to the pylorus; the distal duodenal segment (stump) is then oversewn. Small intestine is 
transected approximately 1/3 of its length to the ileocecal valve. The distal transected 
segment is used in the production of an anastomosis to proximal duodenum and the 
proximal transected segment is used in the production of an entero-enteric anastomosis 
(which is 75 to 100 cm proximal to the ileocecal valve). 
In comparison to RYGB, low serum levels of zinc and copper are more common in 
individuals after biliopancreatic diversion (38). A randomized trial of RYGB compared to 
duodenal switch revealed increased deficiencies of thiamine, vitamin A, and vitamin D in 
the first year after duodenal switch (107).  
5. Medical origins for micronutrient deficiencies 
5.1 Preoperative deficiencies 
Major micronutrients that have been examined preoperatively include vitamin D (vitamin D 
deficiency is reported in 25% to 96% of morbidly obese individuals) (39-42) and thiamine 
(15% prevalence of low preoperative thiamine levels among 437 consecutive obese patients) 
(43). Obesity was identified as a risk factor, in a preoperative surgical population, for 
finding low plasma ascorbic acid concentrations (44). In preoperative obese patients in 
Israel, common micronutrient deficiencies included iron (35%), folic acid (24%), and vitamin 
B12 (3.6%) with high levels of parathyroid hormone identified in 39% of patients (45). A 
high prevalence of vitamin A deficiency in obese, preoperative patients has been described 
(46), but daily supplementation with 5,000 IU of retinol acetate (ester derivative of Vitamin 
A) did not fully resolve vitamin A deficiency 6 months after RYGB.  
 
Origins for Micronutrient Deficiencies 
 
237 
5.2 Weight loss supplements and programs 
Special dietary programs and dietary supplements, which are commonly utilized by 
morbidly obese individuals, have been associated with development of micronutrient 
deficiency (47, 48). Starvation, which has been previously suggested as a treatment for 
obesity, can also contribute to the development of thiamine deficiency.  
5.3 Pharmacological agents 
Pharmacologic agents can result in micronutrient depletion through multiple mechanisms. 
Excretion of urinary zinc is enhanced by diuretics, such as hydrochlorothiazide (49, 50).  
A second proposed mechanism involves molecular mimicry. The prototype drug for this 
proposed mechanism is conversion of metronidazole to an analog of thiamine, an inhibitor 
of thiamine pyrophosphokinase (51).  
Thiamine deficiency induced by parenteral feedings (52) may be caused by consumption 
induced by a high glucose load or may be induced by development of sepsis (53), 
especially in patients being treated for postoperative complications. More severe beriberi 
is associated with the development of lactic acidosis and “fulminant beriberi” may be 
related to thiamine depletion induced by a high glucose load in patients receiving total 
parenteral nutrition (54).  
Alcohol consumption appears to be a toxic origin for depletion of multiple micronutrients, 
including B vitamins (55), folate (due to a weak antifolate effect) (56), and zinc and selenium 
(57).  
5.4 Small intestinal bacterial overgrowth 
Small intestinal bacterial overgrowth is another potential explanation for the development 
of micronutrient deficiencies. After Roux-en-Y gastric bypass, there is relative achlorhydria 
of the gastric pouch, which may permit upper gut bacterial overgrowth. As another 
potential origin for small bowel bacterial overgrowth, it has been suggested that small 
intestinal bacterial overgrowth in patients with diabetes mellitus is related to the presence of 
a gut motility disorder (58). In support of this mechanism, the prevalence of small intestinal 
bacterial overgrowth is higher in diabetic patients who have evidence for autonomic 
neuropathy (59). In a preliminary study, we have previously noted upper gut bacterial 
overgrowth among patients who have undergone an adjustable gastric band, perhaps 
induced by stasis in the proximal gastric pouch (60).  
In our previous study, postoperative thiamine deficiency after RYGB was associated with 
small intestinal bacterial overgrowth (31). Consumption of micronutrients by small 
intestinal bacteria has been reported but is not fully understood. There are multiple 
studies of the effect of bacteria on vitamin B12 and thiamine. A major observation in this 
field has been that bacteria secrete thiaminases, which can cleave thiamine (61-63). 
Staphylococcus aureus produces a thiaminase type II that is regulated at both the 
transcriptional as well as the enzymatic level. Thiaminase type II catalyzes the cleavage 
(deamination) of thiamine.  
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6. Deficiencies of micronutrients 
6.1 Water soluble vitamins 
The biochemical roles of water-soluble vitamins and their associated deficiency disorders 
are shown in Table 2. There is only minor storage in the body of most water-soluble 
vitamins.  
 
VITAMIN   DEFICIENCY STATE SYMPTOMS 
 
Thiamine (Vitamin B1)   Beriberi   See Table 3 
Riboflavin (Vitamin B2)   Ariboflavinosis  Anemia, Stomatitis, Glossitis, 
Dermatitis 
Niacin (Vitamin B3)   Pellagra   Diarrhea, Dermititis, Ataxia, 
Confusion 
Folic Acid Folate deficiency anemia Weakness, Anorexia, Weight 
Loss 
Pyridoxine (Vitamin B6) Dermititis, Confusion, 
Neuropathy 
Cobalamin (Vitamin B12)  Pernicious Anemia Depression, Ataxia, 
Parasthesias 
Ascorbic Acid (Vitamin C)  Scurvy  Malaise, Myalgias, Petechia, 
Gum Disease 
Table 2. Water soluble vitamins and their deficiencies 
6.1.1 Thiamine 
Thiamine or vitamin B1 deficiency is a major nutritional complication following RYGB (31). 
Thiamine deficiency or beriberi was originally described in individuals with multi-organ 
involvement, including cardiac, gastrointestinal or neuropsychiatric symptoms that 
corrected with “beriberi factor” or thiamine (see Table 3)). We have described after RYGB 
the presence of thiamine deficiency that does not correct with oral thiamine. “Bariatric 
beriberi” is associated with small intestinal bacterial overgrowth and antibiotic therapy may 
be required to correct thiamine deficiency.  
Among the major clinical presentations of beriberi, patients with neuropsychiatric beriberi 
may have auditory and visual hallucinations, or aggressive behavior. Wernicke’s disease 
presents with confusion (impairment of memory or altered mental state), nystagmus, ataxia, 
and ophthalmoplegia. Patients with high output cardiovascular disease (wet beriberi) have 
been reported to have tachycardia, respiratory distress, or lower extremity edema, with 
right ventricular dilation and lactic acidosis. Patients with neurological (dry beriberi) 
present with numbness or muscle weakness, pain of lower greater than upper extremities, 
or convulsions. Gastrointestinal beriberi induces delayed emptying of the stomach. After 
gastric bypass surgery, common symptoms include nausea and emesis in patients who may 
have megajejunum and constipation in patients who may have megacolon. A recent case 
study supports the notion that thiamine deficiency can induce both a sensory ataxia and 
optic neuropathy (64), a symptom complex more commonly believed to suggest copper 
deficiency.  
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Only a small percentage of total body thiamine is present in whole blood. Measurement of 
erythrocyte transketolase activity is an alternative approach for determination of thiamine 
deficiency (65). This bioassay is based upon binding of the catalytic activity of the enzyme 
transketolase to thiamine pyrophosphate. Due to the seriousness of thiamine deficiency, 
recent European guidelines suggest that after bariatric surgery, patients should have follow-
up evaluation of their thiamine status for at least 6 months and receive parenteral thiamine 
supplementation (66).  
A standard therapy for thiamine deficiency is thiamine HCl 100 mg taken orally twice daily. 
In patients who do not respond to oral thiamine, the presence of small intestinal bacterial 
overgrowth must be considered. Acute psychosis and Wernicke’s encephalopathy are 
medical emergencies. These conditions require hospitalization with supportive care and a 
minimum of 250 mg of thiamine given daily intramuscular or intravenously (infused over 3 
to 4 hours to reduce the risk of an anaphylactoid reaction) for at least 3 to 5 days (67). Most 
patients report symptomatic improvement within several days after the first parenteral dose 
of thiamine HCl. An autopsy is recommending for those individuals who have died from 
suspected Wernicke encephalopathy (66).  
 
BERIBERI SUBTYPE      SYMPTOMS AND FINDINGS 
 
Neuropsychiatric Hallucinations; Aggressive Behavior; 
 Confusion; Nystagmus; Ataxia; Ophthalmoplegia 
 
Neurologic    Numbness; Muscle Weakness and Pain of 
Lower>Upper Extremities; 
(Dry beriberi)     Convulsions; Exaggerated Tendon Reflexes 
 
High Output Cardiac Tachycardia; Bradycardia; Respiratory Distress; Leg 
Edema; 
(Wet beriberi) Right Ventricular Dilation; L-Lactic Acidosis 
 
Gastroenterologic Nausea; Vomiting; Slow Gastric Emptying; 
Megajejunum; Constipation; Megacolon 
Table 3. Clinical features of beriberi  
6.1.2 Riboflavin 
Riboflavin or vitamin B2 is present in the flavocoenzymes, flavin adenine dinucleotide and 
flavin mononucleotide. Flavocoenzymes are a major participant in a number of reactions 
important in metabolic pathways and in the proper functioning of glutathione peroxidase 
(required for metabolism of hydroperoxides) and glutathione reductase (generates reduced 
glutathione from oxidized glutathione). Biochemical but not clinical riboflavin deficiency 
has been reported after bariatric surgery (30). Clinical symptoms of riboflavin deficiency 
include sore throat, stomatitis, anemia, and a scaly dermatitis. It has been suggested that 
riboflavin deficiency may play a role in the development of migraine-like headaches. The 
standard treatment for riboflavin deficiency is 5-10 mg daily of oral riboflavin.  
Since the reliability of the serum assay for vitamin B2 is uncertain, a clinical improvement in 
a potential symptom during supplementation with oral riboflavin may support the 
diagnosis of a deficiency state.  
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Nicotonic acid or vitamin B3 is converted into both nicotinamide, a component of 
nicotinamide adenine dinucleotide (involved in catabolic reactions), and nicotinamide 
adenine dinucleotide phosphate (involved in anabolic reactions). Clinical deficiency of 
niacin has not been reported after bariatric surgery, although it has likely been present in 
patients with multiple B vitamin deficiencies. It is difficult to diagnose niacin deficiency by 
laboratory studies, but the diagnosis is supported by low plasma niacin. Deficiency of niacin 
is termed pellagra, which includes neurologic, dermatologic, and gastrointestinal 
involvement. Patients may present with headaches, ataxia or myoclonus, anxiety-
depression, delusions or hallucinations, painful, scaly dermititis, and a malabsorptive 
disorder or diarrhea with colitis. The initial treatment of pellagra is initiation of oral niacin 
100-500 mg, three times daily (this may induce flushing). Symptomatic improvement during 
niacin supplementation could support a diagnosis of niacin deficiency. 
6.1.4 Folate 
In studies of patients with small intestinal bacterial overgrowth, a high serum folate level is 
an identified and validated marker for bacterial overgrowth (68). Folate levels in patients 
after RYGB must therefore be considered in the context of a patient’s risk for development 
of small intestinal bacterial overgrowth. In patients who have folate deficiency after bariatric 
surgery, the potential for another small intestinal malabsorptive disorder, including celiac 
sprue, should be considered. Patients with folate deficiency are generally detected in this 
patient population in individuals with a normocytic, mixed anemia with an increased red 
cell distribution width. Symptoms of folate deficiency include weakness, anorexia, and 
weight loss. Treatment of folate deficiency begins with oral folic acid, 1 to 5 mg daily. 
6.1.5 Vitamin B6 
The active form of vitamin B6 is pyridoxal phosphate. A clinical diagnosis of vitamin B6 
deficiency has not been widely recognized after bariatric surgery. Patients with vitamin B6 
deficiency can present with dermatitis, confusion, anemia and neurologic symptoms. 
Peripheral neuropathy has also been reported with vitamin B6 deficiency (69). Treatment 
can be started with oral vitamin B6 at 30 mg daily; a post-therapy increased level of 
pyridoxal phosphate is then consistent with repletion of vitamin B6.  
6.1.6 Vitamin B12 
Vitamin B12 deficiency is a well-described nutritional deficiency after bariatric surgery and 
is likely multifactorial in origin (30). RYGB results in the exclusion of the majority of parietal 
cell mass, which is a site of R factor and intrinsic factor production. Relative achlorhydria 
after bariatric surgery prevents oral cyanocobalamin from being deconjugated from pteryl 
groups, before cyanocobalamin absorption.  
Because of vitamin B12 storage in the body, development of vitamin B12 deficiency may 
become clinically relevant 3 to 5 years after bariatric surgery. Methyl malonic acid blood 
levels will increase when vitamin B12 stores are depleted (70). A low normal blood level of 
vitamin B12 can indicate the presence of deficiency. Clinical manifestations of vitamin B12 
deficiency include the multiple presentations of pernicious anemia or the development of 
 
Origins for Micronutrient Deficiencies 
 
241 
peripheral neuropathy. In treatment of vitamin B12 deficiency, daily oral cobalamin is 
considered less effective than the intra-muscular preparation. Treatments for Vitamin B12 
deficiency include: i. oral vitamin B12 (cyanocobalamin) 350 to 500 mcg per day, ii. 
intramuscular vitamin B12 1,000 mcg every month or 3,000 mcg every 6 months, iii. nasal 
(500 mcg once weekly), or iv. sublingual (500 mcg, once daily) preparation.  
6.1.7 Vitamin C 
Biochemical evidence for vitamin C or ascorbic acid deficiency is common after bariatric 
surgery (44). Ascorbic acid deficiency is suggested by clinical symptoms. In our clinical 
practice, bariatric patients present with fatigue or complaint of arthralgias. Early reported 
symptoms include malaise, myalgias, and petechia, with progression to gum disease 
(scurvy). Standard treatment for a patient with vitamin C deficiency is oral ascorbic acid 200 
mg daily.  
6.2 Fat soluble vitamins 
Signs and symptoms of the fat soluble vitamin (A, D, E, and K) deficiency are summarized 
in Table 4.  
 
VITAMIN   SYMPTOMS 
A    Nyctalopia, Blindness 
D    Arthralgias, Myalgias, Fasciculations 
E Anemia, Dysarthria, Ataxia, Myopathy 
K    Bleeding Disorder 
Table 4. Fat soluble vitamins and their deficiencies 
6.2.1 Vitamin A 
Vitamin A complex includes retinols, beta-carotenes, and carotenoids, and there is 
approximately a 1 year supply stored in human liver. When ingested in high doses, 
excessive doses of vitamin A may cause headache, vomiting, diplopia, alopecia, dryness 
of the mucous membranes, bone abnormalities, and liver damage. Signs of toxicity 
usually appear with sustained daily intakes exceeding 15,000 IU. As alternative therapy, 
signs of toxicity have not been observed while receiving beta-carotene, a previtamin A 
analogue.  
Vitamin A deficiency after bariatric surgery is most commonly seen in patients who have 
undergone a biliopancreatic diversion, duodenal switch, or extended Roux-en-Y gastric 
bypass. In these procedures, the mechanism of deficiency is most likely related to fat soluble 
vitamin malabsorption induced by bile acid deficiency. In addition, individuals with zinc 
deficiency have impaired protein synthesis that may alter retinol transport from the liver to 
other organs. Manifestations of vitamin A deficiency in a bariatric patient include nocturnal 
visual difficulty, dry skin, dry hair, and pruritus. Other potential manifestations include 
decreased visual acuity and reduced resistance to infections. Treatment of vitamin A 
deficiency includes supplemental vitamin A, 10,000 IU daily by mouth (with co-therapy of 
any existing iron deficiency since vitamin A deficiency may persist in the presence of iron 
deficiency).  
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symptoms include malaise, myalgias, and petechia, with progression to gum disease 
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approximately a 1 year supply stored in human liver. When ingested in high doses, 
excessive doses of vitamin A may cause headache, vomiting, diplopia, alopecia, dryness 
of the mucous membranes, bone abnormalities, and liver damage. Signs of toxicity 
usually appear with sustained daily intakes exceeding 15,000 IU. As alternative therapy, 
signs of toxicity have not been observed while receiving beta-carotene, a previtamin A 
analogue.  
Vitamin A deficiency after bariatric surgery is most commonly seen in patients who have 
undergone a biliopancreatic diversion, duodenal switch, or extended Roux-en-Y gastric 
bypass. In these procedures, the mechanism of deficiency is most likely related to fat soluble 
vitamin malabsorption induced by bile acid deficiency. In addition, individuals with zinc 
deficiency have impaired protein synthesis that may alter retinol transport from the liver to 
other organs. Manifestations of vitamin A deficiency in a bariatric patient include nocturnal 
visual difficulty, dry skin, dry hair, and pruritus. Other potential manifestations include 
decreased visual acuity and reduced resistance to infections. Treatment of vitamin A 
deficiency includes supplemental vitamin A, 10,000 IU daily by mouth (with co-therapy of 
any existing iron deficiency since vitamin A deficiency may persist in the presence of iron 
deficiency).  
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6.2.2 Vitamin D 
Vitamin D deficiency after RYGB induces metabolic bone disease (71). Vitamin D deficiency 
activates a metabolic cascade resulting in decreased calcium absorption and insufficient 
calcium availability. This cascade induces subsequently hypocalcemia, secondary 
hyperparathyroidism, and development of osteoporosis and osteomalacia (72-74). Patients 
will see their physician for symptoms of bony pain, back pain, or aching of the limbs (75).  
There is a high frequency of and serious nature of metabolic bone disease after RYGB 
including bone biopsy-proven osteomalacia with marrow fibrosis (76). Symptoms may be 
present for as long as 2 to 5 years prior to evaluation.  
Studies of patients after RYGB demonstrate that maintenance of normal serum calcium 
involves increasing bony release of calcium and decreasing urinary calcium secretion. After 
RYGB, a high prevalence of bone resorption and hyperparathyroidism may exist 
independent of intake of calcium and Vitamin D status (77, 78). This raises a concern that the 
present recommendations for daily calcium and vitamin D supplementation may not be 
protective after RYGB, especially in female patients. Commonly, in postoperative follow up 
after RYGB, patients will still have evidence for inadequate blood levels of vitamin D 
despite vitamin D oral supplements.  
For monitoring, 24-hour urinary calcium determination and a serum alkaline phosphatase 
level every 6 to 12 months is commonly suggested. However, urine calcium secretion can be 
altered by concomitant use of diuretics. If urinary calcium excretion is low and the serum 
alkaline phosphatase activity is increased, alkaline phosphatase should be fractionated. If 
the alkaline phosphatase is of bone origin, then a serum parathyroid level should be 
measured. An increase in serum parathyroid level supports supplementation with 
additional vitamin D and calcium. It is important to obtain a total 25-hydroxy vitamin D 
level every 12 months or earlier if a patient has a low 24-hour urinary calcium excretion. 
Low vitamin D levels require consideration of several explanations, including bile salt 
deficiency, rapid weight loss phase, and small intestinal bacterial overgrowth (which may 
interfere with vitamin D absorption). 
To try to prevent vitamin D deficiency and thus secondary metabolic bone disease, post-
operative RYGB patients should receive at least 1.2 grams daily of elemental calcium and 
800 international units (IU) of vitamin D daily. In those patients with low serum levels of 25-
hydroxy vitamin D, 50,000 IU of vitamin D (ergocalciferol) taken orally once per week for 
six to eight weeks is prescribed with a recheck of the 25-hydroxy Vitamin D level after eight 
weeks to confirm repletion (79). The reported dose for treatment of rickets is at least 600,000 
IU, which has been given as rapidly as 150,000 IU, taken four times daily during 1 day of 
treatment. In treatment of osteomalacia, significant improvement in patients’ clinical 
symptoms, functional status, biochemical indices and bone mineral density has been 
reported after treatment with a combination of ergocalciferol (100,000 IU daily) and calcium 
carbonate (1 to 2.5 g daily).  
6.2.3 Vitamin E 
Vitamin E consists of tocopherols and tocotrienols. This fat-soluble vitamin is located in cell 
membranes, and it may be active in preventing lipid peroxidation. Most adults tolerate 
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doses of vitamin E up to 1000 mg/day (0.67 mg of vitamin E is 1 IU) without gross signs or 
biochemical evidence of toxicity (80).  
Deficiency of vitamin E should be considered in bariatric patients who have visual 
symptoms (retinopathy), non-specific neurological symptoms (ataxia, dysarthria, muscle 
weakness due to myopathy, or ptosis), or hemolytic anemia. Treatment of vitamin E 
deficiency should include oral vitamin E 800 to 1200 IU daily.  
6.2.4 Vitamin K 
Vitamin K describes a group of compounds which contain the 2-methyl-1,4-naphthoquinone 
moiety. These compounds are essential for the formation of prothrombin, and five factors 
(factors VII, IX, and X, and proteins C and S) involved in regulation of blood clotting. 
Vitamin K is moderately (40 to 70%) well absorbed from the jejunum and ileum (81).  
Absorption of vitamin K depends on the normal flow of bile and pancreatic secretion, and 
its absorption is enhanced by dietary fat. The total body pool of vitamin K is small. Most of 
the daily requirements for vitamin K is provided through biosynthesis by the intestinal 
flora. Deficiency of vitamin K leads to increase risk of bleeding disorders.  
Vitamin K deficiency is rare after bariatric surgery. There is a report of 5 babies with 
intracranial hemorrhage whose mothers had undergone bariatric surgery (82), suggesting 
vitamin K deficiency. Replacement of vitamin K can be accomplished with an oral form (2.5 
to 25 mg daily) or with parenteral delivery of vitamin K (5-15 mg, intramuscularly or 
subcutaneously).  
6.3 Essential minerals 
Most studies of essential minerals after bariatric surgery involve iron and calcium. It is not 
presently known whether long-term deficiencies occur with other minerals after bariatric 
surgery.  
6.3.1 Iron 
Development of anemia after bariatric surgery is common and the origins for anemia are 
complex. Many patients after bariatric surgery require iron supplementation for treatment 
of anemia. Several potential mechanisms may explain iron malabsorption after bariatric 
surgery, including relative achlorhydria (acid may improve absorption of non-heme iron 
from plant sources by oxidation of Fe2+ to the better-absorbed Fe3+ cation) and bypass of 
proximal small intestine (the major location for iron absorption). Identification of iron 
deficiency in a bariatric patient requires consideration of other potential gastrointestinal 
origins for the development of iron deficiency anemia. Routine treatment of iron deficiency 
includes use of an iron/vitamin C complex or 150 to 200 mg/day of oral elemental iron in 
any preparation (gluconate/sulfate/fumarate). Parenteral iron is occasionally needed in 
those patients who have a poor response to oral iron therapy, especially in premenopausal 
women with heavy menstrual bleeding (83).  
It is not commonly known that iron supplementation has risks. Iron supplementation for 
whatever purpose should be monitored, since electron transfer from transition metals such 
as iron to oxygen-containing molecules can initiate free radical reactions. Large doses of 
unnecessary iron supplements could induce an acquired iron overload disorder.  
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doses of vitamin E up to 1000 mg/day (0.67 mg of vitamin E is 1 IU) without gross signs or 
biochemical evidence of toxicity (80).  
Deficiency of vitamin E should be considered in bariatric patients who have visual 
symptoms (retinopathy), non-specific neurological symptoms (ataxia, dysarthria, muscle 
weakness due to myopathy, or ptosis), or hemolytic anemia. Treatment of vitamin E 
deficiency should include oral vitamin E 800 to 1200 IU daily.  
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Vitamin K describes a group of compounds which contain the 2-methyl-1,4-naphthoquinone 
moiety. These compounds are essential for the formation of prothrombin, and five factors 
(factors VII, IX, and X, and proteins C and S) involved in regulation of blood clotting. 
Vitamin K is moderately (40 to 70%) well absorbed from the jejunum and ileum (81).  
Absorption of vitamin K depends on the normal flow of bile and pancreatic secretion, and 
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the daily requirements for vitamin K is provided through biosynthesis by the intestinal 
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vitamin K deficiency. Replacement of vitamin K can be accomplished with an oral form (2.5 
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subcutaneously).  
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Most studies of essential minerals after bariatric surgery involve iron and calcium. It is not 
presently known whether long-term deficiencies occur with other minerals after bariatric 
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6.3.1 Iron 
Development of anemia after bariatric surgery is common and the origins for anemia are 
complex. Many patients after bariatric surgery require iron supplementation for treatment 
of anemia. Several potential mechanisms may explain iron malabsorption after bariatric 
surgery, including relative achlorhydria (acid may improve absorption of non-heme iron 
from plant sources by oxidation of Fe2+ to the better-absorbed Fe3+ cation) and bypass of 
proximal small intestine (the major location for iron absorption). Identification of iron 
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origins for the development of iron deficiency anemia. Routine treatment of iron deficiency 
includes use of an iron/vitamin C complex or 150 to 200 mg/day of oral elemental iron in 
any preparation (gluconate/sulfate/fumarate). Parenteral iron is occasionally needed in 
those patients who have a poor response to oral iron therapy, especially in premenopausal 
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It is not commonly known that iron supplementation has risks. Iron supplementation for 
whatever purpose should be monitored, since electron transfer from transition metals such 
as iron to oxygen-containing molecules can initiate free radical reactions. Large doses of 
unnecessary iron supplements could induce an acquired iron overload disorder.  
 




Vitamin D deficiency and calcium malabsorption can occur simultaneously. Vitamin D 
deficiency activates a metabolic cascade resulting in hypocalcemia and secondary 
hyperparathyroidism. Steatorrhea due to malabsorption induces calcium malabsorption 
through the interaction of dietary calcium with intraluminal triglycerides.  
Isolated serum calcium measurement is not an adequate marker of calcium metabolism. 
Patients may present with complaints of bony pain, back pain, or aching of the limbs. 
Bariatric surgery patients can maintain normal serum calcium by decreasing urinary 
calcium secretion. Urine calcium secretion can however be altered by concomitant use of 
diuretics. Treatment of calcium deficiency requires minimally oral calcium of ≥ 1.2 grams 
daily and concomitant correction of vitamin D deficiency.  
6.3.3 Iodine 
There are no reports of iodine deficiency after bariatric surgery. Weight loss after bariatric 
surgery is associated with resolution of subclinical hypothyroidism (84). 
6.4 Trace elements 
Trace elements function as co-factors for antioxidant enzymes or proteins. Trace elements in 
supplements provide a relatively narrow range of safety between deficiency and toxicity. 
Because of their ability to donate or accept electrons, transition metals have potential 
antioxidant properties.  
6.4.1 Zinc 
Zinc is important in the bioactivity of hundreds of mammalian proteins and is a co-factor in 
cytosolic superoxide dismutase. Zinc may reduce the formation of the highly toxic 
hydroxyradical (OH-) from H2O2 produced through the antagonism of redox-active 
transition metals, such as iron and copper (85). There are reports of biochemical zinc 
deficiency after bariatric surgery (86). However, clinical zinc deficiency in bariatric patients 
has not been well studied. Symptoms of zinc deficiency can include a dermatological 
eruption, alopecia, glossitis, hypoalbuminemia and nail dystrophy. Initial treatment of zinc 
deficiency is with oral zinc gluconate, 50 mg, taken every other day.  
6.4.2 Copper 
Copper is a co-factor in cytosolic superoxide dismutase as well as cytochrome oxidase. 
Animal studies support a linkage in the absorption of copper and zinc (most likely in the 
stomach and upper small intestine), but a recent study using a human cell line suggests that 
a different copper transport protein is active in copper absorption in humans (87). Ingestion 
of fructose appears to reduce the biological activity of copper, as demonstrated by 
decreasing the activity of superoxide dismutase in erythrocytes (88).  
Copper deficiency may result from the use of liquid vitamin supplements that do not 
contain copper. The occurrence of decreased serum copper levels has been reported through 
case reports involving bariatric patients, generally >10 years after RYGB (89). Copper 
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deficiency in susceptible individuals can induce anemia and neutropenia, or pancytopenia 
(90, 91). There have also been, in the past several years, reports of RYGP patients who have 
developed a myelopathy-like disorder with spastic gait and sensory ataxia associated with 
low serum copper levels (92). The clinical and neuroimaging findings in these patients are 
similar to the findings identified in patients with vitamin B12 deficiency. Similar symptoms 
associated with low serum copper have been reported in individuals with Celiac sprue (93). 
This condition has been termed by Dr. Kumar “human swayback”, which is an unfortunate 
description since research workers studying swayback in lambs have been reported to 
develop multiple sclerosis, raising the question of an infectious etiology (94). Unfortunately, 
copper supplements given to patients with low serum copper levels and symptoms of 
myeloneuropathy do not appear to lead to a significant improvement in their neurologic 
symptoms (95). Further work is needed to better understand the origin for and the treatment 
for this rare neurologic complication.  
Optic neuropathy has been reported to occur in patients after bariatric surgery in association 
with low serum copper levels (96). However, copper infusion therapy had no effect on the 
optic neuropathy. From this report, it is therefore unclear whether the damage was 
irreversible or whether other micronutrient deficiencies may have been involved in the optic 
neuropathy.  
Treatment of copper deficiency can begin with oral copper gluconate, 2 to 4 mg, taken every 
other day. Higher daily oral doses involving use of 6 mg copper have been reported to be 
required in some patients (97). Correction of copper deficiency in individual patients may 
necessitate intravenous infusions of copper chloride (98).  
6.4.3 Selenium 
Selenium is a trace element that is known to be essential for activation of glutathione 
peroxidase, a key enzyme in the body’s defense against oxygen-derived free radicals. Selenium 
supplementation, alone and in combination with other micronutrients, has been extensively 
studied. Selenium deficiency induces a cardiomyopathy in those regions of the world in which 
selenium levels in the soil are low, as in China. There is a case report of a patient presenting 
with a severe cardiomyopathy 9 months after biliopancreatic diversion (99). Treatment of 
selenium deficiency begins with sodium selenite, 100 micrograms daily taken orally.  
6.4.4 Chromium 
It is not known whether chromium is a required cofactor in humans. Chromium deficiency 
has not been reported after bariatric surgery. The potential role of chromium in human 
nutrition is based on observations from patients receiving total parenteral nutrition. Case 
reports have discussed, in patients with total parenteral nutrition, development of an 
abnormal intravenous glucose tolerance test, weight loss, and peripheral neuropathy 
associated with decreased blood chromium levels (100).  
6.4.5 Manganese 
Manganese is an important cofactor in inducible mitochondrial superoxide dismutase. 
Manganese deficiency has not been reported after bariatric surgery. Deficiency of 
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studied. Selenium deficiency induces a cardiomyopathy in those regions of the world in which 
selenium levels in the soil are low, as in China. There is a case report of a patient presenting 
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6.4.4 Chromium 
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associated with decreased blood chromium levels (100).  
6.4.5 Manganese 
Manganese is an important cofactor in inducible mitochondrial superoxide dismutase. 
Manganese deficiency has not been reported after bariatric surgery. Deficiency of 
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manganese in animal models inhibits collagen deposition during wound healing and 
induces skeletal deformation.  
7. Symptoms and findings of micronutrient deficiencies 
7.1 Anemia 
This is the most commonly recognized and treatable nutrient deficiency after bariatric 
surgery (101, 102). Patients with normal hemoglobin levels can have low ferritin levels after 
RYGB, supporting the addition of iron supplementation at that time. Iron deficiency anemia 
can be monitored by checking hemoglobin, hematocrit, and mean corpuscular volume as 
part of a complete blood count. Routine treatment of iron deficiency includes treatment with 
an iron/vitamin C complex or with 150 to 200 mg/day of oral elemental iron in any 
preparation (gluconate/sulfate/fumarate). If there is an incomplete response to oral iron 
therapy and vitamin B12 and an evaluation by a gastrointestinal specialist has not provided 
a specific diagnosis, one must then consider additional micronutrient deficiencies and other 
origins for anemia. Other nutritional origins of anemia must be excluded by examining 
levels of folate, zinc, copper, and vitamins A and E (see Table 5).  
As mentioned above, a gastrointestinal specialist should be consulted when anemia does not 
correct with iron and vitamin B12 supplementation, in order to exclude blood (i.e. iron) loss 
from a colon source, a stomal ulcer, a duodenal ulcer, or antritis. Blood loss from the gastric 
remnant can at times be addressed by a double balloon enteroscopy. The lengths of the 
Roux limb and the pancreaticobiliary limb may preclude direct endoscopic visualization of 
the duodenum and bypassed stomach. If one needs to visualize the “bypassed” stomach 
and duodenum, this can be accomplished by intraoperative endoscopy performed through a 
laparoscopically-assisted gastrotomy, which will allow insertion of an endoscope directly 
into the bypassed stomach.  
7.2 Neurologic symptoms 
Neurologic complaints are reported by about 1% of post-operative patients in surveys, but 
are described by 5% of patients in prospective studies (103). A main determination is 
whether the neurologic complaint is indeed related to a post-operative disorder. Patients 
present most commonly with peripheral neuropathy after RYGB (104). Micronutrient 
deficiencies involving vitamin B12 and copper are reported in bariatric surgery patients who 
have been seen for neurologic symptoms (105). Reported neurologic emergencies include 
Wernicke’s disease and Guillain-Barre syndrome.  
In patients with neurologic symptoms, blood levels of vitamin B12, vitamin B2, vitamin B6, 
vitamin E, copper, thiamine, and niacin should be obtained (see Table 5). Physicians must 
remember that patients may expect to have neurological symptoms after RYGB (and 
therefore may not report their symptoms) and patients may believe that neurologic 
symptoms are related to their history of diabetes mellitus.  
It is not clear whether the routine use of chewable multivitamins containing minerals after 
bariatric surgery prevent neurologic disorders. It is not known whether neurologic 
symptoms can be consistently reversed by treatment of specific micronutrient deficiencies. 
There are only anecdotal reports of the use of micronutrient infusions for the treatment of 
neurologic symptoms (a typical intravenous infusion would include, mixed in 5% dextrose 
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in aqueous solution, a standard injectable multivitamin formulation [several are 
commercially available] with a mixture of trace elements, such as Multitrace 5 concentrate, 
and both 100 mg thiamine hydrochloride and 1 mg folic acid). Revision of bariatric surgery 
in order to reduce the length of bypassed small intestine has been reported to be of clinical 
benefit in a patient with neurologic symptoms (105). Physicians should be cautious, should 
encourage strongly the use of supplemental multivitamins, and should routinely screen all 
patients for neurologic symptoms during their postoperative visits.  
SYMPTOM           LABORATORY TESTING 
Anemia     Ferritin; Vitamin B12; Folate; Zinc; Copper; 
     Vitamins A; Vitamin E 
Neurologic Symptoms   Vitamin B12; Vitamin E; Copper; Thiamine;  
     Vitamin B2; Vitamin B6; Plasma Niacin 
Visual Symptoms   Vitamin A; Vitamin E; Whole blood thiamine;  
  Copper 
Bleeding Disorder Complete Blood Count; Prothrombin Time 
Skin Disorders Vitamin A; Vitamins B2; Vitamin B6; Zinc; Plasma 
 Niacin 
Edema Selenium; Plasma Niacin; Whole Blood Thiamine 
Table 5. Laboratory testing after bariatric surgery 
7.3 Visual disorders 
Manifestations of vitamin A deficiency include nocturnal visual difficulty and decreased 
visual acuity. Vitamin E deficiency can induce visual symptoms related to retinopathy. 
Patients with thiamine deficiency can present with complaints of difficulty focusing their 
vision or persistent blurred vision; on physical examination, nystagmus is often identified. 
Optic neuropathy has been reported in patients with deficiencies of copper and thiamine. In 
laboratory evaluation, one should consider obtaining serum levels of vitamin A, vitamin E, 
copper and whole blood thiamine (see Table 5).  
7.4 Skin disorders 
Symptoms of zinc deficiency include a dermatological eruption, but it is unclear whether 
this occurs after bariatric surgery. Manifestations of vitamin A deficiency include xerosis 
and pruritus. Essential fatty acid deficiency, niacin deficiency, and riboflavin deficiency can 
cause a scaly dermititis. The two essential fatty acids, linoleic acid and linolenic acid, are 
both present in flaxseed oil, soybean oil, and canola oil. One can consider ordering serum 
levels of vitamin B2, vitamin A, zinc, and plasma niacin (see Table 5).  
7.5 Edema 
Underlying heart failure is a major concern when a bariatric patient presents with edema. 
Patients with thiamine deficiency can develop high output cardiovascular disease (wet 
beriberi) and may present with tachycardia, bradycardia, respiratory distress, lower 
extremity edema, right > left ventricular dilation, and lactic acidosis. Selenium deficiency is 
another known cause of heart failure. Evaluation of edema could include determination of 
serum selenium, plasma niacin, and whole blood thiamine levels (see Table 5).  
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In considering other medical conditions, edema could be caused by obstructive sleep 
apnea. Edema can develop in patients with hypoalbuminemia. An underlying hepatic 
disorder, potentially the end result of steatohepatitis, should be considered. Other origins 
of hypoalbuminemia include an inflammatory process and small intestinal bacterial 
overgrowth. There is a serious syndrome of post-operative diarrhea associated with 
hypoalbuminenia and diffuse edema. This disorder may be induced by severe protein-
calorie malnutrition due to a physiological biliopancreatic diversion, such as an extended 
(distal) Roux-en-Y gastric bypass or a duodenal switch. In addition, it has been reported 
that this syndrome improves with antibiotic therapy (106) supporting the role of small 
intestinal bacterial overgrowth. Finally, niacin deficiency can induce a diarrheal illness or 
colitis that may be responsible for development of hypoalbuminemia as an origin for 
peripheral edema.  
8. Conclusions 
There is an increasing prevalence of obesity in developed countries. Dietary intake may be 
both an origin for obesity as well as an origin for the development of micronutrient 
deficiencies. Since dietary and activity programs fail to produce sufficient weight loss in 
most obese individuals, bariatric surgery will continue to be the major therapeutic options 
for patients with medically-complicated obesity. Many patients after bariatric surgery will 
develop micronutrient deficiencies despite suggestions for the use of ongoing vitamin and 
mineral supplementation. Common micronutrient deficiencies after bariatric surgery 
include deficiencies of iron, vitamin B12, thiamine, and vitamin D. The risks of 
micronutrient deficiencies are highest in those individuals who have undergone a 
malabsorptive surgical procedure. Other origins for micronutrient deficiencies include the 
utilization of pharmacological agents or dietary supplements, and the presence of upper gut 
or small intestinal bacterial overgrowth. Micronutrient deficiencies must be considered 
when patients develop specific symptom complexes. It is not yet known whether an 
ongoing survey of symptoms or a regularly scheduled determination of blood levels of 
micronutrients will prove to be the best detection method to screen bariatric patients for 
micronutrient deficiencies.  
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1. Introduction 
Peroneal neuropathy, causing foot drop, is a common mononeuropathy accounting for 
approximately 15 % of all the mononeuropathies in adults. (A. Cruz-Martinez, et al. 2000, E. 
Shahar , et al., 2007) A relationship between peroneal nerve palsy and weight loss has been 
well documented over the last decades. (D.G. Sherman, et al., 1977, K.A. Sotaniemi ,1984, E. 
Streib, 1993, I. Aprile et al.,  2000, M.J.H. Harrison, 1984) During World War II, foot drop 
was frequently observed in prisoners of war. Prolonged sitting as well as weight loss were 
speculated to be the cause of foot drop. (F. Kaminsky. 1947, D. Denny-Brown, 1947) In the 
sixties, foot drop was also related to cancer. Paraneoplastic phenomena were thought to be 
the cause of this neurological condition, however all patients with foot drop had significant 
weight loss due to the primary disease. (D.I. Rubin, et al.,1998) In severe diabetes (with 
weight loss) also many patients developed peripheral nerve problems. Here, ‘diabetic 
neuropathy’ was thought to be the main reason for this condition. During the last decade 
many reports of foot drop due to starvation or weight loss were published. (A. Cruz-
Martinez, et al. 2000, E. Shahar , et al., 2007, D.G. Sherman, et al., 1977, K.A. Sotaniemi ,1984, 
E. Streib, 1993, I. Aprile et al.,  2000, D.I. Rubin, et al., 1998, P.J. Koehler, et al., 1997, I. Lutte, 
et al., 1997) It became clear that substantial weight loss itself could cause foot drop. Further 
study of the pathogenesis of this condition is required.  
2. Material and methods 
In our institution 160 patients were operated for persisting foot drop between January 1995 
and December 2005. In all cases an L5 radiculopathy was excluded and a peroneal 
neuropathy -with a conduction block at the fibular head- was demonstrated by 
electromyography. When selected, all patients were interviewed to detect the possible cause 
of their neurological condition. The different pathophysiological conditions are summarized 
in figure 1. Weight loss (>10% of body weight) was found in 43.5 % of the patients, the 
reasons being dieting, bariatric surgery, severe illness (pneumonia, cancer, diabetes,…), 
psychiatric disorder, etc. 
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Fig. 1. Cause of peroneal palsy in 160 operated patients: 77 pts with weight loss, 51 pts with 
unknown cause, 19 pts with external compression ( due to positioning ), 10 pts with internal 
compression ( fibular fracture, haematoma, cystic lesions) and 3 patients with other diseases 
( rheumatoid arthritis, diabetes and later diagnosed amyotrophic lateral sclerosis (ALS)) 
The patients with foot drop following bariatric surgery were compared to a matched control 
group of patients who did not develop foot drop after bariatric surgery. This control group 
consisted of patients who all underwent a  gastric banding procedure for obesity. Both study 
groups were statistically similar for sex, age and total weight loss. Statistical analysis was 
performed using the method of logistic regression and the Chi-square test. 
3. Results 
Between January 1995 and December 2005, 160 patients were operated for persisting foot 
drop (Figure 2 and 3). Of these 160 patients, 43,5% (78 patients) developed their pathology 
after a period of serious weight loss (>10% of their body weight). There were many reasons 
for this weight loss: dieting, bariatric surgery, severe illness (pneumonia, cancer, 
diabetes,…), psychiatric disorder, etc. The influence of weight loss on the development of 
foot drop is clearly demonstrated in this population. This matter will be described in a 
separate article. In these analyses we noted that the weight loss occurred in a very short 
period. For all 78 patients maximal weight loss was observed within 18 months ( varying 
from two weeks to 18 months with a mean time interval of 4 months). 
Nine patients developed foot drop after bariatric surgery. These patients are listed in table 1. 
The mean weight loss for these patients was 45 kg (38.3 % of their initial body weight), 
ranging from 20 kg to 74 kg. This weight reduction took place during a mean period of 8.6 
months (ranging from 1 month to 18 months). We compared this patient group with a 
control group of patients who underwent bariatric surgery (gastric banding) but did not 
develop peroneal neuropathy. Our control group consists of ten patients, listed in table 2. 
The mean weight loss in these patients was 43.8 kg (38.5 % of their initial body weight), 
ranging from 23 kg to 98 kg. The weight reduction took place during a mean period of 21.7 
months (ranging from 10 months to 36 months).  
 

























Fig. 2. Incision for peroneal nerve decompression. Dotted line shows the region of sensory 
deficit. 
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Fig. 2. Incision for peroneal nerve decompression. Dotted line shows the region of sensory 
deficit. 
 



























Fig. 3. Peroperative view after decompression of the peroneal nerve with internal neurolysis 
of the two branches: superficial and deep peroneal nerve. 
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Using the Chi-square test, we found statistically significant differences in the amount of 
weight loss between the two study groups (p<0.0457). Using the method of logistic 
regression, we can conclude that weight loss in a short period of time is associated with a 
higher risk for developing foot drop (Odds ratio = 0.822 with 95% reliability interval 
between 0.678 and 0.996). The nerve palsy was resolved by neurolysis of the peroneal nerve 
at the fibular head in all cases. 
 
patient age sex type of surgery weight loss time period 
    kg (%) (months) 
1 39 M gastric banding 50(33%) 18 
2 46 F bypass 20(20%) 7 
3 27 F gastric banding 28(29%) 9 
4 48 F gastric banding 64(46%) 12 
5 45 M bypass 74(53%) 7 
6 45 F bypass 64(50%) 6 
7 22 F bypass 42(38%) 5 
8 30 F gastric banding 30(37%) 6 
9 40 F gastric banding 34(39%) 7 
Table 1. Nine patients developed foot drop after bariatric surgery 
 
patient age sex type of surgery weight loss time period 
    kg (%) (months) 
1 37 F gastric banding 39(39%) 36 
2 27 F gastric banding 29(30%) 18 
3 50 F gastric banding 98(58%) 36 
4 44 F gastric banding 33(39%) 18 
5 54 F gastric banding 29(24%) 12 
6 19 F gastric banding 50(38%) 24 
7 57 F gastric banding 39(42%) 21 
8 30 F gastric banding 41(42%) 30 
9 49 M gastric banding 47(37%) 12 
10 46 M gastric banding 39(36%) 10 
Table 2. Ten control patients without peroneal palsy. 
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Peroneal nerve palsy is a common mononeuropathy accounting for approximately 15 % of 
all the mononeuropathies in adults.( A. Cruz-Martinez, et al. 2000, E. Shahar , et al., 2007) As 
early as 1876, it was recognized that some patients with chronic disease, developed peroneal 
nerve palsies.(13,14) While weight loss may have played a role, the neuropathy was 
generally ascribed to a toxin or infectious agent. In 1929 Woltman was the first author to 
report the association of massive weight reduction to the existence of foot drop. In 1947 
Kaminsky as well as Denny-Brown reported several cases of peroneal nerve palsy in 
prisoners of war (up to 10 % of prisoners) and attributed this neurological condition to the 
prolonged dietary restriction. Later peroneal nerve palsy was correlated to cancer.( D.I. 
Rubin DI, et al., 1998) In a population of more than 400, 000 patients (in which more than 
8000 newly diagnosed cases of cancer), Koehler et al. found a relative risk of 8,6 to develop 
peroneal nerve palsy compared with patients without cancer.( P.J. Koehler, et al., 1997) A 
paraneoplastic factor or neurotoxicity due to the use of different antineoplastic drugs were 
considered to cause this syndrome. (P.J. Koehler, et al., 1997) Here as well, malnutrition and 
secondary weight loss were mentioned as side-phenomena.  
Over the last decades, the correlation between weight loss and peroneal neuropathy was 
well documented. (A. Cruz-Martinez, et al. 2000, D.G. Sherman, et al 1977, K.A. Sotaniemi 
,1984, E. Streib, 1993, I. Aprile et al., 2000, M.J.H. Harrison, 1984) In 1977 Sherman et al. 
described this correlation in 7 patients after excessive weight loss. In their study weight 
reduction was the only obvious common feature to all their patients. Cruz-Martinez et al. 
(2000) demonstrated a peroneal neuropathy due to excessive weight loss in 20% of 150 
patients with peroneal symptoms. There were many reasons for this weight loss: dieting, 
bariatric surgery, psychiatric disorders and other severe diseases like cancer, diabetes, acute 
pneumonia, etc.( E. Shahar , et al., 2007, M.J.H. Harrison, 1984, D. Denny-Brown, 1947, D.I. 
Rubin DI, et al., 1998, B.E. Sprofkin, 1958, E.W. Massey, J.M. Massey, 1987, G.D. Scott, 1979) 
Until now the exact way in which weight loss causes nerve palsy, is still unknown. We 
consider it due to a compression syndrome caused by nerve oedema as it is known in 
diabetic neuropathy. This intraneural oedema, caused by metabolic changes can cause nerve 
dysfunction especially at risk areas (anatomical tunnel regions). Electromyographic studies 
in all our patients confirmed peroneal nerve palsy with a conduction block at the fibular 
head. For this reason, we operated upon all patients with persisting foot drop longer than 3 
weeks. Up until now, there are controversies upon the optimal therapy for this specific 
condition. In literature, there are no large studies comparing the conservative and the 
surgical treatment of peroneal neuropathy in this condition. Recovery after conservative 
treatment varies strongly from study to study and most of these studies deal with only small 
groups of patients. (A. Cruz-Martinez, et al. 2000, E. Shahar , et al., 2007, D.G. Sherman, et al. 
1977, K.A. Sotaniemi ,1984, E. Streib, 1993, D.I. Rubin DI, et al., 1998, E.W. Massey, J.M. 
Massey, 1987) 
We were also able to demonstrate a statistically significant correlation between weight loss 
and peroneal neuropathy. In addition we illustrated the short time interval in which the 
weight loss occurred (2 weeks to 18 months with an average of 4 months). These findings 
are described in a separate article. To investigate the importance of the period in which 
patients develop their weight loss, especially in a population of bariatric surgery patients, a 
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comparison was made between a subgroup of our peroneal nerve palsy patients and a 
matched control group of patients who were submitted for bariatric surgery (gastric 
banding) but did not develop peroneal neuropathy. Of the 160 patients who were treated 
surgically for persisting peroneal nerve palsy, 9 patients developed foot drop after obesity 
surgery (table 2). The mean weight loss for these patients was 45 kg (38.3 % of their initial 
body weight). The weight reduction took place during a mean period of 8.6 months. Our 
control group consisted of 10 patients(table 2). The mean weight loss for these patients was 
42.6 kg (37.4 % of their initial body weight). The weight reduction took place during a mean 
period of 21.7 months. 
In contrast to earlier studies (eg. Waldström et al., 1991), we demonstrated that important 
weight loss is correlated with a higher risk to develop foot drop and that the time period in 
which the weight loss is achieved is important. A rapid reduction of body weight is 
correlated with a higher risk to develop foot drop. A slow weight reduction is 
recommended to avoid such disabling disease. 
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early as 1876, it was recognized that some patients with chronic disease, developed peroneal 
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generally ascribed to a toxin or infectious agent. In 1929 Woltman was the first author to 
report the association of massive weight reduction to the existence of foot drop. In 1947 
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prisoners of war (up to 10 % of prisoners) and attributed this neurological condition to the 
prolonged dietary restriction. Later peroneal nerve palsy was correlated to cancer.( D.I. 
Rubin DI, et al., 1998) In a population of more than 400, 000 patients (in which more than 
8000 newly diagnosed cases of cancer), Koehler et al. found a relative risk of 8,6 to develop 
peroneal nerve palsy compared with patients without cancer.( P.J. Koehler, et al., 1997) A 
paraneoplastic factor or neurotoxicity due to the use of different antineoplastic drugs were 
considered to cause this syndrome. (P.J. Koehler, et al., 1997) Here as well, malnutrition and 
secondary weight loss were mentioned as side-phenomena.  
Over the last decades, the correlation between weight loss and peroneal neuropathy was 
well documented. (A. Cruz-Martinez, et al. 2000, D.G. Sherman, et al 1977, K.A. Sotaniemi 
,1984, E. Streib, 1993, I. Aprile et al., 2000, M.J.H. Harrison, 1984) In 1977 Sherman et al. 
described this correlation in 7 patients after excessive weight loss. In their study weight 
reduction was the only obvious common feature to all their patients. Cruz-Martinez et al. 
(2000) demonstrated a peroneal neuropathy due to excessive weight loss in 20% of 150 
patients with peroneal symptoms. There were many reasons for this weight loss: dieting, 
bariatric surgery, psychiatric disorders and other severe diseases like cancer, diabetes, acute 
pneumonia, etc.( E. Shahar , et al., 2007, M.J.H. Harrison, 1984, D. Denny-Brown, 1947, D.I. 
Rubin DI, et al., 1998, B.E. Sprofkin, 1958, E.W. Massey, J.M. Massey, 1987, G.D. Scott, 1979) 
Until now the exact way in which weight loss causes nerve palsy, is still unknown. We 
consider it due to a compression syndrome caused by nerve oedema as it is known in 
diabetic neuropathy. This intraneural oedema, caused by metabolic changes can cause nerve 
dysfunction especially at risk areas (anatomical tunnel regions). Electromyographic studies 
in all our patients confirmed peroneal nerve palsy with a conduction block at the fibular 
head. For this reason, we operated upon all patients with persisting foot drop longer than 3 
weeks. Up until now, there are controversies upon the optimal therapy for this specific 
condition. In literature, there are no large studies comparing the conservative and the 
surgical treatment of peroneal neuropathy in this condition. Recovery after conservative 
treatment varies strongly from study to study and most of these studies deal with only small 
groups of patients. (A. Cruz-Martinez, et al. 2000, E. Shahar , et al., 2007, D.G. Sherman, et al. 
1977, K.A. Sotaniemi ,1984, E. Streib, 1993, D.I. Rubin DI, et al., 1998, E.W. Massey, J.M. 
Massey, 1987) 
We were also able to demonstrate a statistically significant correlation between weight loss 
and peroneal neuropathy. In addition we illustrated the short time interval in which the 
weight loss occurred (2 weeks to 18 months with an average of 4 months). These findings 
are described in a separate article. To investigate the importance of the period in which 
patients develop their weight loss, especially in a population of bariatric surgery patients, a 
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comparison was made between a subgroup of our peroneal nerve palsy patients and a 
matched control group of patients who were submitted for bariatric surgery (gastric 
banding) but did not develop peroneal neuropathy. Of the 160 patients who were treated 
surgically for persisting peroneal nerve palsy, 9 patients developed foot drop after obesity 
surgery (table 2). The mean weight loss for these patients was 45 kg (38.3 % of their initial 
body weight). The weight reduction took place during a mean period of 8.6 months. Our 
control group consisted of 10 patients(table 2). The mean weight loss for these patients was 
42.6 kg (37.4 % of their initial body weight). The weight reduction took place during a mean 
period of 21.7 months. 
In contrast to earlier studies (eg. Waldström et al., 1991), we demonstrated that important 
weight loss is correlated with a higher risk to develop foot drop and that the time period in 
which the weight loss is achieved is important. A rapid reduction of body weight is 
correlated with a higher risk to develop foot drop. A slow weight reduction is 
recommended to avoid such disabling disease. 
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1. Introduction  
Obesity rates are increasing worldwide. Free fatty acids derived from visceral adipose tissue 
impair insulin sensitivity and β-cell function (lipo-toxicity), leading to the metabolic 
syndrome and type 2 diabetes. 
Weight loss is the cornerstone for diabetes prevention and treatment, thus lifestyle and 
eventually pharmacological interventions that achieve significant weight loss are widely 
accepted. Nevertheless, long-term compliance to diet and exercise as well as safety and 
efficacy concerns regarding obesity drugs limit their benefits in real world. Moreover, weight 
gain is a common and undesirable side-effect of several oral antidiabetic drugs and insulins. 
Bariatric surgery has demonstrated to be an effective and safe treatment option for type 2 
diabetic patients who are severely obese, what is linked to weight loss and other 
mechanisms. Considering weight loss-independent mechanisms for diabetes improvement, 
investigators in several countries have started mostly metabolic than bariatric procedures 
for mildly obese or even overweight patients, focused on diabetes rather than obesity, and 
their early results have been encouraging.  
1.1 Obesity and type 2 diabetes 
Obesity is and its related metabolic disorders are increasing worldwide, especially in 
developing countries in western hemisphere (Ford & Mokdad, 2008). In most cases, an 
increase in body mass index (BMI) reflects an underlying increase in body fat that leads to 
diabetes, hypertension and dyslipidaemia (Bays, 2009), cardiovascular risk factors that are 
associated with increased mortality (Berrington et al, 2010).  
Cardiometabolic risk increases not only with BMI, but waist circumference as well (National 
Institutes of Health [NIH], 1998). Waist circumference correlates tightly with visceral 
adipose tissue, and currently is a widely accepted assessment of the accumulation of 
intraabdominal or visceral adiposity (Despres et al, 2001).  
Visceral adipose tissue is more likely to be related to insulin resistance than subcutaneous 
adipose tissue (Banerji et al, 1997, as cited in Zinman, 2006). Visceral obesity-derived 
cardiometabolic risk factors are frequently linked to insulin resistance and tend to cluster, 
what is clinically recognised as the metabolic syndrome (Alberti et al, 2009).  
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These factors follow a common and progressive course, so the prevalence of metabolic 
syndrome is 10 to 15% in normoglycaemic individuals, 44 to 64% in prediabetic, and 78 to 
84% in type 2 diabetic patients (Isomaa et al, 2001). In other words, the more 
hyperglycaemic, the more dysmetabolic the individual will be. 
Metabolic and ultimately cardiovascular complications of visceral obesity are summarised 
in Figure 1.  
Visceral Adipose Tissue
















Cardiovascular Events and Mortality  
Fig. 1. Cardiometabolic risk derived from visceral obesity. 
Visceral adipose tissue shows a high lipolytic activity, releasing free fatty acids (FFAs) to 
portal and then systemic circulation (Wajchenberg, 2000). FFAs, as well as cytokines and 
tumor necrosis factor-α (TNF-α), both derived from visceral adipose tissue, impair insulin 
action at target cells in liver and muscle, causing a postbinding defect that blocks tyrosine 
kinase activity,1 uncoupling insulin signal transduction (Le Roith & Zick, 2001). Insulin 
resistance is a key factor for the development of non-alcoholic fatty liver disease (NAFLD), 
and atherogenic dyslipidaemia.  
Insulin resistance is followed by pancreatic β-cell compensation and hyperinsulinaemia, due 
to fuel and neurohormonal signals derived from fat, liver, intestine, and brain (Prentki, 
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2006). Hyperinsulinaemia stimulates sodium reabsortion at kidneys, as well as sympathetic 
nervous system activity, leading to vasoconstriction and enhanced cardiac output, 
increasing blood pressure (Reaven et al, 1996). In addition, hyperinsulinaemia exerts anti-
lipolytic and lipogenic actions, thus maintaining and increasing visceral adipose tissue 
(Wajchenberg, 2000).   
Nevertheless, while FFAs are one of the β-cell compensation signals, they can cause ultimately 
β-cell apoptosis, leading to prediabetic states and type 2 diabetes (Bell, 2003; Kasuga, 2006).  
Prediabetes (impaired fasting glucose and/or impaired glucose tolerance), in other words, 
slightly elevated plasma glucose levels, accelerates pancreatic failure through gluco-toxicity. 
1.2 Weight loss in diabetes prevention and treatment 
Weight loss is the cornerstone for diabetes prevention and treatment, thus lifestyle and 
eventually pharmacological interventions that achieve significant weight loss are widely 
accepted.  
1.2.1 Lifestyle intervention in diabetes prevention 
Modest weight loss, as part of a comprehensive intervention in lifestyle, has demonstrated 
significant reductions in the incidence of diabetes in high risk populations. In the Finnish 
Diabetes Prevention Study the intervention group showed a greater lose of weight when 
compared with a control group (weight reduction >5% in 43 versus 13% of the subjects, 
respectively), with a risk of type 2 diabetes reduced by 58% at 3.2 years (Tuomilehto et al, 
2001). In the American Diabetes Prevention Program, the average weight loss in the lifestyle 
intervention group was 5.6 kg compared with 0.1 kg in the placebo group, with a risk of 
type 2 diabetes reduced by 58% at 2.8 years (Diabetes Prevention Program [DPP] Research 
Group, 2002). In the Indian Diabetes Prevention Programme, the lifestyle modification 
group reduced their risk of type 2 diabetes by 28.5% at 2.5 years compared with the control 
group, without loosing weight (Ramachandran et al, 2006). 
1.2.2 Pharmacologic Interventions in diabetes prevention 
Weight loss and antidiabetic drugs have been tested in the prevention of type 2 diabetes. 
Orlistat, a gastrointestinal lipase inhibitor used in the treatment of overweight and obesity, 
showed a 37.3% reduction in diabetes incidence at 4 years in obese subjects (Torgerson et al, 
2004). Acarbose, an enteric -glycosidase inhibitor used in the treatment of type 2 diabetes, 
reduced diabetes incidence by 25% at 3.3 years in subjects with impaired glucose tolerance 
(Chiasson et al, 2002). Another antidiabetic drug, metformin, which enhances insulin 
sensitivity at liver and muscle tissues, showed a 31% reduction in diabetes incidence at 2.8 
years (DPP Research Group, 2002).  
Two effective obesity drugs, rimonabant and sibutramine, have been recently withdrawn in 
several countries because long-term safety concerns. 
1.2.3 Lifestyle intervention in diabetes treatment 
One-year results of the ongoing Look-AHEAD clinical trial, which is intended to assess 
whether intensive lifestyle intervention decreases major cardiovascular events in type 2 
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diabetic subjects, showed a significant weight reduction with lifestyle intervention when 
compared with a control group (-8.6 vs. -0.7%, respectively). Diabetes control and other 
cardiovascular disease risk factors were also improved, with reduced medicine use (Pi-
Sunyer et al, 2007).    
Long-term compliance to diet and exercise could be a major issue in clinical practice. In 
addition, weight gain is a common and undesirable side-effect of several oral antidiabetic 
drugs and insulins (Turner et al, 1998; Kahn et al, 2006). 
2. Diabetes improvement following weight loss surgery   
Currently accepted indications for bariatric surgery are BMI 40 kg/m2 or BMI 35 kg/m2 
when comorbidities are associated (NIH, 1998). Bariatric surgery has demonstrated significant 
weight reduction, and improvement on cardiometabolic risk factors such as type 2 diabetes 
mellitus, dyslipidaemia, and hypertension, in severely obese patients. Moreover, this 
procedures are associated with 29% decreased overall mortality at 15-year follow-up (Sjostrom 
et al, 2007). Because the improvement observed not only in excess weight reduction, but in 
cardiometabolic risk factors as well, these procedures have been recently recognised as 
“bariatric and metabolic”. Principal mechanisms leading to diabetes and metabolic 
improvement following bariatric and metabolic procedures are summarised in Table 1. 
 
MECHANISM CLINICAL BENEFIT 
Decreased Lipo-toxicity (weight loss) Improved metabolic syndrome 
Decreased  ghrelin and increased PYY Decreased appetite and increased satiety 
Enhanced incretin effect Improved diabetes control 
Table 1. Main mechanisms for diabetes and metabolic improvement following surgery.  
2.1 Decreased lipo-toxicity 
Diabetes remission, defined as fasting plasma glucose <126 mg/dL (7.0 mmol/L) without 
hypoglycaemic therapy, occurs in 72 and 36% at two an ten years respectively in surgical 
patients, compared with 21 and 13% in conventionally treated subjects. On the other hand, 
diabetes incidence in non-diabetics is 1 and 8% at two and ten years respectively in the 
surgical group compared with 8 and 24% in the control group (Sjostrom et al, 2004, as cited 
in Dixon et al, 2011).  
Undoubtedly, such metabolic benefit is closely related to weight loss because a marked 
reduction in FFA-derived lipo-toxicity. Lipo-toxicity impairs insulin action at target tissues 
and increases pancreatic β-cell apoptosis. One randomised controlled trial that compared 
laparoscopic adjustable gastric banding (LAGB), a pure restrictive technique, versus 
comprehensive medical therapy for obese type 2 diabetic individuals showed a significant 
5.5-fold higher remission at two years in the surgical group (Dixon et al, 2008). In this 
regard, procedures that achieve weight loss and decrease lipo-toxicity should be viewed as 
“metabolic”.  
2.2 Weight loss-independent mechanisms for diabetes control 
Bypass or malabsortive procedures appear to result in greater metabolic benefit than 
restrictive ones, and a common observation is that diabetes remission is achieved within 
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days to weeks of undergoing surgery, before significant weight loss has occurred (Pories et 
al, 1995). These facts lead to conclude that additional and, at some extent, weight loss-
independent mechanisms are involved. These mechanisms, thus more metabolic than 
bariatric, could be summarised as reduced caloric intake and enhanced incretin effect 
(Lahsen & Berry, 2010). 
2.2.1 Reduced caloric intake  
Gastrointestinal hormones and peptides involved in the regulation of energy homeostasis 
may be modified following bariatric surgery. Roux-en-Y Gastric Bypass (RYGB) and Sleeve 
Gastrectomy (SG) increase peptide YY (PYY) (Morinigo et al, 2006) and reduce ghrelin levels 
(Cummings et al, 2002, Karamanakos et al, 2008). PYY is an appetite suppressant peptide 
secreted by distal ileum and colon, whereas ghrelin is an orexigenic hormone secreted by 
gastric fundus. Thus, post surgery changes in gut-derived hormones result in decreased 
appetite and increased satiety, which enhance patients’ compliance to lifestyle intervention 
guidance.   
2.2.2 Incretin effect  
Food intake is followed by the release of several intestinal peptides, some of which increase 
insulin levels. The increase in insulin secretion is higher after oral or enteral glucose 
ingestion when compared to intravenous administration, what is called the incretin effect. 
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are 
the two most studied peptides, being GLP-1 probably the most important in terms of 
carbohydrate homeostasis. GLP-1 secretion from L-cells at the ileum rises after a meal and 
enhances insulin biosynthesis and release by pancreatic β-cells, decreases glucagon release 
by pancreatic -cells, improves glucose uptake and glycogen synthesis in liver and 
peripheral tissues, slows gastric emptying, and decreases appetite and increases satiety at 
central nervous system. GIP is released from K-cells in duodenum, and stimulates post-meal 
insulin secretion and promotes β-cell mass expansion (Drucker, 2003). Type 2 diabetes is 
associated with a reduced or lost incretin effect that contributes with impaired insulin 
secretion (Toft-Nielsen et al, 2001). Bariatric surgery, especially RYGB, significantly 
enhances GLP-1 levels and activity in severely obese subjects with or without diabetes 
(Laferrere et al, 2007). 
3. Metabolic surgery in non-severely obese type 2 diabetics 
Theoretically, it could be plausible the design of surgical techniques focused mainly on 
weight loss, caloric intake, or incretin effect, depending on patients’ individual needs and 
careful clinical judgment. 
3.1 Duodenal-Jejunal bypass and the Hindgut and Foregut hypothesis 
Experimental studies were performed in non-obese diabetic rats, who underwent duodenal-
jejunal bypass (DJB), a stomach-preserving RYGB that excludes proximal intestine, or 
gastrojejunostomy (GJ), which creates a shortcut for ingested nutrients without bypassing 
intestine (Rubino et al, 2006). No differences in body weight, food intake, or nutrient 
absorption were observed between surgical groups, however DJB-treated rats improved 
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absorption were observed between surgical groups, however DJB-treated rats improved 
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their oral glucose tolerance. When GJ rats were reoperated to exclude proximal intestine a 
marked improvement in oral glucose tolerance was observed and, conversely, restoration of 
duodenal passage in DJB rats impaired oral glucose tolerance. In this study, Rubino 
demonstrated that bypassing proximal intestine directly ameliorates diabetes by weight 
loss-independent mechanisms. 
At some extent, two theories are born. The “hindgut hypothesis”, is explained by the rapid 
nutrient delivery to distal intestine that enhance the secretion of GLP-1, PYY, and 
oxyntomodulin, which are involved in the reduction of food intake and gastrointestinal 
motility, and improvement in glucose homeostasis. The second theory, the “foregut 
hypothesis” or duodenal exclusion, clearly demonstrates that duodenum and proximal 
jejunum bypass of nutrients plays a major role in diabetes resolution.  
3.2 Rationale for metabolic surgery in diabetic patients with BMI <35 kg/m2 
The American Diabetes Association established for first time in 2009 that bariatric 
procedures should be considered for diabetic adults with BMI ≥35 kg/m2 when diabetes is 
poor controlled with lifestyle and pharmacologic therapy. American Diabetes Association 
does not recommend surgery in patients with BMI <35 kg/m2 outside a research protocol 
(American Diabetes Association, 2009). Nevertheless, and as observed in landmark diabetes 
clinical trials, most type 2 diabetic individuals are overweight or mildly obese, with a BMI 
close to 30 kg/m2, below the cut-off for eligibility in current guidelines, disregarding the 
presence of a visceral pattern of obesity (Lahsen & Berry, 2010). Precisely, type 2 diabetic 
individuals having the metabolic syndrome have a very high risk of cardiovascular 
complications (Isomaa et al, 2001). Table 2 summarises the criteria followed by the authors 
to consider bariatric and metabolic surgery in type 2 diabetic subjects. 
 
BODY MASS INDEX (kg/m2) OBSERVATIONS 
 35 Consider surgery 
< 35 Consider surgery when metabolic syndrome is present 
< 30 Consider surgery only as part of a Clinical Research Protocol 
Table 2. Selection criteria for bariatric and metabolic surgery in type 2 diabetes. 
In recent years, several groups performing both established and novel surgical procedures 
in type 2 subjects with BMI <35 kg/m2 have shown encouraging metabolic results. It must 
be noted that these procedures should be performed as part of a clinical research protocol 
with local ethical approval. 
3.3 Clinical results of metabolic surgery  
Our group started a clinical research protocol assessing DJB in early 2008, and 19 non-obese 
(BMI <30 kg/m2) type 2 diabetic patients underwent surgery by late 2010. Our preliminary 
metabolic results are encouraging, however surgical technique modifications have been 
done due to concerns regarding gastroparesis, a previously reported surgery-derived 
adverse effect on gastric emptying. This issue was handled performing a non-restrictive SG, 
turning DJB into a modified duodenal switch, a well known procedure with proven benefits 
on glucose metabolism. The authors have seen better results, less morbidity (no 
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gastroparesis) and a better metabolic control with diabetes remission in near 75% of the 
cases, what was presented at the XIV Latin American Diabetes Association Congress held in 
Santiago, Chile, in november 2010 (Table 3).  
 
Variable Pre-Surgery Post-Surgery P* 




163                 
(9.1) 
131                 
(7.3) 0.01 
HbA1c, % 8.3 6.7 <0.001 
Patients with HbA1c 
<7%, % 26.3 73.60 0.05** 
Pharmacologic treatment (n) 
None 0 6  
Oral monotherapy 2 9  
Oral combination 
therapy 15 3  
Insulin 2 1  
* T test; ** Fisher test. 
Table 3. Clinical results of Modified Duodenal-Jejunal Bypass in 19 non-obese type 2 
diabetic patients.  
But, Why to perform “the most aggressive” surgery in non-obese patients? What about their 
weight loss? To answer the first question it must be considered the almost pure hormonal 
effect that is achieved in this subset of patients, where weight loss is not the “common 
factor” observed in restrictive and malabsortive bariatric procedures. Answering the second 
question requires considering that obese patients with different degree of severity who 
undergo the same surgery lose almost the same excess weight proportion, what can be 
explained as an “accommodation” of the caloric intake to the metabolism “real 
requirements”. Our patients, with BMI between 25 and 30 kg/m2, experienced a moderated 
lose of weight during the first 12 weeks after surgery, recovering later their inicial weight or 
maintaining BMI close to 25 kg/m2, with no excessive weight loss. This fact was also noted 
by Scopinaro, who performed a novel surgical procedure in type 2 diabetic individuals with 
BMI <35 kg/m2, achieving metabolic control and moderated weight loss (Scopinaro et al, 
2007). 
3.4 Novel metabolic procedures  
Clinical researchers worldwide are performing novel surgical and endoscopic procedures 
and assessing their metabolic and surgical long-term efficacy and safety.   
3.4.1 Sleeve gastrectomy 
While SG is considered a pure restrictive technique, it is noteworthy that weight loss-
mediated decrease in lipo-toxicity is metabolic per se, and SG reduces ghrelin, increases 
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peptide YY, and increases GLP-1 (Peterli et al, 2009), so SG must be viewed as metabolic 
surgery as well. We have assessed clinical and metabolic results in obese patients with easily 
controlled or recently diagnosed diabetes, which underwent SG with promising results: 
remission of the disease, no medication longer required, and very low morbidity rates.  
3.4.2 Endobarrier® 
One of the non invasive metabolic procedures currently under investigation is the 
“Endobarrier®”, a polypropylene sleeve endoscopically installed, anchored to the pylorus, 
that extends until the first portion of the jejunum. Its mechanism of action is the isolation of 
the food from the pancreatic enzymes and bile. This device has to be removed at 12 month, 
while an acceptable glycaemic control has been observed, and early results in obese patients 
also shows a moderated weight loss. 
4. Current and future indications for metabolic surgery 
Current obesity guidelines consider surgery when type 2 diabetes is associated with BMI 
≥35 kg/m2, however diabetes guidelines have incorporated surgical options very recently. 
In 2009 the American Diabetes Association established that bariatric surgery should be 
considered for diabetic adults with BMI ≥35 kg/m2 if metabolic control is difficult to achieve 
with lifestyle and pharmacological therapy. In March 2011 the International Diabetes 
Federation released a position paper which considers with some restrictions bariatric 
surgery for type 2 diabetic patients with BMI ≥30 kg/m2, and historically, for first time 
includes bariatric surgery in a diabetes treatment algorithm. 
Probably future guidelines will consider not only BMI but also waist circumference and 
other elements of the metabolic syndrome as well as the presence and extent of diabetic 
chronic complications, patients’ preference and quality of life. 
5. Conclusions 
Bariatric surgery has demonstrated to be an effective and safe therapy for obesity in subjects 
with BMI ≥40 kg/m2, and in type 2 diabetic patients with BMI ≥35 kg/m2. 
The major factor involved in metabolic improvement after surgery is weight loss, which 
decreases lipo-toxicity. Any procedure that achieves weight loss must be recognised as 
metabolic. 
There are weight loss-independent mechanisms for metabolic improvement that can be 
summarised as decreased appetite and increased satiety, due to post surgical changes in 
ghrelin and PYY, and enhanced β-cell function, due to an increased incretin effect. 
Novel surgical techniques have been developed in recent years, aimed to correct 
dysmetabolism through weight loss-independent mechanisms in type 2 diabetic patients 
who are mildly obese or even overweight, with promissory early results. 
Nowadays, these procedures have been part of clinical investigation protocols approved by 
each local ethics committee.  
Future indications for metabolic procedures will consider other factors than BMI. 
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Amidst a worldwide epidemic of diabetes, the World Health Organization estimates that 
346 million people have diabetes and an estimated 3.4 million people died from 
consequences of high blood sugar in 20041). Over time, diabetes can damage the heart, blood 
vessels, eyes, kidneys, and nerves. Especially diabetes increases the risk of heart disease and 
stroke. 
Obesity carries with it significant risks of diabetes. Improvement in obesity is attendant 
with improvements in this ailment2)3), and obese people consequently have been treated 
through pharmacotherapy, and intervention in life habits, including diet and exercise. 
Even with such treatment, however, it is very difficult to have satisfactory body weight 
loss. In the last few years, many studies have performed to compare intensive glucose 
control therapy with standard therapy. Most of the results show that body weight did not 
change with both intensive glucose control therapy and standard therapy4)5). Moreover, 
many patients who are initially successful at weight loss then go on to rebound6). Thus, 
promoting weight loss is a major issue in treatment, especially in severely obese patients. 
Recently, there has been an increase in patients with a BMI > 35 undergoing bariatric 
surgery and there has been a notable increase in studies describing effect of bariatric 
surgery on type 2 diabetes patients6). 
2. Effect of bariatric surgery on obesity and diabetes 
Although an average of 55.9% loss in excess body weight was observed in bariatric 
surgery6), the extent of operation-induced weight loss varies depending on the surgical 
method7). While loss in body weight from intervention in life habits is insufficient, it was 
46.2% for gastric binding and 59.5% for gastric bypass, respectively, thus showing that 
bariatric surgery leads to more efficient weight-loss results6). However, although bariatric 
surgery generally leads to a great improvement in diabetes8) (Table 1), there is a gradation of 
results depending on the procedure9). Additionally for type 2 diabetes patients, studies on 
gastric bypass have shown that improvements in fasting plasma glucose and insulin 
sensitivity are evident prior to weight loss10)11). These kinds of changes are not observed in 
gastric binding6)12). From these results, apart from improvements in insulin sensitivity 
induced through weight loss, gastric bypass is also thought to improve glucose metabolism. 
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 Total (n) Gastric Binding (n) Gastric Bypass (n) 
Absolute Weight Loss (Kg) 
BMI Decrease (kg/m2) 
Excess Loss (%) 
Fasting Insulin (pmol/L) 
HbA1c (%) 



















BMI: body mass index    
Table 1. Efficacy for Improvement in Diabetes-Related Outcomes for Diabetic and Glucose-
Intolerant Patients 8). 
 
Incretin Secretion Function Change after  
bariatric surgery 
GLP-1 Distal ileum , 
Colon 
Increase insulin release 
Slowing gastric emptying 
Controlling Glucagon secretion  
Induce satiety by working on the central 
nervous system 
Increase 
Ghrelin Stomach Stimulate appetite 
Increasing activity in the stomach 
Suppression of insulin secretion 




Table 2. Summary of Intestin. 
3. Effects of bariatric surgery on intestine hormone 
One hypothesis to explain this phenomenon is the influence of gastrointestinal hormones. 
Glucagon-like peptide-1 (GLP-1), an intestinal hormone secreted from the distal ileum and 
colon in response to nutrient ingestion9). GLP-1 acts on the beta cells to increase the level of 
cyclic AMP, leading to replenishment of the readily releasable pool of insulin granules 
during glucose-stimulated insulin secretion13). Not only improving beta-cell function, GLP-1 
is also involved in the proliferation and regeneration of pancreatic β-cells14)15). Outside 
pancreatic effects, GLP-1 decreases dietary intake by slowing gastric emptying16), controlling 
secretion of gastric acid17) and glucagon18), and induce satiety by working on the central 
nervous system19)20)). There have been numerous studies detailing a post-operative increase 
in GLP-1 secretion from gastric bypass, and this increase occurs prior to post-gastric bypass 
weight loss21-24). Studies show that the post-gastric bypass GLP-1 level is significantly higher 
when compared to the post-gastric binding GLP-1 level25) 26). When considering the effect of 
GLP-1, it is possible that the increase in endogenous GLP-1 secretion plays an important role 
in the improvement of glucose metabolism by the gastric bypass surgery. 
Although ghrelin is similar to GLP-1 in that it is related to the appetite, it is actually an 
appetite-stimulating hormone27-29). It is likely that the appetite stimulating from ghrelin is 
due to its increasing activity in the stomach28)30) and suppressing of insulin secretion30). 
Ghrelin levels increase in dietary restriction-induced weight loss and when there is a 
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negative energy balance, and conversely, decrease when eating or in the case of the 
obese31)32). However in the case of the obese, ghrelin levels become unchanged even when 
eating, and therefore, ghrelin level is a potential factor in obesity33). There are many reports 
demonstrating that fasting ghrelin levels decrease after Roux-en-Y Gastric Bypass compared 
to pre-operation34)35). It has been reported that decrease in ghrelin levels occurs immediately 
following surgery and lasts for more than a year36) 37). Through Roux-en-Y Gastric Bypass, 
food bypasses the distal stomach in which ghrelin is released, and this may account for the 
post-bypass decrease in ghrelin levels34).  
4. Incretin-therapy on type 2 diabetes patients 
Recently GLP-1 analog/receptor agonists and GLP-1 degradation inhibitors are in clinical 
use. The beneficial points of these antidiabetes agents are glucose-dependent 
insulinotropism which may be reduced the risk of hypoglycemia38). Liraglutide is a GLP-1 
analog with 97% sequence identity to human hormone. The mean reduction in HbA1c by 
liraglutide (1.8mg) was 1.14%39). In addition to effective glucose lowering, liraglutide 
produced beneficial effects on body weight. The mean reduction in body weight after 
16weeks treatment of 1.8mg liraglutide was 3.6kg and was sustained thoughout the 52 week 
study39). These results support the hypothesis that the bariatric surgery leads to a great 
improvement of diabetes not only by the reduction of the storage capacity of the stomach 
but also by the change in intestinal hormone. 
5. Clinical application of bariatric surgery in Asia 
As previously stated, there are reports that bariatric surgery leads to dramatic improvement 
in type 2 diabetes compared to pharmacotherapy and lifestyle intervention-based treatment. 
Will bariatric surgery replace conventional medication and/or life style intervention-based 
treatment in Asia? At present, however, most of these reports are not necessarily targeting 
regular subjects, given the subjects’ extremely high average BMI of 47.9 kg/m2 and 
relatively young average age of 40.2 years old6). 
Obesity in the Asian population is much less than in Western populations. The Ministry of 
Health, Labour and Welfare, Japan reported that only 3.7% of the population is obese 
(BMI>30)40). The rate of obesity in diabetes is reported to be similar to that in the rest of the 
Japanese population41), and at present bariatric surgery has only a limited application in 
Japan. To increase the application of bariatric surgery in Asia, there is a need for a high-
evidence level cohort study based on previous research that varies by age and obesity level 
in order to further the discussion on whether bariatric surgery should be given precedence 
over conventional medication and life style intervention-based treatment in patients with a 
BMI > 35. 
6. Summary 
Recently, in certain countries, there has been an increase in obese patients undergoing 
bariatric surgery which leads to more efficient weight-loss results. Bariatric surgery is an 
effective treatment option for severely obese patients for whom weight loss has been 
problematic with conventional pharmacotherapy and/or life style intervention-based 
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over conventional medication and life style intervention-based treatment in patients with a 
BMI > 35. 
6. Summary 
Recently, in certain countries, there has been an increase in obese patients undergoing 
bariatric surgery which leads to more efficient weight-loss results. Bariatric surgery is an 
effective treatment option for severely obese patients for whom weight loss has been 
problematic with conventional pharmacotherapy and/or life style intervention-based 
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treatment. Gastric bypass has been shown not only to decrease body weight but to have an 
effect on incretin (Table2). Change in incretin, especially GLP-1, could support the 
improvement in body weight. GLP-1 also has beneficially affect on pancreatic β-cells 
function, proliferation and regeneration. Thus even if diabetes did not cure by bariatric 
surgery, change in incretin have beneficially effect on diabetes. Therefore to choose the 
operative procedure of bariatric surgery, especially on patients who have basic disease, it is 
necessary to think about dynamic state of incretin. 
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1. Introduction 
Over the past few decades, there has been a dramatic increase in the prevalence of obesity in 
many countries. The World Health Organization (WHO) estimates that more than 1 billion 
adults worldwide are overweight; of these, at least 300 millions are obese. (1) Obesity is 
associated with multiple chronic diseases, including type 2 diabetes, hypertension, coronary 
heart disease, stroke and several cancers.(2) 
Definitions of overweight (BMI >25) and obesity (BMI>30) are based essentially on criteria 
derived from studies that involved populations of European origin. The validity of these 
criteria in Asian populations has yet to be determined. It has been suggested that the 
associations of BMI with body composition and health outcomes may differ between Asian 
and European populations. Studies have shown that for a given BMI, Asians generally have 
a higher percentage of body fat than do Europeans. Asian populations have also been 
shown to have elevated risks of type 2 diabetes, hypertension, and hyperlipidemia at a 
relatively low level of BMI.(3)   
2. Obesity in Asia 
In most Asian countries, the prevalence of overweight and obesity have increased many 
times over in the past few decades, and the magnitude varies between countries (4,5,6). 
Southeast Asia and the Western Pacific region are currently facing an epidemic of diseases 
associated with obesity such as diabetes and CVD. India has the highest number of people 
with diabetes in the world and China occupies the second position (7). 
Table 1 (8) shows the prevalence of overweightness and obesity in Asian countries in 
comparison with the United States. Many Asian countries have rates which are not very 
different from that of the U.S. 
The highest rate of obesity in Asia is in Thailand(9) and the lowest is in India (6) followed by 
Philippines (10). China, which once had the leanest of populations, is now rapidly catching 
up with the West in terms of prevalence of overweight and obesity which had occurred in a 
remarkably short time (11,12) 
The obesity pandemic was restricted to developed, high-income countries until a few 
decades ago, but recently it has penetrated even the poorest of nations. Asia has undergone 
considerable socioeconomic transition in the last three decades, which has resulted in 
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increased availability of food, better transport facilities and better health care facilities. The 
changing trend was seen first in urban populations and in recent years, with improving 
socioeconomic scenarios in rural areas, the changes were seen even among the urbanizing 
rural populations. The recent epidemiological data among urban and semi urban southern 
Indian populations illustrates the changing scenario (13). In addition, reduced physical 
activity at work due to mechanization, improved motorized transport and preferences for 
viewing television and video games to outdoor games during leisure time, have resulted in 
positive energy balance in most Asian countries (14). 
 
 Survey year Prevalence of overweight adults (%) 
Prevalence of obese adult 
(%) 
United States 2007-2008 34.0 0.2 
India 1998-1999 10.0 2.2 
Malaysia 1996-1997 16.6 4.4 
Philippines 1998 16.9 3.3 
Taiwan 1993–1996 21.1 4.0 
Japan 2001 23.0 3.0 
Singapore 1998 24.4 6.0 
China 1999-2000 25.0 4.0 
Hong Kong 1996-1997 25.1 3.8 
South Korea 2001 27.4 3.2 
Table 1. Comparison of prevalence of adult obesity in Asian countries versus the United 
States. 
In parallel with the increase in adult obesity, obesity in children is also increasing. 
Childhood obesity has reached more than 25% in many developing countries. The 
etiological factors for childhood obesity include genetic, metabolic, and behavioral 
components. An imbalanced energy intake versus energy expenditure due to consumption 
of energy dense food and increase in sedentary habits has mainly contributed to increases in 
childhood obesity, both in developed and developing countries (15). 
Asian populations generally have a lower BMI than many other ethnic groups, but the 
association between BMI and glucose intolerance is as strong as in any other population 
(16). The risk of diabetes (odds ratio) was significant for urban Indian populations with a 
BMI of >23kg/m2 (17). This has been confirmed by studies from other parts of India (18), by 
studies in migrant Indians and in other Asian populations (19). According to WHO 
recommendations, a BMI of 18.5–22kg/m2 is considered healthy for Asian populations (20). 
Insulin resistance is one of the major etiological factors for diabetes and the risk association 
between obesity and diabetes is mediated through insulin resistance. 
Many Asian populations have a higher total and central adiposity for a given body weight 
when compared to matched Caucasian populations. A higher prevalence of metabolic 
syndrome in south Asians is mostly attributed to the higher prevalence of central adiposity. 
The IDF criteria for metabolic syndrome recommends use of ethnic specific thresholds for 
waist circumference, which includes ≥ 90 cm in men, and ≥ 80 cm in women of Asian origin 
(21). The Japanese population is an exception. 
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It has also been noted that for a given BMI, Asians have higher body fat percentage compared 
with Caucasians (22,23). Higher insulin resistance and an increased risk of diabetes may be 
partially attributed to this feature. The differences in anthropometric characteristics are evident 
even in Asian children who are shown to have higher body fat percentage at lower levels of 
body weight (24,25) and also a tendency for abdominal obesity (26). 
In the cohorts of East Asians(27), including Chinese, Japanese, and South Koreans, the 
lowest risk of death was seen among persons with a BMI in the range of 22.6 to 27.5. The 
risk was elevated among persons with BMI levels either higher or lower than that range — 
by a factor of up to 1.5 among those with a BMI of more than 35.0 and by a factor of 2.8 
among those with a BMI of 15.0 or less. A similar U-shaped association was seen between 
BMI and the risks of death from cancer, cardiovascular diseases and other causes. 
A WHO expert consultation concluded in 2004 that Asians generally have a higher 
percentage of body fat than Caucasian people of the same age, sex, and BMI. Also, the 
proportion of Asians with risk factors for type 2 diabetes and cardiovascular disease is 
substantial even below the existing WHO BMI cut-off point of 25 kg/m2. Thus, WHO cut-
off points did not provide an adequate basis for taking action on risks related to overweight 
and obesity in many populations in Asia. The WHO recommended for many Asian 
populations additional trigger points for public health action, which were identified as 23 
kg/m2 or higher, representing increased risk, and 27·5 kg/m2 or higher, as representing 
high risk. The suggested categories are as follows: less than 18·5 kg/m2 underweight; 18·5–
23 kg/m2 increasing but acceptable risk; 23–27·5 kg/m2 increased risk; and 27·5 kg/m2 or 
higher high risk. (3) 
3. Diabetes in Asia 
Type 2 diabetes is now a global health priority.(28) The International Diabetes Federation 
has predicted that the number of individuals with diabetes will increase from 240 million in 
2007 to 380 million in 2025, with 80% of the disease burden in low- and middle-income 
countries.(29) More than 60% of the world’s population with diabetes will come from Asia, 
because it remains the world’s most populous region. The number of individuals with 
diabetes and impaired glucose tolerance (IGT) in each Asian country will increase 
substantially in coming decades (Table 2).(30)  
 
 Diabetes Impaired Glucose Tolerance 
Country 2007 2025 2007 2025 
India 40850 69882 35906 56228 
China 39809 59270 64323 79058 
Japan 6978 7171 12891 12704 
Bangladesh 3848 7416 6819 10647 
Korea 3074 4163 3224 4240 
Total Asia 113536 179742 157067 213218 
All values are in thousands 
Table 2. Top 5 Countries in Asia With the Highest Number of Persons With Type 2 Diabetes 
and Impaired Glucose Tolerance in the Age Group 20 to 79 Years in 2007 and Projected Data 
in 2025 (30) 
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Indian populations illustrates the changing scenario (13). In addition, reduced physical 
activity at work due to mechanization, improved motorized transport and preferences for 
viewing television and video games to outdoor games during leisure time, have resulted in 
positive energy balance in most Asian countries (14). 
 
 Survey year Prevalence of overweight adults (%) 
Prevalence of obese adult 
(%) 
United States 2007-2008 34.0 0.2 
India 1998-1999 10.0 2.2 
Malaysia 1996-1997 16.6 4.4 
Philippines 1998 16.9 3.3 
Taiwan 1993–1996 21.1 4.0 
Japan 2001 23.0 3.0 
Singapore 1998 24.4 6.0 
China 1999-2000 25.0 4.0 
Hong Kong 1996-1997 25.1 3.8 
South Korea 2001 27.4 3.2 
Table 1. Comparison of prevalence of adult obesity in Asian countries versus the United 
States. 
In parallel with the increase in adult obesity, obesity in children is also increasing. 
Childhood obesity has reached more than 25% in many developing countries. The 
etiological factors for childhood obesity include genetic, metabolic, and behavioral 
components. An imbalanced energy intake versus energy expenditure due to consumption 
of energy dense food and increase in sedentary habits has mainly contributed to increases in 
childhood obesity, both in developed and developing countries (15). 
Asian populations generally have a lower BMI than many other ethnic groups, but the 
association between BMI and glucose intolerance is as strong as in any other population 
(16). The risk of diabetes (odds ratio) was significant for urban Indian populations with a 
BMI of >23kg/m2 (17). This has been confirmed by studies from other parts of India (18), by 
studies in migrant Indians and in other Asian populations (19). According to WHO 
recommendations, a BMI of 18.5–22kg/m2 is considered healthy for Asian populations (20). 
Insulin resistance is one of the major etiological factors for diabetes and the risk association 
between obesity and diabetes is mediated through insulin resistance. 
Many Asian populations have a higher total and central adiposity for a given body weight 
when compared to matched Caucasian populations. A higher prevalence of metabolic 
syndrome in south Asians is mostly attributed to the higher prevalence of central adiposity. 
The IDF criteria for metabolic syndrome recommends use of ethnic specific thresholds for 
waist circumference, which includes ≥ 90 cm in men, and ≥ 80 cm in women of Asian origin 
(21). The Japanese population is an exception. 
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It has also been noted that for a given BMI, Asians have higher body fat percentage compared 
with Caucasians (22,23). Higher insulin resistance and an increased risk of diabetes may be 
partially attributed to this feature. The differences in anthropometric characteristics are evident 
even in Asian children who are shown to have higher body fat percentage at lower levels of 
body weight (24,25) and also a tendency for abdominal obesity (26). 
In the cohorts of East Asians(27), including Chinese, Japanese, and South Koreans, the 
lowest risk of death was seen among persons with a BMI in the range of 22.6 to 27.5. The 
risk was elevated among persons with BMI levels either higher or lower than that range — 
by a factor of up to 1.5 among those with a BMI of more than 35.0 and by a factor of 2.8 
among those with a BMI of 15.0 or less. A similar U-shaped association was seen between 
BMI and the risks of death from cancer, cardiovascular diseases and other causes. 
A WHO expert consultation concluded in 2004 that Asians generally have a higher 
percentage of body fat than Caucasian people of the same age, sex, and BMI. Also, the 
proportion of Asians with risk factors for type 2 diabetes and cardiovascular disease is 
substantial even below the existing WHO BMI cut-off point of 25 kg/m2. Thus, WHO cut-
off points did not provide an adequate basis for taking action on risks related to overweight 
and obesity in many populations in Asia. The WHO recommended for many Asian 
populations additional trigger points for public health action, which were identified as 23 
kg/m2 or higher, representing increased risk, and 27·5 kg/m2 or higher, as representing 
high risk. The suggested categories are as follows: less than 18·5 kg/m2 underweight; 18·5–
23 kg/m2 increasing but acceptable risk; 23–27·5 kg/m2 increased risk; and 27·5 kg/m2 or 
higher high risk. (3) 
3. Diabetes in Asia 
Type 2 diabetes is now a global health priority.(28) The International Diabetes Federation 
has predicted that the number of individuals with diabetes will increase from 240 million in 
2007 to 380 million in 2025, with 80% of the disease burden in low- and middle-income 
countries.(29) More than 60% of the world’s population with diabetes will come from Asia, 
because it remains the world’s most populous region. The number of individuals with 
diabetes and impaired glucose tolerance (IGT) in each Asian country will increase 
substantially in coming decades (Table 2).(30)  
 
 Diabetes Impaired Glucose Tolerance 
Country 2007 2025 2007 2025 
India 40850 69882 35906 56228 
China 39809 59270 64323 79058 
Japan 6978 7171 12891 12704 
Bangladesh 3848 7416 6819 10647 
Korea 3074 4163 3224 4240 
Total Asia 113536 179742 157067 213218 
All values are in thousands 
Table 2. Top 5 Countries in Asia With the Highest Number of Persons With Type 2 Diabetes 
and Impaired Glucose Tolerance in the Age Group 20 to 79 Years in 2007 and Projected Data 
in 2025 (30) 
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Fig. 1. Number of persons with diabetes in different age group (30) 
 
Deaths attributable to diabetes , Age 20~79 years. 
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Unlike in the West, where older populations are most affected, the burden of diabetes in 
Asian countries is disproportionately high in young to middle-aged adults. (Figure 1) And 
also the number of deaths attributable to diabetes in Asian Pacific region is extremely 
high.(Figure 2) (30) 
Amid this global epidemic of diabetes, Asian countries undergoing economic and 
nutritional transitions have experienced a particularly notable increase.(30) In China, the 
prevalence of diabetes increased from 1% in 1980 to 5.5% in 2001(31), with much higher 
rates in urban areas such as Shanghai(32). Nearly 10% of Chinese adults residing in affluent 
regions such as Hong Kong and Taiwan have diabetes (33). Among individuals with 
diabetes, two-thirds in mainland China and one-half in Hong Kong and Taiwan remain 
undiagnosed. 
In urban Indian adults, diabetes prevalence increased from 3% in the early 1970s to 12% in 
2000, with a narrowing rural-urban gradient (34). In 2006, the rate of type 2 diabetes in rural 
south India was 9.2%, compared with an increase from 13.9% in 2000 to 18.6% in 2006 in 
urban south India. (35) 
Asians have lower rates of overweightness and obesity than their Western counterparts, 
using conventional definitions. Despite lower BMI, some Asian countries have similar or 
even higher prevalence of diabetes than Western countries.(36) These data confirm that the 
risk of type 2 diabetes starts at a lower BMI for Asians than for Europeans.(37) 
Asian populations, especially those of South Asian descent, are more prone to abdominal 
obesity and low muscle mass with increased insulin resistance compared with their Western 
counterparts. (38,39,40,41,42,43,44) Thus, waist circumference reflecting central obesity is a 
useful measure of obesity-related risk of type 2 diabetes, especially in individuals with 
normal BMI values. (38,45) 
Data suggest that the increased risk of type 2 diabetes in Asian populations may be 
attributed to increased abdominal and visceral adiposity for a given BMI.(46) 
In Asian populations, the amount of visceral fat (including mesenteric fat) and fatty liver 
was significantly associated with subclinical atherosclerosis.(47) In addition, increased waist 
circumference has been associated with substantially increased risk of developing diabetes 
(48,49) as well as increased risk of cardiovascular and all-cause mortality, independent of 
BMI.(50,51,52,53) 
In the 1980s, Japanese researchers first revealed that reduced early insulin response was an 
independent predictor for diabetes.(54) Fukushima et al (55) found that at all stages of 
glucose intolerance, Japanese individuals had reduced early and late phases of insulin 
responses. In Japanese men with normal glucose tolerance, even a small increase in BMI 
produced a decrease in beta cell function disproportionate to that in insulin sensitivity. (56) 
In a sample of Chinese patients with type 2 diabetes, 50% were of normal weight, with low 
BMI correlating with low levels of fasting plasma C-peptide and high glycated hemoglobin 
levels.(57) In a prospective survey of Japanese Americans, visceral fat area and reduced 
incremental insulin response were independent predictors for diabetes. (58) Taken together, 
in some Asian populations, inadequate beta cell response to increasing insulin resistance 
results in a loss of glycemic control and increased risk of diabetes, even with relatively little 
weight gain. 
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Among lean, healthy individuals matched for age, BMI, waist circumference, birth weight, 
and current diet, Asians had higher levels of postprandial glycemia and lower insulin 
sensitivity than Caucasians in response to a 75-g carbohydrate load.(59) These findings raise 
the possibility that Asians are more genetically susceptible to insulin resistance and diabetes 
than Caucasians. 
Asian patients with diabetes continue to exhibit high risk for renal complications. (60) In 
observational studies as well as clinical trials, Asian patients with diabetes were more likely 
to develop end stage renal disease (ESRD) than their Caucasian counterparts. In a 25-year 
prospective survey, 60% of young Japanese patients with type 2 diabetes diagnosed before 
age 35 became blind or had developed ESRD at a mean age of 50. (61)  
4. Bariatric and metabolic surgery in Asia 
The history of bariatric surgery started when Taiwan adopted the JI bypass as the first 
bariatric surgery in Asia in the 1970s. (62) The first gastric partitioning was performed at 
Taiwan in 1981. (63) The first gastric bypass was introduced into Japan in 1982 and the VBG 
into Singapore in 1987. (64,65)  
With the development of laparoscopic surgery, bariatric surgery has entered the realm of 
minimally invasive surgery. Laparoscopic VBG (LVBG) was successfully performed in 
Taiwan in 1998 and emerged as an alternative to the conventional VBG. (66) After the 
success of laparoscopic adjustable gastric banding (LAGB) in Europe and Australia, Asian 
countries also started to perform LAGB since 1999, first in Singapore.(13) Further, 
laparoscopic Roux-en-Y gastric bypass (LRYGBP) was also introduced into Taiwan in 
2000(67) and subsequently proven to be a more effective but complicated bariatric operation 
than LVBG.(68) LRYGBP has also been developed in Japan 2002 and other Asian countries. 
(69). Laparoscopic Sleeve Gastrectomy was introduced into South Korea in 2002 (70)  
Asian Pacific Bariatric Surgery Group (APBSG), which was founded in 2004 and officially 
changed its name to Asian Pacific Metabolic and Bariatric Surgery Society (APMBSS) in 2008, 
held a consensus meeting in 2005 and modified the indication for bariatric surgery for Asian.  
Consensus in Asia-Pacific 2005 (63)  
1. Obese patients with a BMI >37  
2. Obese patients with a BMI >32 and the presence of diabetes or two significant obesity-
related co-morbidities.  
3. Have been unable to lose or maintain weight loss using dietary or medical measures.  
4. Age of patient >18 years and <65 years. Under special circumstance and in consultation 
with a pediatrician, bariatric surgery may be used on children under 18. 
Because bariatric surgery currently is the most effective treatment for type 2 diabetes, 
APBSG not only modified the indications for bariatric surgery but also emphasized its role 
in diabetic treatment. It was the first bariatric guideline of the world to mention a focus 
especially on diabetes. 
In the national report session at the 2nd congress of the International Federation for Surgery 
of Obesity and Metabolic Disorders Asian Pacific Chapter (IFSO-APC), which was held in 
Hokkaido, Japan, in 2011, the representatives of Asian countries reported on their respective 
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situations. According to the session reports, more than 5,500 cases of bariatric and metabolic 
surgery were performed in Asia 2010. India had 3000 cases followed by Taiwan (Figure 3).  
 
Fig. 3. Bariatric and Metabolic Surgery Cases in 2010 (IFSO-APC 2011 National Report) 
Laparoscopic Gastric bypass still formed the majority of the procedures and LSG was 
rapidly increasing. 
A systematic review of bariatric surgery in Asia with citation of 160 papers from Asia was 
also reported IFSO-APC 2011 by Seki Y, et al. The report summarized as Table3.  
 
 Asian  (Seki et al) All 
RYGBP               %EWL 74.8% 61.6% a 
                            Mortality 0% 0.5% in Open, 0.2% in laparoscopic 
LAGB                 %EWL 59.1% 45.5% a 
                            Mortality 0.07% 0.1% 
LSG                    %EWL 67.9% 55.4% b 
                            Mortality 0.32% 0.19% 
a) Buchwald et al. (n=22094, pre-OP mean BMI 46.9 kg/m2), 
b) Brethauer et al. (n=2570, pre-OP mean BMI 51.2 kg/m2) 
RYGBP: Roux en Y Gastric Bypass, LAGB: Laparoscopic Adjustable Gastric Banding, LSG: Laparoscopic 
Sleeve Gastrectomy  
Table 3. Systemic review results of bariatric surgery for Asians. 
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From the current evidence, including 14 studies and 4,257 patients, bariatric surgery for 
Asians is an effective weight loss procedure although long-term data are limited. The 
postoperative mortality rates have been acceptably low.  
Regarding the anti-diabetic effect of bariatric surgery for Caucasians, LRYGB and LSG 
showed similar results. (71) But for East Asians, a prospective randomized control study for 
type 2 diabetes patients by Lee WJ et al.(72) suggested different results. Gastric bypass was 
far superior to LSG on remission of diabetes and metabolic disorders. Duodenal exclusion 
would play significant role in remission of type 2 diabetes for East Asian populations. 
Limitation of remission of diabetes after LSG was also reported (73). Patients with fasting C-
peptide over 6ng/ml could have a very good remission of diabetes and patients with c-
peptide less than 3ng/ml could only have 14% of remission rate of diabetes after LSG. The 
problem is that a majority of East Asian diabetes patients are more prone to having a beta 
cell dysfunction than Caucasians and with fasting C-peptide less than 3 ng/ml (74). These 
results provide us with data showing that Asians, at least East Asians including Taiwanese, 
Chinese, South Korean and Japanese, have a higher rate of remission from type 2 diabetes 
after bypass surgery than with LSG. 
4. IFSO-APC consensus statement 2011 
According to the ethnicity of Asians, the IFSO-Asian Pacific chapter (APC) consensus 
statement was established in 2011. Forty four bariatric experts from the Asia Pacific and 
other regions were chosen to have voting privileges for the IFSO-APC consensus at 2nd IFSO 
APC congress on 24th February 2011 in Rusutsu, Hokkaido, Japan. All voting delegates 
represented their respective societies or countries. The IFSO-APC consensus based upon the 
antecedent statements and guidelines regarding bariatric and metabolic surgery, especially 
in the Asian Pacific region, including the National Institute of Health (NIH) statements (75), 
Obesity Surgery Society of India (OSSI), Japan Society for Surgery of Obesity (JSSO), Asian 
Consensus Meeting on Metabolic Surgery (ACMOMS)(76), Obesity Surgery Society of 
Australia and New Zealand (OSSANZ), APMBSS(63), Diabetes Surgery Summit (DSS)(77) 
and Asian Diabetes Surgery Summit (ADSS). Before voting on the consensus, 
representatives from each society presented their statements or guidelines. These statements 
and guidelines were used to establish the consensus of the IFSO-APC.  A computerized 
audience-response voting system was used to analyze agreement or disagreement with the 
wording of the consensus. 
“Consensus” was established with the agreement of over 75% of delegates and a 
“Viewpoint” was recognized with an agreement between 66% and 75%.  
Results: Ninety five percent of the delegates agreed with the necessity of establishment of 
the IFSO-APC consensus statement, and 98% agreed with the necessity of new indicators for 
Asian patients. 
IFSO-APC Consensus statements 2011    
 Bariatric surgery should be considered for the treatment of obesity for acceptable Asian 
candidates with BMI > 35 regardless of the existence of co-morbidities 
 Agree 75％ Consensus 
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 Bariatric/ GI metabolic surgery should be considered for the treatment of T2DM or 
metabolic syndrome for patients who are inadequately controlled by lifestyle 
alternations or medical treatment for acceptable Asian candidates with BMI > 30 
 Agree 76.7% Consensus  
 The surgical approach may be considered as a non-primary alternative to treat 
inadequately controlled T2DM or metabolic syndrome for suitable Asian candidates 
with BMI > 27.5. 
 Agree 67.5% Viewpoints 
 Any surgery for T2DM or metabolic syndrome for Asian patients with a BMI < 27.5 
should be strictly performed only under clinical study protocols with the informed 
consent of the patient and prior approval from an ethics committee.  
 Agree 88.1% Consensus 
 Any surgery for T2DM or metabolic syndrome for Asian patients with a BMI < 27.5 
should be strictly performed only under clinical study protocols with the informed 
consent of the patient and prior approval from the ethics committee.  
 Agree 88.1% Consensus 
 IFSO-APC generally recommends the procedures below for Bariatric and GI metabolic 
surgery for Asians, currently 
 Gastric bypass, Sleeve gastrectomy, Gastric banding, BPD/DS 
 Agree 95.3% Consensus 
 Although novel GI surgical procedures show promising results for Asians other than 
the four mentioned previously, currently these should be used only in the context of 
IRB approval. 
 Agree 97.6% Consensus 
 Clinical study should be organized by highly experienced bariatric surgeons, with 
experience in over 100 cases of bariatric surgery 
 Agree 80% Consensus 
And another three sentences were agreed to by a majority of the voting delegates to form 
IFSO-APC consensus statements. 
Furthermore, an International Diabetes Federation (IDF) position statement in 2011 March 
(78) also concluded surgery should be considered as an alternative treatment option in 
Asian patients with a BMI between 27.5 and 32.5 kgm2 when diabetes cannot be adequately 
controlled by an optimal medical regimen, especially in the presence of other major 
cardiovascular disease risk factors.  
These results indicate the progress of the Asian region differs from other regions and that it 
will play significant role in progression of metabolic surgery not only in Asia but also all 
over the world. 
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the four mentioned previously, currently these should be used only in the context of 
IRB approval. 
 Agree 97.6% Consensus 
 Clinical study should be organized by highly experienced bariatric surgeons, with 
experience in over 100 cases of bariatric surgery 
 Agree 80% Consensus 
And another three sentences were agreed to by a majority of the voting delegates to form 
IFSO-APC consensus statements. 
Furthermore, an International Diabetes Federation (IDF) position statement in 2011 March 
(78) also concluded surgery should be considered as an alternative treatment option in 
Asian patients with a BMI between 27.5 and 32.5 kgm2 when diabetes cannot be adequately 
controlled by an optimal medical regimen, especially in the presence of other major 
cardiovascular disease risk factors.  
These results indicate the progress of the Asian region differs from other regions and that it 
will play significant role in progression of metabolic surgery not only in Asia but also all 
over the world. 
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1. Introduction 
Obesity is a serious public health problem in the United States. The prevalence of obesity is 
growing every year, not only in adults but also in the pediatric population (Ogden et al., 
2002). Obesity is now the second leading cause of death in the United States after  
tobacco-related disease, and 400,000 Americans died of obesity-related causes in 2000 
(Mokdad et al., 2004). It is well known that obesity contributes to such comorbidities as 
noninsulin- dependent diabetes mellitus, hypertension, and hypertri-glyceridemia or 
hypercholesterolemia. Surgical treatment of morbid obesity is recognized as long-term 
effective therapy, and its goal is to limit or eliminate these comorbidities (Dixon & O’Brien, 
2002; Giusti et al., 2004). 
Robotically-assisted surgery’s most notable contributions are reflected in its ability to extend 
the already well-established benefits of minimally invasive surgery to procedures not 
routinely performed using minimal access techniques (i.e., total esophagectomies, coronary 
artery bypass grafting, and radical prostatectomies). This technology may ultimately 
increase the number of physicians who are able to provide the benefits of minimal access 
surgery to their patients without the increased risks of complications associated with initial 
learning curves. We believe that the progress and development of robotic surgery will 
eventually provide all bariatric surgeons with the option of a minimally invasive approach. 
As more patients become aware of the clinical outcomes from minimally invasive surgical 
treatment for morbid obesity, they will actively seek a bariatric surgeon skilled in these 
techniques. The additional advantages afforded by the use of minimally invasive surgical 
techniques, coupled with the desire to retain the natural ergonomics and visual advantages 
of open surgery, have propelled the development and progression of robot-assisted surgery. 
Current robotics systems have already begun to return the “natural feel” of open access 
afforded by laparotomy to minimally invasive surgeons. 
A survey of surgeons in 2003 revealed that only few surgeons in the United States were 
currently using a robotic surgical system for bariatric surgery (Jacobsen et al., 2003). This 
statistic can be explained by the small number of bariatric cases performed laparoscopically 
and by the limited number of institutions with a robotics system available for use. The first 
robot-assisted adjustable gastric banding was reported in 1999 (Cadiere et al., 1999), and 
Horgan and collaborators performed the first robot-assisted gastric bypass in September 
2000 (Horgan et al., 2001). Since that time there have been numerous publications detailing 
the use of robotic assistance in bariatric surgery. 
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Herein, we examine the current use of robotics in bariatric surgery as well as its potential 
advantages and disadvantages. 
1.1 The da Vinci robotic system 
Using robots to perform surgery once seemed a futuristic fantasy. Nonetheless, since the 
FDA approval in the year 2000, robotic surgery and the use of the da Vinci Surgical 
SystemTM (DVSS Intuitive Surgical Corporation, Sunnyvale, Calif) has widely extended. The 
DVSS became the first robotic surgical system cleared by the FDA for general laparoscopic 
surgery. In the following years, the FDA cleared the da Vinci Surgical System™ for 
thoracoscopic surgery, for cardiac procedures, urologic, and gynecologic procedures. 
 
Fig. 1. Operating room setup for Robotic-Assisted Gastric Banding. 
In the US, approximately 1,950 units are actually working, 347 in Europe, and 182 
distributed throughout the rest of the world. 
The equipment has three different components (1). 
 Surgeon Console: At which the surgeon operates while comfortably seated, using 
four pedals, a set of console switches, and two master controls. The movements of 
the surgeon's fingers are transmitted by the master controls, to the tip of the 
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instruments located inside the patient. A high-resolution three-dimensional view of 
the surgical field is obtained using a 12 mm scope, which contains two 5 mm three-
chip video cameras that integrate images. 
 Control Tower:  monitor, light sources, and cord attachments for the cameras. 
 Patient side cart: consisting of four robotic arms, one arm positions the laparoscope 
and the other three arms allow placement and manipulation of a variety of da 
Vinci-specific instruments. 
The bariatric procedures performed vary from a simple laparoscopic adjustable gastric band 
up to the most complex biliopancreatic diversion/duodenal switch (BPD/DS). 
2. Robotic gastric adjustable band placement 
Laparoscopic adjustable gastric banding (LAGB) is one of the preferred methods for surgical 
treatment of morbid obesity (Muhlman et al., 2003). Excellent long-term results and 
postoperative improvement in quality of life have been reported (Cadiere et al., 2002; 
Dargent, 1999; Nehoda et al., 2001). The expanding use of the LAGB is probably driven by 
the encouraging data on its safety and effectiveness. LAGB is associated with a shorter 
learning curve and decreased perioperative complications compared to gastric bypass. For 
that reason, adoption of robotic technology for this procedure is scarce. Nevertheless, 
Cadiere et al., described the first robotic gastric band placement in 1999 (Cadiere et al., 
1999). Later, several studies in the literature have reported the use of robotics for LAGB 
(Edelson et al., 2011; Moser & Horgan, 2004). 
2.1 Surgical technique 
The surgical technique was previously described Moser et al (Moser & Horgan, 2004). In 
brief, the patient is placed in the low lithotomy position with the legs and arms open. The 
surgeon operates between the patient’s legs, with the assistant at the patient’s left side (1). 
Pneumoperitoneum can be achieved with the Veress needle technique or with the optiview 
assistance trocar up to 15 or 20 mm Hg. The rst trocar used is a 10- to 12-mm trocar, which 
is inserted under direct vision or with an optiview trocar, 15 to 20 cm from the xyphoid 
process using a 10-mm, 0 or 30-degree scope, the rest of the trocars are introduced under 
direct vision. An 8-mm trocar (robotic arm) is placed immediately below the left rib cage in 
the mid clavicular line; also a 12-mm trocar is then placed on the left ank at the same level 
as the camera. Then, the patient is placed in the reverse Trendelenburg position, to allow a 
better visualization of the His Angle. A Nathanson liver retractor is inserted through a 5-
mm incision placed below the xyphoid process. The last 8-mm trocar (robotic arm) is placed 
approximately 8 cm below the right rib cage. A Cadiere forceps or robotic grasper is used 
attached to the right arm and the harmonic scalpel to the left arm. The operation begins with 
detaching the phrenogastric ligament to expose the left crura. Then, the gastrohepatic 
ligament is opened to expose the caudate lobe of the liver, the inferior vena cava and the 
right crura. A retrogastric tunnel is created between the edge of the right crura and the 
posterior wall of the stomach until the articulated tip of the robotic instrument is visualized 
at the angle of His. The band is placed inside the abdomen, through the 12-mm trocar and 
the tip of the tubing is placed between the jaws of the Cadiere forceps, attached to the left 
arm, and the band is threaded around the stomach [2]. 
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Fig. 2. The band is threaded around the stomach with Cadiere forceps. 
The tip of the tubing is inserted into the band buckle and locked. After the band is in place, a 
wrap is fashioned out of the stomach to secure it using several nonabsorbable seromuscular 
sutures [3]. Finally, the port is then secured with nonabsorbable sutures or using built-in 
hooks. 
 
Fig. 3. A wrap is fashioned out of the stomach to secure the band in place. 
3. Robotic-assisted Roux-en-Y gastric bypass 
During the past 40 to 50 years, Roux-en-Y gastric bypass (RYGB) has been the preferred 
surgical procedure performed by bariatric surgeons in the United States. However, due to 
its complexity, this operation has always been challenged by alternative surgical 
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procedures. Although gastric bypass has been shown to be safe and effective in maintaining 
long-lasting weight loss, it is associated with a steep learning curve and is not free from 
complications (Podnos et al., 2003; Schauer et al., 2003). 
Robotic surgery is potentially ideal for the Roux-en-Y gastric bypass (RYGB), for a variety of 
reasons including: the shorter learning curve to perform advanced maneuvers such as 
suturing, precise dissection, and the ability to be used in patients with a high BMI (Kim & 
Buffington, 2011). For these reasons, currently gastric bypass is the fastest growing robotic-
assisted bariatric procedure with a 50% growth in 2009. 
3.1 Surgical technique 
3.1.1 Robotic-assisted gastric bypass (Hybrid approach) 
The patient is placed in the low lithotomy position with the legs and arms open; a beanbag 
is placed under the patient to support the steep reverse Trendelenburg position during the 
operation. Initially, the pneumoperitoneum is achieved by inserting a 12-mm trocar placed 
in the supraumbilical position using the Optiview system. Additional 12-mm trocars are 
placed in the left lower quadrant, right upper quadrant and left mid abdomen. Later, a 5-
mm incision will be made below the xyphoid process to introduce a Nathanson liver 
retractor. Final configuration is shown in Figure 4. 
 
Fig. 4. Ports placement for Robotic-Assisted Gastric Bypass. 
The next step consists in identifying the ligament of Treitz (LT) to run the small bowel distally 
50 cm and dividing it using a vascular stapler; the mesentery of the bowel is divided using a 
vascular stapler or the harmonic scalpel. After creating a 100-cm jejunal limb (some authors 
used 150 cm [Moser & Horgan 2004]), a side-to-side jejunojejunal anastomosis is performed 
using a vascular stapler. The bowel opening can be closed using a needle holder with 
interrupted stitches of 3-0 silk or stapler. The defect between the mesentery is closed using a 2-
0 Ethibond suture. The patient is then placed in a reverse Trendelenburg position (5). 
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Fig. 5. Patient placed in reverse trendelenburg for Robotic-Assisted Gastric Bypass. 
 
Fig. 6. da Vinci Surgical System™ positioned over the head of the patient. 
 





Fig. 7. Creation of the gastrojejunostomy. 
 
 
Fig. 8. Gastrojejunal anastomosis posterior running suture created. 
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Fig. 7. Creation of the gastrojejunostomy. 
 
 
Fig. 8. Gastrojejunal anastomosis posterior running suture created. 
 
Advanced Bariatric and Metabolic Surgery 
 
302 
As previously described, a 5-mm incision is made in the subxiphoid area to insert the 
Nathanson retractor for the anterior mobilization of the left liver lobe. The omentum is 
mobilized and sectioned using the harmonic scalpel. The retrogastric tunnel is created 
using the harmonic scalpel starting at the lesser curve approximately 5 cm from the 
gastroesophageal junction. Two or three fires (one perpendicular and one/two parallels) 
to the lesser curvature of the stomach are used to create the gastric pouch. The Roux limb 
is brought up antecolic for creation of the gastrojejunostomy. Horgan et al. (Horgan & 
Vanuno, 2001) first described the technique for the creation of the gastrojejunostomy in 
2001. 
The surgical arm cart of the da Vinci Surgical System™ (Intuitive Surgical, Inc., Sunnyvale, 
CA) is positioned over the head of the patient with the arms going through right upper 
quadrant and left upper quadrant ports (6). 
The da Vinci ports are introduced into the 12-mm trocars. A Cadiere forceps is attached to 
the right arm and a needle holder to the left arm. The gastrojejunal (GJ) anastomosis (7, 8) is 
performed hand sewn in two layers using running 3-0 Ethibond for the posterior layer and 
3-0 Vycril of the anterior layer [1]. 
Then, using a harmonic scalpel, a 1.5-cm opening is created in both the jejunum and the 





Fig 9. An opening is created in the jejunum limb with the harmonic scalpel. 
 





Fig. 10. An opening is created in both the jejunum and the stomach. 
 
 
Fig. 11. Creation of the anterior layer of the GJ anastomosis using 3-0 Vycril on a running 
fashion. 
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Fig. 12. An NGT is passed down to the gastric pouch and into the jejunum limb to maintain 
patency of the anastomosis. 
 
Fig. 13. Posterior layer of the GJ anastomosis using 3-0 Ethibond running suture. 
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Once gastrotomy and enterotomy are created the anterior layer of the anastomosis is started 
using 3-0 Vycril on a running fashion (11). A nasogastric tube (NGT) is passed down the 
gastric pouch and into the Roux limb to maintain the patency of the anastomosis (12). The 
posterior layer is then completed with running 3-0 Ethibon (13). Once the anastomosis is 
nished, using the NGT, the jejunum is clamped distally, and 60 mL of methylene blue is 
introduced to rule out the presence of leak. Peterson space is closed in a running fashion 
with non-reabsorbable suture. 
3.1.2 Totally robotic gastric bypass 
The orientation of the left and right robot arms reflects the console surgeon’s and assistant’s 
left and right (14). 
 
Fig. 14. Operating room setup. Totally robotic gastric bypass. 
Mohr et al. (Mohr et al., 2005) describes the technique with six ports using a double 
cannulation of the Intuitive Surgical cannulas of 8 mm, which fitted inside a 10/12 mm port, 
this allows the robot arm to be removed from the port with the cannula still attached for a 
stapling tool and also, for the quick replacement of the robotic arm. Laparoscopy is started 
first placing the camera port using an Optiview nonbladed trocar and a 0° scope. 
Pneumoperitoneum is achieved. A total of 5 ports [a left subcostal port, two right trocars 
(one at the subcostal margin and one at the right flank), two trocars for the assistant (one at 
the left flank and one to the right of the supraumbilical midline)] are placed under direct 
visualization (15). The transverse mesocolon is retracted superiorly with a laparoscopic 
grasper allowing visualization of the ligament of Treitz. 
 




Fig. 12. An NGT is passed down to the gastric pouch and into the jejunum limb to maintain 
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Fig. 15. Operative port placement. A, Port positions in a patient. B, Diagram of port 
placement. L indicates left; C,camera; A1, assistant1; A2, assistant2;  R1, right 1; R2, right 2. 
The robot is then docked in and it is positioned at the patient’s left shoulder at a steep angle 
(15° - 30° off patient midline) and as close to the table as the base permits (16). 
 
Fig. 16. Base position with respect to the operating room table. 
The left arm is positioned such that the external yaw axis is as close to vertical as possible. 
The right arm should be brought in relatively low, and the setup joints tucked close to the 
base so that the tool holder is in the middle of its range of motion in the pitch axis (17). 
The jejunojejunostomy is made first, but some authors prefer to make the gastric pouch first 
(Kim & Buffington, 2011). The surgeon manipulates the bowel with Cadiere graspers or 
bowel graspers at the robotic console, aided by the surgeon's assistant who also transects the 
bowel 20 to 40 cm from the LT using a white stapler through the left flank assistant's port 
(15). The jejunal mesentery is further divided by the surgeon's assistant using a LigaSure 
Atlas, da Vinci ultrasonic shears or stapler (Galvani et al., 2006; Horgan & Vanuno, 2001; 
Moser & Horgan, 2004). 
 




Fig. 17. The external yaw axis. 
The assistant and the console surgeon then measure 100 to 150 cm of bowel for the Roux 
limb and align the Roux and biliopancreatic limbs joined by a 7-inch 3-0 Ethibond stay stitch 
placed by the console surgeon, aligning the bowel for the jejunojejunostomy using a needle 
driver and Debakey forceps and also creates the enterotomies with the Endowrist 
Permanent Hook below the stay stitch. 
The stay stitch is used to provide counter traction for the assistant to complete the internal 
portion of the jejunojejunostomy with the linear stapler. The console surgeon closes the 
enterotomy with a running 3-0 Ethibond single-layer suture. The mesenteric defect is then 
closed with interrupted or running non-absorbable sutures. The surgeon’s assistant with a 
Ligasure Atlas divides the omentum and the Roux limb is brought up antecolic. The next 
step is to work at the gastroesophageal (GE) area that involves removing the right robot arm 
from the right flank double cannulated port, inserting the Intuitive Surgical port at the right 
subcostal port position (15), and redocking the arm. 
The liver is retracted using a 5-mm liver retractor through the assistant's right supraumbilcal 
port and held in place with a laparoscopic instrument holder. The console surgeon is then 
ready to work at the GE junction after repositioning the surgical instruments and camera 
visualizing the angle of His which is dissected with the electrocautery hook. 
When completed, dissection of the gastric pouch begins. Dissection initiates 5 cm along the 
lesser curve and with the electrocautery hook into the retrogastric space. The assistant 
removes the left robotic arm from the double cannulated left subcostal margin port, 
introduces the stapler, and creates the lower border of the gastric pouch with a blue 
cartridge (3.5 mm). 
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The left robot arm is replaced, and the console surgeon provides traction for the surgeon's 
assistant to staple the lateral border of the pouch, which is sized using a transoral 36F tube, 
aided by an esophageal retractor. 
The console surgeon then creates the enterotomies and a 2-layer sutured anastomosis. The 
outer and inner layers are sutured with running 7-in and 6-in 3-0 Ethibond sutures, 
respectively, with the 36F tube used to stent the anastomosis open while completing the 
anastomosis. A leak test is then performed insufflating it underwater; or using the 
methylene blue leak test (Galvani et al., 2006; Kim & Buffington, 2011; Moser & Horgan, 
2004). The robot and all ports are removed and the skin incisions closed. 
4. Robotic sleeve gastrectomy 
The laparoscopic sleeve gastrectomy was initially reported by Ren et al. (Ren et al., 2000) in 
2000 as part of the duodenal switch for super-super morbidly obese patients and later 
described by Regan (Regan et al., 2003) as a staged operation for morbid obesity in 2003. The 
rationale for sleeve gastrectomy was initially to lower the morbidity of this complex surgical 
procedure by offering a less challenging operation, decreasing operative time, and allowing 
patients to lose weight before proceeding with the second stage. Because of the excellent 
results in these patients, several studies (Lee et al., 2007) have supported the use of the 
sleeve gastrectomy as a primary bariatric operation. The main advantages of this operation 
are that it is not as technically challenging as gastric bypass or biliopancreatic diversion-
duodenal switch (BPD-DS), thereby decreasing operative times and morbidity. As a result, 
robotic technology for sleeve gastrectomy has not been widely adopted amongst bariatric 
surgeons. The use of the robot for this procedure is still debated. However, few series have 
been reported in the literature (Ayloo et al., 2011; Diamantis et al., 2011). 
4.1 Surgical technique 
The surgical technique is described by Diamantis et al. in their first clinical experience series 
(Ayloo et al., 2011; Diamantis et al., 2011), which is similar to a Standard Laparoscopic 
Sleeve Gastrectomy (LSG). The first step is achieving pneumoperitoneum. Then, a 12-mm 
port 8 cm above the umbilicus for the camera, a right 12-mm trocar is positioned at the 
epigastrium, 5 cm towards the left of the midline, and a left 12-mm trocar placed at least 8 
cm far away from the camera port, in order to avoid collision of the robotic arms that would 
hamper the advancement of the procedure. A double cannulation technique is used 
inserting the 8-mm metallic robotic ports through the standard 12-mm trocars. Two further 
12-mm trocars are inserted, one at the right anterior axillary line, 2 cm below the subcostal 
arch for liver retraction and one at the symmetrical site on the left side to retract the 
gastrosplenic ligament (18). 
All the trocars and robotic cannulas are inserted under the guidance of the standard 
laparoscopic camera and the robotic system approached the patient and is installed 
(“docked”) afterwards. The robotic camera is docked last, and the robotic cart is positioned 
over the patient’s left shoulder. 
Only three arms of the da Vinci S Surgical System™ are used (camera and two working 
arms). Once the general setup is ready, the procedure begin with the console surgeon 
grasping with a Cadiere forceps, the greater curvature of the stomach at its lowest part and 
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the gastrocolic ligament is cut with the da Vinci harmonic scalpel. The division of the 
gastrocolic and gastrosplenic ligament continues exactly like in a standard LSG. Once the 
angle of His is clearly visible and mobilized from the left crus, division of the gastrocolic 
ligament ends 4-6 cm proximally from the pylorus. At this point instead of a bougie 
preferred by some surgeons, an intra-operative endoscopy can be used for the calibration of 
the gastric sleeve. Once the endoscope lies across the lesser gastric curvature will taylor the 
gastrectomy. The console surgeon holds and abducts the mobilized greater gastric curvature 
with a Cadiere forceps through the right working trocar and the left robotic arm is 
undocked. The table surgeon inserts the stapler, loaded with a green cartridge, through the 
working port at the right site of the patient and divides the stomach in a direction from the 
lowest tip of the greater gastric curvature, 4 cm proximally to the pylorus, towards the 
lateral edge of the endoscope. 
 
Fig. 18. Port Placement. C = camera. 
All staple lines are regularly reinforced with prosthetic material (GORE SEAMGUARD 
bioabsorbable staple line reinforcement, W. L. GORE and Associates Inc.). The left robotic 
arm is docked once again after the first two fires. The stapling continues in a cephalad 
direction with the traction of the gastric sleeve using the Cadiere forceps, while the right 
arm is undocked for the insertion of the stapler, and division of the stomach; also the 
laparoscopic could be used to mobilize the greater gastric curvature. The stomach is divided 
till the angle of His, then the endoscope is smoothly withdrawn. Ayloo et al. (Ayloo, et al., 
2011) also describes the assistance of the robot to invert the stapling line by placing sero-
serosal sutures of 2-0 PDS (Ethicon) beginning at the angle of His. The staple line is then 
inspected from inside bleeding and air leak. A leak test is also performed filled with diluted 
Povidone 10% solution or methylene blue by some other authors (Galvani et al., 2006; Moser 
& Horgan, 2004). Finally, the transected, redundant part of the stomach is removed through 
the left lateral port site mainly through a fascial digital dilation. 
5. Robotic-assisted biliopancreatic diversion and duodenal switch 
The duodenal switch (DS) operation for bariatric surgery was initially described by Hess as 
a modication of the Scopinaro biliary pancreatic diversion (BPD). Today, it is accepted as 
the most effective weight reduction procedure (Anthone et al., 2003). In spite of this, the 
operation represents only about 0.89% of the bariatric procedures performed in the US 
(DeMaria et al., 2010). This is probably due to the technical challenges that surgeons are 
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faced with BPD-DS. Consequently, the vast majority of procedures are done primarily open. 
However, the introduction of laparoscopy has decreased its morbidity (Kim et al., 2003). The 
addition of robotics could potentially increase the number of minimally invasive BPD-DS 
procedures performed. Conversely, there are only two reports in the literature describing 
the use of robotic technology for BPD-DS (Sudan et al., 2007). 
5.1 Surgical technique 
Sudan et al. (Sudan et al., 2007) describes the surgical technique placing the patient in a 
supine position. After achieving pneumoperitoneum, a 12-mm port with a 0° camera is used 
to enter the abdominal cavity. Four additional 12-mm ports are placed, and the Nathanson 
liver retractor is placed intraoperatively through an epigastric 5-mm incision (19). 
 
Fig. 19. Port sites. The midclavicular line ports are used for robotic arms. LR, site for 
Nathanson liver retractor placement. 
 
Fig. 20. Appendectomy followed by placement of marking stitches at points 100 and 250 cm 
proximal to the ileocecal valve. Bowel is transected 250 cm proximal to the ileocecal valve. 
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Midclavicular ports are used for the da Vinci arms when the duodeno-ileal (proximal 
alimentary limb) anastomosis is performed. Standard laparoscopic procedure is made first 
by positioning the patient in the Trendelenberg position and tilted to the left and an 
appendectomy is performed, as practiced by open BPD/DS surgeons. Marking sutures are 
placed 100 and 250 cm from the ileocecal junction, and the bowel is divided at the 250-cm 
mark using an endolinear cutter stapler (20). 
The mesentery of the alimentary limb of small bowel is divided using the Harmonic Scalpel 
for a tension-free anastomosis to the duodenum. The biliary limb then is anastomosed to the 
common channel at the 100-cm mark using two applications of the 45-mm vascular 
endolinear cutter staplers (21). 
 
Fig. 21. The distal enteroenteric anastomosis is performed using a 45-mm vascular load 
endoscopic stapler. The 100-cm-long common channel (CC) is shown. AL, eventual 
alimentary limb; BPL, eventual biliopancreatic limb. 
The enterotomy for the staplers is closed transversely using hand sewn intracorporeal 
suturing. The mesenteric defect between the biliary limb and the common channel is closed 
with running nonabsorbable suture, and the distal anastomosis is marked with three large 
radio-opaque hemoclips for future identication purposes. After performance of a 
cholecystectomy, the greater curvature of the stomach is mobilized using the Harmonic 
Scalpel, beginning 4 cm distal to the pylorus and working proximally to the angle of His. 
The duodenum is divided using the endolinear cutter stapler, and a sleeve gastrectomy is 
performed to reduce the capacity of the stomach to 150 ml (22). Methylene blue is used to 
ensure absence of leaks in the gastric staple line. The stapled edge of the alimentary limb is 
next positioned in a retrocolic fashion, and the da Vinci system is docked by bringing it over 
the patient´s right shoulder. 
After setting up the robot, a two-layer sutured anastomosis is then created using 2–0 
Surgilon and 2–0 Vicryl in a running fashion (23). 
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The mesenteric defect between the alimentary limb and the retroperitoneum and transverse 
mesocolon is closed. The duodenoileal anastomosis then is checked with methylene blue to 
exclude a leak. All the specimens that had been resected (i.e., gallbladder, resected stomach, 
appendix) are placed in endobags and retrieved through the umbilical port site. After 
removal of the ports, the incisions are closed with skin staples. Final configuration is shown 
in Figure 24. 
 
Fig. 22. Mobilization of the proximal 4 cm of the duodenum and the greater curvature of 
stomach is followed by transection of the duodenum and resection of the greater curvature 
of the stomach to result in a gastric remnant with a capacity of 150 ml. 
 
 
Fig. 23. A two-layered anastomosis is performed between the duodenum (Duo) and the 
alimentary limb (AL), which is brought up in retrocolic fashion. The robotic arms are used 
for suturing. The laparoscopic instruments handled by the bedside surgeon provide 
exposure and traction with stay sutures. 
 




Fig. 24. The nal conguration results in a 100-cm-long common channel (CC). The 
alimentary limb (AL) and the biliopancreatic limb (BPL) are demonstrated. The length of the 
AL is 250 cm. 
6. Discussion 
6.1 Laparoscopic adjustable gastric band vs. robotic adjustable gastric band (RAGB) 
There are two series that compared LAGB vs. RAGB in the literature. Both of them 
demonstrated no advantages in using robotic surgery in terms of hospital stay, 
complications and postoperative weight loss (Edelson et al., 2011; Moser & Horgan, 2004). 
However, both series noticed benefits in the super obese patients such as those BMI > 50 
kg/m2. In this particular group of patients the thickness of the abdominal wall increases the 
torque of standard bariatric instruments. The authors attributed these findings to the 
characteristics of the robotic system such as longer and stiffer instrumentation, and 
mechanical power (Edelson et al., 2011; Jacobsen et al., 2003). Specifically, operative time in 
these patients is reported to be shorter than the LAGB counterparts (Edelson et al., 2011). In 
addition, gastric banding seems to be an acceptable training platform for the novice robotic 
surgeon. The increased procedural cost is another mayor disadvantage for the widespread 
implementation of robotics (Gill et al., 2011). 
6.2 Laparoscopic gastric bypass vs. robotic assisted gastric bypass (RYGB) and 
totally robotic gastric bypass (TRYGB) 
Robotic RYGB is increasingly accepted as a safe alternative to laparoscopic RYGB (Gill et al., 
2011; Jacobsen et al., 2003; Moser & Horgan 2004). Evidence shows that both offer the same 
long-term postoperative benefits like excess weight loss and resolution of comorbidities 
(Snyder et al., 2008). Several authors have described a decreased gastrojejunostomy leak rate 
while using the robotic system (Galvani et al, 2006; Gill et al., 2011; Moser & Horgan, 2004; 
Snyder et al., 2008; Wilson et al., 2008). Therefore, lowering the overall complications rate of 
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mesocolon is closed. The duodenoileal anastomosis then is checked with methylene blue to 
exclude a leak. All the specimens that had been resected (i.e., gallbladder, resected stomach, 
appendix) are placed in endobags and retrieved through the umbilical port site. After 
removal of the ports, the incisions are closed with skin staples. Final configuration is shown 
in Figure 24. 
 
Fig. 22. Mobilization of the proximal 4 cm of the duodenum and the greater curvature of 
stomach is followed by transection of the duodenum and resection of the greater curvature 
of the stomach to result in a gastric remnant with a capacity of 150 ml. 
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the procedure and potentially decreasing costs (Snyder et al, 2008). An additional advantage 
is the shortening of the learning curve, since it has been suggested that the learning curve 
for laparoscopic RYGB is about a 100 cases (Schauer et al., 2003). Our experience suggested 
that the learning curve for achieving optimal outcomes and low complication rate plateau 
after the first 20 cases, indicating a shorter learning curve than conventional laparoscopy. 
These advantages of the robotic RYGB include the limited possibility to access different 
areas of the abdomen after the system is docked (Jacobsen et al., 2003; Moser & Horgan, 
2004; Snyder et al., 2008). For that reason, surgeons have opted to go either the hybrid or the 
totally robotic approach. It is worth mentioning, that in the so-called "Totally robotic gastric 
bypass" a qualified bedside assistant is necessary to perform stapling of the stomach and 
small bowel. Making obvious also the need of further instrumentation. For these reasons, in 
spite of a shorter learning curve, the totally robotic gastric bypass is not widely accepted. 
6.3 Laparoscopic sleeve gastrectomy (LSG) vs. robotic sleeve gastrectomy (RSG) 
The reported experience in RSG is scarce (Ayloo et al., 2011; Diamantis et al., 2011). 
Available evidence demonstrates that the procedure is safe and feasible. No clinical 
advantages have been shown when using RSG in terms of hospitalization, morbidity, 
mortality and 1-year weight loss. The use of the robot can be of benefit in the super obese 
with the mechanical force needed to overcome the torque of a thick abdominal wall. 
Obviously the precision of the system is a key advantage for surgeons that routinely 
oversaw the staple line. Additionally, it is also helpful as a training model for fellows and 
residents. 
An important point to keep in mind at the time of making the decision to perform a RSG is 
to consider the added cost of the procedure. The routine use of the Robot for Sleeve 
Gastrectomy has yet to be defined. 
6.4 Robotic assisted biliopancreatic diversion and duodenal switch (RABPD) 
The operation represents only about 0.89% of the bariatric procedures performed in the US 
(DeMaria et al., 2010). Since most of the BPD/DS are done open, the introduction of the 
robotics could potentially increase the number of minimally invasive cases performed. 
Conversely, the experience with RABPD is very limited. Today, there are only two studies in 
the literature about the use of the RABPD (Sudan et al., 2007; Wilson et al., 2008). The 
authors described that the main advantages include accurate suturing, better control over 
the size of the anastomosis, elimination of the potential for oropharyngeal and esophageal 
trauma while inserting the anvil of the circular stapler. The impossibility to work in 
different areas of the abdomen after setup it is also a disadvantage. The precision of the 
robot has shown low complication rates. 
7. Conclusion 
The advantages of the robotic surgery are more obvious in more technically demanding 
procedures that require the creation of gastrointestinal anastomosis. The mechanical power 
offered by the robotic system makes this approach the attractive alternative for super obese 
patients. 
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The learning curve of the robotic system is shorter than for the standard laparoscopic 
approach, allowing more surgeons to offer patients the same safety and successful outcomes 
currently available through open surgical techniques but without the significant morbidities 
of large surgical wounds. 
The limitation of the robotic system still remains the high operational and acquisitional cost 
of the system. Moreover, for certain bariatric procedures like RAGB, RSG, and the RABPD 
its benefits have yet to be defined. 
The development of new robotic instruments, minimization of the robotic systems and cost 
reduction will potentially encourage bariatric surgeons to adopt this technology. 
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1. Introduction 
Bariatric surgery has been established as the best and most effective treatment for morbid 
obesity. It leads to sustained weight loss, life style changes and improves quality of life. 
Since Wittgrove et al. introduced the laparoscopic Roux-en-Y gastric bypass technique in 
1994, the number of operations performed has grown rapidly, and there has been a rapid 
reduction in the number of complications with quicker recovery. At present, the 
laparoscopic approach has become the most popular technique in performing bariatric 
surgery in the world. However laparoscopic technique requires five to seven abdominal 
incisions to facilitate placement of the multiple trocars. Because of the need for the 
numerous ports, the cosmetic results are unacceptable to some patient subgroup, like young 
females. These visible scars may fade over time; however, the healing process is highly 
individualistic, and the cosmetic outcome may not be appealing to all patients. In recent 
years, concept of “No scar surgery” is quickly expanding in various surgical fields, 
including weight loss surgery. 
Newer techniques have eliminated the need for multiple ports and the inevitable scarring 
that follows. Natural orifice transluminal endoscopic surgery (NOTES), which produces no 
scarring, has been considered to be a landmark in the advancement of laparoscopy. 
Recently, another emerging procedure, single-incision laparoscopic surgery (SILS), has been 
used for appendectomy, cholecystectomy and colectomy. This new approach minimizes the 
scars and is considered minimally invasive. In bariatric surgeries, the SILS technique has 
been employed to perform adjustable banding , sleeve gastrectomy, Roux-en –Y gastric 
bypass and biliopancreatic diversion procedures. Here we will review the surgical 
techniques and results of various scarless bariatric surgery, including NOTES and SILS. 
2. NOTES bariatric surgery 
Since the introduction of NOTES in 2004, researchers have used it for various surgical 
interventions [1-3]. This new approach minimizes the scars and is considered minimally 
invasive. Even with the worldwide popularity of NOTES, the present techniques and 
instruments used are still under-developed before making it really applicable in clinical 
employment. There is also ethical concern because of transvaginal or transrectal approach, 
sacrificing the integrity of organ. There is also technical difficulty due to the long distance 
between vagina/rectum and stomach making instrument handling and tissue manipulation 
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between vagina/rectum and stomach making instrument handling and tissue manipulation 
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more complicated with present technology, and there is also concern about the closure of 
orifice. The implication on bariatric surgery was only reported in sleeve gastrectomy and 
adjustable gastric banding with hybrid method, combining laparoscopic and endoscopic 
approach [4-6]. For more complicated procedures, such as gastric bypass are still at 
experimental stage [7]. 
3. SILS bariatric surgery 
Single-incision laparoscopic surgery (SILS) was first described as early as 1992 by Pelosi et 
al. performed single-puncture laparoscopic appendectomy and hysterectomy [8, 9]. 
Currently SILS is considered to be a bridging technique to natural orifice transluminal 
endoscopic surgery (NOTES). It has emerged as another modality of carrying out the 
bariatric procedures. SILS can be performed using refinements of existing technology and 
experienced surgeons can perform SILS even with traditional laparoscopic instruments. 
Applications of SILS have expanded rapidly and various procedures including bariatric 
surgery have been carried out with this technique. Initially, SILS was used in bariatric 
procedures such as adjustable gastric banding (AGB) and sleeve gastrectomy because these 
procedures require the extension of a trocar incision for the placement of a subcutaneous 
port or for extracting the resected gastric specimen [10-12]. The incision was mainly in the 
upper abdomen in the beginning in this single-incision transabdominal (SITA) laparoscopic 
approach. It was felt that the patients would have a better cosmetic outcome if the SILS 
could be performed via a transumbilical incision as the umbilicus can hide the surgical 
wound, leaving no visible abdominal scars. Single incision transumbilical (SITU) 
laparoscopic procedures seem to attract more surgeons because of the higher satisfaction 
from patients. Recently surgeons started to perform SILS in more complex bariatric 
procedures such as gastric bypass and biliopancreatic diversion procedures that require 
gastrointestinal anastomosis [13-14]. Here we review the surgical technique of SITA and 
SITU bariatric surgery. 
3.1 Liver retraction in SILS bariatric surgery 
For upper gastrointestinal laparoscopic surgery, liver retraction is necessary to ensure 
adequate working space. In morbidly obese patients, the hypertrophic left lobe of liver 
invariably hinders the surgeon’s view of the entire stomach. In multi-port bariatric 
procedures, most surgeons use a Nathanson’s liver retractor via a subxiphoid incision to 
retract liver. To avoid the incision in SILS, retraction of the liver is a major challenge. 
Sakaguchi et al [15] invented a device for the retraction of the liver during conventional 
laparoscopic gastrectomy. However, in morbidly obese patients, the technique, which 
involves the dissection of the left triangular ligament of the left liver lobe, is more difficult to 
employ because most of these patients have a hypertrophic left liver lobe. Tacchino et al. 
used a transfixation suture, applied on the right crus and suspended outside as a liver 
retractor suture [14, 16-17]. We have invented a new liver suspension tape technique via 
puncturing liver at peripheral area that can be used to lift even massive livers in morbidly 
obese patients. [Figures 1-3] [13]. Another non-puncturing method with a penrose drain and 
endo-hernia stapler has also been reported by us [18]. These techniques have been proved to 
be a quick and safe method in SILS bariatric surgery. 
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Fig. 3. The lateral segment of the left liver is suspended by passing the suture through it. 
3.2 Adjustable gastric bading 
Laparoscopic AGB (LAGB) is considered to be the most physiological and safe bariatric 
surgery, not involving cutting and anastomosis of gastrointestinal tract [19]. Although the 
weight loss observed is slower, the procedure is popular. In AGB, the surgeons utilize the pars 
flaccida approach to place a band and then place 2-3 gastro-gastric sutures to hold it in place. It 
was believed that LAGB is a good surgery for bariatric surgeons to start the SILS bariatric 
 
Fig. 4. Port positioning for SITU procedure. 
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procedure because it is a technically less demanding procedure and a 4-cm incision is required 
for placement of the port. Nguyen et al [10] reported the first case of single-incision 
laparoscopic AGB. This is also believed to be the first SILS bariatric surgery reported. 
Although the procedure was performed with a SITA method, it opened up the possibility of 
SILS in bariatric surgery. Keidar et al [20] also used the SITA method by adding a liver 
retractor incision and the operative time was about 60 minutes. SITU-LAGB was reported by 
Teixeira et al [21] and the patients included had neither hepatomegaly nor central obesity. 
Super-obese patients were also not considered for inclusion in this study. One conversion was 
observed in 22 reported patients. We also reported two cases with SITU method where 
through single transumbilical incision multiple fascial punctures were performed to carry out 
the procedure (Figure 4) [22]. Tacchino et al used SILS port for the procedure [16].  But till 
now, there are no reported series comparing the outcomes of SILS LAGB and multiple-port 
LAGB. 
3.3 Sleeve gastrectomy 
Sleeve gastrectomy is an emerging procedure for weight loss that provides rapid and 
satisfactory weight loss without any long-term vitamin deficiency. The procedure starts by 
mobilizing the greater curvature starting 4-6-cm from the pylorus till the angle of His. A 
vertical gastrectomy is then performed with endoscopic staplers. The resected stomach is 
extracted via an incision. The SILS approach was applied to sleeve gastrectomy as an incision 
was required for extraction of the resected gastric tube anyway. Saber et al reported both SITU 
and SITA combined with a single port or multiple trocars [23, 24]. They also compared the 
result of SILS and multiport sleeve gastrectomy. Single-incision laparoscopic sleeve 
gastrectomy was associated with less postoperative pain, a lower need for analgesics and a 
decreased length of hospital stay compared to the conventional multi-port laparoscopic sleeve 
gastrectomy [25]. In these studies, most patients were superobese and one patient developed 
wound infection that required drainage [26]. We are also doing SITU procedures for sleeve 
gastrectomy in selected patients and trocar positioning is similar as AGB. 
3.4 Gastric bypass 
Laparoscopic Roux-en-Y gastric bypass (LRYGB) has been considered as the gold 
standard of bariatric surgery. In the standard Roux-en-Y gastric bypass, a 25-ml pouch is 
constructed and anastomosed to a Roux loop of jejunum. This is followed by closure of 
the mesenteric and Peterson’s defect. Till now only two authors have reported the results 
of the SILS approach for gastric bypass. Tacchino et al elongated the gastric pouch to 6 cm 
in length to speed up the dissection and decrease the tension on the gastrojejunal 
anastomosis. Two gastric bypass procedures were adopted - 16 patients receiving a single 
loop and two receiving a double loop. The single-loop gastric bypass involved only one 
anastomosis, and was thought to decrease the difficulties of technique [27]. We also 
developed a novel method using a SITU approach and subsequently performing an 
omega-umbilicoplasty for the Roux-en-Y gastric bypass [22, 28]. The increased space of 
manipulation in the 6-cm incision and subsequent umbilicoplasty design makes the 
procedure easier, saves time and is still scarless [Figures 5-6]. It could be offered as a 
bridge surgery in the early learning curve of performing SITU procedures, and then you 
can directly go to the 4 cm umbilical incision without need of umbilicoplasty. In fact, the 
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procedure because it is a technically less demanding procedure and a 4-cm incision is required 
for placement of the port. Nguyen et al [10] reported the first case of single-incision 
laparoscopic AGB. This is also believed to be the first SILS bariatric surgery reported. 
Although the procedure was performed with a SITA method, it opened up the possibility of 
SILS in bariatric surgery. Keidar et al [20] also used the SITA method by adding a liver 
retractor incision and the operative time was about 60 minutes. SITU-LAGB was reported by 
Teixeira et al [21] and the patients included had neither hepatomegaly nor central obesity. 
Super-obese patients were also not considered for inclusion in this study. One conversion was 
observed in 22 reported patients. We also reported two cases with SITU method where 
through single transumbilical incision multiple fascial punctures were performed to carry out 
the procedure (Figure 4) [22]. Tacchino et al used SILS port for the procedure [16].  But till 
now, there are no reported series comparing the outcomes of SILS LAGB and multiple-port 
LAGB. 
3.3 Sleeve gastrectomy 
Sleeve gastrectomy is an emerging procedure for weight loss that provides rapid and 
satisfactory weight loss without any long-term vitamin deficiency. The procedure starts by 
mobilizing the greater curvature starting 4-6-cm from the pylorus till the angle of His. A 
vertical gastrectomy is then performed with endoscopic staplers. The resected stomach is 
extracted via an incision. The SILS approach was applied to sleeve gastrectomy as an incision 
was required for extraction of the resected gastric tube anyway. Saber et al reported both SITU 
and SITA combined with a single port or multiple trocars [23, 24]. They also compared the 
result of SILS and multiport sleeve gastrectomy. Single-incision laparoscopic sleeve 
gastrectomy was associated with less postoperative pain, a lower need for analgesics and a 
decreased length of hospital stay compared to the conventional multi-port laparoscopic sleeve 
gastrectomy [25]. In these studies, most patients were superobese and one patient developed 
wound infection that required drainage [26]. We are also doing SITU procedures for sleeve 
gastrectomy in selected patients and trocar positioning is similar as AGB. 
3.4 Gastric bypass 
Laparoscopic Roux-en-Y gastric bypass (LRYGB) has been considered as the gold 
standard of bariatric surgery. In the standard Roux-en-Y gastric bypass, a 25-ml pouch is 
constructed and anastomosed to a Roux loop of jejunum. This is followed by closure of 
the mesenteric and Peterson’s defect. Till now only two authors have reported the results 
of the SILS approach for gastric bypass. Tacchino et al elongated the gastric pouch to 6 cm 
in length to speed up the dissection and decrease the tension on the gastrojejunal 
anastomosis. Two gastric bypass procedures were adopted - 16 patients receiving a single 
loop and two receiving a double loop. The single-loop gastric bypass involved only one 
anastomosis, and was thought to decrease the difficulties of technique [27]. We also 
developed a novel method using a SITU approach and subsequently performing an 
omega-umbilicoplasty for the Roux-en-Y gastric bypass [22, 28]. The increased space of 
manipulation in the 6-cm incision and subsequent umbilicoplasty design makes the 
procedure easier, saves time and is still scarless [Figures 5-6]. It could be offered as a 
bridge surgery in the early learning curve of performing SITU procedures, and then you 
can directly go to the 4 cm umbilical incision without need of umbilicoplasty. In fact, the 
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procedures might need some modifications including use of an Endostich device for 
suturing and some stay sutures for counter traction. No complications were observed in 
these two reports. 
 
 
Fig. 5. Design of single-incision transumbilical laparoscopic bariatric surgery (multiple 
ports) by Huang et al. Schematic of a 4-6-cm ω-incision in the supra-umbilical area. 
(A) Schematic of the distance between the trocars (5 mm, 12 mm, 12 mm) that can reach 
(B) 4-cm more with this design thus increasing the space for manipulation. 
 
 
Fig. 6. Closure of the ω-incision (A) At the conclusion of the surgery the trocars are removed 
and the fascia is repaired. The subcutaneous fat and skin at the angle is removed (Green 
area). (B) An umbilicoplasty is performed. (C) The wound becomes circular and is buried in 
the umbilicus. 
3.5 Biliopancreatic diversion 
Biliopancreatic diversion is a malabsorptive technique of bariatric surgery that has gained 
wide acceptance especially in super-obesity. It is performed by carrying out a horizontal 
transaction of stomach combined with a gastroenterostomy and enteroenterostomy. The 
surgery is considered to be the most complex bariatric procedure. Tacchino et al reported the 
first case with SITU / single-port method [14] in a 57-year-old man with a body mass index of 
43 kg/m2. The procedure took 130 minutes to finish and there were no complications. 
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4. Discussion 
SILS has recently gained acceptance in bariatric surgery as the procedure has possible 
benefits. It is an alternative to NOTES - an experimental procedure whose feasibility is 
frequently debated. [21, 22] The surgical technique involved is almost identical to that 
required for conventional laparoscopic surgery. If the surgery is performed transumbilically, 
the surgical scar is almost completely hidden inside the belly button and the surgical site is 
scarless. Although some surgeons argue that very obese patients are not concerned about 
the scarring up to 70% of patients undergoing bariatric procedures are women and consider 
scarring to be an important factor. We have done a comparative study in SITU-LRYGB and 
5-port LRYGB [29]. Also, though the operation times were longer, the recovery and 
hospitalization was similar in both groups. The promising result showed better patient 
satisfaction regarding the cosmesis in the SITU group (Figure 7). Despite its advantages in 
SILS bariatric surgery, the small umbilical incision tends to “crowd” the trocars in a very 
limited surgical field. The resulting reduced instrument triangulation and inability to retract 
tissue by the assistant make this procedure more arduous. At first, it is essential to use a 30º 
5-mm laparoscope to avoid conflict with other surgical instruments. Some surgeons have 
used a semi-flexible endoscopic camera system to make the procedure more comfortable. 
Second, handling a hypertrophic liver and abundant visceral fat is also critical in morbidly 
obese patients. Third, longer endoscope, longer graspers and longer linear staplers are also 
highly recommended. In addition, patient selection is important for this surgery and some 
patients are not well-suited for these procedure. Most authors do not recommend this 
procedure for those with a BMI greater than 50 kg/m2. Not only because of abundant 
abdominal fat that makes surgery very difficult, especially for a LRYGB, which needs 
anastomosis technique, also mostly postoperative abdomino-plasty is inevitable in super-
obese patients after gravid weight loss. Due to the longer-than-normal working distance 
between the angle of His and the umbilicus in the SILS procedure, it should be avoided in 
tall patients (height >180 cm). As this procedure requires far more skill than a conventional 
5-port surgery, it should only be undertaken by very experienced bariatric surgeons. 
 
Fig. 7. Scar of SITU LRYGB in follow up. 
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To start with the 3-ports surgery could make surgeons more familiar with the surgcial 
setting without assistant’s counter-traction and could bring you steady to the success of SILS 
procedure. 
5. Conclusions 
In conclusion, no scar bariatric surgery is a new unavoidable trend because of concern about 
the privacy and quality of life. At present, SILS bariatric has been shown to be a technically 
more feasible and reproducible procedure for a select group of morbidly obese patients than 
NOTES. Because of the abundant visceral and subcutaneous fat and multiple co-morbidities 
in morbid obesity, it is more challenging for surgeons to perform the procedures with SILS. 
It is clear that extensive development of new instruments and technology will make these 
procedures easier to perform. Careful selection of candidate is a key for the success of this 
surgery. Nevertheless, randomized studies to compare the SILS bariatric procedures with 
traditional multi-port surgery are essential to further develop this highly technique-
dependent surgery. 
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